- entity: node
  type: pdq_cancer_information_summary
  title: 'High-Dose Vitamin C (PDQ®)–Health Professional Version'
  status: 1
  langcode: en
  moderation_state:
    value: published
  field_pdq_url:
    value: /about-cancer/treatment/cam/hp/vitamin-c-pdq
  field_pdq_cdr_id:
    value: 742114
  field_pdq_audience:
    value: Health Professionals
  field_pdq_summary_type:
    value: Integrative, alternative, and complementary therapies
  field_date_posted:
    value: '2013-02-08'
  field_date_updated:
    value: '2017-12-13'
  field_short_title:
    value: 'High-Dose Vitamin C'
  field_page_description:
    value: 'High-dose vitamin C, with and without conventional cancer therapies, appeared promising in early studies and was well tolerated. However, these studies have several limitations due to lack of rigor in trial design. Get detailed information about high-dose vitamin C in cancer in this clinician summary.'
  field_public_use:
    value: 1
  field_summary_sections:
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _1
      field_pdq_section_title:
        - format: plain_text
          value: 'Overview'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_1" class="pdq-sections"><div class="pdq-hp-patient-toggle"><a href="/about-cancer/treatment/cam/patient/vitamin-c-pdq">Go to Patient Version</a></div><p id="_3" tabindex="-1">This <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45333&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045333&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cancer</a> information summary provides an overview of the use of high-<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44664&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044664&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">dose</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=439435&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000439435&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">vitamin C</a> (also known as ascorbate or L-<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=439436&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000439436&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">ascorbic acid</a>) as a treatment for people with cancer.  This summary includes a brief history of early <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45961&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045961&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">clinical trials</a> of high-dose vitamin C; reviews of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44512&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044512&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">laboratory</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=454774&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000454774&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">animal</a>, and human studies; and current clinical trials.</p><p id="_46" tabindex="-1">This summary contains the following key information:</p><div class="pdq-content-list"><ul id="_47"><li>Vitamin C is an essential <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44697&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044697&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">nutrient</a> with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=770929&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000770929&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">redox</a> functions at normal <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45837&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045837&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">physiologic</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=683342&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000683342&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">concentrations</a>.</li><li><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44006&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044006&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">Case series</a> and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=286105&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000286105&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">observational studies</a> from the 1970&#x2019;s of cancer patients who received high-dose <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44068&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044068&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">oral</a> and/or <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46682&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046682&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">intravenous</a> vitamin C seemed to indicate a clinical benefit.</li><li>Two early <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45858&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045858&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">randomized</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44840&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044840&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">placebo-controlled</a> trials of high-dose oral vitamin C (10 g/d) noted no <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=390271&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000390271&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">significant</a> differences between ascorbate-treated and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46688&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046688&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">placebo</a>-treated groups for <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45022&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045022&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">symptoms,</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44174&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044174&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">performance status</a>, or <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44301&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044301&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">survival</a>.</li><li>Laboratory studies have reported that high-dose vitamin C has redox properties and decreased <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46479&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046479&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cell proliferation</a> in <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=445079&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000445079&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">prostate</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44521&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044521&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">pancreatic</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46363&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046363&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">hepatocellular</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44237&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044237&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">colon</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44323&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044323&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">mesothelioma</a>, and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45418&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045418&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">neuroblastoma</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=695994&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000695994&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cell lines</a>.</li><li>Studies of vitamin C combined with other <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=348921&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000348921&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">drugs</a> in <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43996&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043996&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">animal models</a>  have shown mixed results.</li><li>Intravenous vitamin C has been generally well tolerated in clinical trials.</li><li>Intravenous <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=478733&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000478733&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">administration</a> of vitamin C of doses over 500 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44213&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044213&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">mg</a> produces much higher <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=270735&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000270735&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">blood</a> concentrations of ascorbate than oral administration of the same dose.</li><li><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45916&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045916&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">Supplementation</a> with vitamin C alone as ascorbate versus ascorbate formulations plus standard cancer therapies have been shown to be well tolerated in clinical trials.</li><li>Two studies of high-dose vitamin C in cancer patients  reported improved <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45417&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045417&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">quality of life</a> and decreases in cancer-related toxicities.</li><li>Although early observations from preclinical and clinical trials of high-dose vitamin C with and without conventional cancer therapies appear promising and the therapy well tolerated, these studies have several limitations due to lack of rigor in trial design.</li></ul></div><p id="_52" tabindex="-1">Many of the medical and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44724&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044724&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">scientific</a> terms used in this summary are hypertext linked (at first use in each section) to the <a href="https://www.cancer.gov/publications/dictionaries/cancer-terms/" title="https://www.cancer.gov/publications/dictionaries/cancer-terms/">NCI Dictionary of Cancer Terms</a>, which is oriented toward nonexperts. When a linked term is clicked, a definition will appear in a separate window.</p><p id="_53" tabindex="-1">Reference citations in some <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44271&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044271&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">PDQ</a> cancer information summaries may include links to external Web sites that are operated by individuals or organizations for the purpose of marketing or advocating the use of specific treatments or products. These reference citations are included for informational purposes only. Their inclusion should not be viewed as an endorsement of the content of the Web sites, or of any treatment or product, by the PDQ Integrative, Alternative, and Complementary Therapies Editorial Board or the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44266&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044266&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">National Cancer Institute</a>.</p></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _4
      field_pdq_section_title:
        - format: plain_text
          value: 'General Information'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_4" class="pdq-sections"><p id="_6" tabindex="-1"><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=439435&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000439435&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">Vitamin C</a> is an essential <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44697&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044697&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">nutrient</a> that has <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=770929&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000770929&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">redox</a> functions, is a cofactor for several <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46081&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046081&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">enzymes</a>, and plays an important role in the synthesis of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44196&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044196&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">collagen</a>.<a href="#cit/section_2.1">1</a>   A severe <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=321364&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000321364&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">deficiency</a> in vitamin C results in scurvy, which is associated with malaise, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=476353&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000476353&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">lethargy</a>, easy bruising, and spontaneous bleeding.<a href="#cit/section_2.2">2</a> One of the effects of scurvy is a change in collagen structure to a thinner consistency. Normal consistency is achieved with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=478733&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000478733&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">administration</a> of vitamin C.</p><p id="_7" tabindex="-1">In the mid-20th century, a study hypothesized that <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45333&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045333&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cancer</a> may be related to changes in <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44013&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044013&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">connective tissue</a>, which may be a consequence of vitamin C deficiency.<a href="#cit/section_2.3">3</a> A review of evidence published in 1974 suggested that high-<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44664&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044664&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">dose</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=439436&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000439436&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">ascorbic acid</a> may increase host resistance and be a potential cancer <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44737&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044737&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">therapy</a>.<a href="#cit/section_2.4">4</a></p><p id="_8" tabindex="-1">Vitamin C is synthesized from D-<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44033&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044033&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">glucose</a> or D-galactose by many plants and animals. However, humans lack the enzyme L-gulonolactone oxidase required for ascorbic acid synthesis and must obtain vitamin C through food or <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=373932&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000373932&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">supplements</a>.<a href="#cit/section_2.1">1</a></p><h6 do-not-show="toc">References</h6><ol><li id="section_2.1">Naidu KA: Vitamin C in human health and disease is still a mystery? An overview. Nutr J 2: 7, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14498993&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14498993&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.2">Padayatty S, Espey MG, Levine M: Vitamin C. In: Coates PM, Betz JM, Blackman MR, et al., eds.: Encyclopedia of Dietary Supplements. 2nd ed. New York, NY: Informa Healthcare, 2010, pp 821-31.</li><li id="section_2.3">McCORMICK WJ: Cancer: a collagen disease, secondary to a nutritional deficiency. Arch Pediatr 76 (4): 166-71, 1959.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=13638066&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=13638066&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.4">Cameron E, Pauling L: The orthomolecular treatment of cancer. I. The role of ascorbic acid in host resistance. Chem Biol Interact 9 (4): 273-83, 1974.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4609626&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4609626&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _9
      field_pdq_section_title:
        - format: plain_text
          value: 'History'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_9" class="pdq-sections"><p id="_10" tabindex="-1">The earliest experience of using high-<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44664&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044664&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">dose</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=439435&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000439435&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">vitamin C</a> (<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46682&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046682&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">intravenous</a> [IV] and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44068&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044068&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">oral</a>) for <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45333&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045333&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cancer</a> treatment was by a Scottish <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44306&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044306&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">surgeon</a>, Ewan Cameron, and his colleague, Allan Campbell, in the 1970s.<a href="#cit/section_3.1">1</a> This work led to a collaboration between Cameron and the Nobel Prize&#x2013;winning chemist Linus Pauling, further promoting the potential of vitamin C <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44737&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044737&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">therapy</a> in cancer management.<a href="#cit/section_3.2">2</a><a href="#cit/section_3.3">3</a>  As a result, two <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45961&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045961&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">clinical trials</a> of oral vitamin C were conducted in the late 1970s and early 1980s.<a href="#cit/section_3.4">4</a><a href="#cit/section_3.5">5</a></p><p id="_11" tabindex="-1">(Refer to the <a href="/about-cancer/treatment/cam/hp/vitamin-c-pdq#link/_16">Human Studies</a> section of this summary for more information about these early studies.)</p><p id="_12" tabindex="-1"><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44324&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044324&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">Pharmacokinetic</a> studies later revealed substantial differences in the maximum achieved <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=270735&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000270735&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">blood</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=683342&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000683342&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">concentrations</a> of vitamin C based on the route of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=478733&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000478733&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">administration</a>. When vitamin C is taken orally, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45839&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045839&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">plasma</a> concentrations of the vitamin are tightly controlled, with a peak achievable concentration less than 300 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=372932&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000372932&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">&#xB5;M</a>. However, this tight control is bypassed with IV administration of the vitamin, resulting in very high levels of vitamin C plasma concentration (i.e., levels up to 20 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=659791&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000659791&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">mM</a>).<a href="#cit/section_3.6">6</a><a href="#cit/section_3.7">7</a>  Further research suggests that <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=463167&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000463167&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">pharmacologic</a> concentrations of ascorbate, such as those achieved with IV administration, may result in <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46476&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046476&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cell</a> death in many <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=695994&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000695994&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cancer cell lines</a>.<a href="#cit/section_3.8">8</a></p><p id="_13" tabindex="-1">Health care <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=463164&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000463164&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">practitioners</a> attending <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44964&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044964&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">complementary and alternative medicine</a> conferences in 2006 and 2008 were surveyed about usage of high-dose IV vitamin C in patients. Of the 199 total respondents, 172 had administered vitamin C to patients. In general, IV vitamin C was commonly used to treat <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45364&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045364&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">infections</a>,  cancer, and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=321374&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000321374&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">fatigue</a>.<a href="#cit/section_3.9">9</a></p><h6 do-not-show="toc">References</h6><ol><li id="section_3.1">Cameron E, Campbell A: The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact 9 (4): 285-315, 1974.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4430016&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4430016&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.2">Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A 73 (10): 3685-9, 1976.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1068480&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1068480&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.3">Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A 75 (9): 4538-42, 1978.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=279931&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=279931&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.4">Creagan ET, Moertel CG, O'Fallon JR, et al.: Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 301 (13): 687-90, 1979.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=384241&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=384241&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.5">Moertel CG, Fleming TR, Creagan ET, et al.: High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 312 (3): 137-41, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3880867&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3880867&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.6">Padayatty SJ, Sun H, Wang Y, et al.: Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 140 (7): 533-7, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15068981&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15068981&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.7">Hoffer LJ, Levine M, Assouline S, et al.: Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol 19 (11): 1969-74, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18544557&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18544557&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.8">Verrax J, Calderon PB: Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic Biol Med 47 (1): 32-40, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19254759&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19254759&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.9">Padayatty SJ, Sun AY, Chen Q, et al.: Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One 5 (7): e11414, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20628650&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20628650&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _14
      field_pdq_section_title:
        - format: plain_text
          value: 'Laboratory/Animal/Preclinical Studies'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_14" class="pdq-sections"><section id="_20"><h3 id="_20_toc"><em>In Vitro</em> Studies</h3><p id="_21" tabindex="-1">Numerous studies have demonstrated that <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=463167&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000463167&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">pharmacological</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44664&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044664&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">doses</a> of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=439436&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000439436&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">ascorbic acid</a> (0.1&#x2013;100 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=659791&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000659791&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">mM)</a>   decrease <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46479&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046479&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cell proliferation</a> in a variety of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=695994&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000695994&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cancer cell lines</a>.<a href="#cit/section_4.1">1</a><a href="#cit/section_4.2">2</a><a href="#cit/section_4.3">3</a><a href="#cit/section_4.4">4</a><a href="#cit/section_4.5">5</a>  Specifically, decreases in <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46476&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046476&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cell</a> proliferation after ascorbic acid treatment have been reported for <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=445079&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000445079&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">prostate</a>,<a href="#cit/section_4.6">6</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44074&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044074&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">pancreatic</a>,<a href="#cit/section_4.7">7</a><a href="#cit/section_4.8">8</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46363&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046363&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">hepatocellular</a>,<a href="#cit/section_4.9">9</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44237&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044237&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">colon</a>,<a href="#cit/section_4.10">10</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44323&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044323&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">mesothelioma</a>,<a href="#cit/section_4.11">11</a> and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45418&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045418&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">neuroblastoma</a> <a href="#cit/section_4.12">12</a> cell lines.</p><p id="_23" tabindex="-1">The potential mechanisms through which treatment with high-dose ascorbic acid may exert its effects on cancer cells have been extensively investigated. Several studies have demonstrated that the <em><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45733&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045733&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">in vitro</a></em> direct <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44020&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044020&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cytotoxic</a> effect of ascorbic acid on various types of cancer cells is mediated through a <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=643008&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000643008&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">chemical</a> reaction that generates <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44113&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044113&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">hydrogen peroxide</a>.<a href="#cit/section_4.1">1</a><a href="#cit/section_4.7">7</a><a href="#cit/section_4.13">13</a><a href="#cit/section_4.14">14</a> Treating <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44237&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044237&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">colon cancer</a> cells with 2 mM to 3 mM of ascorbic acid resulted in downregulation of specificity protein (Sp) <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=390290&amp;version=healthprofessional&amp;language=English&amp;dictionary=genetic" onclick="javascript:popWindow('defbyid','CDR0000390290&amp;version=healthprofessional&amp;language=English&amp;dictionary=genetic'); return(false);">transcription</a> factors, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=446805&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000446805&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">iron</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46173&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046173&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">metabolism</a> disruption, and Sp-regulated <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45693&amp;version=healthprofessional&amp;language=English&amp;dictionary=genetic" onclick="javascript:popWindow('defbyid','CDR0000045693&amp;version=healthprofessional&amp;language=English&amp;dictionary=genetic'); return(false);">genes</a> involved in cancer <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44078&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044078&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">progression</a>.<a href="#cit/section_4.10">10</a><a href="#cit/section_4.15">15</a> One study suggested that ascorbate-mediated prostate cancer cell death may occur through activation of an <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=561319&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000561319&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">autophagy</a> pathway.<a href="#cit/section_4.6">6</a> </p><p id="_24" tabindex="-1">Differences in <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=372925&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000372925&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">chemosensitivity</a> to ascorbate treatment in <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=444971&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000444971&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">breast cancer</a> cell lines may depend on expression of the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44731&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044731&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">sodium</a>-dependent <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=439435&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000439435&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">vitamin C</a> transporter 2 (SVCT-2).<a href="#cit/section_4.16">16</a></p><p id="_54" tabindex="-1">Research has suggested that pharmacological doses of ascorbic acid enhance the effects of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46018&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046018&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">arsenic trioxide</a> on <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=445074&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000445074&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">ovarian cancer</a> cells,<a href="#cit/section_4.17">17</a> gemcitabine on pancreatic cancer cells,<a href="#cit/section_4.8">8</a> and combination treatment of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45347&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045347&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">gemcitabine</a> and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=687212&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000687212&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">epigallocatechin-3-gallate</a> (EGCG) on mesothelioma cells.<a href="#cit/section_4.18">18</a></p><p id="_25" tabindex="-1">Findings from one study reported in 2012 suggested that high-dose ascorbate increases radiosensitivity of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45699&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045699&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">glioblastoma multiforme</a> cells, resulting in more cell death than from radiation alone.<a href="#cit/section_4.19">19</a></p><p id="_26" tabindex="-1">However, not all studies combining vitamin C with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45214&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045214&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">chemotherapy</a> have shown improved outcomes.  Treating <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45343&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045343&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">leukemia</a> and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45368&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045368&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">lymphoma</a> cells with dehydroascorbic acid (the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=654996&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000654996&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">oxidized</a> form of vitamin C that increases levels of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44047&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044047&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">intracellular</a> ascorbic acid) reduced the cytotoxic effects  of various <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44816&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044816&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">antineoplastic</a> agents tested, including <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45140&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045140&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">doxorubicin</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45393&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045393&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">methotrexate</a>, and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45230&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045230&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cisplatin</a> (relative reductions in cytotoxicity ranged from 30% to 70%).<a href="#cit/section_4.20">20</a> In another study, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45793&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045793&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">multiple myeloma</a> cells were treated with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=269133&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000269133&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">bortezomib</a> and/or <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45839&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045839&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">plasma</a> obtained from healthy volunteers who had taken vitamin C <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=373932&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000373932&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">supplements</a>. Cells treated with a combination of bortezomib and volunteers&#x2019; plasma exhibited lower cytotoxicity than did cells treated with bortezomib alone.<a href="#cit/section_4.21">21</a></p></section><section id="_27"><h3 id="_27_toc">Animal Studies</h3><p id="_82" tabindex="-1"> Using <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45797&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045797&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">N-acetylcysteine</a>  and vitamin C, researchers showed in 2007 that these <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=422394&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000422394&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">compounds</a>, both thought to act predominantly as <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43997&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043997&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">antioxidants</a>, may have antitumorigenic actions <em><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46352&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046352&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">in vivo</a></em> by decreasing levels of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=302460&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000302460&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">hypoxia</a>-inducible factor-1, a <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=390290&amp;version=healthprofessional&amp;language=English&amp;dictionary=genetic" onclick="javascript:popWindow('defbyid','CDR0000390290&amp;version=healthprofessional&amp;language=English&amp;dictionary=genetic'); return(false);">transcription</a> factor that targets <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44222&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044222&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">vascular endothelial growth factor</a> and plays a role in <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46529&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046529&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">angiogenesis</a>.<a href="#cit/section_4.22">22</a></p><p id="_28" tabindex="-1">Studies have demonstrated <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46634&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046634&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">tumor</a> growth inhibition after treatment with pharmacological ascorbate in <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43996&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043996&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">animal models</a> of pancreatic cancer,<a href="#cit/section_4.1">1</a><a href="#cit/section_4.7">7</a><a href="#cit/section_4.8">8</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44242&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044242&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">liver cancer</a>,<a href="#cit/section_4.3">3</a> prostate cancer,<a href="#cit/section_4.23">23</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45562&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045562&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">sarcoma</a>,<a href="#cit/section_4.24">24</a> mesothelioma,<a href="#cit/section_4.11">11</a> and ovarian cancer.<a href="#cit/section_4.4">4</a></p><p id="_29" tabindex="-1">The effects of high-dose ascorbic acid in combination with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44930&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044930&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">standard treatments</a> on tumors have been investigated. In a <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=561606&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000561606&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">mouse model</a> of pancreatic cancer, the combination of gemcitabine (30 or 60 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44213&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044213&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">mg</a>/<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44576&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044576&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">kg</a> every 4 days) and ascorbate (4 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=373014&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000373014&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">g</a>/kg daily) resulted in greater decreases in <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=467873&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000467873&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">tumor volume</a> and weight, compared with gemcitabine treatment alone.<a href="#cit/section_4.8">8</a> According to a study reported in 2012, ascorbate enhanced the cancer cell&#x2013;killing effects of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45238&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045238&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">photodynamic therapy</a> in mice <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44678&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044678&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">injected</a> with breast cancer cells.<a href="#cit/section_4.25">25</a> A study of mouse models of ovarian cancer found that ascorbate enhanced the tumor inhibitory effect of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45182&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045182&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">carboplatin</a> and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45258&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045258&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">paclitaxel</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=346494&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000346494&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">first-line</a> chemotherapy used in ovarian cancer.<a href="#cit/section_4.26">26</a> One study working with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44095&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044095&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">xenograft</a> models of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45323&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045323&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">non-small cell lung cancer</a> and glioblastoma multiforme showed that the combination of chemotherapy (carboplatin for lung cancer and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45387&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045387&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">temozolomide</a> for glioblastoma), radiation therapy, and pharmacologic ascorbate (4 g/kg/d) <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46339&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046339&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">intraperitoneal</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44678&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044678&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">injection</a> resulted in prolonged survival compared with  just the combination of chemotherapy and radiation therapy.<a href="#cit/section_4.15">15</a></p><p id="_30" tabindex="-1">There have also been reports of animal studies in which vitamin C has interfered with the anticancer activity of various drugs.  In a study reported in 2008, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=478733&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000478733&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">administration</a> of dehydroascorbic acid to lymphoma-xenograft mice prior to doxorubicin treatment resulted in significantly larger tumors than did treatment with doxorubicin alone.<a href="#cit/section_4.20">20</a> Notably, this study used dehydroascorbate, the oxidized form of vitamin C that is known to be transported actively into cells and then reduced to vitamin C. Treating multiple myeloma xenograft mice with a combination of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44068&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044068&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">oral</a> vitamin C and bortezomib resulted in significantly greater tumor volume than did treatment with bortezomib alone.<a href="#cit/section_4.21">21</a> This increase in tumor volume was caused by a chemical reaction that occurs in the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46189&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046189&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">gastrointestinal tract</a> but does not appear to be relevant to <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46682&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046682&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">intravenous</a> administration.</p></section><h6 do-not-show="toc">References</h6><ol><li id="section_4.1">Chen P, Stone J, Sullivan G, et al.: Anti-cancer effect of pharmacologic ascorbate and its interaction with supplementary parenteral glutathione in preclinical cancer models. Free Radic Biol Med 51 (3): 681-7, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21672627&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21672627&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.2">Chen Q, Espey MG, Krishna MC, et al.: Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci U S A 102 (38): 13604-9, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16157892&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16157892&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.3">Verrax J, Calderon PB: Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic Biol Med 47 (1): 32-40, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19254759&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19254759&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.4">Chen Q, Espey MG, Sun AY, et al.: Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci U S A 105 (32): 11105-9, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18678913&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18678913&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.5">Fr&#xF6;mberg A, Gutsch D, Schulze D, et al.: Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs. Cancer Chemother Pharmacol 67 (5): 1157-66, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20694726&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20694726&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.6">Chen P, Yu J, Chalmers B, et al.: Pharmacological ascorbate induces cytotoxicity in prostate cancer cells through ATP depletion and induction of autophagy. Anticancer Drugs 23 (4): 437-44, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22205155&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22205155&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.7">Du J, Martin SM, Levine M, et al.: Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin Cancer Res 16 (2): 509-20, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20068072&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20068072&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.8">Espey MG, Chen P, Chalmers B, et al.: Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Radic Biol Med 50 (11): 1610-9, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21402145&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21402145&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.9">Lin ZY, Chuang WL: Pharmacologic concentrations of ascorbic acid cause diverse influence on differential expressions of angiogenic chemokine genes in different hepatocellular carcinoma cell lines. Biomed Pharmacother 64 (5): 348-51, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19932582&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19932582&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.10">Pathi SS, Lei P, Sreevalsan S, et al.: Pharmacologic doses of ascorbic acid repress specificity protein (Sp) transcription factors and Sp-regulated genes in colon cancer cells. Nutr Cancer 63 (7): 1133-42, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21919647&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21919647&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.11">Takemura Y, Satoh M, Satoh K, et al.: High dose of ascorbic acid induces cell death in mesothelioma cells. Biochem Biophys Res Commun 394 (2): 249-53, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20171954&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20171954&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.12">Hardaway CM, Badisa RB, Soliman KF: Effect of ascorbic acid and hydrogen peroxide on mouse neuroblastoma cells. Mol Med Report 5 (6): 1449-52, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22469841&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22469841&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.13">Du J, Cullen JJ, Buettner GR: Ascorbic acid: chemistry, biology and the treatment of cancer. Biochim Biophys Acta 1826 (2): 443-57, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22728050&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22728050&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.14">Levine M, Padayatty SJ, Espey MG: Vitamin C: a concentration-function approach yields pharmacology and therapeutic discoveries. Adv Nutr 2 (2): 78-88, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22332036&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22332036&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.15">Schoenfeld JD, Sibenaller ZA, Mapuskar KA, et al.: O2&#x22C5;- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell 32 (2): 268, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28810149&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28810149&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.16">Hong SW, Lee SH, Moon JH, et al.: SVCT-2 in breast cancer acts as an indicator for L-ascorbate treatment. Oncogene 32 (12): 1508-17, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22665050&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22665050&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.17">Ong PS, Chan SY, Ho PC: Differential augmentative effects of buthionine sulfoximine and ascorbic acid in As2O3-induced ovarian cancer cell death: oxidative stress-independent and -dependent cytotoxic potentiation. Int J Oncol 38 (6): 1731-9, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21455570&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21455570&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.18">Martinotti S, Ranzato E, Burlando B: In vitro screening of synergistic ascorbate-drug combinations for the treatment of malignant mesothelioma. Toxicol In Vitro 25 (8): 1568-74, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21645609&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21645609&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.19">Herst PM, Broadley KW, Harper JL, et al.: Pharmacological concentrations of ascorbate radiosensitize glioblastoma multiforme primary cells by increasing oxidative DNA damage and inhibiting G2/M arrest. Free Radic Biol Med 52 (8): 1486-93, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22342518&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22342518&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.20">Heaney ML, Gardner JR, Karasavvas N, et al.: Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res 68 (19): 8031-8, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18829561&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18829561&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.21">Perrone G, Hideshima T, Ikeda H, et al.: Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia 23 (9): 1679-86, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19369963&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19369963&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.22">Gao P, Zhang H, Dinavahi R, et al.: HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 12 (3): 230-8, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17785204&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17785204&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.23">Pollard HB, Levine MA, Eidelman O, et al.: Pharmacological ascorbic acid suppresses syngeneic tumor growth and metastases in hormone-refractory prostate cancer. In Vivo 24 (3): 249-55, 2010 May-Jun.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20554995&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20554995&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.24">Yeom CH, Lee G, Park JH, et al.: High dose concentration administration of ascorbic acid inhibits tumor growth in BALB/C mice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis. J Transl Med 7: 70, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19671184&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19671184&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.25">Wei Y, Song J, Chen Q, et al.: Enhancement of photodynamic antitumor effect with pro-oxidant ascorbate. Lasers Surg Med 44 (1): 69-75, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22246986&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22246986&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.26">Ma Y, Chapman J, Levine M, et al.: High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med 6 (222): 222ra18, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24500406&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24500406&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _16
      field_pdq_section_title:
        - format: plain_text
          value: 'Human/Clinical Studies'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_16" class="pdq-sections"><section id="_31"><h3 id="_31_toc">Early Case Series Studies and Clinical Trials With Ascorbate Only </h3><p id="_32" tabindex="-1">In the early 1970s, a <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285747&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285747&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">consecutive case series</a> was conducted in which 50 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=478743&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000478743&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">advanced-cancer</a> patients were treated with large <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44664&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044664&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">doses</a> of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=439436&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000439436&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">ascorbic acid</a>.<a href="#cit/section_5.1">1</a> These patients began ascorbic acid treatment after <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44198&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044198&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">conventional therapies</a> were deemed unlikely to be effective. Patients received <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46682&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046682&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">intravenous</a> (IV) ascorbic acid (10 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=373014&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000373014&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">g</a>/day for 10 consecutive days; some patients received higher doses), <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44068&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044068&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">oral</a> ascorbic acid (10 g/day), or both. The subjects exhibited a wide variety of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44085&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044085&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">responses</a> to treatment, including no or minimal response, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46634&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046634&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">tumor</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46039&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046039&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">regression</a>, and tumor <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=373015&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000373015&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">hemorrhage</a>. However, the authors noted that lack of controls prevented definitive assignment of any beneficial responses to the ascorbic acid treatment. A <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44007&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044007&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">case report</a> published in 1975 detailed one of the patients who had experienced tumor regression.<a href="#cit/section_5.2">2</a> Diagnosed with reticulum <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46476&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046476&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cell</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45562&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045562&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">sarcoma</a>, the patient exhibited improvement in well-being and resolution of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=270740&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000270740&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">lung</a> masses after being treated with ascorbic acid. When the patient's daily dose of ascorbic acid was reduced, some of signs of the disease returned; however, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45867&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045867&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">remission</a> was achieved again after the patient reverted to the higher initial dose.</p><p id="_33" tabindex="-1">A larger <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44006&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044006&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">case series</a> of terminal cancer patients treated with ascorbate was reported in 1976. In this study, 100 terminal cancer patients (50 of whom were reported on previously)  <a href="#cit/section_5.1">1</a> were treated with ascorbate (10 g/day for 10 days IV, then orally) and compared with 1,000 matched controls from the same hospital. The <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285974&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285974&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">mean survival</a> time for ascorbate-treated patients was 300 days longer than that of the matched controls.<a href="#cit/section_5.3">3</a><a href="#cit/section_5.4">4</a></p><p id="_34" tabindex="-1">Two studies tried to reproduce earlier results. These studies were <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45858&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045858&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">randomized</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44840&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044840&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">placebo-controlled</a> trials in which cancer patients received either 10 g oral <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=439435&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000439435&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">vitamin C</a> or placebo daily until signs of cancer progression. At the end of each study, no <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=390271&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000390271&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">significant</a> differences were noted between the two ascorbate-treated and placebo-treated groups for <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45022&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045022&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">symptoms</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44174&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044174&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">performance status</a>, or <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44301&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044301&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">survival</a>.<a href="#cit/section_5.5">5</a><a href="#cit/section_5.6">6</a></p></section><section id="_35"><h3 id="_35_toc">Recent Case Series Studies and Clinical Trials With Ascorbate Only </h3><p id="_57" tabindex="-1">One study reported three case reports of cancer patients who received IV vitamin C as their main <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44737&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044737&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">therapy</a>. During vitamin C therapy, the patients used additional treatments, including <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44744&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044744&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">vitamins</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45787&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045787&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">minerals</a>, and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=367458&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000367458&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">botanicals</a>.  According to the authors, the cases were reviewed in accordance with the <a href="https://cam.cancer.gov/indentifying_novel_cam_therapies/best_case_protocol.htm" title="https://cam.cancer.gov/indentifying_novel_cam_therapies/best_case_protocol.htm"> NCI Best Case Series guidelines</a>. <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=467841&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000467841&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">Histopathologic</a> examination suggested poor <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45849&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045849&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">prognoses</a> for these patients, but they had long survival times after being treated with IV vitamin C.<a href="#cit/section_5.7">7</a> Vitamin C was given at doses ranging from 15 g to 65 g, initially once or twice a week for several months; two patients then received it less frequently for 1 to 4 years.</p><p id="_36" tabindex="-1">Two studies demonstrated that IV vitamin C treatment resulted in improved <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45417&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045417&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">quality of life</a> and decreases in cancer-related <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46580&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046580&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">side effects</a> in cancer patients.<a href="#cit/section_5.8">8</a><a href="#cit/section_5.9">9</a></p><p id="_38" tabindex="-1">Studies have shown that vitamin C can be safely administered to healthy volunteers or cancer patients at doses up to 1.5 g/<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44576&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044576&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">kg</a> and with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46171&amp;version=healthprofessional&amp;language=English&amp;dictionary=genetic" onclick="javascript:popWindow('defbyid','CDR0000046171&amp;version=healthprofessional&amp;language=English&amp;dictionary=genetic'); return(false);">screening</a> to eliminate treating individuals with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45873&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045873&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">risk factors</a> for <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=445093&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000445093&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">toxicity</a> (e.g., <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=748114&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000748114&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">glucose-6-phosphate dehydrogenase deficiency</a>, renal diseases, or urolithiasis). These studies have also found that <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45839&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045839&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">plasma</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=683342&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000683342&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">concentrations</a> of vitamin C are higher with IV <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=478733&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000478733&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">administration</a> than with oral administration and are maintained for more than 4 hours.<a href="#cit/section_5.10">10</a><a href="#cit/section_5.11">11</a></p></section><section id="_39"><h3 id="_39_toc">Early Phase Ascorbate Trials Combined With Standard Cancer Therapies</h3><p id="_40" tabindex="-1">A <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45830&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045830&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">phase I</a> study published in 2012 examined the safety and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=346517&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000346517&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">efficacy</a> of combining IV ascorbate with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45347&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045347&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">gemcitabine</a> and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=508929&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000508929&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">erlotinib</a> in <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45511&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045511&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">stage IV pancreatic cancer</a> patients. Fourteen subjects entered the study and planned to receive IV gemcitabine (1,000 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44213&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044213&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">mg</a>/m<span class="sup">2</span> over 30 minutes, once a week for 7 weeks), oral erlotinib (100 mg daily for 8 weeks), and IV ascorbate (50 g/<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45738&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045738&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">infusion</a>, 75 g/infusion, or 100 g/infusion 3 times per week for 8 weeks). Minimal <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44922&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044922&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">adverse effects</a> were reported for ascorbic acid treatment. Five subjects received fewer than 18 of the planned 24 ascorbate infusions and thus did not have <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44671&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044671&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">follow-up</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46361&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046361&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">imaging</a> to assess response. Three of those patients had clinically determined <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45850&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045850&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">progressive disease</a>. All of the other nine patients had repeat imaging to assess tumor size, and each met the criteria for having <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45884&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045884&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">stable disease</a>.<a href="#cit/section_5.12">12</a></p><p id="_62" tabindex="-1">A 2013 phase I <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44195&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044195&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">clinical study</a> evaluated the safety of combining pharmacological ascorbate with gemcitabine in treating stage IV pancreatic cancer patients. During each 4-week cycle, patients received gemcitabine weekly for 3 weeks (1,000 mg/m<span class="sup">2</span> over 30 minutes) and twice weekly ascorbate infusions for 4 weeks (15 g over 30 minutes during the first week, followed by weekly escalations in dose until plasma levels reached at least 350 mg/dL [20 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=659791&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000659791&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">mM</a>]). Among nine patients, mean <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44782&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044782&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">progression-free survival</a> was 26 weeks and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=655245&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000655245&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">overall survival</a> was 12 months. The combination treatment was well tolerated, and no significant adverse events were reported.<a href="#cit/section_5.13">13</a></p><p id="_68" tabindex="-1">In 2014, a <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45832&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045832&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">phase I/IIA</a> clinical trial evaluated the toxicities of combining IV ascorbate with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45182&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045182&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">carboplatin</a> and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45258&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045258&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">paclitaxel</a> in <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45901&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045901&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">stage III</a>/<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45902&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045902&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">IV ovarian cancer</a>. Twenty-seven patients were randomly assigned to receive either <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45214&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045214&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">chemotherapy</a> alone or chemotherapy and IV vitamin C concurrently. Chemotherapy was given for 6 months, and IV vitamin C was given for 12 months. The addition of IV vitamin C was associated with  reduced chemotherapy-related toxicities.<a href="#cit/section_5.14">14</a></p><p id="_41" tabindex="-1">Trials of high-dose IV vitamin C with other <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=348921&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000348921&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">drugs</a> are ongoing.<a href="#cit/section_5.12">12</a><a href="#cit/section_5.14">14</a> A number of studies have included IV ascorbic acid treatment (1,000 mg) with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46018&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046018&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">arsenic trioxide</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45864&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045864&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">regimens</a>, with mixed results. The combination therapies were well tolerated and suggested beneficial effects in <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45793&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045793&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">multiple myeloma</a> patients, although the specific contribution of vitamin C could not be determined.<a href="#cit/section_5.15">15</a><a href="#cit/section_5.16">16</a><a href="#cit/section_5.17">17</a><a href="#cit/section_5.18">18</a>  However, similar combination regimens resulted in severe side effects, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45669&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045669&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">disease progression</a>, and no anticancer effect  in patients with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=350245&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000350245&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">refractory</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44058&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044058&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">metastatic</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=444983&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000444983&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">colorectal cancer</a> <a href="#cit/section_5.19">19</a> and metastatic <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45135&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045135&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">melanoma</a>.<a href="#cit/section_5.20">20</a> Because these were not placebo-controlled trials, the extent that ascorbate contributed to the toxicity demonstrated in these studies is unclear.</p><p id="_83" tabindex="-1">Informed by their preclinical data,<a href="#cit/section_5.15">15</a> researchers at the University of Iowa treated patients with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45323&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045323&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">non-small cell lung</a> carcinoma (NSCLC)  and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45699&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045699&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">glioblastoma multiforme</a> (GBM) in two pilot clinical trials (<a href="https://clinicaltrials.gov/ct2/show/NCT02420314" title="https://clinicaltrials.gov/ct2/show/NCT02420314">NCT02420314</a> and <a href="https://clinicaltrials.gov/ct2/show/NCT01752491" title="https://clinicaltrials.gov/ct2/show/NCT01752491">NCT01752491</a>).<a href="#cit/section_5.21">21</a> Participants in both trials were given <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44198&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044198&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">conventional therapy</a> plus intravenous vitamin C, with dosing individualized to achieve a 20 mM plasma concentration of ascorbate in each patient. The GBM study was a phase I design with 13 total patients. Intravenous vitamin C was given with both <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44971&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044971&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">radiation therapy</a> and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45387&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045387&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">temozolomide</a> and toxicity, progression-free survival, and overall survival all compared favorably to the outcomes of historical controls. The NSCLC trial was a <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45831&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045831&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">phase II</a> design of 14 patients with advanced cancer who received both chemotherapy and intravenous vitamin C (median maximum plasma concentration,  16.4 mM). The disease control and confirmed <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44067&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044067&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">objective response</a> rates of the study group again compared favorably with those of historical controls.  Limitations of these studies included the use of historical controls and small numbers of enrolled participants.</p></section><section id="_TrialSearch_16_sid_5"><h3 id="_TrialSearch_16_sid_5_toc">Current Clinical Trials</h3><p id="_TrialSearch_16_22" tabindex="-1">Use our <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search">advanced clinical trial search</a> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/">General information</a> about clinical trials is also available.</p></section><h6 do-not-show="toc">References</h6><ol><li id="section_5.1">Cameron E, Campbell A: The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact 9 (4): 285-315, 1974.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4430016&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4430016&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.2">Cameron E, Campbell A, Jack T: The orthomolecular treatment of cancer. III. Reticulum cell sarcoma: double complete regression induced by high-dose ascorbic acid therapy. Chem Biol Interact 11 (5): 387-93, 1975.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1104207&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1104207&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.3">Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A 73 (10): 3685-9, 1976.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1068480&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1068480&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.4">Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A 75 (9): 4538-42, 1978.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=279931&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=279931&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.5">Creagan ET, Moertel CG, O'Fallon JR, et al.: Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 301 (13): 687-90, 1979.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=384241&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=384241&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.6">Moertel CG, Fleming TR, Creagan ET, et al.: High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 312 (3): 137-41, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3880867&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3880867&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.7">Padayatty SJ, Riordan HD, Hewitt SM, et al.: Intravenously administered vitamin C as cancer therapy: three cases. CMAJ 174 (7): 937-42, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16567755&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16567755&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.8">Vollbracht C, Schneider B, Leendert V, et al.: Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany. In Vivo 25 (6): 983-90, 2011 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22021693&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22021693&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.9">Yeom CH, Jung GC, Song KJ: Changes of terminal cancer patients' health-related quality of life after high dose vitamin C administration. J Korean Med Sci 22 (1): 7-11, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17297243&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17297243&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.10">Padayatty SJ, Sun H, Wang Y, et al.: Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 140 (7): 533-7, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15068981&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15068981&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.11">Hoffer LJ, Levine M, Assouline S, et al.: Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol 19 (11): 1969-74, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18544557&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18544557&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.12">Monti DA, Mitchell E, Bazzan AJ, et al.: Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One 7 (1): e29794, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22272248&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22272248&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.13">Welsh JL, Wagner BA, van't Erve TJ, et al.: Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol 71 (3): 765-75, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23381814&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23381814&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.14">Ma Y, Chapman J, Levine M, et al.: High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med 6 (222): 222ra18, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24500406&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24500406&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.15">Abou-Jawde RM, Reed J, Kelly M, et al.: Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial. Med Oncol 23 (2): 263-72, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16720927&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16720927&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.16">Berenson JR, Matous J, Swift RA, et al.: A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res 13 (6): 1762-8, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17363530&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17363530&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.17">Qazilbash MH, Saliba RM, Nieto Y, et al.: Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant 14 (12): 1401-7, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19041063&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19041063&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.18">Berenson JR, Boccia R, Siegel D, et al.: Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. Br J Haematol 135 (2): 174-83, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17010047&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17010047&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.19">Subbarayan PR, Lima M, Ardalan B: Arsenic trioxide/ascorbic acid therapy in patients with refractory metastatic colorectal carcinoma: a clinical experience. Acta Oncol 46 (4): 557-61, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17497326&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17497326&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.20">Bael TE, Peterson BL, Gollob JA: Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases. Melanoma Res 18 (2): 147-51, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18337652&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18337652&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.21">Schoenfeld JD, Sibenaller ZA, Mapuskar KA, et al.: O2&#x22C5;- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell 32 (2): 268, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28810149&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28810149&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _18
      field_pdq_section_title:
        - format: plain_text
          value: 'Adverse Effects'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_18" class="pdq-sections"><p id="_19" tabindex="-1"><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46682&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046682&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">Intravenous</a> (IV) high-<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44664&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044664&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">dose</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=439436&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000439436&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">ascorbic acid</a> has been generally well tolerated in <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45961&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045961&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">clinical trials</a>.<a href="#cit/section_6.1">1</a><a href="#cit/section_6.2">2</a><a href="#cit/section_6.3">3</a><a href="#cit/section_6.4">4</a><a href="#cit/section_6.5">5</a><a href="#cit/section_6.6">6</a><a href="#cit/section_6.7">7</a><a href="#cit/section_6.8">8</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=462925&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000462925&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">Renal failure</a> following ascorbic acid treatment has been reported in patients with preexisting renal <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=407758&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000407758&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">disorders</a>.<a href="#cit/section_6.9">9</a></p><p id="_42" tabindex="-1"><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44007&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044007&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">Case reports</a> have indicated that patients with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=748114&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000748114&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">glucose-6-phosphate dehydrogenase (G-6-PD) deficiency</a> should not receive high doses of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=439435&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000439435&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">vitamin C</a> because of the risk of developing <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=687883&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000687883&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">hemolysis</a>.<a href="#cit/section_6.10">10</a><a href="#cit/section_6.11">11</a><a href="#cit/section_6.12">12</a></p><p id="_43" tabindex="-1">Vitamin C may increase <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44225&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044225&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">bioavailability</a> of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=446805&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000446805&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">iron</a>, and high doses of the vitamin are not recommended for patients with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=446804&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000446804&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">hemochromatosis</a>.<a href="#cit/section_6.13">13</a></p><section id="_49"><h3 id="_49_toc">Drug Interactions</h3><p id="_50" tabindex="-1">When administered in high doses, vitamin C may result in adverse interactions with some anticancer agents. These interactions have primarily been detected in <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44517&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044517&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">preclinical studies</a>. A 2013 phase I clinical study evaluated the safety of combining high-dose IV ascorbate with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45347&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045347&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">gemcitabine</a> in stage IV pancreatic cancer patients. The combination therapy was well tolerated by patients, and no significant adverse events were reported.<a href="#cit/section_6.14">14</a></p><p id="_51" tabindex="-1"><em><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45733&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045733&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">In vitro</a></em> and <em><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46352&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046352&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">in vivo</a></em> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=454774&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000454774&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">animal studies</a> have suggested that combining <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44068&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044068&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">oral</a> vitamin C with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=269133&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000269133&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">bortezomib</a> interferes with the drug&#x2019;s ability to act as a <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=393541&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000393541&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">proteasome inhibitor</a> and blocks bortezomib-initiated <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46524&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046524&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">apoptosis</a>.<a href="#cit/section_6.15">15</a><a href="#cit/section_6.16">16</a><a href="#cit/section_6.17">17</a> This interference occurred even with the oral administration of vitamin C (40 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44213&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044213&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">mg</a>/<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44576&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044576&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">kg</a>/day)  to animals. Studies in <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=556412&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000556412&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cell culture</a> and performed by adding <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=270735&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000270735&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">blood</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45839&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045839&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">plasma</a> from healthy volunteers given  oral vitamin C (1 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=373014&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000373014&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">g</a>/day) also showed a <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=390271&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000390271&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">significant</a> decrease in bortezomib&#x2019;s growth inhibitory effect on <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45793&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045793&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">multiple myeloma</a> cells. Another study found similar results. Plasma from healthy volunteers who took 1 g of oral vitamin C per day was shown to decrease bortezomib growth inhibition in multiple myeloma cells and to block its inhibitory effect on 20S proteasome activity.<a href="#cit/section_6.17">17</a> However, a study that utilized mice harboring human <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=445079&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000445079&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">prostate cancer</a> cell <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44095&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044095&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">xenografts</a> failed to find any significant effect of oral vitamin C (40 mg/kg/day or 500 mg/kg/day) on the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46634&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046634&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">tumor</a> growth inhibitory action of bortezomib.<a href="#cit/section_6.18">18</a>  </p><p id="_55" tabindex="-1">Several studies have been performed to assess the potential <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=330184&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000330184&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">synergistic</a> or inhibitory action of vitamin C on certain <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45214&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045214&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">chemotherapy</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=348921&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000348921&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">drugs</a>, with variable results. A series of studies in cell culture and in animals bearing tumors has shown that when given at high concentrations or dosages, dehydroascorbic acid (an oxidized form of vitamin C) can interfere with the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44020&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044020&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cytotoxic</a> effects of several chemotherapy drugs.<a href="#cit/section_6.19">19</a>  However, dehydroascorbic acid is generally present only at low concentrations in <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=373932&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000373932&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">dietary supplements</a> and fresh foods.</p></section><h6 do-not-show="toc">References</h6><ol><li id="section_6.1">Padayatty SJ, Sun H, Wang Y, et al.: Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 140 (7): 533-7, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15068981&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15068981&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.2">Hoffer LJ, Levine M, Assouline S, et al.: Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol 19 (11): 1969-74, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18544557&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18544557&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.3">Chen Q, Espey MG, Sun AY, et al.: Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci U S A 105 (32): 11105-9, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18678913&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18678913&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.4">Monti DA, Mitchell E, Bazzan AJ, et al.: Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One 7 (1): e29794, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22272248&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22272248&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.5">Abou-Jawde RM, Reed J, Kelly M, et al.: Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial. Med Oncol 23 (2): 263-72, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16720927&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16720927&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.6">Berenson JR, Matous J, Swift RA, et al.: A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res 13 (6): 1762-8, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17363530&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17363530&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.7">Qazilbash MH, Saliba RM, Nieto Y, et al.: Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant 14 (12): 1401-7, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19041063&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19041063&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.8">Ma Y, Chapman J, Levine M, et al.: High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med 6 (222): 222ra18, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24500406&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24500406&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.9">Padayatty SJ, Sun AY, Chen Q, et al.: Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One 5 (7): e11414, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20628650&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20628650&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.10">Campbell GD Jr, Steinberg MH, Bower JD: Letter: Ascorbic acid-induced hemolysis in G-6-PD deficiency. Ann Intern Med 82 (6): 810, 1975.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1138591&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1138591&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.11">Mehta JB, Singhal SB, Mehta BC: Ascorbic-acid-induced haemolysis in G-6-PD deficiency. Lancet 336 (8720): 944, 1990.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1976956&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1976956&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.12">Rees DC, Kelsey H, Richards JD: Acute haemolysis induced by high dose ascorbic acid in glucose-6-phosphate dehydrogenase deficiency. BMJ 306 (6881): 841-2, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8490379&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8490379&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.13">Barton JC, McDonnell SM, Adams PC, et al.: Management of hemochromatosis. Hemochromatosis Management Working Group. Ann Intern Med 129 (11): 932-9, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9867745&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9867745&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.14">Welsh JL, Wagner BA, van't Erve TJ, et al.: Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol 71 (3): 765-75, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23381814&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23381814&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.15">Zou W, Yue P, Lin N, et al.: Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells. Clin Cancer Res 12 (1): 273-80, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16397052&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16397052&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.16">Llobet D, Eritja N, Encinas M, et al.: Antioxidants block proteasome inhibitor function in endometrial carcinoma cells. Anticancer Drugs 19 (2): 115-24, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18176107&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18176107&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.17">Perrone G, Hideshima T, Ikeda H, et al.: Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia 23 (9): 1679-86, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19369963&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19369963&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.18">Bannerman B, Xu L, Jones M, et al.: Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea. Cancer Chemother Pharmacol 68 (5): 1145-54, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21400028&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21400028&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.19">Heaney ML, Gardner JR, Karasavvas N, et al.: Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res 68 (19): 8031-8, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18829561&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18829561&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _44
      field_pdq_section_title:
        - format: plain_text
          value: 'Changes to This Summary (12/13/2017)'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_44" class="pdq-sections"><p id="_56" tabindex="-1">The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.</p><p id="_84" tabindex="-1"><strong><a href="/about-cancer/treatment/cam/hp/vitamin-c-pdq#link/_1">Overview</a></strong></p><p id="_99" tabindex="-1">Revised <a href="/about-cancer/treatment/cam/hp/vitamin-c-pdq#link/_47">list</a> of key information about high-dose vitamin C.</p><p id="_86" tabindex="-1"><strong><a href="/about-cancer/treatment/cam/hp/vitamin-c-pdq#link/_14">Laboratory/Animal/Preclinical Studies</a></strong></p><p id="_87" tabindex="-1">Revised <a href="/about-cancer/treatment/cam/hp/vitamin-c-pdq#link/_23">text</a> to state that treating colon cancer cells with 2 mM to 3 mM of ascorbic acid resulted in downregulation of specificity protein  transcription factors, iron metabolism disruption, and Sp-regulated genes involved in cancer progression (cited Schoenfeld et al. as reference 15).</p><p id="_89" tabindex="-1">Added <a href="/about-cancer/treatment/cam/hp/vitamin-c-pdq#link/_29">text</a> to state that one study working with xenograft models of non-small cell lung cancer and glioblastoma multiforme showed that the combination of chemotherapy, radiation therapy, and pharmacologic ascorbate resulted in prolonged survival compared with just the combination of chemotherapy and radiation therapy.</p><p id="_98" tabindex="-1"><strong><a href="/about-cancer/treatment/cam/hp/vitamin-c-pdq#link/_16">Human/Clinical Studies</a></strong></p><p id="_90" tabindex="-1">The <strong><a href="/about-cancer/treatment/cam/hp/vitamin-c-pdq#link/_31">Early Case Series Studies and Clinical Trials With Ascorbate Only</a></strong>  subsection was renamed from Early Ascorbate-Only Trials.</p><p id="_92" tabindex="-1">The <strong><a href="/about-cancer/treatment/cam/hp/vitamin-c-pdq#link/_35">Recent Case Series Studies and Clinical Trials With Ascorbate Only </a></strong> was renamed from Recent Ascorbate-Only Trials.</p><p id="_94" tabindex="-1">The <strong><a href="/about-cancer/treatment/cam/hp/vitamin-c-pdq#link/_39">Early Phase Ascorbate Trials Combined With Standard Cancer Therapies</a></strong> was renamed from Ascorbate-Combination Trials.</p><p id="_97" tabindex="-1">Added <a href="/about-cancer/treatment/cam/hp/vitamin-c-pdq#link/_83">text</a> about the results of two pilot clinical trials of patients with non-small cell lung cancer and glioblastoma multiforme (cited Abou-Jawde  et al. as reference 15 and Schoenfeld  et al. as reference 21).</p><p id="_disclaimerHP_3" tabindex="-1">This summary is written and maintained by the <a href="https://www.cancer.gov/publications/pdq/editorial-boards/cam" title="https://www.cancer.gov/publications/pdq/editorial-boards/cam">PDQ Integrative, Alternative, and Complementary Therapies Editorial Board</a>, which is
            editorially independent of NCI.  The summary reflects an independent review of
            the literature and does not represent a policy statement of NCI or NIH.  More
            information about summary policies and the role of the PDQ Editorial Boards  in
            maintaining the PDQ summaries can be found on the <a href="/about-cancer/treatment/cam/hp/vitamin-c-pdq#link/_AboutThis_1">About This PDQ Summary</a> and <a href="https://www.cancer.gov/publications/pdq" title="https://www.cancer.gov/publications/pdq">PDQ&#xAE; - NCI's Comprehensive Cancer Database</a> pages.
            </p></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _AboutThis_1
      field_pdq_section_title:
        - format: plain_text
          value: 'About This PDQ Summary'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_AboutThis_1" class="pdq-sections"><section id="_AboutThis_2"><h3 id="_AboutThis_2_toc">Purpose of This Summary</h3><p id="_AboutThis_3" tabindex="-1">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the use of high-dose vitamin C in the treatment of people with cancer. It is intended as a resource to inform and assist clinicians who care for cancer patients.  It does not provide formal guidelines or recommendations for making health care decisions.</p></section><section id="_AboutThis_4"><h3 id="_AboutThis_4_toc">Reviewers and Updates</h3><p id="_AboutThis_5" tabindex="-1">This summary is reviewed regularly and updated as necessary by the <a href="https://www.cancer.gov/publications/pdq/editorial-boards/cam" title="https://www.cancer.gov/publications/pdq/editorial-boards/cam">PDQ Integrative, Alternative, and Complementary Therapies Editorial Board</a>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</p><p id="_AboutThis_22" tabindex="-1"> Board members review recently published articles each month to determine whether an article should:</p><div class="pdq-content-list"><ul id="_AboutThis_6"><li>be discussed at a meeting,</li><li>be cited with text, or</li><li>replace or update an existing article that is already cited.</li></ul></div><p id="_AboutThis_7" tabindex="-1">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</p><p id="" tabindex="-1">The lead reviewers for High-Dose Vitamin C are:</p><div class="pdq-content-list"><ul id=""><li>Nagi B. Kumar, PhD, RD, FADA (Fellow of the American Dietetic Association)</li><li>Jeffrey D. White, MD (National Cancer Institute)</li></ul></div><p id="_AboutThis_9" tabindex="-1">Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's <a href="https://www.cancer.gov/contact/email-us" title="https://www.cancer.gov/contact/email-us">Email Us</a>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</p></section><section id="_AboutThis_10"><h3 id="_AboutThis_10_toc">Levels of Evidence</h3><p id="_AboutThis_11" tabindex="-1">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Integrative, Alternative, and Complementary Therapies Editorial Board uses a <a href="/publications/pdq/levels-evidence/cam">formal evidence ranking system</a> in developing its level-of-evidence designations.</p></section><section id="_AboutThis_12"><h3 id="_AboutThis_12_toc">Permission to Use This Summary</h3><p id="_AboutThis_13" tabindex="-1">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as &#x201C;NCI&#x2019;s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].&#x201D;</p><p id="_AboutThis_14" tabindex="-1">The preferred citation for this PDQ summary is:</p><p id="_AboutThis_15" tabindex="-1">PDQ&#xAE; Integrative, Alternative, and Complementary Therapies Editorial Board. PDQ High-Dose Vitamin C. Bethesda, MD: National Cancer Institute. Updated  &lt;MM/DD/YYYY&gt;. Available at: <a href="https://www.cancer.gov/about-cancer/treatment/cam/hp/vitamin-c-pdq" title="https://www.cancer.gov/about-cancer/treatment/cam/hp/vitamin-c-pdq">https://www.cancer.gov/about-cancer/treatment/cam/hp/vitamin-c-pdq</a>.  Accessed &lt;MM/DD/YYYY&gt;. [PMID: 26389504]</p><p id="_AboutThis_16" tabindex="-1">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <a href="https://visualsonline.cancer.gov/" title="https://visualsonline.cancer.gov/">Visuals Online</a>, a collection of over 2,000 scientific images.
            </p></section><section id="_AboutThis_17"><h3 id="_AboutThis_17_toc">Disclaimer</h3><p id="_AboutThis_19" tabindex="-1">The information in these summaries should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <a href="https://www.cancer.gov/about-cancer/managing-care" title="https://www.cancer.gov/about-cancer/managing-care">Managing Cancer Care</a> page.</p></section><section id="_AboutThis_20"><h3 id="_AboutThis_20_toc">Contact Us</h3><p id="_AboutThis_21" tabindex="-1">More information about contacting us or receiving help with the Cancer.gov website can be found on our <a href="https://www.cancer.gov/contact" title="https://www.cancer.gov/contact">Contact Us for Help</a> page. Questions can also be submitted to Cancer.gov through the website&#x2019;s <a href="https://www.cancer.gov/contact/email-us" title="https://www.cancer.gov/contact/email-us">Email Us</a>.</p></section></div>
  title__ES:
    value: 'Dosis altas de vitamina C (PDQ®)–Versión para profesionales de salud'
  status__ES:
    value: 1
  langcode__ES:
    value: es
  moderation_state__ES:
    value: published
  field_pdq_url__ES:
    value: /cancer/tratamiento/mca/pro/vitamina-c-pdq
  field_pdq_cdr_id__ES:
    value: 773659
  field_pdq_audience__ES:
    value: Health Professionals
  field_pdq_summary_type__ES:
    value: Integrative, alternative, and complementary therapies
  field_date_posted__ES:
    value: '2015-07-01'
  field_date_updated__ES:
    value: '2018-01-18'
  field_short_title__ES:
    value: 'Dosis altas de vitamina C'
  field_page_description__ES:
    value: 'Resumen de información revisada por expertos sobre el uso de dosis altas de vitamina C como tratamiento para personas con cáncer.'
  field_public_use__ES:
    value: 1
  field_summary_sections__ES:
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _1
      field_pdq_section_title:
        - format: plain_text
          value: 'Aspectos generales'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_1" class="pdq-sections"><div class="pdq-hp-patient-toggle"><a href="/espanol/cancer/tratamiento/mca/paciente/vitamina-c-pdq">Vaya a la versi&#xF3;n para pacientes</a></div><p id="_3" tabindex="-1">Este sumario de informaci&#xF3;n sobre <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45333&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045333&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer</a> proporciona una visi&#xF3;n general del uso de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44664&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044664&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">dosis</a> altas de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=439435&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000439435&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">vitamina C</a> (tambi&#xE9;n denominada ascorbato o <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=439436&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000439436&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">&#xE1;cido L-asc&#xF3;rbico</a>) como tratamiento en personas con c&#xE1;ncer. Este sumario incluye una descripci&#xF3;n breve de los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45961&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045961&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">ensayos cl&#xED;nicos</a> iniciales sobre las dosis altas de vitamina C, la revisi&#xF3;n de estudios de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44512&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044512&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">laboratorio</a>, en <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=454774&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000454774&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">animales</a> y en humanos, as&#xED; como los ensayos cl&#xED;nicos vigentes.</p><p id="_46" tabindex="-1">Este sumario contiene la siguiente informaci&#xF3;n clave:</p><div class="pdq-content-list"><ul id="_47"><li>La vitamina C es un <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44697&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044697&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">nutriente</a> esencial que en <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=683342&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000683342&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">concentraciones</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45837&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045837&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">fisiol&#xF3;gicas</a> normales tiene funciones de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=770929&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000770929&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">oxidorreducci&#xF3;n</a> (redox).</li><li>En algunas <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44006&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044006&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">series de casos</a> y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=286105&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000286105&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">estudios de observaci&#xF3;n</a> de la d&#xE9;cada de 1970 de pacientes de c&#xE1;ncer que recibieron dosis altas de vitamina C por v&#xED;a <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44068&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044068&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">oral</a> o <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46682&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046682&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">intravenosa</a> se apunta a un posible beneficio cl&#xED;nico.</li><li>En dos ensayos <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44840&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044840&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">controlados con placebo</a>  y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45858&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045858&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">aleatorizados</a>  de vitamina C en dosis altas (10 g/d), no se observaron diferencias <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=390271&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000390271&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">significativas</a> en los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45022&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045022&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">s&#xED;ntomas</a>, el <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44174&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044174&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">estado funcional</a> o la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44301&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044301&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">supervivencia</a> entre los grupos que recibieron ascorbato o <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46688&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046688&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">placebo</a> de acuerdo con sus <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45022&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045022&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">s&#xED;ntomas</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44174&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044174&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">estado funcional</a> o <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44301&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044301&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">supervivencia</a>.</li><li>En estudios de laboratorio se notific&#xF3; que las dosis altas de vitamina C tienen propiedades de oxidorreducci&#xF3;n y que disminuyen la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46479&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046479&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">proliferaci&#xF3;n celular</a> en las <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=695994&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000695994&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">l&#xED;neas celulares</a> de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=445079&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000445079&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">pr&#xF3;stata</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44521&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044521&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">p&#xE1;ncreas</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46363&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046363&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">h&#xED;gado</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44237&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044237&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">colon</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44323&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044323&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">mesotelioma</a> y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45418&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045418&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">neuroblastoma</a>.</li><li>Los estudios en <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43996&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043996&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">modelos animales</a> sobre la combinaci&#xF3;n de vitamina C con otros <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=348921&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000348921&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">medicamentos</a> arrojaron resultados desiguales.</li><li>Por lo general, la vitamina C <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46682&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046682&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">intravenosa</a> se toler&#xF3; bien en los ensayos cl&#xED;nicos.</li><li>La <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=478733&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000478733&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">administraci&#xF3;n</a> intravenosa de vitamina C de dosis de m&#xE1;s de 500 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44213&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044213&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">mg</a> produce concentraciones <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=270735&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000270735&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">sangu&#xED;neas</a> de ascorbato mucho m&#xE1;s altas que la administraci&#xF3;n oral de la misma dosis.</li><li>En los ensayos cl&#xED;nicos, se toler&#xF3; bien la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45916&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045916&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">administraci&#xF3;n de complementos</a> con vitamina C sola como ascorbato versus las formulaciones de ascorbato con terapias est&#xE1;ndares contra el c&#xE1;ncer.</li><li>En dos estudios de administraci&#xF3;n de vitamina C en dosis altas a pacientes de c&#xE1;ncer, se notific&#xF3; una mejora de la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45417&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045417&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">calidad de vida</a> y una disminuci&#xF3;n de los efectos t&#xF3;xicos relacionados con el c&#xE1;ncer.</li><li>Aunque las observaciones iniciales de los ensayos cl&#xED;nicos del uso de la vitamina C en dosis altas (con las terapias convencionales contra el c&#xE1;ncer y sin estas) parecen prometedoras y se toleran bien, estos estudios presentan limitaciones por la falta de rigor en su dise&#xF1;o.</li></ul></div><p id="_52" tabindex="-1">Muchos de los t&#xE9;rminos m&#xE9;dicos y cient&#xED;ficos en este sumario tienen un enlace  al <a href="https://www.cancer.gov/espanol/publicaciones/diccionario" title="https://www.cancer.gov/espanol/publicaciones/diccionario">Diccionario de c&#xE1;ncer del NCI</a> la primera vez que se mencionan en cada secci&#xF3;n. Este diccionario se orienta a personas sin conocimientos especializados. Al pulsar sobre un t&#xE9;rmino con un enlace, aparece la definici&#xF3;n en una ventana separada.</p><p id="_53" tabindex="-1">Las referencias bibliogr&#xE1;ficas citadas en los sumarios de informaci&#xF3;n sobre el c&#xE1;ncer del <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44271&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044271&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">PDQ</a> pueden tener enlaces a otros sitios de Internet gestionados por individuos u organizaciones con el prop&#xF3;sito de comercializar o promover el uso de tratamientos o productos espec&#xED;ficos. Estas referencias bibliogr&#xE1;ficas se ofrecen solo con fines informativos. Su inclusi&#xF3;n no se debe interpretar como aprobaci&#xF3;n del contenido de las p&#xE1;ginas de Internet ni de ning&#xFA;n tratamiento o producto por parte del Consejo editorial del PDQ sobre terapias integrales, alternativas y complementarias, o del <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44266&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044266&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">Instituto Nacional del C&#xE1;ncer</a>.</p></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _4
      field_pdq_section_title:
        - format: plain_text
          value: 'Información general'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_4" class="pdq-sections"><p id="_6" tabindex="-1">La <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=439435&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000439435&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">vitamina C</a> es un <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44697&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044697&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">nutriente</a> esencial con funciones de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=770929&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000770929&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">oxidorreducci&#xF3;n</a>. Adem&#xE1;s, es un cofactor de varias <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46081&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046081&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">enzimas</a> y cumple una funci&#xF3;n importante en la s&#xED;ntesis del <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44196&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044196&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">col&#xE1;geno</a>.<a href="#cit/section_2.1">1</a> Una <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=321364&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000321364&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">deficiencia</a> grave de vitamina C provoca escorbuto, que se relaciona con malestar general, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=476353&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000476353&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">letargo</a>, tendencia a la formaci&#xF3;n de equimosis y hemorragias espont&#xE1;neas.<a href="#cit/section_2.2">2</a> Uno de los efectos del escorbuto es el cambio en la estructura del col&#xE1;geno que se torna de un espesor m&#xE1;s fino. Se logra un espesor normal mediante la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=478733&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000478733&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">administraci&#xF3;n</a> de vitamina C.</p><p id="_7" tabindex="-1">En un estudio de mitad del siglo XX, se plante&#xF3; la hip&#xF3;tesis de que el <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45333&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045333&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer</a> se podr&#xED;a relacionar con cambios del <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44013&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044013&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">tejido conjuntivo</a> que podr&#xED;an ser consecuencia de una deficiencia de vitamina C.<a href="#cit/section_2.3">3</a> En una revisi&#xF3;n de datos experimentales publicada en 1974 se indic&#xF3; que las <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44664&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044664&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">dosis</a> altas de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=439436&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000439436&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">&#xE1;cido asc&#xF3;rbico</a> podr&#xED;an aumentar la resistencia del hospedero y podr&#xED;an servir como <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44737&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044737&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">tratamiento</a> del c&#xE1;ncer.<a href="#cit/section_2.4">4</a></p><p id="_8" tabindex="-1">Muchas plantas y animales sintetizan vitamina C a partir de D-<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44033&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044033&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">glucosa</a> o D-galactosa. Sin embargo, los seres humanos carecen de la enzima L-gulonolactona oxidasa, que es necesaria para la s&#xED;ntesis del &#xE1;cido asc&#xF3;rbico y, por lo tanto, deben obtener la vitamina C de los alimentos o <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=373932&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000373932&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">suplementos</a>.<a href="#cit/section_2.1">1</a></p><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_2.1">Naidu KA: Vitamin C in human health and disease is still a mystery? An overview. Nutr J 2: 7, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14498993&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14498993&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.2">Padayatty S, Espey MG, Levine M: Vitamin C. In: Coates PM, Betz JM, Blackman MR, et al., eds.: Encyclopedia of Dietary Supplements. 2nd ed. New York, NY: Informa Healthcare, 2010, pp 821-31.</li><li id="section_2.3">McCORMICK WJ: Cancer: a collagen disease, secondary to a nutritional deficiency. Arch Pediatr 76 (4): 166-71, 1959.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=13638066&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=13638066&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.4">Cameron E, Pauling L: The orthomolecular treatment of cancer. I. The role of ascorbic acid in host resistance. Chem Biol Interact 9 (4): 273-83, 1974.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4609626&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4609626&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _9
      field_pdq_section_title:
        - format: plain_text
          value: 'Antecedentes'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_9" class="pdq-sections"><p id="_10" tabindex="-1">El <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44306&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044306&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">cirujano</a> escoc&#xE9;s Ewan Cameron y su colega Allan Campbell, fueron los primeros en experimentar con el uso de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44664&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044664&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">dosis</a> altas de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=439435&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000439435&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">vitamina C</a> (<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46682&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046682&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">intravenosa</a> [IV] y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44068&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044068&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">oral</a>) para tratar el <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45333&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045333&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer</a> en la d&#xE9;cada de 1970.<a href="#cit/section_3.1">1</a> Este proyecto dio paso a la colaboraci&#xF3;n entre Cameron y el qu&#xED;mico Linus Pauling, galardonado con el premio Nobel, lo que promocion&#xF3; el potencial <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44737&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044737&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">terap&#xE9;utico</a> de la vitamina C para la atenci&#xF3;n del c&#xE1;ncer.<a href="#cit/section_3.2">2</a><a href="#cit/section_3.3">3</a> Como resultado, se llevaron a cabo dos <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45961&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045961&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">ensayos cl&#xED;nicos</a> con vitamina C oral a fines de la d&#xE9;cada de 1970 y a principios de la d&#xE9;cada de 1980.<a href="#cit/section_3.4">4</a><a href="#cit/section_3.5">5</a></p><p id="_11" tabindex="-1">(Para obtener m&#xE1;s informaci&#xF3;n sobre estos estudios iniciales, consultar la secci&#xF3;n de este sumario: <a href="/espanol/cancer/tratamiento/mca/pro/vitamina-c-pdq#link/_16">Estudios cl&#xED;nicos con seres humanos</a>).</p><p id="_12" tabindex="-1">M&#xE1;s tarde, en los estudios sobre <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44324&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044324&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">farmacocin&#xE9;tica</a> se descubrieron diferencias notables en las <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=683342&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000683342&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">concentraciones</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=270735&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000270735&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">sangu&#xED;neas</a> m&#xE1;ximas de vitamina C que se obtienen seg&#xFA;n la v&#xED;a de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=478733&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000478733&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">administraci&#xF3;n</a>. Cuando la vitamina C se toma por v&#xED;a oral, las concentraciones <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45839&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045839&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">plasm&#xE1;ticas</a> de la misma se controlan estrictamente con un valor m&#xE1;ximo viable menor de 300 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=372932&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000372932&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">&#xB5;M</a>. Sin embargo, este control estricto se evita con la administraci&#xF3;n IV de la vitamina, que origina concentraciones plasm&#xE1;ticas muy altas de vitamina C (es decir, concentraciones de hasta 20 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=659791&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000659791&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">mM</a>).<a href="#cit/section_3.6">6</a><a href="#cit/section_3.7">7</a> En estudios de investigaci&#xF3;n posteriores se indic&#xF3; que las concentraciones <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=463167&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000463167&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">farmacol&#xF3;gicas</a> de ascorbato, como las que se logran con la administraci&#xF3;n IV, podr&#xED;an causar destrucci&#xF3;n <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46476&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046476&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">celular</a> en muchas <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=695994&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000695994&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">l&#xED;neas de c&#xE9;lulas cancerosas</a>.<a href="#cit/section_3.8">8</a></p><p id="_13" tabindex="-1">Se encuest&#xF3; a <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=463164&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000463164&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">profesionales</a> sanitarios, que asistieron a reuniones de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44964&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044964&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">medicina complementaria y alternativa</a> en 2006 y 2008, sobre la utilizaci&#xF3;n de dosis altas de vitamina C en pacientes. De los 199 encuestados, 172 hab&#xED;a administrado vitamina C a pacientes. En general, los usos m&#xE1;s comunes de la vitamina C IV fueron como tratamiento de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45364&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045364&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">infecciones</a>, c&#xE1;ncer y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=321374&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000321374&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">fatiga</a>.<a href="#cit/section_3.9">9</a></p><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_3.1">Cameron E, Campbell A: The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact 9 (4): 285-315, 1974.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4430016&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4430016&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.2">Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A 73 (10): 3685-9, 1976.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1068480&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1068480&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.3">Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A 75 (9): 4538-42, 1978.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=279931&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=279931&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.4">Creagan ET, Moertel CG, O'Fallon JR, et al.: Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 301 (13): 687-90, 1979.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=384241&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=384241&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.5">Moertel CG, Fleming TR, Creagan ET, et al.: High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 312 (3): 137-41, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3880867&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3880867&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.6">Padayatty SJ, Sun H, Wang Y, et al.: Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 140 (7): 533-7, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15068981&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15068981&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.7">Hoffer LJ, Levine M, Assouline S, et al.: Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol 19 (11): 1969-74, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18544557&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18544557&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.8">Verrax J, Calderon PB: Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic Biol Med 47 (1): 32-40, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19254759&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19254759&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.9">Padayatty SJ, Sun AY, Chen Q, et al.: Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One 5 (7): e11414, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20628650&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20628650&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _14
      field_pdq_section_title:
        - format: plain_text
          value: 'Estudios preclínicos de laboratorio o con animales'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_14" class="pdq-sections"><section id="_20"><h3 id="_20_toc">Estudios <em>in vitro</em></h3><p id="_21" tabindex="-1">En muchos estudios se demostr&#xF3; que las <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44664&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044664&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">dosis</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=463167&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000463167&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">farmacol&#xF3;gicas</a> de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=439436&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000439436&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">&#xE1;cido asc&#xF3;rbico</a> (0,1&#x2013;100 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=659791&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000659791&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">mm</a>) disminuyen la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46479&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046479&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">proliferaci&#xF3;n celular</a> de diversas <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=695994&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000695994&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">l&#xED;neas de c&#xE9;lulas cancerosas</a>.<a href="#cit/section_4.1">1</a><a href="#cit/section_4.2">2</a><a href="#cit/section_4.3">3</a><a href="#cit/section_4.4">4</a><a href="#cit/section_4.5">5</a> En concreto, despu&#xE9;s del tratamiento con &#xE1;cido asc&#xF3;rbico se notific&#xF3; disminuci&#xF3;n de la proliferaci&#xF3;n <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46476&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046476&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">celular</a> en las l&#xED;neas celulares de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=445079&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000445079&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">pr&#xF3;stata</a>,<a href="#cit/section_4.6">6</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44074&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044074&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">p&#xE1;ncreas</a>,<a href="#cit/section_4.7">7</a><a href="#cit/section_4.8">8</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46363&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046363&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">h&#xED;gado</a>,<a href="#cit/section_4.9">9</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44237&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044237&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">colon</a>,<a href="#cit/section_4.10">10</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44323&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044323&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">mesotelioma</a> <a href="#cit/section_4.11">11</a> y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45418&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045418&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">neuroblastoma</a>.<a href="#cit/section_4.12">12</a></p><p id="_23" tabindex="-1">Se han estudiado a fondo los posibles mecanismos mediante los que el tratamiento con dosis altas de &#xE1;cido asc&#xF3;rbico produce efectos en c&#xE9;lulas cancerosas. En varios estudios se demostr&#xF3; que el efecto <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44020&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044020&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">citot&#xF3;xico</a> directo <em><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45733&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045733&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">in vitro</a></em> del &#xE1;cido asc&#xF3;rbico en varios tipos de c&#xE9;lulas cancerosas est&#xE1; mediado por una reacci&#xF3;n <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=643008&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000643008&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">qu&#xED;mica</a> que produce <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44113&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044113&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">per&#xF3;xido de hidr&#xF3;geno</a>.<a href="#cit/section_4.1">1</a><a href="#cit/section_4.7">7</a>  <a href="#cit/section_4.13">13</a><a href="#cit/section_4.14">14</a>  En c&#xE9;lulas de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44237&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044237&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer de colon</a>, el tratamiento con 2 a 3 mM de &#xE1;cido asc&#xF3;rbico produjo un descenso regulado de los factores de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=390290&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000390290&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">transcripci&#xF3;n</a> con prote&#xED;na de especificidad (Sp), interferencia con el <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46173&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046173&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">metabolismo</a> del <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=446805&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000446805&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">hierro</a> y de los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45693&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045693&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">genes</a> regulados por Sp que participan en la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44078&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044078&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">progresi&#xF3;n</a> del c&#xE1;ncer.<a href="#cit/section_4.10">10</a><a href="#cit/section_4.15">15</a> En un estudio, se indic&#xF3; que la destrucci&#xF3;n de c&#xE9;lulas cancerosas de pr&#xF3;stata mediada por ascorbato se puede deber a la activaci&#xF3;n de una v&#xED;a de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=561319&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000561319&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">autofagia</a>.<a href="#cit/section_4.6">6</a></p><p id="_24" tabindex="-1">Las diferencias en la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=372925&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000372925&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">quimiosensibilidad</a> de las l&#xED;neas celulares de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=444971&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000444971&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer de mama</a> al tratamiento con ascorbato pueden obedecer a la expresi&#xF3;n del transportador 2 de la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=439435&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000439435&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">vitamina C</a> que depende del <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44731&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044731&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">sodio</a> (SVCT-2).<a href="#cit/section_4.16">16</a></p><p id="_54" tabindex="-1">En investigaci&#xF3;n se se&#xF1;al&#xF3; que las dosis farmacol&#xF3;gicas de &#xE1;cido asc&#xF3;rbico intensifican los efectos del <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46018&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046018&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">tri&#xF3;xido de ars&#xE9;nico</a> en las c&#xE9;lulas de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=445074&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000445074&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer de ovario</a>;<a href="#cit/section_4.17">17</a> de la gemcitabina, en las c&#xE9;lulas de c&#xE1;ncer de p&#xE1;ncreas <a href="#cit/section_4.8">8</a> y del tratamiento combinado de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45347&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045347&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">gemcitabina</a> con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=687212&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000687212&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">3-galato de epigalocatequina</a> (GEGC), en las c&#xE9;lulas de mesotelioma.<a href="#cit/section_4.18">18</a></p><p id="_25" tabindex="-1">En los hallazgos de un estudio publicado en 2012 se indic&#xF3; que las dosis altas de ascorbato aumentan la radiosensibilidad celular del <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45699&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045699&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">glioblastoma multiforme</a>, lo que produce m&#xE1;s destrucci&#xF3;n celular que la radiaci&#xF3;n sola.<a href="#cit/section_4.19">19</a></p><p id="_26" tabindex="-1">No obstante, no en todos los estudios se han observado mejores desenlaces al combinar vitamina C con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45214&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045214&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">quimioterapia</a>. El tratamiento de c&#xE9;lulas de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45343&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045343&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">leucemia</a> y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45368&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045368&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">linfoma</a> con &#xE1;cido deshidroasc&#xF3;rbico (la forma <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=654996&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000654996&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">oxidada</a> de la vitamina C que aumenta las concentraciones <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44047&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044047&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">intracelulares</a> de &#xE1;cido asc&#xF3;rbico) disminuy&#xF3; los efectos citot&#xF3;xicos de varios <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44816&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044816&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">antineopl&#xE1;sicos</a> ya evaluados, como la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45140&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045140&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">doxorrubicina</a>, el <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45393&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045393&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">metotrexato</a> y el <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45230&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045230&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">cisplatino</a> (las reducciones relativas de citotoxicidad oscilaron entre 30 y 70&#xA0;%).<a href="#cit/section_4.20">20</a> En otro estudio, se trataron c&#xE9;lulas de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45793&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045793&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">mieloma m&#xFA;ltiple</a> con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=269133&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000269133&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">bortezomib</a> o con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45839&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045839&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">plasma</a> obtenido de voluntarios sanos que tomaron <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=373932&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000373932&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">suplementos</a> de vitamina C. Las c&#xE9;lulas tratadas con la combinaci&#xF3;n de bortezomib y plasma de voluntarios presentaron menor citotoxicidad que las c&#xE9;lulas tratadas con bortezomib solo.<a href="#cit/section_4.21">21</a></p></section><section id="_27"><h3 id="_27_toc">Estudios con animales</h3><p id="_77" tabindex="-1">En 2007, un grupo de investigadores demostr&#xF3; que el uso de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45797&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045797&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">N-acetilciste&#xED;na</a>  y vitamina C, ambos <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=422394&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000422394&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">compuestos</a> que se caracterizan sobre todo por su capacidad <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43997&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043997&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">antioxidante</a>, tal vez produzca efectos antineopl&#xE1;sicos <em><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46352&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046352&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">in vivo</a></em> mediante la disminuci&#xF3;n de las concentraciones del factor inducible por <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=302460&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000302460&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">hipoxia</a> 1, un factor de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=390290&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000390290&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">transcripci&#xF3;n</a> que se dirige al  <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44222&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044222&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">factor de crecimiento endotelial vascular</a> y que cumple una funci&#xF3;n en la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46529&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046529&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">angiog&#xE9;nesis</a>.<a href="#cit/section_4.22">22</a></p><p id="_28" tabindex="-1">En los estudios se demostr&#xF3; inhibici&#xF3;n del crecimiento <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46634&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046634&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">tumoral</a> despu&#xE9;s del tratamiento con ascorbato farmacol&#xF3;gico en <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43996&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043996&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">modelos animales</a> de c&#xE1;ncer de p&#xE1;ncreas,<a href="#cit/section_4.1">1</a><a href="#cit/section_4.7">7</a><a href="#cit/section_4.8">8</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44242&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044242&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer de h&#xED;gado</a>,<a href="#cit/section_4.3">3</a> c&#xE1;ncer de pr&#xF3;stata,<a href="#cit/section_4.23">23</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45562&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045562&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">sarcoma</a>,<a href="#cit/section_4.24">24</a> mesotelioma<a href="#cit/section_4.11">11</a> y c&#xE1;ncer de ovario.<a href="#cit/section_4.4">4</a></p><p id="_29" tabindex="-1">Se investigaron los efectos tumorales de las dosis altas de &#xE1;cido asc&#xF3;rbico combinadas con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44930&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044930&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">tratamientos est&#xE1;ndar</a>. En un <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=561606&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000561606&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">modelo murino</a> de c&#xE1;ncer de p&#xE1;ncreas, la combinaci&#xF3;n de gemcitabina (30 o 60 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44213&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044213&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">mg</a>/<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44576&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044576&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">kg</a> cada 4 d&#xED;as) con ascorbato (4 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=373014&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000373014&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">g</a>/kg diarios) logr&#xF3; disminuciones m&#xE1;s pronunciadas del peso y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=467873&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000467873&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">volumen tumoral</a>, en comparaci&#xF3;n con el tratamiento con gemcitabina sola.<a href="#cit/section_4.8">8</a> Seg&#xFA;n un estudio publicado en 2012, el ascorbato mejora los efectos oncocitol&#xED;ticos de la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45238&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045238&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">terapia fotodin&#xE1;mica</a> en ratones <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44678&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044678&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">inyectados</a> con c&#xE9;lulas de c&#xE1;ncer de mama.<a href="#cit/section_4.25">25</a> En un estudio de modelos murinos de c&#xE1;ncer de ovario, se encontr&#xF3; que el ascorbato mejor&#xF3; el efecto inhibitorio tumoral de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45182&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045182&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">carboplatino</a> y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45258&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045258&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">paclitaxel</a>, la quimioterapia de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=346494&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000346494&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">primera l&#xED;nea</a> para el c&#xE1;ncer de ovario.<a href="#cit/section_4.26">26</a> En un estudio con modelos de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44095&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044095&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">xenoinjertos</a> de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45323&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045323&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer de pulm&#xF3;n de c&#xE9;lulas no peque&#xF1;as</a> y de glioblastoma multiforme, se observ&#xF3; que la combinaci&#xF3;n de quimioterapia (carboplatino para el c&#xE1;ncer de pulm&#xF3;n y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45387&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045387&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">temozolomida</a> para el glioblastoma), radioterapia e <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44678&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044678&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">inyecci&#xF3;n</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46339&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046339&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">intraperitoneal</a> de ascorbato farmacol&#xF3;gico (4 g/kg diarios) dio como resultado una supervivencia prolongada en comparaci&#xF3;n con la administraci&#xF3;n de la combinaci&#xF3;n  sola de quimioterapia y radioterapia.<a href="#cit/section_4.15">15</a></p><p id="_30" tabindex="-1">Tambi&#xE9;n hay informes de estudios en animales en los que la vitamina C interfiri&#xF3; con el efecto anticanceroso de diversos medicamentos. En un estudio descrito en 2008, la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=478733&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000478733&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">administraci&#xF3;n</a> de &#xE1;cido deshidroasc&#xF3;rbico antes del tratamiento con doxorrubicina en ratones con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44095&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044095&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">xenoinjertos</a> de linfoma produjo tumores significativamente m&#xE1;s grandes que los del tratamiento con la doxorrubicina sola.<a href="#cit/section_4.20">20</a> Cabe destacar que en este estudio se utiliz&#xF3; el deshidroascorbato, la forma oxidada de la vitamina C que se sabe que ingresa en las c&#xE9;lulas mediante transporte activo y que luego se reduce a vitamina C. Los ratones con xenoinjertos de mieloma m&#xFA;ltiple tratados con la combinaci&#xF3;n de vitamina C <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44068&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044068&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">oral</a> y bortezomib presentaron vol&#xFA;menes tumorales mayores que los tratados con bortezomib solo.<a href="#cit/section_4.21">21</a> Este aumento de volumen tumoral lo caus&#xF3; una reacci&#xF3;n qu&#xED;mica que se presenta en el <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46189&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046189&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">tubo gastrointestinal</a>, pero que no es importante en la administraci&#xF3;n <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46682&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046682&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">intravenosa</a>.</p></section><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_4.1">Chen P, Stone J, Sullivan G, et al.: Anti-cancer effect of pharmacologic ascorbate and its interaction with supplementary parenteral glutathione in preclinical cancer models. Free Radic Biol Med 51 (3): 681-7, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21672627&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21672627&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.2">Chen Q, Espey MG, Krishna MC, et al.: Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci U S A 102 (38): 13604-9, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16157892&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16157892&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.3">Verrax J, Calderon PB: Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic Biol Med 47 (1): 32-40, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19254759&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19254759&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.4">Chen Q, Espey MG, Sun AY, et al.: Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci U S A 105 (32): 11105-9, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18678913&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18678913&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.5">Fr&#xF6;mberg A, Gutsch D, Schulze D, et al.: Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs. Cancer Chemother Pharmacol 67 (5): 1157-66, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20694726&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20694726&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.6">Chen P, Yu J, Chalmers B, et al.: Pharmacological ascorbate induces cytotoxicity in prostate cancer cells through ATP depletion and induction of autophagy. Anticancer Drugs 23 (4): 437-44, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22205155&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22205155&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.7">Du J, Martin SM, Levine M, et al.: Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin Cancer Res 16 (2): 509-20, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20068072&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20068072&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.8">Espey MG, Chen P, Chalmers B, et al.: Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Radic Biol Med 50 (11): 1610-9, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21402145&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21402145&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.9">Lin ZY, Chuang WL: Pharmacologic concentrations of ascorbic acid cause diverse influence on differential expressions of angiogenic chemokine genes in different hepatocellular carcinoma cell lines. Biomed Pharmacother 64 (5): 348-51, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19932582&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19932582&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.10">Pathi SS, Lei P, Sreevalsan S, et al.: Pharmacologic doses of ascorbic acid repress specificity protein (Sp) transcription factors and Sp-regulated genes in colon cancer cells. Nutr Cancer 63 (7): 1133-42, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21919647&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21919647&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.11">Takemura Y, Satoh M, Satoh K, et al.: High dose of ascorbic acid induces cell death in mesothelioma cells. Biochem Biophys Res Commun 394 (2): 249-53, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20171954&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20171954&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.12">Hardaway CM, Badisa RB, Soliman KF: Effect of ascorbic acid and hydrogen peroxide on mouse neuroblastoma cells. Mol Med Report 5 (6): 1449-52, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22469841&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22469841&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.13">Du J, Cullen JJ, Buettner GR: Ascorbic acid: chemistry, biology and the treatment of cancer. Biochim Biophys Acta 1826 (2): 443-57, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22728050&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22728050&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.14">Levine M, Padayatty SJ, Espey MG: Vitamin C: a concentration-function approach yields pharmacology and therapeutic discoveries. Adv Nutr 2 (2): 78-88, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22332036&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22332036&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.15">Schoenfeld JD, Sibenaller ZA, Mapuskar KA, et al.: O2&#x22C5;- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell 32 (2): 268, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28810149&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28810149&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.16">Hong SW, Lee SH, Moon JH, et al.: SVCT-2 in breast cancer acts as an indicator for L-ascorbate treatment. Oncogene 32 (12): 1508-17, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22665050&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22665050&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.17">Ong PS, Chan SY, Ho PC: Differential augmentative effects of buthionine sulfoximine and ascorbic acid in As2O3-induced ovarian cancer cell death: oxidative stress-independent and -dependent cytotoxic potentiation. Int J Oncol 38 (6): 1731-9, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21455570&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21455570&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.18">Martinotti S, Ranzato E, Burlando B: In vitro screening of synergistic ascorbate-drug combinations for the treatment of malignant mesothelioma. Toxicol In Vitro 25 (8): 1568-74, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21645609&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21645609&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.19">Herst PM, Broadley KW, Harper JL, et al.: Pharmacological concentrations of ascorbate radiosensitize glioblastoma multiforme primary cells by increasing oxidative DNA damage and inhibiting G2/M arrest. Free Radic Biol Med 52 (8): 1486-93, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22342518&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22342518&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.20">Heaney ML, Gardner JR, Karasavvas N, et al.: Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res 68 (19): 8031-8, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18829561&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18829561&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.21">Perrone G, Hideshima T, Ikeda H, et al.: Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia 23 (9): 1679-86, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19369963&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19369963&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.22">Gao P, Zhang H, Dinavahi R, et al.: HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 12 (3): 230-8, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17785204&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17785204&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.23">Pollard HB, Levine MA, Eidelman O, et al.: Pharmacological ascorbic acid suppresses syngeneic tumor growth and metastases in hormone-refractory prostate cancer. In Vivo 24 (3): 249-55, 2010 May-Jun.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20554995&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20554995&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.24">Yeom CH, Lee G, Park JH, et al.: High dose concentration administration of ascorbic acid inhibits tumor growth in BALB/C mice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis. J Transl Med 7: 70, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19671184&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19671184&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.25">Wei Y, Song J, Chen Q, et al.: Enhancement of photodynamic antitumor effect with pro-oxidant ascorbate. Lasers Surg Med 44 (1): 69-75, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22246986&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22246986&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.26">Ma Y, Chapman J, Levine M, et al.: High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med 6 (222): 222ra18, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24500406&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24500406&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _16
      field_pdq_section_title:
        - format: plain_text
          value: 'Estudios clínicos con seres humanos'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_16" class="pdq-sections"><section id="_31"><h3 id="_31_toc">Estudios de series de casos y ensayos cl&#xED;nicos iniciales con ascorbato solo</h3><p id="_32" tabindex="-1">A principios de la d&#xE9;cada de 1970, se llev&#xF3; a cabo una <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285747&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285747&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">serie de casos consecutivos</a> en 50 pacientes de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=478743&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000478743&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer avanzado</a> tratados con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44664&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044664&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">dosis</a> altas de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=439436&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000439436&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">&#xE1;cido asc&#xF3;rbico</a>.<a href="#cit/section_5.1">1</a> Estos pacientes comenzaron el tratamiento con &#xE1;cido asc&#xF3;rbico despu&#xE9;s de que se considerara improbable la eficacia de las <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44198&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044198&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">terapias convencionales</a>. Los pacientes recibieron &#xE1;cido asc&#xF3;rbico <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46682&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046682&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">intravenoso</a> (IV) (10 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=373014&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000373014&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">g</a>/d&#xED;a durante 10 d&#xED;as consecutivos; algunos pacientes recibieron dosis m&#xE1;s altas), &#xE1;cido asc&#xF3;rbico <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44068&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044068&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">oral</a> (10 g/d&#xED;a), o ambos. Los participantes presentaron una variedad amplia de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44085&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044085&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">respuestas</a> al tratamiento; entre otras, ausencia de respuesta o respuesta m&#xED;nima, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46039&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046039&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">regresi&#xF3;n</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46634&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046634&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">tumoral</a> y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=373015&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000373015&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">hemorragia</a> tumoral. Sin embargo, los autores anotaron que la falta de controles evit&#xF3; que se se&#xF1;alara en forma definitiva alguna respuesta beneficiosa del tratamiento con &#xE1;cido &#xF3;rbico. En un <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44007&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044007&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">informe de caso</a> publicado en 1975, se describi&#xF3; con pormenores uno de los pacientes que present&#xF3; regresi&#xF3;n tumoral.<a href="#cit/section_5.2">2</a> El paciente, con diagn&#xF3;stico de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45562&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045562&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">sarcoma</a> de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46476&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046476&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE9;lulas</a> reticulares, present&#xF3; mejora en el bienestar y las masas <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=270740&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000270740&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">pulmonares</a> desaparecieron despu&#xE9;s del tratamiento con &#xE1;cido asc&#xF3;rbico. Algunas de las manifestaciones de la enfermedad reaparecieron en el paciente cuando se disminuy&#xF3; la dosis diaria de &#xE1;cido asc&#xF3;rbico; sin embargo, la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45867&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045867&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">remisi&#xF3;n</a> se logr&#xF3; nuevamente despu&#xE9;s de que el paciente retom&#xF3; la dosis inicial m&#xE1;s alta.</p><p id="_33" tabindex="-1">En 1976, se describi&#xF3; una <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44006&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044006&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">serie de casos</a> m&#xE1;s numerosa de pacientes con c&#xE1;ncer en estadio terminal tratados con ascorbato. En este estudio, 100 pacientes con c&#xE1;ncer en estadio terminal (de los cuales 50 fueron notificados antes)<a href="#cit/section_5.1">1</a> fueron tratados con ascorbato (10 g/d&#xED;a IV durante 10 d&#xED;as y, luego, oral) y se les compar&#xF3; con 1000 controles emparejados del mismo hospital. La <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285974&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285974&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">media de supervivencia</a> de los pacientes tratados con ascorbato fue 300 d&#xED;as m&#xE1;s larga que la de los controles emparejados.<a href="#cit/section_5.3">3</a><a href="#cit/section_5.4">4</a></p><p id="_34" tabindex="-1">En dos estudios se intent&#xF3; repetir los resultados iniciales. Estos estudios fueron ensayos <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45858&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045858&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">aleatorizados</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44840&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044840&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">controlados con placebo</a> en los que pacientes con c&#xE1;ncer recibieron 10 g diarios de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=439435&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000439435&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">vitamina C</a> oral o placebo, hasta que presentaran signos de progresi&#xF3;n del c&#xE1;ncer. Al final de cada estudio, no se encontraron diferencias <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=390271&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000390271&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">significativas</a> en cuanto a <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45022&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045022&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">s&#xED;ntomas</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44174&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044174&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">estado funcional</a> o <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44301&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044301&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">supervivencia</a> entre los grupos tratados con ascorbato y placebo.<a href="#cit/section_5.5">5</a><a href="#cit/section_5.6">6</a></p></section><section id="_35"><h3 id="_35_toc">Estudios de series de casos y ensayos cl&#xED;nicos recientes con ascorbato solo</h3><p id="_57" tabindex="-1">Un estudio incluy&#xF3; tres informes de casos de pacientes con c&#xE1;ncer que recibieron vitamina C IV como <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44737&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044737&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">terapia</a> principal. En el transcurso del tratamiento con vitamina C, los pacientes utilizaron otros tratamientos, como <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44744&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044744&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">vitaminas</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45787&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045787&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">minerales</a> y productos <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=367458&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000367458&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">bot&#xE1;nicos</a>. Seg&#xFA;n los autores, revisaron los casos en conformidad con las directrices <a href="https://cam.cancer.gov/indentifying_novel_cam_therapies/best_case_protocol.htm" title="https://cam.cancer.gov/indentifying_novel_cam_therapies/best_case_protocol.htm">NCI Best Case Series guidelines</a>. El an&#xE1;lisis <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=467841&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000467841&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">histopatol&#xF3;gico</a> permiti&#xF3; suponer <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45849&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045849&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">pron&#xF3;sticos</a> precarios para estos pacientes; pero presentaron periodos de supervivencia largos despu&#xE9;s del tratamiento IV con vitamina C.<a href="#cit/section_5.7">7</a> La vitamina C se administr&#xF3; en dosis de 15 a 65 g. Al principio, una o dos veces por semana durante varios meses y, luego, dos pacientes la recibieron con menor frecuencia durante 1 a 4 a&#xF1;os.</p><p id="_36" tabindex="-1">En dos estudios se demostr&#xF3; que el tratamiento IV con vitamina C mejor&#xF3; la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45417&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045417&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">calidad de vida</a> y disminuy&#xF3; los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46580&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046580&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">efectos secundarios</a> relacionados con el c&#xE1;ncer en los pacientes con esta enfermedad.<a href="#cit/section_5.8">8</a><a href="#cit/section_5.9">9</a></p><p id="_38" tabindex="-1">En los estudios se observ&#xF3; que la vitamina C se puede administrar en forma inocua a voluntarios sanos y pacientes con c&#xE1;ncer en dosis de hasta 1,5 g/<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44576&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044576&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">kg</a>, con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46171&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046171&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">ex&#xE1;menes de detecci&#xF3;n</a> para evitar el tratamiento de personas con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45873&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045873&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">factores de riesgo</a> de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=445093&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000445093&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">toxicidad</a> (por ejemplo, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=748114&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000748114&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">deficiencia de glucosa-6-fosfato deshidrogenasa</a>, enfermedades renales o urolitiasis). En estos estudios tambi&#xE9;n se encontr&#xF3; que las concentraciones <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45839&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045839&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">plasm&#xE1;ticas</a> de vitamina C son m&#xE1;s altas luego de la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=478733&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000478733&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">administraci&#xF3;n</a> IV que en la oral, y que estas se mantienen durante m&#xE1;s de 4 horas.<a href="#cit/section_5.10">10</a><a href="#cit/section_5.11">11</a></p></section><section id="_39"><h3 id="_39_toc">Ensayos de fase temprana con ascorbato combinado con tratamientos est&#xE1;ndar contra el c&#xE1;ncer</h3><p id="_40" tabindex="-1">En un estudio de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45830&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045830&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">fase I</a> publicado en 2012 se examin&#xF3; la inocuidad y la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=346517&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000346517&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">eficacia</a> de combinar ascorbato IV con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45347&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045347&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">gemcitabina</a> y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=508929&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000508929&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">erlotinib</a> para pacientes con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45511&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045511&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer de p&#xE1;ncreas en estadio IV</a>. Se inscribieron en el estudio 14 participantes y se plane&#xF3; que recibieran gemcitabina IV (1000 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44213&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044213&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">mg</a>/m<span class="sup">2</span> durante 30 minutos, una vez por semana, por 7 semanas), erlotinib oral (100 mg diarios, por 8 semanas) y ascorbato IV (50 g/<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45738&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045738&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">infusi&#xF3;n</a>, 75 g/infusi&#xF3;n o 100 g/infusi&#xF3;n, 3 veces por semana, durante 8 semanas). Se notificaron <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44922&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044922&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">efectos adversos</a> m&#xED;nimos del tratamiento con &#xE1;cido asc&#xF3;rbico. Cinco participantes recibieron menos de 18 de las 24 infusiones de ascorbato previstas y, por lo tanto, no se sometieron a <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46361&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046361&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">imaginolog&#xED;a</a> de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44671&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044671&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">seguimiento</a> para evaluar la respuesta. Tres de los pacientes presentaron <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45850&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045850&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">enfermedad progresiva</a> definida por evaluaci&#xF3;n cl&#xED;nica. Los otros nueve pacientes contaban con im&#xE1;genes repetidas para evaluar el tama&#xF1;o tumoral, y cada uno cumpli&#xF3; con los criterios para definir <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45884&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045884&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">enfermedad estable</a>.<a href="#cit/section_5.12">12</a></p><p id="_62" tabindex="-1">En un <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44195&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044195&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">ensayo cl&#xED;nico</a> de fase I de 2013, se evalu&#xF3; la inocuidad de combinar ascorbato farmacol&#xF3;gico con gemcitabina en el tratamiento de pacientes con c&#xE1;ncer de p&#xE1;ncreas en estadio IV. Durante cada ciclo de 4 semanas, los pacientes recibieron gemcitabina semanal por 3 semanas (1000 mg/m<span class="sup">2</span> durante 30 minutos) e infusiones de ascorbato dos veces por semana, durante 4 semanas (15 g durante 30 minutos en la primera semana, seguido de aumentos semanales en la dosis hasta que se alcanzaran concentraciones plasm&#xE1;ticas de por lo menos 350 mg/dl [20 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=659791&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000659791&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">mm</a>]). En los 9 pacientes, la media de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44782&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044782&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">supervivencia sin progresi&#xF3;n</a> fue de 26 semanas y la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=655245&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000655245&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">supervivencia general</a> fue de 12 meses. El tratamiento combinado se toler&#xF3; bien y no se notificaron eventos adversos significativos.<a href="#cit/section_5.13">13</a></p><p id="_68" tabindex="-1">En 2014, en un ensayo cl&#xED;nico de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45832&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045832&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">fase I/IIA</a> se investig&#xF3; la toxicidad de combinar ascorbato IV con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45182&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045182&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">carboplatino</a> y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45258&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045258&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">paclitaxel</a> para el c&#xE1;ncer epitelial de ovario en <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45901&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045901&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">estadio III</a>/<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45902&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045902&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">IV</a>. Se aleatoriz&#xF3; a 27 pacientes para recibir <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45214&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045214&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">quimioterapia</a> sola o quimioterapia junto con vitamina C IV. Se administr&#xF3; quimioterapia durante 6 meses y vitamina C IV durante 12 meses. La incorporaci&#xF3;n de la vitamina C IV redujo la toxicidad relacionada con la quimioterapia.<a href="#cit/section_5.14">14</a></p><p id="_41" tabindex="-1">Est&#xE1;n en curso ensayos con dosis altas IV de vitamina C junto con otros <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=348921&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000348921&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">medicamentos</a>.<a href="#cit/section_5.12">12</a><a href="#cit/section_5.14">14</a> En varios estudios con resultados desiguales, se incluy&#xF3; tratamiento con &#xE1;cido asc&#xF3;rbico IV (1000 mg) junto con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45864&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045864&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">reg&#xED;menes</a> de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46018&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046018&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">tri&#xF3;xido de ars&#xE9;nico</a>. La combinaci&#xF3;n de tratamientos se toler&#xF3; bien y se indicaron efectos ben&#xE9;ficos en pacientes con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45793&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045793&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">mieloma m&#xFA;ltiple</a>, aunque no se logr&#xF3; determinar la contribuci&#xF3;n espec&#xED;fica de la vitamina C.<a href="#cit/section_5.15">15</a><a href="#cit/section_5.16">16</a><a href="#cit/section_5.17">17</a><a href="#cit/section_5.18">18</a> Sin embargo, reg&#xED;menes combinados semejantes produjeron efectos secundarios graves,  <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45669&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045669&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">progresi&#xF3;n de la enfermedad</a>, y ning&#xFA;n efecto anticancer&#xED;geno en pacientes con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=444983&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000444983&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer colorrectal</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44058&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044058&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">metast&#xE1;sico</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=350245&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000350245&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">resistente al tratamiento</a> <a href="#cit/section_5.19">19</a> y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45135&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045135&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">melanoma</a> metast&#xE1;sico.<a href="#cit/section_5.20">20</a> Debido a que no se trataba de ensayos controlados con placebo, no queda claro el grado en que el ascorbato contribuy&#xF3; a la toxicidad observada en los estudios.</p><p id="_78" tabindex="-1">A partir de datos precl&#xED;nicos,<a href="#cit/section_5.15">15</a>  un grupo de investigadores de la University of Iowa trataron a pacientes con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45323&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045323&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer de pulm&#xF3;n de c&#xE9;lulas no peque&#xF1;as</a> (CPCNP)  y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45699&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045699&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">glioblastoma multiforme</a> (GBM) en dos ensayos cl&#xED;nicos preliminares (<a href="https://clinicaltrials.gov/ct2/show/NCT02420314" title="https://clinicaltrials.gov/ct2/show/NCT02420314">NCT02420314</a> y <a href="https://clinicaltrials.gov/ct2/show/NCT01752491" title="https://clinicaltrials.gov/ct2/show/NCT01752491">NCT01752491</a>).<a href="#cit/section_5.21">21</a> Los participantes de ambos ensayos recibieron <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44198&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044198&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">terapia convencional</a> con vitamina C intravenosa, de acuerdo con una dosificaci&#xF3;n individualizada para lograr una concentraci&#xF3;n plasm&#xE1;tica de ascorbato de 20 mM en cada paciente. El estudio de GBM tuvo un dise&#xF1;o de fase I con 13 pacientes. La vitamina C se administr&#xF3; por v&#xED;a intravenosa con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44971&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044971&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">radioterapia</a> y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45387&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045387&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">temozolomida</a>; la toxicidad, la supervivencia sin progresi&#xF3;n y la supervivencia general fueron favorables en comparaci&#xF3;n con los desenlaces de los controles hist&#xF3;ricos. El ensayo sobre CPCNP tuvo un dise&#xF1;o de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45831&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045831&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">fase II</a> con 14 pacientes de c&#xE1;ncer avanzado que recibieron quimioterapia y vitamina C intravenosa (concentraci&#xF3;n media plasm&#xE1;tica m&#xE1;xima de 16,4 mM). Las tasas de control de la enfermedad y de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44067&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044067&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">respuesta objetiva</a> confirmada  del grupo de estudio tambi&#xE9;n fueron favorables en comparaci&#xF3;n con los controles hist&#xF3;ricos. Entre otras limitaciones de estos estudios, se  incluy&#xF3; el uso de controles   hist&#xF3;ricos y el n&#xFA;mero bajo de participantes inscritos.</p></section><section id="_TrialSearch_16_sid_5"><h3 id="_TrialSearch_16_sid_5_toc">Ensayos cl&#xED;nicos en curso</h3><p id="_TrialSearch_16_25" tabindex="-1">Realizar una <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search">b&#xFA;squeda avanzada</a> en ingl&#xE9;s de los ensayos cl&#xED;nicos sobre c&#xE1;ncer auspiciados por el NCI que ahora aceptan pacientes. La b&#xFA;squeda se puede simplificar por ubicaci&#xF3;n del ensayo, tipo de tratamiento, nombre del f&#xE1;rmaco y otros criterios. Tambi&#xE9;n se dispone de <a href="https://www.cancer.gov/espanol/cancer/tratamiento/estudios-clinicos" title="https://www.cancer.gov/espanol/cancer/tratamiento/estudios-clinicos">informaci&#xF3;n general</a> sobre los ensayos cl&#xED;nicos. </p></section><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_5.1">Cameron E, Campbell A: The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact 9 (4): 285-315, 1974.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4430016&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4430016&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.2">Cameron E, Campbell A, Jack T: The orthomolecular treatment of cancer. III. Reticulum cell sarcoma: double complete regression induced by high-dose ascorbic acid therapy. Chem Biol Interact 11 (5): 387-93, 1975.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1104207&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1104207&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.3">Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A 73 (10): 3685-9, 1976.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1068480&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1068480&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.4">Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A 75 (9): 4538-42, 1978.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=279931&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=279931&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.5">Creagan ET, Moertel CG, O'Fallon JR, et al.: Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med 301 (13): 687-90, 1979.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=384241&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=384241&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.6">Moertel CG, Fleming TR, Creagan ET, et al.: High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med 312 (3): 137-41, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3880867&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3880867&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.7">Padayatty SJ, Riordan HD, Hewitt SM, et al.: Intravenously administered vitamin C as cancer therapy: three cases. CMAJ 174 (7): 937-42, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16567755&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16567755&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.8">Vollbracht C, Schneider B, Leendert V, et al.: Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany. In Vivo 25 (6): 983-90, 2011 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22021693&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22021693&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.9">Yeom CH, Jung GC, Song KJ: Changes of terminal cancer patients' health-related quality of life after high dose vitamin C administration. J Korean Med Sci 22 (1): 7-11, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17297243&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17297243&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.10">Padayatty SJ, Sun H, Wang Y, et al.: Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 140 (7): 533-7, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15068981&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15068981&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.11">Hoffer LJ, Levine M, Assouline S, et al.: Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol 19 (11): 1969-74, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18544557&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18544557&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.12">Monti DA, Mitchell E, Bazzan AJ, et al.: Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One 7 (1): e29794, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22272248&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22272248&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.13">Welsh JL, Wagner BA, van't Erve TJ, et al.: Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol 71 (3): 765-75, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23381814&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23381814&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.14">Ma Y, Chapman J, Levine M, et al.: High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med 6 (222): 222ra18, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24500406&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24500406&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.15">Abou-Jawde RM, Reed J, Kelly M, et al.: Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial. Med Oncol 23 (2): 263-72, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16720927&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16720927&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.16">Berenson JR, Matous J, Swift RA, et al.: A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res 13 (6): 1762-8, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17363530&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17363530&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.17">Qazilbash MH, Saliba RM, Nieto Y, et al.: Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant 14 (12): 1401-7, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19041063&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19041063&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.18">Berenson JR, Boccia R, Siegel D, et al.: Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study. Br J Haematol 135 (2): 174-83, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17010047&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17010047&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.19">Subbarayan PR, Lima M, Ardalan B: Arsenic trioxide/ascorbic acid therapy in patients with refractory metastatic colorectal carcinoma: a clinical experience. Acta Oncol 46 (4): 557-61, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17497326&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17497326&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.20">Bael TE, Peterson BL, Gollob JA: Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases. Melanoma Res 18 (2): 147-51, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18337652&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18337652&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.21">Schoenfeld JD, Sibenaller ZA, Mapuskar KA, et al.: O2&#x22C5;- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell 32 (2): 268, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28810149&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28810149&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _18
      field_pdq_section_title:
        - format: plain_text
          value: 'Efectos adversos'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_18" class="pdq-sections"><p id="_19" tabindex="-1">En general, las <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44664&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044664&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">dosis</a> altas <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46682&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046682&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">intravenosas</a> (IV) de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=439436&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000439436&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">&#xE1;cido asc&#xF3;rbico</a> se toleraron bien en los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45961&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045961&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">ensayos cl&#xED;nicos</a>.<a href="#cit/section_6.1">1</a><a href="#cit/section_6.2">2</a><a href="#cit/section_6.3">3</a><a href="#cit/section_6.4">4</a><a href="#cit/section_6.5">5</a><a href="#cit/section_6.6">6</a><a href="#cit/section_6.7">7</a><a href="#cit/section_6.8">8</a> Se ha notificado <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=462925&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000462925&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">insuficiencia renal</a> despu&#xE9;s del tratamiento con &#xE1;cido asc&#xF3;rbico en pacientes con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=407758&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000407758&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">trastornos</a> renales preexistentes.<a href="#cit/section_6.9">9</a></p><p id="_42" tabindex="-1">En <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44007&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044007&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">informes de casos</a> se indic&#xF3; que los pacientes con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=748114&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000748114&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">deficiencia de glucosa-6-fosfato deshidrogenasa (G-6-PD)</a> deben evitar las dosis altas de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=439435&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000439435&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">vitamina C</a> debido al riesgo de presentar <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=687883&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000687883&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">hem&#xF3;lisis</a>.<a href="#cit/section_6.10">10</a><a href="#cit/section_6.11">11</a><a href="#cit/section_6.12">12</a></p><p id="_43" tabindex="-1">La vitamina C puede aumentar la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44225&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044225&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">biodisponibilidad</a> del <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=446805&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000446805&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">hierro</a>, y se desaconsejan las dosis altas de vitamina en los pacientes con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=446804&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000446804&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">hemocromatosis</a>.<a href="#cit/section_6.13">13</a></p><section id="_49"><h3 id="_49_toc">Interacciones farmacol&#xF3;gicas</h3><p id="_50" tabindex="-1">La vitamina C, cuando se administra en dosis altas, puede ocasionar interacciones adversas con algunos antineopl&#xE1;sicos. Estas interacciones se detectaron principalmente en <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44517&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044517&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">estudios precl&#xED;nicos</a>. En un estudio cl&#xED;nico de fase 1 de 2013, se evalu&#xF3; la inocuidad de combinar dosis altas IV de ascorbato con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45347&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045347&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">gemcitabina</a> en pacientes con c&#xE1;ncer de p&#xE1;ncreas en estadio IV. Los pacientes toleraron bien el tratamiento combinado y no se notificaron efectos adversos de importancia.<a href="#cit/section_6.14">14</a></p><p id="_51" tabindex="-1">En los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=454774&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000454774&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">estudios en animales</a> <em><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45733&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045733&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">in vitro</a></em> e <em><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46352&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046352&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">in vivo</a></em>, se indic&#xF3; que al combinar vitamina C <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44068&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044068&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">oral</a> con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=269133&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000269133&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">bortezomib</a> se interfiere con la capacidad del f&#xE1;rmaco para actuar como <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=393541&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000393541&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">inhibidor del proteasoma</a> y se impide la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46524&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046524&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">apoptosis</a> mediada por bortezomib.<a href="#cit/section_6.15">15</a><a href="#cit/section_6.16">16</a><a href="#cit/section_6.17">17</a> Esta interferencia se present&#xF3; incluso cuando los animales recibieron la vitamina C por v&#xED;a oral (40 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44213&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044213&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">mg</a>/<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44576&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044576&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">kg</a> diarios). En los estudios de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=556412&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000556412&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">cultivos celulares</a> y los realizados con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45839&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045839&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">plasma</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=270735&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000270735&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">sangu&#xED;neo</a> de voluntarios sanos que recibieron vitamina C oral (1 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=373014&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000373014&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">g</a> diario), tambi&#xE9;n se observ&#xF3; una reducci&#xF3;n <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=390271&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000390271&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">significativa</a> de los efectos inhibitorios del bortezomib sobre la proliferaci&#xF3;n de c&#xE9;lulas de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45793&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045793&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">mieloma m&#xFA;ltiple</a>. En otro estudio, se encontraron resultados similares. Se observ&#xF3; que el plasma de voluntarios sanos, que tomaron 1 g de vitamina C oral por d&#xED;a, disminuy&#xF3; la inhibici&#xF3;n de la proliferaci&#xF3;n del bortezomib en las c&#xE9;lulas de mieloma m&#xFA;ltiple e impidi&#xF3; el efecto inhibitorio sobre la actividad del proteasoma 20S.<a href="#cit/section_6.17">17</a> Sin embargo, en un estudio con ratones que ten&#xED;an <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44095&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044095&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">xenoinjertos</a> de c&#xE9;lulas de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=445079&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000445079&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer de pr&#xF3;stata</a> humano, no se logr&#xF3; encontrar alg&#xFA;n efecto significativo de la vitamina C oral (40 o 500 mg/kg diarios) sobre la actividad inhibitoria del bortezomib en la proliferaci&#xF3;n <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46634&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046634&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">tumoral</a>.<a href="#cit/section_6.18">18</a>  </p><p id="_55" tabindex="-1">Se han llevado a cabo muchos estudios, con resultados desiguales, para evaluar las posibles acciones <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=330184&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000330184&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">sin&#xE9;rgicas</a> o inhibitorias de la vitamina C sobre ciertos <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=348921&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000348921&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">medicamentos</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45214&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045214&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">quimioterap&#xE9;uticos</a>. En una serie de estudios en cultivos celulares y en animales con tumores, se observ&#xF3; que cuando se administran concentraciones o dosis altas de &#xE1;cido deshidroasc&#xF3;rbico (forma oxidada de la vitamina C), &#xE9;stas puede interferir con los efectos <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44020&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044020&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">citot&#xF3;xicos</a> de varios medicamentos quimioterap&#xE9;uticos.<a href="#cit/section_6.19">19</a> Sin embargo, por lo general, el &#xE1;cido deshidroasc&#xF3;rbico est&#xE1; presente solo en concentraciones bajas en los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=373932&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000373932&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">suplementos alimentarios</a> y en los alimentos frescos.</p></section><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_6.1">Padayatty SJ, Sun H, Wang Y, et al.: Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med 140 (7): 533-7, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15068981&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15068981&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.2">Hoffer LJ, Levine M, Assouline S, et al.: Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol 19 (11): 1969-74, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18544557&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18544557&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.3">Chen Q, Espey MG, Sun AY, et al.: Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci U S A 105 (32): 11105-9, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18678913&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18678913&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.4">Monti DA, Mitchell E, Bazzan AJ, et al.: Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One 7 (1): e29794, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22272248&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22272248&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.5">Abou-Jawde RM, Reed J, Kelly M, et al.: Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial. Med Oncol 23 (2): 263-72, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16720927&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16720927&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.6">Berenson JR, Matous J, Swift RA, et al.: A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res 13 (6): 1762-8, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17363530&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17363530&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.7">Qazilbash MH, Saliba RM, Nieto Y, et al.: Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant 14 (12): 1401-7, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19041063&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19041063&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.8">Ma Y, Chapman J, Levine M, et al.: High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med 6 (222): 222ra18, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24500406&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24500406&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.9">Padayatty SJ, Sun AY, Chen Q, et al.: Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One 5 (7): e11414, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20628650&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20628650&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.10">Campbell GD Jr, Steinberg MH, Bower JD: Letter: Ascorbic acid-induced hemolysis in G-6-PD deficiency. Ann Intern Med 82 (6): 810, 1975.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1138591&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1138591&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.11">Mehta JB, Singhal SB, Mehta BC: Ascorbic-acid-induced haemolysis in G-6-PD deficiency. Lancet 336 (8720): 944, 1990.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1976956&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1976956&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.12">Rees DC, Kelsey H, Richards JD: Acute haemolysis induced by high dose ascorbic acid in glucose-6-phosphate dehydrogenase deficiency. BMJ 306 (6881): 841-2, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8490379&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8490379&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.13">Barton JC, McDonnell SM, Adams PC, et al.: Management of hemochromatosis. Hemochromatosis Management Working Group. Ann Intern Med 129 (11): 932-9, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9867745&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9867745&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.14">Welsh JL, Wagner BA, van't Erve TJ, et al.: Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol 71 (3): 765-75, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23381814&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23381814&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.15">Zou W, Yue P, Lin N, et al.: Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells. Clin Cancer Res 12 (1): 273-80, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16397052&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16397052&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.16">Llobet D, Eritja N, Encinas M, et al.: Antioxidants block proteasome inhibitor function in endometrial carcinoma cells. Anticancer Drugs 19 (2): 115-24, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18176107&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18176107&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.17">Perrone G, Hideshima T, Ikeda H, et al.: Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia 23 (9): 1679-86, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19369963&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19369963&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.18">Bannerman B, Xu L, Jones M, et al.: Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea. Cancer Chemother Pharmacol 68 (5): 1145-54, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21400028&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21400028&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.19">Heaney ML, Gardner JR, Karasavvas N, et al.: Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res 68 (19): 8031-8, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18829561&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18829561&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _69
      field_pdq_section_title:
        - format: plain_text
          value: 'Modificaciones a este sumario 01/18/2018)'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_69" class="pdq-sections"><p id="_70" tabindex="-1">Los sumarios del <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44271&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044271&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">PDQ</a> con informaci&#xF3;n sobre el <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45333&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045333&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer</a> se revisan con regularidad y se actualizan a medida que se obtiene nueva informaci&#xF3;n. Esta secci&#xF3;n describe los cambios m&#xE1;s recientes introducidos en este sumario a partir de la fecha arriba indicada.</p><p id="_79" tabindex="-1"><strong><a href="/espanol/cancer/tratamiento/mca/pro/vitamina-c-pdq#link/_1">Aspectos generales</a></strong></p><p id="_80" tabindex="-1">Se revis&#xF3; la <a href="/espanol/cancer/tratamiento/mca/pro/vitamina-c-pdq#link/_47">lista</a> con informaci&#xF3;n clave sobre la vitamina C en dosis altas.</p><p id="_81" tabindex="-1"><strong><a href="/espanol/cancer/tratamiento/mca/pro/vitamina-c-pdq#link/_14">Estudios precl&#xED;nicos de laboratorio o con animales</a></strong></p><p id="_82" tabindex="-1">Se revis&#xF3; el <a href="/espanol/cancer/tratamiento/mca/pro/vitamina-c-pdq#link/_23">texto</a> para indicar que el tratamiento de c&#xE9;lulas de c&#xE1;ncer de colon con 2 a 3 mM de &#xE1;cido asc&#xF3;rbico produjo un descenso regulado de los factores de transcripci&#xF3;n con prote&#xED;na de especificidad (Sp), la interferencia con el metabolismo del hierro y los genes regulados por Sp que participan en la progresi&#xF3;n del c&#xE1;ncer (se cit&#xF3; a Schoenfeld et al. como referencia 15).</p><p id="_83" tabindex="-1">Se a&#xF1;adi&#xF3; <a href="/espanol/cancer/tratamiento/mca/pro/vitamina-c-pdq#link/_27">texto</a> para indicar que en un estudio con modelos de xenoinjertos de c&#xE1;ncer de pulm&#xF3;n de c&#xE9;lulas no peque&#xF1;as y de glioblastoma multiforme, se observ&#xF3; que la combinaci&#xF3;n de quimioterapia, radioterapia y ascorbato farmacol&#xF3;gico dio como resultado una supervivencia prolongada en comparaci&#xF3;n con la administraci&#xF3;n de la combinaci&#xF3;n  sola de quimioterapia y radioterapia.</p><p id="_84" tabindex="-1"><strong><a href="/espanol/cancer/tratamiento/mca/pro/vitamina-c-pdq#link/_16">Estudios cl&#xED;nicos con seres humanos</a></strong></p><p id="_85" tabindex="-1">Se cambi&#xF3; el t&#xED;tulo de la subsecci&#xF3;n Ensayos iniciales con ascorbato solo a <strong><a href="/espanol/cancer/tratamiento/mca/pro/vitamina-c-pdq#link/_31">Estudios de series de casos y ensayos cl&#xED;nicos iniciales con ascorbato solo</a></strong>.</p><p id="_86" tabindex="-1">Se cambi&#xF3; el t&#xED;tulo de la subsecci&#xF3;n Ensayos recientes con ascorbato solo a <strong><a href="/espanol/cancer/tratamiento/mca/pro/vitamina-c-pdq#link/_35">Estudios de series de casos y ensayos cl&#xED;nicos recientes con ascorbato solo</a></strong>.</p><p id="_87" tabindex="-1"> Se cambi&#xF3; el t&#xED;tulo de la subsecci&#xF3;n Estudios de combinaciones con ascorbato a <strong><a href="/espanol/cancer/tratamiento/mca/pro/vitamina-c-pdq#link/_39">Ensayos de fase temprana con ascorbato combinados con tratamientos est&#xE1;ndar contra el c&#xE1;ncer</a></strong>.</p><p id="_88" tabindex="-1">Se a&#xF1;adi&#xF3; <a href="/espanol/cancer/tratamiento/mca/pro/vitamina-c-pdq#link/_78">texto</a> sobre los resultados de dos ensayos cl&#xED;nicos preliminares con pacientes de c&#xE1;ncer de pulm&#xF3;n de c&#xE9;lulas no peque&#xF1;as y glioblastoma multiforme (se cit&#xF3; a Abou-Jawde  et al. como referencia 15 y a Schoenfeld  et al. como referencia 21).</p><p id="_disclaimerHP_3" tabindex="-1">Este sumario est&#xE1; redactado y mantenido por el <a href="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/medicina-complementaria-alternativa" title="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/medicina-complementaria-alternativa">Consejo editorial del PDQ&#xAE; sobre las terapias integrales, alternativas y complementarias</a>, que es editorialmente independiente del NCI. El sumario refleja una revisi&#xF3;n independiente de la bibliograf&#xED;a y no representa una declaraci&#xF3;n de pol&#xED;ticas del NCI o de los NIH. Para mayor informaci&#xF3;n sobre las pol&#xED;ticas de los sumarios y la funci&#xF3;n de los  consejos editoriales  del PDQ que mantienen los sumarios del PDQ, consultar en <a href="/espanol/cancer/tratamiento/mca/pro/vitamina-c-pdq#link/_AboutThis_1">Informaci&#xF3;n sobre este sumario del PDQ</a> y  la p&#xE1;gina sobre <a href="https://www.cancer.gov/espanol/publicaciones/pdq" title="https://www.cancer.gov/espanol/publicaciones/pdq">Banco de datos de informaci&#xF3;n de c&#xE1;ncer - PDQ&#xAE;</a>.
            </p></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _AboutThis_1
      field_pdq_section_title:
        - format: plain_text
          value: 'Información sobre este sumario del PDQ'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_AboutThis_1" class="pdq-sections"><section id="_AboutThis_2"><h3 id="_AboutThis_2_toc">Prop&#xF3;sito de este sumario</h3><p id="_AboutThis_3" tabindex="-1">Este sumario del PDQ con informaci&#xF3;n sobre el c&#xE1;ncer para profesionales de la salud proporciona informaci&#xF3;n integral revisada por expertos y con fundamento en datos probatorios sobre el uso de dosis altas de vitamina C en el tratamiento de personas con c&#xE1;ncer. El prop&#xF3;sito es servir como fuente de informaci&#xF3;n y ayuda para los m&#xE9;dicos que atienden a pacientes de c&#xE1;ncer. No  ofrece pautas ni recomendaciones formales para tomar decisiones relacionadas con la atenci&#xF3;n sanitaria.</p></section><section id="_AboutThis_21"><h3 id="_AboutThis_21_toc">Revisores y actualizaciones</h3><p id="_AboutThis_22" tabindex="-1">El  <a href="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/medicina-complementaria-alternativa" title="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/medicina-complementaria-alternativa">Consejo editorial del PDQ&#xAE; sobre las terapias integrales, alternativas y complementarias</a>, cuya funci&#xF3;n editorial es independiente del Instituto Nacional del C&#xE1;ncer (NCI), revisa con regularidad este sumario y, en caso necesario,   lo actualiza. Este sumario refleja una revisi&#xF3;n bibliogr&#xE1;fica independiente y no constituye una declaraci&#xF3;n de la pol&#xED;tica del Instituto Nacional del C&#xE1;ncer ni de los Institutos Nacionales de la Salud (NIH).</p><p id="_AboutThis_26" tabindex="-1">Cada mes, los miembros de este Consejo  examinan art&#xED;culos  publicados recientemente para determinar si se deben:</p><div class="pdq-content-list"><ul id="_AboutThis_23"><li>tratar en una reuni&#xF3;n,</li><li>citar textualmente, o</li><li>sustituir o actualizar, si ya se citaron con anterioridad.</li></ul></div><p id="_AboutThis_24" tabindex="-1">Los cambios en los sumarios se deciden mediante consenso, una vez que  los integrantes del Consejo eval&#xFA;an la solidez de los datos probatorios en los art&#xED;culos publicados y determinan la forma en que se incorporar&#xE1;n al sumario.</p><p id="" tabindex="-1">Los revisores principales del sumario sobre Dosis altas de vitamina C son:</p><div class="pdq-content-list"><ul id=""><li>Nagi B. Kumar, PhD, RD, FADA (Fellow of the American Dietetic Association)</li><li>Jeffrey D. White, MD (National Cancer Institute)</li></ul></div><p id="_AboutThis_25" tabindex="-1">Cualquier comentario o pregunta sobre el contenido de este sumario se debe enviar mediante el   <a href="https://www.cancer.gov/espanol/contactenos/correo-electronico" title="https://www.cancer.gov/espanol/contactenos/correo-electronico">formulario de comunicaci&#xF3;n</a> en Cancer.gov/espanol del NCI.  No comunicarse con los miembros del Consejo para enviar preguntas o comentarios sobre los sumarios.  Los miembros del Consejo no responder&#xE1;n a preguntas del p&#xFA;blico. </p></section><section id="_AboutThis_9"><h3 id="_AboutThis_9_toc">Grados de comprobaci&#xF3;n cient&#xED;fica</h3><p id="_AboutThis_10" tabindex="-1">En algunas referencias bibliogr&#xE1;ficas de este sumario se indica el grado de comprobaci&#xF3;n cient&#xED;fica. El prop&#xF3;sito de estas designaciones es ayudar al lector a evaluar la solidez de los datos probatorios que sustentan el uso de  ciertas intervenciones  o enfoques. El Consejo editorial del PDQ&#xAE; sobre las terapias integrales, alternativas y complementarias emplea un <a href="/espanol/publicaciones/pdq/grados-comprobacion/cam">sistema de jerarquizaci&#xF3;n formal</a> para establecer  las designaciones del grado de comprobaci&#xF3;n cient&#xED;fica.</p></section><section id="_AboutThis_11"><h3 id="_AboutThis_11_toc">Permisos para el uso de este sumario</h3><p id="_AboutThis_12" tabindex="-1">PDQ (Physician Data Query) es una marca registrada. Se autoriza el libre uso del texto  de los documentos del PDQ. Sin embargo, no se podr&#xE1; identificar como un sumario de informaci&#xF3;n sobre c&#xE1;ncer del PDQ del  NCI,  salvo que se reproduzca en su totalidad y se actualice con regularidad. Por otra parte, se permitir&#xE1; que un autor  escriba una oraci&#xF3;n como &#x201C;En el sumario del PDQ  del NCI de informaci&#xF3;n sobre la prevenci&#xF3;n del c&#xE1;ncer de mama se describen, en breve, los siguientes riesgos: [incluir fragmento del sumario]&#x201D;.</p><p id="_AboutThis_13" tabindex="-1">Se sugiere citar la referencia bibliogr&#xE1;fica de este sumario del PDQ de la siguiente forma:</p><p id="_AboutThis_14" tabindex="-1">PDQ&#xAE; . PDQ Dosis altas de vitamina C. Bethesda, MD: National Cancer Institute. Actualizaci&#xF3;n:  &lt;MM/DD/YYYY&gt;. Disponible en: <a href="https://www.cancer.gov/espanol/cancer/tratamiento/mca/pro/vitamina-c-pdq" title="https://www.cancer.gov/espanol/cancer/tratamiento/mca/pro/vitamina-c-pdq">https://www.cancer.gov/espanol/cancer/tratamiento/mca/pro/vitamina-c-pdq</a>.  Fecha de acceso: &lt;MM/DD/YYYY&gt;. </p><p id="_AboutThis_15" tabindex="-1">Las im&#xE1;genes  en este sumario se reproducen  con el permiso del autor, el artista o la  editorial para uso exclusivo en los sumarios del PDQ. La utilizaci&#xF3;n de las im&#xE1;genes fuera del  PDQ requiere la autorizaci&#xF3;n del propietario, que el Instituto Nacional del C&#xE1;ncer no  puede otorgar. Para obtener m&#xE1;s informaci&#xF3;n sobre el uso de las ilustraciones de este sumario o de  otras im&#xE1;genes relacionadas con el c&#xE1;ncer, consultar <a href="https://visualsonline.cancer.gov/" title="https://visualsonline.cancer.gov/">Visuals Online</a>, una colecci&#xF3;n de m&#xE1;s de 2000 im&#xE1;genes cient&#xED;ficas.</p></section><section id="_AboutThis_16"><h3 id="_AboutThis_16_toc">Cl&#xE1;usula sobre el descargo de responsabilidad</h3><p id="_AboutThis_18" tabindex="-1">La informaci&#xF3;n en estos sumarios  no se debe utilizar como base para determinar reembolsos por parte de las aseguradoras. Para obtener m&#xE1;s informaci&#xF3;n  sobre la cobertura de seguros, consultar la p&#xE1;gina <a href="https://www.cancer.gov/espanol/cancer/manejo-del-cancer" title="https://www.cancer.gov/espanol/cancer/manejo-del-cancer">Manejo de la atenci&#xF3;n del c&#xE1;ncer</a> disponible en Cancer.gov/espanol.</p></section><section id="_AboutThis_19"><h3 id="_AboutThis_19_toc">Para obtener m&#xE1;s informaci&#xF3;n</h3><p id="_AboutThis_20" tabindex="-1">En Cancer.gov/espanol,  se ofrece m&#xE1;s informaci&#xF3;n sobre c&#xF3;mo comunicarse o recibir ayuda en  <a href="https://www.cancer.gov/espanol/contactenos" title="https://www.cancer.gov/espanol/contactenos">&#xBF;En qu&#xE9; podemos ayudarle?</a>.
            Tambi&#xE9;n se puede enviar un mensaje de  correo electr&#xF3;nico  mediante este  <a href="https://www.cancer.gov/espanol/contactenos/correo-electronico" title="https://www.cancer.gov/espanol/contactenos/correo-electronico">formulario</a>.</p></section></div>

- entity: node
  type: pdq_cancer_information_summary
  title: 'Mistletoe Extracts (PDQ®)–Health Professional Version'
  status: 1
  langcode: en
  moderation_state:
    value: published
  field_pdq_url:
    value: /about-cancer/treatment/cam/hp/mistletoe-pdq
  field_pdq_cdr_id:
    value: 269596
  field_pdq_audience:
    value: Health Professionals
  field_pdq_summary_type:
    value: Integrative, alternative, and complementary therapies
  field_date_posted:
    value: '2002-12-21'
  field_date_updated:
    value: '2018-10-05'
  field_short_title:
    value: 'Mistletoe Extracts'
  field_page_description:
    value: 'Mistletoe, a semiparasitic plant that grows on several types of trees such as apple, oak, pine and elm, is commonly used in cancer patients in Europe. Read about laboratory and human studies of extracts, such as Iscador and Eurixor, and their effects on quality of life, survival and symptom relief in this expert-review'
  field_public_use:
    value: 1
  field_summary_sections:
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _1
      field_pdq_section_title:
        - format: plain_text
          value: 'Overview'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_1" class="pdq-sections"><div class="pdq-hp-patient-toggle"><a href="/about-cancer/treatment/cam/patient/mistletoe-pdq">Go to Patient Version</a></div><p id="_2" tabindex="-1">This <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45333&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045333&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cancer</a> information summary provides an overview of the use of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285939&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285939&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">mistletoe</a> as a treatment for people with cancer. The summary includes a brief history of mistletoe research, the results of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45961&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045961&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">clinical trials</a>, and possible <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46580&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046580&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">side effects</a> of mistletoe use.</p><p id="_3" tabindex="-1">This summary contains the following key information:</p><div class="pdq-content-list"><ul id="_4"><li>Mistletoe is a <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44075&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044075&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">semiparasitic</a> plant that has been used for centuries to treat numerous human ailments.</li><li>Mistletoe is used commonly in Europe, where a variety of different extracts are manufactured and marketed as <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44678&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044678&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">injectable</a> prescription drugs. These  injectable drugs are not available commercially in the United States and are not approved as a  treatment for people with cancer.</li><li>Mistletoe is one of the most widely studied CAM therapies for cancer. In certain European countries, the preparations made from European mistletoe (<em>Viscum album</em>, Loranthaceae) are among the most prescribed drugs offered to cancer patients.</li><li>Although mistletoe plants and berries are considered poisonous to humans, few serious side effects have been associated with mistletoe extract use.       </li><li>
            The use of mistletoe as a treatment for people with cancer has been investigated in <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44195&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044195&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">clinical studies</a>. Reports of improved survival and/or <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45417&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045417&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">quality of life</a> have been common, but many of the studies had major weaknesses that raise doubts about the reliability of the findings.</li><li>At present, the use of mistletoe cannot be recommended outside the context of well-designed clinical trials. Such trials will be valuable to determine more clearly whether mistletoe can be useful in the treatment of specific subsets of cancer patients.</li></ul></div><p id="_5" tabindex="-1">Many of the medical and scientific terms used in this summary are hypertext linked (at first use in each section) to the <a href="https://www.cancer.gov/publications/dictionaries/cancer-terms/" title="https://www.cancer.gov/publications/dictionaries/cancer-terms/">NCI Dictionary of Cancer Terms</a>, which is oriented toward nonexperts. When a linked term is clicked, a definition will appear in a separate window. </p><p id="_6" tabindex="-1">Reference citations in some <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44271&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044271&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">PDQ</a> cancer information summaries may include links to external websites that are operated by individuals or organizations for the purpose of marketing or advocating the use of specific treatments or products. These reference citations are included for informational purposes only. Their inclusion should not be viewed as an endorsement of the content of the websites, or of any treatment or product,            by the PDQ Integrative, Alternative, and Complementary Therapies Editorial Board or the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44266&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044266&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">National Cancer Institute</a>.</p></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _7
      field_pdq_section_title:
        - format: plain_text
          value: 'General Information'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_7" class="pdq-sections"><p id="_9" tabindex="-1"><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285939&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285939&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">Mistletoe</a>, a <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44075&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044075&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">semiparasitic</a> plant, holds interest as a potential anticancer agent because <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=407760&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000407760&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">extracts</a> derived from it have been shown to kill <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45333&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045333&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cancer</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46476&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046476&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cells</a> <em><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45733&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045733&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">in vitro</a></em>
            <a href="#cit/section_2.1">1</a><a href="#cit/section_2.2">2</a><a href="#cit/section_2.3">3</a><a href="#cit/section_2.4">4</a><a href="#cit/section_2.5">5</a><a href="#cit/section_2.6">6</a><a href="#cit/section_2.7">7</a><a href="#cit/section_2.8">8</a><a href="#cit/section_2.9">9</a><a href="#cit/section_2.10">10</a> to down-regulate central <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45693&amp;version=healthprofessional&amp;language=English&amp;dictionary=genetic" onclick="javascript:popWindow('defbyid','CDR0000045693&amp;version=healthprofessional&amp;language=English&amp;dictionary=genetic'); return(false);">genes</a> involved in tumor progression, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45771&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045771&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">malignancy</a>, and cell migration and invasion, such as TGF-&#x3B2; and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44211&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044211&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">matrix-metalloproteinases</a>.<a href="#cit/section_2.11">11</a><a href="#cit/section_2.12">12</a>
            Mistletoe extracts have been shown to enforce <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44062&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044062&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">natural killer cell</a>-mediated <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46634&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046634&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">tumor</a> cell <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44606&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044606&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">lysis,</a> reduce the migratory and invasive potential of tumor cells, and stimulate <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46356&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046356&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">immune system</a> cells both <em>in vitro</em>  and <em><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46352&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046352&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">in vivo</a></em>.<a href="#cit/section_2.10">10</a><a href="#cit/section_2.11">11</a><a href="#cit/section_2.12">12</a><a href="#cit/section_2.13">13</a><a href="#cit/section_2.14">14</a><a href="#cit/section_2.15">15</a><a href="#cit/section_2.16">16</a><a href="#cit/section_2.17">17</a><a href="#cit/section_2.18">18</a><a href="#cit/section_2.19">19</a><a href="#cit/section_2.20">20</a><a href="#cit/section_2.21">21</a><a href="#cit/section_2.22">22</a><a href="#cit/section_2.23">23</a><a href="#cit/section_2.24">24</a><a href="#cit/section_2.25">25</a><a href="#cit/section_2.26">26</a><a href="#cit/section_2.27">27</a><a href="#cit/section_2.28">28</a><a href="#cit/section_2.29">29</a><a href="#cit/section_2.30">30</a><a href="#cit/section_2.31">31</a> Three components of mistletoe, namely <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44094&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044094&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">viscotoxins</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44162&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044162&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">polysaccharides</a>, and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44051&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044051&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">lectins</a>, may be responsible for these effects.<a href="#cit/section_2.10">10</a><a href="#cit/section_2.13">13</a><a href="#cit/section_2.14">14</a><a href="#cit/section_2.15">15</a><a href="#cit/section_2.19">19</a><a href="#cit/section_2.20">20</a><a href="#cit/section_2.21">21</a><a href="#cit/section_2.23">23</a><a href="#cit/section_2.24">24</a><a href="#cit/section_2.25">25</a><a href="#cit/section_2.32">32</a><a href="#cit/section_2.33">33</a><a href="#cit/section_2.34">34</a><a href="#cit/section_2.35">35</a><a href="#cit/section_2.36">36</a><a href="#cit/section_2.37">37</a><a href="#cit/section_2.38">38</a><a href="#cit/section_2.39">39</a>  Viscotoxins are small <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46092&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046092&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">proteins</a> that exhibit cell-killing activity and possible immune system&#x2013;stimulating activity.<a href="#cit/section_2.1">1</a><a href="#cit/section_2.6">6</a><a href="#cit/section_2.20">20</a><a href="#cit/section_2.21">21</a><a href="#cit/section_2.40">40</a><a href="#cit/section_2.41">41</a> Lectins are complex <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45065&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045065&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">molecules</a> made of both protein and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285960&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285960&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">carbohydrates</a> that are capable of binding to the outside of cells (e.g., immune system cells) and inducing biochemical changes in them.<a href="#cit/section_2.10">10</a><a href="#cit/section_2.42">42</a><a href="#cit/section_2.43">43</a>
            <a href="#cit/section_2.44">44</a><a href="#cit/section_2.45">45</a> In view of mistletoe&#x2019;s ability to stimulate the immune system, it has been classified as a type of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45616&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045616&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">biological response modifier</a>.<a href="#cit/section_2.42">42</a> Biological response modifiers constitute a diverse group of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44510&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044510&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">biological</a> molecules that have been used individually, or in combination with other agents, to treat cancer or to lessen the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46580&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046580&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">side effects</a> of anticancer drugs. Mistletoe extracts have been demonstrated in preclinical settings to have other mechanisms of action, such as antiangiogenesis.<a href="#cit/section_2.29">29</a></p><p id="_10" tabindex="-1">Preparations from mistletoe extracts are  most frequently used in the treatment of cancer patients in German-speaking countries.<a href="#cit/section_2.46">46</a>              Commercially available extracts are marketed under a variety of brand names, including Iscador (see explanation of suffixes below), Eurixor, Helixor, Isorel, Iscucin, Plenosol, and abnobaVISCUM. Some extracts are marketed under more than one name.  Iscador, Isorel, and Plenosol are also sold as Iscar, Vysorel, and Lektinol, respectively. All of these products are prepared from  <em>Viscum album</em> (Loranthaceae)  (<em>Viscum album</em> L. or European mistletoe). They are not sold as a drug in the United States. Eurixor, Isorel, and Vysorel are no longer available  on the market for sale.</p><p id="_100" tabindex="-1">In addition to European mistletoe, extracts from a type of Korean mistletoe (<em>Viscum album </em>var. <em>coloratum</em> [Kom.] Ohwi) have demonstrated <em>in vitro</em> and  <em>in vivo</em> cytotoxicity in laboratory studies.<a href="#cit/section_2.47">47</a><a href="#cit/section_2.48">48</a><a href="#cit/section_2.49">49</a><a href="#cit/section_2.50">50</a><a href="#cit/section_2.51">51</a></p><p id="_11" tabindex="-1">Mistletoe grows on several types of trees, and the chemical composition of extracts derived from it depends on the species of the host tree (e.g., apple, elm, oak, pine, poplar, and spruce), the time of year harvested, how the extracts are prepared, and the commercial producer.<a href="#cit/section_2.8">8</a><a href="#cit/section_2.43">43</a><a href="#cit/section_2.52">52</a><a href="#cit/section_2.53">53</a><a href="#cit/section_2.54">54</a><a href="#cit/section_2.55">55</a></p><p id="_12" tabindex="-1">Mistletoe extracts are prepared as <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43998&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043998&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">aqueous</a> solutions or solutions of water and alcohol, and they can be fermented or unfermented.<a href="#cit/section_2.4">4</a><a href="#cit/section_2.6">6</a><a href="#cit/section_2.22">22</a><a href="#cit/section_2.52">52</a><a href="#cit/section_2.53">53</a><a href="#cit/section_2.56">56</a><a href="#cit/section_2.57">57</a><a href="#cit/section_2.58">58</a><a href="#cit/section_2.59">59</a> Some extracts are prepared according to <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45712&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045712&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">homeopathic</a> principles, and others are not. Accordingly, as homeopathic preparations, they are typically not chemically standardized extracts.<a href="#cit/section_2.10">10</a> <a href="#cit/section_2.60">60</a> In addition, the commercial products can be subdivided according to the species of host tree, which is typically indicated in the product name by a suffix letter.  Iscador, a fermented aqueous extract of <em>Viscum album</em> L. that is prepared as a homeopathic drug, is marketed as IscadorM (from apple trees; <em>Malus domestica</em>), IscadorP (from pine trees; <em>Pinus sylvestris</em>), IscadorQu (from oak trees; <em>Quercus robur</em>), and IscadorU (from elm trees; <em>Ulmus minor</em>). Helixor, an unfermented aqueous extract of <em>Viscum album</em> L. that is standardized by its biological effect on human <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45343&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045343&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">leukemia</a> cells <em>in vitro</em>, is marketed as HelixorA (from spruce trees; <em>Picea abies</em>), HelixorM (from apple trees), and HelixorP (from pine trees; <em>Pinus sylvestris</em>).<a href="#cit/section_2.57">57</a> Eurixor (which is no longer available  on the market for sale), an unfermented aqueous extract of <em>Viscum album</em> L. harvested from poplar trees, is reportedly standardized to contain a specific amount of one of mistletoe&#x2019;s lectins (i.e., the lectin ML-1; refer to the  <a href="/about-cancer/treatment/cam/hp/mistletoe-pdq#link/_17">History</a>  section of this summary for more information).<a href="#cit/section_2.57">57</a> Some proponents contend the choice of extract should depend on the type of tumor and the gender of the patient.<a href="#cit/section_2.55">55</a><a href="#cit/section_2.57">57</a><a href="#cit/section_2.61">61</a><a href="#cit/section_2.62">62</a></p><p id="_101" tabindex="-1">A recombinant ML-1 from <em>Escherichia coli</em>     bacteria known as rViscumin or aviscumine has been studied in the laboratory and in phase I clinical trials.   Because this is not an extract of mistletoe,        it is out of the purview of this summary.<a href="#cit/section_2.63">63</a></p><p id="_13" tabindex="-1">Mistletoe extracts are usually given by <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45914&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045914&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">subcutaneous</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44678&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044678&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">injection</a>, although administration by other routes (i.e., <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44068&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044068&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">oral</a>,  <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285972&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285972&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">intrapleural</a>, intratumoral, and intravenous) has been described.<a href="#cit/section_2.19">19</a><a href="#cit/section_2.22">22</a><a href="#cit/section_2.23">23</a><a href="#cit/section_2.24">24</a><a href="#cit/section_2.25">25</a><a href="#cit/section_2.26">26</a><a href="#cit/section_2.39">39</a><a href="#cit/section_2.43">43</a><a href="#cit/section_2.55">55</a><a href="#cit/section_2.57">57</a><a href="#cit/section_2.60">60</a><a href="#cit/section_2.64">64</a><a href="#cit/section_2.65">65</a><a href="#cit/section_2.66">66</a><a href="#cit/section_2.67">67</a><a href="#cit/section_2.68">68</a><a href="#cit/section_2.69">69</a><a href="#cit/section_2.70">70</a> In most reported studies, subcutaneous injections were given 2 to 3 times a week, but the overall duration of treatment varied considerably.</p><p id="_14" tabindex="-1"><em>Viscum album</em> is listed in the Homeopathic Pharmacopoeia of the United States, which is the officially recognized compendium for homeopathic drugs in this country.<a href="#cit/section_2.71">71</a> Although the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=454785&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000454785&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">U.S. Food and Drug Administration</a> (FDA) has regulatory authority over homeopathic drugs,  this  authority is usually not exercised unless the drugs are formulated for injection or there is evidence of severe <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43986&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043986&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">toxicity</a>.</p><p id="_15" tabindex="-1">Before researchers can conduct clinical drug research in the United States, they must file an <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=762975&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000762975&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">Investigational New Drug</a> (IND) application with the FDA. IND approval is also required for clinical investigation of homeopathic drugs. The FDA does not disclose information about IND applications or approvals; this information can be  released  only  by  the applicants. At least  two U.S. <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44685&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044685&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">investigators</a>    were given    IND approval to study mistletoe as a treatment for people with cancer  (NCCAM-02-AT-260 and <a href="/clinicaltrials/NCT00052325">TJUH-01F.45</a>). </p><p id="_16" tabindex="-1">In this summary, the mistletoe extract or product used in each study will be specified wherever  possible.</p><h6 do-not-show="toc">References</h6><ol><li id="section_2.1">Jung ML, Baudino S, Rib&#xE9;reau-Gayon G, et al.: Characterization of cytotoxic proteins from mistletoe (Viscum album L.). Cancer Lett 51 (2): 103-8, 1990.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2344587&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2344587&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.2">Kuttan G, Vasudevan DM, Kuttan R: Effect of a preparation from Viscum album on tumor development in vitro and in mice. J Ethnopharmacol 29 (1): 35-41, 1990.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2345458&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2345458&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.3">Walzel H, Jonas L, Rosin T, et al.: Relationship between internalization kinetics and cytotoxicity of mistletoe lectin I to L1210 leukaemia cells. Folia Biol (Praha) 36 (3-4): 181-8, 1990.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2257937&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2257937&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.4">Janssen O, Scheffler A, Kabelitz D: In vitro effects of mistletoe extracts and mistletoe lectins. Cytotoxicity towards tumor cells due to the induction of programmed cell death (apoptosis). Arzneimittelforschung 43 (11): 1221-7, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8292069&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8292069&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.5">Jurin M, Zarkovi&#x107; N, Hrzenjak M, et al.: Antitumorous and immunomodulatory effects of the Viscum album L. preparation Isorel. Oncology 50 (6): 393-8, 1993 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8233280&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8233280&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.6">Schaller G, Urech K, Giannattasio M: Cytotoxicity of different viscotoxins and extracts from the European subspecies Viscum album L. Phytother Res  10 (6): 473-7, 1996.</li><li id="section_2.7">Gabius HJ, Darro F, Remmelink M, et al.: Evidence for stimulation of tumor proliferation in cell lines and histotypic cultures by clinically relevant low doses of the galactoside-binding mistletoe lectin, a component of proprietary extracts. Cancer Invest 19 (2): 114-26, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11296616&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11296616&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.8">Maier G, Fiebig HH: Absence of tumor growth stimulation in a panel of 16 human tumor cell lines by mistletoe extracts in vitro. Anticancer Drugs 13 (4): 373-9, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11984083&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11984083&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.9">Franz H: Mistletoe lectins and their A and B chains. Oncology 43 (Suppl 1): 23-34, 1986.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3543782&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3543782&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.10">Mengs U, G&#xF6;thel D, Leng-Peschlow E: Mistletoe extracts standardized to mistletoe lectins in oncology: review on current status of preclinical research. Anticancer Res 22 (3): 1399-407, 2002 May-Jun.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12168816&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12168816&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.11">Podlech O, Harter PN, Mittelbronn M, et al.: Fermented mistletoe extract as a multimodal antitumoral agent in gliomas. Evid Based Complement Alternat Med 2012: 501796, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23133496&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23133496&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.12">Sch&#xF6;tterl S, H&#xFC;bner M, Armento A, et al.: Viscumins functionally modulate cell motility-associated gene expression. Int J Oncol 50 (2): 684-696, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28101577&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28101577&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.13">Hostanska K, Hajto T, Spagnoli GC, et al.: A plant lectin derived from Viscum album induces cytokine gene expression and protein production in cultures of human peripheral blood mononuclear cells. Nat Immun 14 (5-6): 295-304, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8933823&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8933823&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.14">Beuth J, Stoffel B, Ko HL, et al.: Immunomodulating ability of galactoside-specific lectin standardized and depleted mistletoe extract. Arzneimittelforschung 45 (11): 1240-2, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8929248&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8929248&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.15">Lenartz D, Stoffel B, Menzel J, et al.: Immunoprotective activity of the galactoside-specific lectin from mistletoe after tumor destructive therapy in glioma patients. Anticancer Res 16 (6B): 3799-802, 1996 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9042260&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9042260&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.16">Fischer S, Scheffler A, Kabelitz D: Oligoclonal in vitro response of CD4 T cells to vesicles of mistletoe extracts in mistletoe-treated cancer patients. Cancer Immunol Immunother 44 (3): 150-6, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9191874&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9191874&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.17">Preisfeld A: Influence of aqueous mistletoe preparations on humoral immune parameters with emphasis on the cytotoxicity of human complement in breast cancer patients. Forsch Komplementarmed  4 (4): 224-8, 1997.</li><li id="section_2.18">Chernyshov VP, Omelchenko LI, Heusser P, et al.: Immunomodulatory actions of Viscum album (Iscador) in children with recurrent respiratory disease as a result of the Chernobyl nuclear accident. Complement Ther Med  5 (3): 141-6, 1997.</li><li id="section_2.19">Heiny BM, Albrecht V, Beuth J: Correlation of immune cell activities and beta-endorphin release in breast carcinoma patients treated with galactose-specific lectin standardized mistletoe extract. Anticancer Res 18 (1B): 583-6, 1998 Jan-Feb.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9568181&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9568181&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.20">Stein GM, Schaller G, Pf&#xFC;ller U, et al.: Characterisation of granulocyte stimulation by thionins from European mistletoe and from wheat. Biochim Biophys Acta 1426 (1): 80-90, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9878694&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9878694&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.21">Stein GM, Schaller G, Pf&#xFC;ller U, et al.: Thionins from Viscum album L: influence of the viscotoxins on the activation of granulocytes. Anticancer Res 19 (2A): 1037-42, 1999 Mar-Apr.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10368652&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10368652&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.22">Mistletoe. In: Murray MT: The Healing Power of Herbs. Roseville, Calif: Prima Publishing, 1995, pp 253-9.</li><li id="section_2.23">Lenartz D, Dott U, Menzel J, et al.: Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe. Anticancer Res 20 (3B): 2073-6, 2000 May-Jun.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10928154&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10928154&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.24">Steuer-Vogt MK, Bonkowsky V, Ambrosch P, et al.: The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. Eur J Cancer 37 (1): 23-31, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11165126&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11165126&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.25">Goebell PJ, Otto T, Suhr J, et al.: Evaluation of an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized phase II trial. J Urol 168 (1): 72-5, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12050495&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12050495&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.26">Stauder H, Kreuser ED: Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: current state of clinical research. Onkologie 25 (4): 374-80, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12232491&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12232491&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.27">Saha C, Das M, Stephen-Victor E, et al.: Differential Effects of Viscum album Preparations on the Maturation and Activation of Human Dendritic Cells and CD4&#x207A; T Cell Responses. Molecules 21 (7): , 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27428940&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27428940&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.28">Hegde P, Maddur MS, Friboulet A, et al.: Viscum album exerts anti-inflammatory effect by selectively inhibiting cytokine-induced expression of cyclooxygenase-2. PLoS One 6 (10): e26312, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22028854&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22028854&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.29">Elluru SR, VAN Huyen JP, Delignat S, et al.: Antiangiogenic properties of viscum album extracts are associated with endothelial cytotoxicity. Anticancer Res 29 (8): 2945-50, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19661299&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19661299&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.30">Elluru SR, Duong van Huyen JP, Delignat S, et al.: Induction of maturation and activation of human dendritic cells: a mechanism underlying the beneficial effect of Viscum album as complimentary therapy in cancer. BMC Cancer 8: 161, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18533025&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18533025&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.31">Elluru S, Duong Van Huyen JP, Delignat S, et al.: Molecular mechanisms underlying the immunomodulatory effects of mistletoe (Viscum album L.) extracts Iscador. Arzneimittelforschung 56 (6A): 461-6, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16927527&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16927527&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.32">Frohne D, Pfander HJ: Viscum album. In: Frohne D, Pfander HJ: Giftpflanzen: ein Handbuch f&#xFC;r Apotheker, &#xC4;rzte,
            Toxikologen und Biologen. 3rd rev. ed. Stuttgart, Germany: Wissenschaftliche Verlagsgesellschaft, 1987, pp 179-80.</li><li id="section_2.33">Pusztai A, Grant G, Pfuller U, et al.: Nutritional and metabolic effects of mistletoe lectin ML-1 (type 2 RIP) in the rat. In: European Cooperation in the Field of Scientific and Technical Research: COST 98: Effects of Antinutrients on the Nutritional Value of Legume Diets. Brussels, Belgium: European Commission, Directorate-General XII, Science, Research and Development, 1998, pp 164-7.</li><li id="section_2.34">Pusztai A, Grant G, Gelencs&#xE9;r E, et al.: Effects of an orally administered mistletoe (type-2 RIP) lectin on growth, body composition, small intestinal structure, and insulin levels in young rats. J Nutr Biochem  9 (1): 31-6, 1998.</li><li id="section_2.35">Ewen SWB, Bardocz S, Grant G, et al.: The effects of PHA and mistletoe lectin binding to epithelium of rat and mouse gut. In: European Cooperation in the Field of Scientific and Technical Research: COST 98: Effects of Antinutrients on the Nutritional Value of Legume Diets. Brussels, Belgium: European Commission, Directorate-General XII, Science, Research and Development, 1998, pp 221-5.</li><li id="section_2.36">Pryme IF, Bardocz S, Grant G, et al.: The plant lectins PHA and ML-1 suppress the growth of a lymphosarcoma tumour in mice. In: European Cooperation in the Field of Scientific and Technical Research: COST 98: Effects of Antinutrients on the Nutritional Value of Legume Diets. Brussels, Belgium: European Commission, Directorate-General XII, Science, Research and Development, 1998, pp 215-20.</li><li id="section_2.37">Tubeuf  KFv, Neckel G, Marzell H: Monographie der Mistel. Munchen, Berlin: R. Oldenbourg, 1923.</li><li id="section_2.38">Teuscher E: Viscum album. In: Hansel R, Keller K, Rimpler H, et al.: Hagers Handbuch der Pharmazeutischen Praxis, Vol. 6. 5th ed. Berlin, Germany: Springer-Verlag, 1994, pp 1160-83.</li><li id="section_2.39">Grossarth-Maticek R, Kiene H, Baumgartner SM, et al.: Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study. Altern Ther Health Med 7 (3): 57-66, 68-72, 74-6 passim, 2001 May-Jun.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11347286&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11347286&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.40">Capernaros Z: The golden bough: the case for mistletoe. Eur J Herbal Med  1 (1):19-24, 1994.</li><li id="section_2.41">Schrader G, Apel K: Isolation and characterization of cDNAs encoding viscotoxins of mistletoe (Viscum album). Eur J Biochem 198 (3): 549-53, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1710983&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1710983&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.42">Gabius HJ, Gabius S, Joshi SS, et al.: From ill-defined extracts to the immunomodulatory lectin: will there be a reason for oncological application of mistletoe? Planta Med 60 (1): 2-7, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8134410&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8134410&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.43">Samtleben R, Hajto T, Hostanska K, et al.: Mistletoe lectins as immunostimulants (chemistry, pharmacology and clinic). In: Wagner H, ed.: Immunomodulatory Agents from Plants. Basel, Switzerland: Birkhauser Verlag, 1999, pp 223-41.</li><li id="section_2.44">Abdullaev FI, de Mejia EG: Antitumor effect of plant lectins. Nat Toxins 5 (4): 157-63, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9407559&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9407559&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.45">Kilpatrick DC: Mechanisms and assessment of lectin-mediated mitogenesis. Mol Biotechnol 11 (1): 55-65, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10367282&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10367282&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.46">Horneber MA, Bueschel G, Huber R, et al.: Mistletoe therapy in oncology. Cochrane Database Syst Rev  (2): CD003297, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18425885&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18425885&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.47">Khil LY, Kim W, Lyu S, et al.: Mechanisms involved in Korean mistletoe lectin-induced apoptosis of cancer cells. World J Gastroenterol 13 (20): 2811-8, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17569116&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17569116&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.48">Kim MS, Lee J, Lee KM, et al.: Involvement of hydrogen peroxide in mistletoe lectin-II-induced apoptosis of myeloleukemic U937 cells. Life Sci 73 (10): 1231-43, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12850239&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12850239&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.49">Choi SH, Lyu SY, Park WB: Mistletoe lectin induces apoptosis and telomerase inhibition in human A253 cancer cells through dephosphorylation of Akt. Arch Pharm Res 27 (1): 68-76, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14969342&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14969342&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.50">Romagnoli S, Fogolari F, Catalano M, et al.: NMR solution structure of viscotoxin C1 from Viscum album species Coloratum ohwi: toward a structure-function analysis of viscotoxins. Biochemistry 42 (43): 12503-10, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14580196&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14580196&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.51">Yoon TJ, Yoo YC, Kang TB, et al.: Antitumor activity of the Korean mistletoe lectin is attributed to activation of macrophages and NK cells. Arch Pharm Res 26 (10): 861-7, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14609136&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14609136&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.52">Rib&#xE9;reau-Gayon G, Jung ML, Di Scala D, et al.: Comparison of the effects of fermented and unfermented mistletoe preparations on cultured tumor cells. Oncology 43 (Suppl 1): 35-41, 1986.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3808575&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3808575&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.53">J&#xE4;ggy C, Musielski H, Urech K, et al.: Quantitative determination of lectins in mistletoe preparations. Arzneimittelforschung 45 (8): 905-9, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7575759&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7575759&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.54">Zee-Cheng RK: Anticancer research on Loranthaceae plants. Drugs Future  22 (5): 519-30, 1997.</li><li id="section_2.55">Kaegi E: Unconventional therapies for cancer: 3. Iscador. Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative. CMAJ 158 (9): 1157-9, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9597967&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9597967&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.56">Stein G, Berg PA: Non-lectin component in a fermented extract from Viscum album L. grown on pines induces proliferation of lymphocytes from healthy and allergic individuals in vitro. Eur J Clin Pharmacol 47 (1): 33-8, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7988621&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7988621&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.57">Kleijnen J, Knipschild P: Mistletoe treatment for cancer: review of controlled trials in humans. Phytomedicine  1: 255-60, 1994.</li><li id="section_2.58">Wagner H, Jordan E, Feil B: Studies on the standardization of mistletoe preparations. Oncology 43 (Suppl 1): 16-22, 1986.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3027640&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3027640&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.59">Zarkovic N, Vukovic T, Loncaric I, et al.: An overview on anticancer activities of the Viscum album extract Isorel. Cancer Biother Radiopharm 16 (1): 55-62, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11279798&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11279798&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.60">Mellor D: Mistletoe in homoeopathic cancer treatment. Prof Nurse 4 (12): 605-7, 1989.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2813459&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2813459&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.61">Fellmer KE: A clinical trial of Iscador: follow-up treatment of irradiated genital carcinomata for the prevention of recurrences. Br Homeopath J  57: 43-7, 1968.</li><li id="section_2.62">Kjaer M: Mistletoe (Iscador) therapy in stage IV renal adenocarcinoma. A phase II study in patients with measurable lung metastases. Acta Oncol 28 (4): 489-94, 1989.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2477047&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2477047&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.63">Sch&#xF6;ffski P, Riggert S, Fumoleau P, et al.: Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group. Ann Oncol 15 (12): 1816-24, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15550588&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15550588&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.64">Matthes HF, Schad F, Buchwald D, et al.: Endoscopic ultrasound-guided fine-needle Injection of Viscum album L. (mistletoe; Helixor M) in the therapy of primary inoperable pancreas cancer:  a pilot study. [Abstract] Gastroenterology  128 (Suppl 2): A-T988, A433-A434, 2005.</li><li id="section_2.65">Matthes HF, Schad F, Schenk G: Viscum album in the therapy of primary inoperable hepatocellular carcinoma (HCC). [Abstract] Gastroenterology  126 (Suppl 2): A-755, A101-A102, 2004.</li><li id="section_2.66">Schaefermeyer G, Schaefermeyer H: Treatment of pancreatic cancer with Viscum album (Iscador): a retrospective study of 292 patients 1986-1996. Complement Ther Med  6 (4): 172-7, 1998.</li><li id="section_2.67">Kleeberg UR, Brocker EB, Lejeune F, et al.: Adjuvant trial in melanoma patients comparing rlFN-alpha to rlFN-gamma to Iscador to a control group after curative resection of high risk primary (&gt;=3mm) or regional lymphnode metastasis (EORTC 18871). [Abstract] Eur J Cancer  35 (Suppl 4): A-264, s82, 1999.</li><li id="section_2.68">Heiny BM, Albrecht V, Beuth J: Stabilization of quality of life with mistletoe lectin-1-standardized extract in advanced colorectal carcinoma. Onkologe  4 (Suppl 1): S35-9, 1998.</li><li id="section_2.69">Wetzel D, Sch&#xE4;fer M: Results of a randomised placebo-controlled multicentre study with PS76A2 (standardised mistletoe preparation) in patients with breast cancer receiving adjuvant chemotherapy. [Abstract] Phytomedicine  7 (Suppl 2): A-SL-66, 2000.</li><li id="section_2.70">Cho JS, Na KJ, Lee Y, et al.: Chemical Pleurodesis Using Mistletoe Extraction (ABNOVAviscum(&#xAE;) Injection) for Malignant Pleural Effusion. Ann Thorac Cardiovasc Surg 22 (1): 20-6, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26639937&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26639937&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.71">Viscum album. In: Homoeopathic Pharmacopoeia Convention of the United States: Homoeopathic Pharmacopoeia of the United States. Washington, DC: 2002, Monograph 9444 Visc.</li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _17
      field_pdq_section_title:
        - format: plain_text
          value: 'History'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_17" class="pdq-sections"><p id="_18" tabindex="-1"><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285939&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285939&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">Mistletoe</a> has been used for centuries for its medicinal properties.<a href="#cit/section_3.1">1</a><a href="#cit/section_3.2">2</a><a href="#cit/section_3.3">3</a> <a href="#cit/section_3.4">4</a><a href="#cit/section_3.5">5</a><a href="#cit/section_3.6">6</a> It was reportedly used by the Druids and the ancient Greeks, and it appears in legend and folklore as a <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44073&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044073&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">panacea</a>. It has been used in various forms to treat <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45333&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045333&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cancer</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44028&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044028&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">epilepsy</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46348&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046348&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">infertility</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46296&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046296&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">menopausal</a> symptoms, nervous tension, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=440101&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000440101&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">asthma</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44038&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044038&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">hypertension</a>, headache, and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45667&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045667&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">dermatitis</a>. The use of mistletoe in the treatment of cancer is about 100 years old, and its use in the treatment of other  indications is much older. Modern interest in mistletoe as an anticancer treatment  began in the 1920s.   Most of the results of clinical studies have been published exclusively in German. Refer to the <a href="/about-cancer/treatment/cam/hp/mistletoe-pdq#link/_35">Human/Clinical Studies</a> section of this summary for more information.</p><p id="_19" tabindex="-1"> Another reported activity of mistletoe that may be relevant to optimum functioning of the immune system in individuals with cancer is stabilization of the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44393&amp;version=healthprofessional&amp;language=English&amp;dictionary=genetic" onclick="javascript:popWindow('defbyid','CDR0000044393&amp;version=healthprofessional&amp;language=English&amp;dictionary=genetic'); return(false);">DNA</a> in <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45993&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045993&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">white blood cells</a>, including white blood cells that have been exposed to DNA-damaging <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45214&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045214&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">chemotherapy</a> drugs.<a href="#cit/section_3.7">7</a><a href="#cit/section_3.8">8</a><a href="#cit/section_3.9">9</a><a href="#cit/section_3.10">10</a><a href="#cit/section_3.11">11</a></p><p id="_20" tabindex="-1">Mistletoe has been shown to stimulate increases in the number and the activity of various types of white blood cells.<a href="#cit/section_3.2">2</a><a href="#cit/section_3.3">3</a><a href="#cit/section_3.9">9</a><a href="#cit/section_3.11">11</a><a href="#cit/section_3.12">12</a><a href="#cit/section_3.13">13</a><a href="#cit/section_3.14">14</a><a href="#cit/section_3.15">15</a><a href="#cit/section_3.16">16</a><a href="#cit/section_3.17">17</a><a href="#cit/section_3.18">18</a><a href="#cit/section_3.19">19</a><a href="#cit/section_3.20">20</a><a href="#cit/section_3.21">21</a><a href="#cit/section_3.22">22</a><a href="#cit/section_3.23">23</a><a href="#cit/section_3.24">24</a><a href="#cit/section_3.25">25</a><a href="#cit/section_3.26">26</a><a href="#cit/section_3.27">27</a><a href="#cit/section_3.28">28</a><a href="#cit/section_3.29">29</a><a href="#cit/section_3.30">30</a><a href="#cit/section_3.31">31</a><a href="#cit/section_3.32">32</a><a href="#cit/section_3.33">33</a><a href="#cit/section_3.34">34</a><a href="#cit/section_3.35">35</a><a href="#cit/section_3.36">36</a><a href="#cit/section_3.37">37</a><a href="#cit/section_3.38">38</a><a href="#cit/section_3.39">39</a><a href="#cit/section_3.40">40</a><a href="#cit/section_3.41">41</a><a href="#cit/section_3.42">42</a><a href="#cit/section_3.43">43</a><a href="#cit/section_3.44">44</a><a href="#cit/section_3.45">45</a><a href="#cit/section_3.46">46</a><a href="#cit/section_3.47">47</a><a href="#cit/section_3.48">48</a><a href="#cit/section_3.49">49</a><a href="#cit/section_3.50">50</a><a href="#cit/section_3.51">51</a><a href="#cit/section_3.52">52</a><a href="#cit/section_3.53">53</a> Immune system&#x2013;enhancing <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46130&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046130&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cytokines</a>, such as <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=350231&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000350231&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">interleukin-1</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44045&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044045&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">interleukin-6</a>, and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45290&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045290&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">tumor necrosis factor</a>-alpha, are released by white blood cells after exposure to mistletoe <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=407760&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000407760&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">extracts</a>.<a href="#cit/section_3.1">1</a><a href="#cit/section_3.3">3</a><a href="#cit/section_3.7">7</a><a href="#cit/section_3.9">9</a><a href="#cit/section_3.10">10</a><a href="#cit/section_3.11">11</a><a href="#cit/section_3.14">14</a><a href="#cit/section_3.19">19</a><a href="#cit/section_3.29">29</a><a href="#cit/section_3.33">33</a><a href="#cit/section_3.37">37</a><a href="#cit/section_3.42">42</a><a href="#cit/section_3.43">43</a><a href="#cit/section_3.44">44</a><a href="#cit/section_3.45">45</a><a href="#cit/section_3.46">46</a><a href="#cit/section_3.48">48</a><a href="#cit/section_3.49">49</a><a href="#cit/section_3.50">50</a><a href="#cit/section_3.52">52</a><a href="#cit/section_3.53">53</a><a href="#cit/section_3.54">54</a> Other evidence suggests that mistletoe exerts its <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44020&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044020&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cytotoxic</a> effects by interfering with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46092&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046092&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">protein</a> synthesis in target cells <a href="#cit/section_3.3">3</a><a href="#cit/section_3.4">4</a><a href="#cit/section_3.8">8</a><a href="#cit/section_3.11">11</a><a href="#cit/section_3.33">33</a><a href="#cit/section_3.42">42</a><a href="#cit/section_3.43">43</a><a href="#cit/section_3.44">44</a><a href="#cit/section_3.45">45</a><a href="#cit/section_3.46">46</a><a href="#cit/section_3.52">52</a><a href="#cit/section_3.55">55</a><a href="#cit/section_3.56">56</a><a href="#cit/section_3.57">57</a><a href="#cit/section_3.58">58</a><a href="#cit/section_3.59">59</a><a href="#cit/section_3.60">60</a><a href="#cit/section_3.61">61</a><a href="#cit/section_3.62">62</a><a href="#cit/section_3.63">63</a> and by inducing <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46524&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046524&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">apoptosis</a>.<a href="#cit/section_3.3">3</a><a href="#cit/section_3.11">11</a><a href="#cit/section_3.36">36</a><a href="#cit/section_3.42">42</a><a href="#cit/section_3.46">46</a><a href="#cit/section_3.52">52</a><a href="#cit/section_3.64">64</a><a href="#cit/section_3.65">65</a><a href="#cit/section_3.66">66</a> Mistletoe may also serve a bridging function, bringing together immune system <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44024&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044024&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">effector cells</a> and tumor cells.<a href="#cit/section_3.18">18</a><a href="#cit/section_3.67">67</a></p><h6 do-not-show="toc">References</h6><ol><li id="section_3.1">Capernaros Z: The golden bough: the case for mistletoe. Eur J Herbal Med  1 (1):19-24, 1994.</li><li id="section_3.2">Mistletoe. In: Murray MT: The Healing Power of Herbs. Roseville, Calif: Prima Publishing, 1995, pp 253-9.</li><li id="section_3.3">Samtleben R, Hajto T, Hostanska K, et al.: Mistletoe lectins as immunostimulants (chemistry, pharmacology and clinic). In: Wagner H, ed.: Immunomodulatory Agents from Plants. Basel, Switzerland: Birkhauser Verlag, 1999, pp 223-41.</li><li id="section_3.4">Olsnes S, Stirpe F, Sandvig K, et al.: Isolation and characterization of viscumin, a toxic lectin from Viscum album L. (mistletoe). J Biol Chem 257 (22): 13263-70, 1982.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7142144&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7142144&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.5">Becker H: Botany of European mistletoe (Viscum album L.). Oncology 43 (Suppl 1): 2-7, 1986.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3808574&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3808574&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.6">Watkins D: A berry Christmas. Nurs Times 93 (51): 28-9, 1997 Dec 17-23.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9455311&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9455311&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.7">B&#xFC;ssing A, Azhari T, Ostendorp H, et al.: Viscum album L. extracts reduce sister chromatid exchanges in cultured peripheral blood mononuclear cells. Eur J Cancer 30A (12): 1836-41, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7880615&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7880615&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.8">B&#xFC;ssing A, Lehnert A, Schink M, et al.: Effect of Viscum album L. on rapidly proliferating amniotic fluid cells. Sister chromatid exchange frequency and proliferation index. Arzneimittelforschung 45 (1): 81-3, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7893276&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7893276&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.9">B&#xFC;ssing A, Regnery A, Schweizer K: Effects of Viscum album L. on cyclophosphamide-treated peripheral blood mononuclear cells in vitro: sister chromatid exchanges and activation/proliferation marker expression. Cancer Lett 94 (2): 199-205, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7634248&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7634248&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.10">Bussing A, Jungmann H, Suzart K, et al.: Suppression of sister chromatid exchange-inducing DNA lesions in cultured peripheral blood mononuclear cells by Viscum album L. J Exp Clin Cancer Res  15 (2): 107-14, 1996.</li><li id="section_3.11">B&#xFC;ssing A, Suzart K, Bergmann J, et al.: Induction of apoptosis in human lymphocytes treated with Viscum album L. is mediated by the mistletoe lectins. Cancer Lett 99 (1): 59-72, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8564930&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8564930&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.12">Rentea R, Lyon E, Hunter R: Biologic properties of iscador: a Viscum album preparation I. Hyperplasia of the thymic cortex and accelerated regeneration of hematopoietic cells following X-irradiation. Lab Invest 44 (1): 43-8, 1981.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7453129&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7453129&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.13">Bloksma N, Schmiermann P, de Reuver M, et al.: Stimulation of humoral and cellular immunity by Viscum preparations. Planta Med 46 (4): 221-7, 1982.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7163417&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7163417&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.14">Hajto T: Immunomodulatory effects of iscador: a Viscum album preparation. Oncology 43 (Suppl 1): 51-65, 1986.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2433654&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2433654&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.15">Hajto T, Lanzrein C: Natural killer and antibody-dependent cell-mediated cytotoxicity activities and large granular lymphocyte frequencies in Viscum album-treated breast cancer patients. Oncology 43 (2): 93-7, 1986.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3951791&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3951791&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.16">Hamprecht K, Handgretinger R, Voetsch W, et al.: Mediation of human NK-activity by components in extracts of Viscum album. Int J Immunopharmacol 9 (2): 199-209, 1987.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3583510&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3583510&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.17">Hajto T, Hostanska K, Gabius HJ: Modulatory potency of the beta-galactoside-specific lectin from mistletoe extract (Iscador) on the host defense system in vivo in rabbits and patients. Cancer Res 49 (17): 4803-8, 1989.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2758413&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2758413&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.18">Mueller EA, Hamprecht K, Anderer FA: Biochemical characterization of a component in extracts of Viscum album enhancing human NK cytotoxicity. Immunopharmacology 17 (1): 11-8, 1989 Jan-Feb.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2708032&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2708032&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.19">Hajto T, Hostanska K, Frei K, et al.: Increased secretion of tumor necrosis factors alpha, interleukin 1, and interleukin 6 by human mononuclear cells exposed to beta-galactoside-specific lectin from clinically applied mistletoe extract. Cancer Res 50 (11): 3322-6, 1990.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2334925&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2334925&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.20">Beuth J, Ko HL, Gabius HJ, et al.: Behavior of lymphocyte subsets and expression of activation markers in response to immunotherapy with galactoside-specific lectin from mistletoe in breast cancer patients. Clin Investig 70 (8): 658-61, 1992.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1392440&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1392440&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.21">Kuttan G, Kuttan R: Immunological mechanism of action of the tumor reducing peptide from mistletoe extract (NSC 635089) cellular proliferation. Cancer Lett 66 (2): 123-30, 1992.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1394116&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1394116&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.22">Kuttan G, Kuttan R: Immunomodulatory activity of a peptide isolated from Viscum album extract (NSC 635 089). Immunol Invest 21 (4): 285-96, 1992.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1398778&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1398778&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.23">Gabius HJ, Walzel H, Joshi SS, et al.: The immunomodulatory beta-galactoside-specific lectin from mistletoe: partial sequence analysis, cell and tissue binding, and impact on intracellular biosignalling of monocytic leukemia cells. Anticancer Res 12 (3): 669-75, 1992 May-Jun.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1622124&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1622124&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.24">Beuth J, Ko HL, Tunggal L, et al.: Thymocyte proliferation and maturation in response to galactoside-specific mistletoe lectin-1. In Vivo 7 (5): 407-10, 1993 Sep-Oct.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8110981&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8110981&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.25">Timoshenko AV, Gabius HJ: Efficient induction of superoxide release from human neutrophils by the galactoside-specific lectin from Viscum album. Biol Chem Hoppe Seyler 374 (4): 237-43, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8392351&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8392351&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.26">Timoshenko AV, Kayser K, Drings P, et al.: Modulation of lectin-triggered superoxide release from neutrophils of tumor patients with and without chemotherapy. Anticancer Res 13 (5C): 1789-92, 1993 Sep-Oct.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8267383&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8267383&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.27">Kuttan G: Tumoricidal activity of mouse peritoneal macrophages treated with Viscum album extract. Immunol Invest 22 (6-7): 431-40, 1993 Aug-Oct.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8262566&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8262566&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.28">Beuth J, Ko HL, Tunggal L, et al.: Immunoprotective activity of the galactoside-specific mistletoe lectin in cortisone-treated BALB/c-mice. In Vivo 8 (6): 989-92, 1994 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7772751&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7772751&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.29">Heiny BM, Beuth J: Mistletoe extract standardized for the galactoside-specific lectin (ML-1) induces beta-endorphin release and immunopotentiation in breast cancer patients. Anticancer Res 14 (3B): 1339-42, 1994 May-Jun.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8067703&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8067703&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.30">Stein G, Berg PA: Non-lectin component in a fermented extract from Viscum album L. grown on pines induces proliferation of lymphocytes from healthy and allergic individuals in vitro. Eur J Clin Pharmacol 47 (1): 33-8, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7988621&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7988621&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.31">Timoshenko AV, Gabius HJ: Influence of the galactoside-specific lectin from Viscum album and its subunits on cell aggregation and selected intracellular parameters of rat thymocytes. Planta Med 61 (2): 130-3, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7753919&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7753919&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.32">Timoshenko AV, Cherenkevich SN, Gabius HJ: Viscum album agglutinin-induced aggregation of blood cells and the lectin effects on neutrophil function. Biomed Pharmacother 49 (3): 153-8, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7647287&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7647287&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.33">Hostanska K, Hajto T, Spagnoli GC, et al.: A plant lectin derived from Viscum album induces cytokine gene expression and protein production in cultures of human peripheral blood mononuclear cells. Nat Immun 14 (5-6): 295-304, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8933823&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8933823&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.34">Beuth J, Stoffel B, Ko HL, et al.: Immunomodulating ability of galactoside-specific lectin standardized and depleted mistletoe extract. Arzneimittelforschung 45 (11): 1240-2, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8929248&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8929248&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.35">Lenartz D, Stoffel B, Menzel J, et al.: Immunoprotective activity of the galactoside-specific lectin from mistletoe after tumor destructive therapy in glioma patients. Anticancer Res 16 (6B): 3799-802, 1996 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9042260&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9042260&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.36">Fischer S, Scheffler A, Kabelitz D: Oligoclonal in vitro response of CD4 T cells to vesicles of mistletoe extracts in mistletoe-treated cancer patients. Cancer Immunol Immunother 44 (3): 150-6, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9191874&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9191874&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.37">Preisfeld A: Influence of aqueous mistletoe preparations on humoral immune parameters with emphasis on the cytotoxicity of human complement in breast cancer patients. Forsch Komplementarmed  4 (4): 224-8, 1997.</li><li id="section_3.38">Chernyshov VP, Omelchenko LI, Heusser P, et al.: Immunomodulatory actions of Viscum album (Iscador) in children with recurrent respiratory disease as a result of the Chernobyl nuclear accident. Complement Ther Med  5 (3): 141-6, 1997.</li><li id="section_3.39">Heiny BM, Albrecht V, Beuth J: Correlation of immune cell activities and beta-endorphin release in breast carcinoma patients treated with galactose-specific lectin standardized mistletoe extract. Anticancer Res 18 (1B): 583-6, 1998 Jan-Feb.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9568181&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9568181&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.40">Stein GM, Schaller G, Pf&#xFC;ller U, et al.: Characterisation of granulocyte stimulation by thionins from European mistletoe and from wheat. Biochim Biophys Acta 1426 (1): 80-90, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9878694&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9878694&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.41">Stein GM, Schaller G, Pf&#xFC;ller U, et al.: Thionins from Viscum album L: influence of the viscotoxins on the activation of granulocytes. Anticancer Res 19 (2A): 1037-42, 1999 Mar-Apr.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10368652&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10368652&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.42">Mengs U, G&#xF6;thel D, Leng-Peschlow E: Mistletoe extracts standardized to mistletoe lectins in oncology: review on current status of preclinical research. Anticancer Res 22 (3): 1399-407, 2002 May-Jun.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12168816&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12168816&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.43">Bocci V: Mistletoe (viscum album) lectins as cytokine inducers and immunoadjuvant in tumor therapy. A review. J Biol Regul Homeost Agents 7 (1): 1-6, 1993 Jan-Mar.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8346712&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8346712&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.44">Gabius HJ, Gabius S, Joshi SS, et al.: From ill-defined extracts to the immunomodulatory lectin: will there be a reason for oncological application of mistletoe? Planta Med 60 (1): 2-7, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8134410&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8134410&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.45">Zee-Cheng RK: Anticancer research on Loranthaceae plants. Drugs Future  22 (5): 519-30, 1997.</li><li id="section_3.46">Kaegi E: Unconventional therapies for cancer: 3. Iscador. Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative. CMAJ 158 (9): 1157-9, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9597967&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9597967&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.47">Lenartz D, Dott U, Menzel J, et al.: Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe. Anticancer Res 20 (3B): 2073-6, 2000 May-Jun.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10928154&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10928154&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.48">Goebell PJ, Otto T, Suhr J, et al.: Evaluation of an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized phase II trial. J Urol 168 (1): 72-5, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12050495&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12050495&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.49">Schaefermeyer G, Schaefermeyer H: Treatment of pancreatic cancer with Viscum album (Iscador): a retrospective study of 292 patients 1986-1996. Complement Ther Med  6 (4): 172-7, 1998.</li><li id="section_3.50">Kunze E, Schulz H, Gabius HJ: Inability of galactoside-specific mistletoe lectin to inhibit N-methyl-N-nitrosourea-induced tumor development in the urinary bladder of rats and to mediate a local cellular immune response after long-term administration. J Cancer Res Clin Oncol 124 (2): 73-87, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9654190&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9654190&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.51">Kunze E, Schulz H, Adamek M, et al.: Long-term administration of galactoside-specific mistletoe lectin in an animal model: no protection against N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder carcinogenesis in rats and no induction of a relevant local cellular immune response. J Cancer Res Clin Oncol 126 (3): 125-38, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10741906&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10741906&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.52">Mengs U, Schwarz T, Bulitta M, et al.: Antitumoral effects of an intravesically applied aqueous mistletoe extract on urinary bladder carcinoma MB49 in mice. Anticancer Res 20 (5B): 3565-8, 2000 Sep- Oct.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11131663&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11131663&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.53">Stauder H, Kreuser ED: Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: current state of clinical research. Onkologie 25 (4): 374-80, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12232491&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12232491&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.54">Kleijnen J, Knipschild P: Mistletoe treatment for cancer: review of controlled trials in humans. Phytomedicine  1: 255-60, 1994.</li><li id="section_3.55">Stirpe F, Sandvig K, Olsnes S, et al.: Action of viscumin, a toxic lectin from mistletoe, on cells in culture. J Biol Chem 257 (22): 13271-7, 1982.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7142145&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7142145&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.56">Walzel H, Jonas L, Rosin T, et al.: Relationship between internalization kinetics and cytotoxicity of mistletoe lectin I to L1210 leukaemia cells. Folia Biol (Praha) 36 (3-4): 181-8, 1990.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2257937&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2257937&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.57">Franz H: Mistletoe lectins and their A and B chains. Oncology 43 (Suppl 1): 23-34, 1986.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3543782&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3543782&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.58">Sweeney EC, Palmer RA, Pf&#xFC;ller U: Crystallization of the ribosome inactivating protein ML1 from Viscum album (mistletoe) complexed with beta-D-galactose. J Mol Biol 234 (4): 1279-81, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8263931&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8263931&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.59">Jung ML, Baudino S, Rib&#xE9;reau-Gayon G, et al.: Characterization of cytotoxic proteins from mistletoe (Viscum album L.). Cancer Lett 51 (2): 103-8, 1990.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2344587&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2344587&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.60">Gabius HJ, Darro F, Remmelink M, et al.: Evidence for stimulation of tumor proliferation in cell lines and histotypic cultures by clinically relevant low doses of the galactoside-binding mistletoe lectin, a component of proprietary extracts. Cancer Invest 19 (2): 114-26, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11296616&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11296616&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.61">Dietrich JB, Rib&#xE9;reau-Gayon G, Jung ML, et al.: Identity of the N-terminal sequences of the three A chains of mistletoe (Viscum album L.) lectins: homology with ricin-like plant toxins and single-chain ribosome-inhibiting proteins. Anticancer Drugs 3 (5): 507-11, 1992.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1450445&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1450445&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.62">J&#xE4;ggy C, Musielski H, Urech K, et al.: Quantitative determination of lectins in mistletoe preparations. Arzneimittelforschung 45 (8): 905-9, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7575759&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7575759&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.63">Burger AM, Mengs U, Sch&#xFC;ler JB, et al.: Anticancer activity of an aqueous mistletoe extract (AME) in syngeneic murine tumor models. Anticancer Res 21 (3B): 1965-8, 2001 May-Jun.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11497284&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11497284&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.64">Janssen O, Scheffler A, Kabelitz D: In vitro effects of mistletoe extracts and mistletoe lectins. Cytotoxicity towards tumor cells due to the induction of programmed cell death (apoptosis). Arzneimittelforschung 43 (11): 1221-7, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8292069&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8292069&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.65">Zarkovic N, Vukovic T, Loncaric I, et al.: An overview on anticancer activities of the Viscum album extract Isorel. Cancer Biother Radiopharm 16 (1): 55-62, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11279798&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11279798&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.66">Maier G, Fiebig HH: Absence of tumor growth stimulation in a panel of 16 human tumor cell lines by mistletoe extracts in vitro. Anticancer Drugs 13 (4): 373-9, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11984083&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11984083&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.67">Mueller EA, Anderer FA: Chemical specificity of effector cell/tumor cell bridging by a Viscum album rhamnogalacturonan enhancing cytotoxicity of human NK cells. Immunopharmacology 19 (1): 69-77, 1990 Jan-Feb.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2407685&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2407685&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _23
      field_pdq_section_title:
        - format: plain_text
          value: 'Laboratory/Animal/Preclinical Studies'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_23" class="pdq-sections"><p id="_24" tabindex="-1">The <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46356&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046356&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">immune system</a>&#x2013;stimulating and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44020&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044020&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cytotoxic</a> properties of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285939&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285939&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">mistletoe</a> have     been investigated in <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44512&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044512&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">laboratory</a> and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=454774&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000454774&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">animal studies</a>.</p><p id="_21" tabindex="-1"> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44094&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044094&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">Viscotoxins</a> and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44051&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044051&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">lectins</a> have  been investigated as active components in mistletoe; most research has focused on the lectins.<a href="#cit/section_4.1">1</a><a href="#cit/section_4.2">2</a><a href="#cit/section_4.3">3</a><a href="#cit/section_4.4">4</a><a href="#cit/section_4.5">5</a><a href="#cit/section_4.6">6</a><a href="#cit/section_4.7">7</a><a href="#cit/section_4.8">8</a><a href="#cit/section_4.9">9</a> Purified <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44994&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044994&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">mistletoe lectins</a> have demonstrated cytotoxic and immune system&#x2013;stimulating activities. Four different lectins: ML-1, ML-2, ML-3, and <em>Viscum album</em> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285965&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285965&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">chitin</a>-binding <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285953&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285953&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">agglutinin</a> have been identified in mistletoe <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=407760&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000407760&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">extracts</a>. ML-1 (or viscumin) may be responsible for many of mistletoe&#x2019;s <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44510&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044510&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">biological</a> effects. When a laboratory method was used to selectively deplete ML-1 from <em>Viscum album</em> extracts, their cytotoxic and immune system&#x2013;stimulating properties were markedly reduced.<a href="#cit/section_4.10">10</a><a href="#cit/section_4.11">11</a> It should be noted that fermentation eliminates most of the ML-1 in mistletoe extracts. Iscador, and other fermented mistletoe extracts, contain only the mistletoe lectins ML-2 and ML-3, whereas the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46092&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046092&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">proteins</a> of the ML-1 complex are missing.<a href="#cit/section_4.12">12</a><a href="#cit/section_4.13">13</a><a href="#cit/section_4.14">14</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44162&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044162&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">Polysaccharide</a> and oligosaccharide components of mistletoe extracts with substantial immune-stimulating properties have been reviewed.<a href="#cit/section_4.15">15</a><a href="#cit/section_4.16">16</a></p><p id="_61" tabindex="-1">The molecular structure of ML-1 consists of an alpha chain and a beta chain, which can be separated from one another.<a href="#cit/section_4.1">1</a><a href="#cit/section_4.6">6</a><a href="#cit/section_4.7">7</a><a href="#cit/section_4.8">8</a><a href="#cit/section_4.9">9</a><a href="#cit/section_4.13">13</a><a href="#cit/section_4.17">17</a><a href="#cit/section_4.18">18</a> Each chain type appears to mediate a subset of the activities described for the intact lectin. Cytotoxicity is associated mainly with the alpha chain. In <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44512&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044512&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">laboratory
            studies</a>, the ML-1 alpha chain has been coupled to <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46066&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046066&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">monoclonal antibodies</a> to produce  <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45730&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045730&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">immunotoxins</a> that target and kill specific cell types.<a href="#cit/section_4.19">19</a><a href="#cit/section_4.20">20</a><a href="#cit/section_4.21">21</a></p><p id="_104" tabindex="-1"><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44619&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044619&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">Recombinant</a> ML-1, rML (also known as rViscumin or aviscumine) appears to have the same <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=346517&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000346517&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">efficacy</a> as plant-based ML-1 in laboratory studies.<a href="#cit/section_4.22">22</a> Because this is not an extract of mistletoe, it is out of the purview of this summary.</p><p id="_105" tabindex="-1">The beta chain of ML-1 is responsible for binding to the surface of a target cell.<a href="#cit/section_4.23">23</a>    Studies of mistletoe lectin binding to cancer cells have examined whether the extent of cell binding can predict disease <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=467853&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000467853&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">outcome</a> or survival.  Studies show that the prognostic value of ML-1 binding depends on the type of cancer.<a href="#cit/section_4.24">24</a> For human <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=444971&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000444971&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">breast cancer</a> cells, the amount of lectin-bound cells correlates positively with disease outcome.  However, for human <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46216&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046216&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">adenocarcinoma</a> of the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=270740&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000270740&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">lung</a>, there is no correlation between the amount of lectin-bound cells and disease survival.<a href="#cit/section_4.25">25</a> Though much research has looked at this particular aspect, there have not been studies that directly link the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=683342&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000683342&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">concentration</a> of that component to any clinical activity of mistletoe.</p><p id="_25" tabindex="-1">Laboratory studies have shown that mistletoe extracts can stimulate the activity of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45993&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045993&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">white blood cells</a> <em><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45733&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045733&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">in vitro</a></em> and cause them to release <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45065&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045065&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">molecules</a> thought to be important for anticancer <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45722&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045722&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">immune responses</a>.<a href="#cit/section_4.4">4</a><a href="#cit/section_4.6">6</a><a href="#cit/section_4.8">8</a><a href="#cit/section_4.9">9</a><a href="#cit/section_4.17">17</a><a href="#cit/section_4.26">26</a><a href="#cit/section_4.27">27</a><a href="#cit/section_4.28">28</a><a href="#cit/section_4.29">29</a><a href="#cit/section_4.30">30</a><a href="#cit/section_4.31">31</a><a href="#cit/section_4.32">32</a><a href="#cit/section_4.33">33</a>   In addition, mistletoe extracts have demonstrated cytotoxic activity against a variety of mouse, rat, and human <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45333&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045333&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cancer</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46476&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046476&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cells</a> <em>in vitro</em>.<a href="#cit/section_4.1">1</a><a href="#cit/section_4.8">8</a><a href="#cit/section_4.23">23</a><a href="#cit/section_4.34">34</a><a href="#cit/section_4.35">35</a><a href="#cit/section_4.36">36</a><a href="#cit/section_4.37">37</a>   </p><p id="_118" tabindex="-1">There are conflicting reports concerning the stimulation of cancer cell growth <em>in vitro</em>. In one study,    the <em>in vitro</em> growth of several types of human cancer cells was stimulated by treatment with low <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44664&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044664&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">doses</a> of the purified <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44051&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044051&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">lectin</a> ML-1.<a href="#cit/section_4.1">1</a> However, various other  studies found that ML-1     and mistletoe extracts did not induce <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46479&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046479&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cell proliferation</a>.<a href="#cit/section_4.38">38</a><a href="#cit/section_4.39">39</a></p><p id="_255" tabindex="-1"><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44517&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044517&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">Preclinical   studies</a> demonstrating biological effects on <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=695994&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000695994&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cancer cell lines</a> and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43996&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043996&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">animal models</a> are summarized in <a href="/about-cancer/treatment/cam/hp/mistletoe-pdq#link/_257">Table 1</a> and <a href="/about-cancer/treatment/cam/hp/mistletoe-pdq#link/_258">Table 2</a>.</p><table id="_257" class="table-default expandable-container"><caption>Table 1.  <em>In Vitro</em> Studies<span class="sup">a</span></caption><colgroup><col align="Left" width="33.33%"><col width="33.33%"><col width="33.33%"></colgroup><TFoot class="pdq-footer"><tr><td colspan="3">IscadorQu =  IscadorQ; ML-1 = mistletoe extracts with mistletoe lectins I.</td></tr><tr><td colspan="3"><span class="sup">a</span>Refer to text and the <a href="https://www.cancer.gov/publications/dictionaries/cancer-terms/" title="https://www.cancer.gov/publications/dictionaries/cancer-terms/">NCI Dictionary of Cancer Terms</a>   for additional information and definition of terms.</td></tr></TFoot><tbody><tr><td colspan="3"><strong>Iscador</strong></td></tr><tr><td align="Center" scope="col"><strong>Cell Line</strong></td><td align="Center" scope="col"><strong>Outcome</strong></td><td align="Center" scope="col"><strong>Reference</strong></td></tr><tr><td>Various human cancer cell
            lines</td><td>Iscador preparations containing a high lectin concentration (15 &#x3BC;g/<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44214&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044214&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">mL</a>)  showed  &gt;70% growth inhibition in the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44560&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044560&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">mammary</a> cancer cell line (MAXF 401NL) compared with untreated control cells;  30%&#x2013;70% growth inhibition in three <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46634&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046634&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">tumor</a> cell lines (<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45343&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045343&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">leukemia</a> RPMI 8226, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45323&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045323&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">non-small cell lung</a> LXFE 66NL, and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=445094&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000445094&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">uterine</a> UXF 1138L) for IscadorM  and in seven tumor cell lines (<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46481&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046481&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">central nervous system</a> SF268, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=454513&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000454513&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">gastric</a> GXF 251L, non-small cell lung LXFE 66NL and LXFL 529L, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=445079&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000445079&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">prostate</a> PC3M, renal RXF 944L, and uterine UXF 1138L) for IscadorQu</td><td><a href="#cit/section_4.35">35</a></td></tr><tr><td>Human
            <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45780&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045780&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">medulloblastoma</a> cells
            Daoy, D341,  D425, and UW 228-2 </td><td><em>Viscum album</em> preparations (0.1 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=306521&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000306521&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">&#xB5;g</a>/mL&#x2013;100 &#xB5;g/mL) induced cell death through <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46524&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046524&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">apoptosis</a>. Growth-inhibition correlated with the lectin content of the used preparation</td><td><a href="#cit/section_4.37">37</a></td></tr><tr><td>Various human cancer cell lines  (central nervous system SF268; gastric GXF 251; lung H460, LXFA 629L, LXFE 66NL, LXFL 529L; leukemia and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45368&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045368&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">lymphoma</a> CCRFCEM, MOLT-4, HL-60, K562, U937, RPMI 8226; mammary MCF7, MAXF 401NL; <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45135&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045135&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">melanoma</a> HT144, MALME-3M, SK-MEL28, MEXF 462NL, MEXF 514L; prostate PC3M; renal RXF 393NL, RXF 944L; <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45562&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045562&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">sarcoma</a> Hs729, SK-LMS-1, SK-UT-1B; and uterus UXF 1138L)</td><td>IscadorM and IscadorQu with a high lectin content demonstrated  <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=446109&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000446109&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">antitumor</a> activity <em>in vitro</em>  at high test concentrations (15&#x2013;150 &#xB5;g/mL)</td><td><a href="#cit/section_4.38">38</a></td></tr><tr><td>Human cell lines: HCC1937, HCC1143 (breast), PA-TU-8902 (<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46254&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046254&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">pancreas</a>), DU145 (prostate), NCI-H460 (lung)</td><td>Cell proliferation inhibition was detected with a mistletoe dose at 100 &#x3BC;g/mL in cell lines PA-TU-8902 and NCI-H460, and a dose at  &#x2265;10 &#x3BC;g/mL in cell lines HCC1937, HCC1143, and DU145</td><td><a href="#cit/section_4.40">40</a></td></tr><tr><td><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45698&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045698&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">Glioblastoma</a> cells: LNT-229, LN-308</td><td>Cell growth was reduced with IscadorQ  and IscadorM at lectin concentrations of 100 &#xB5;g/mL</td><td><a href="#cit/section_4.41">41</a></td></tr><tr><td colspan="3"><strong>Helixor</strong></td></tr><tr><td align="Center" scope="col"><strong>Cell Line</strong> </td><td align="Center" scope="col"><strong>Outcome</strong></td><td align="Center" scope="col"><strong>Reference</strong></td></tr><tr><td>Various human cancer cell lines</td><td>Helixor mistletoe preparations (15 &#xB5;g/mL&#x2013;150 &#xB5;g/mL) and ML-1 (10 ng/mL&#x2013;100 ng/mL) did not induce cell proliferation</td><td><a href="#cit/section_4.39">39</a></td></tr><tr><td colspan="3"><strong>abnobaVISCUM</strong></td></tr><tr><td align="Center" scope="col"><strong>Cell Line</strong></td><td align="Center" scope="col"><strong>Outcome</strong></td><td align="Center" scope="col"><strong>Reference</strong></td></tr><tr><td>Human tumor cell lines (<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45611&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045611&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">B-cell</a> hybridomas, P815, EL-4, Ke37, MOLT-4, and U937)</td><td>Growth arrest was caused by the induction of apoptosis (50% of U937 cells at 100 ng/mL of ML-1 and 40% of B-cell hybridomas  and EL-4 cells at concentrations as low as 1 ng/mL  of ML-1)</td><td><a href="#cit/section_4.10">10</a></td></tr></tbody></table><p id="_256" tabindex="-1">Studies of the ability of mistletoe to inhibit cancer cell growth in animals have yielded mixed and inconsistent results.<a href="#cit/section_4.5">5</a><a href="#cit/section_4.6">6</a><a href="#cit/section_4.7">7</a><a href="#cit/section_4.8">8</a><a href="#cit/section_4.9">9</a><a href="#cit/section_4.36">36</a><a href="#cit/section_4.42">42</a><a href="#cit/section_4.43">43</a><a href="#cit/section_4.44">44</a><a href="#cit/section_4.45">45</a><a href="#cit/section_4.46">46</a><a href="#cit/section_4.47">47</a><a href="#cit/section_4.48">48</a><a href="#cit/section_4.49">49</a><a href="#cit/section_4.50">50</a> In most of these studies, mistletoe extracts were administered either by <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45914&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045914&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">subcutaneous</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44678&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044678&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">injection</a> or by <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46339&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046339&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">intraperitoneal</a> injection; some of the differences in results may have resulted from the difference in route of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=478733&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000478733&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">administration</a>. For example, IscadorM administration was associated with a prolonged survival of female Swiss mice when the route of administration was intraperitoneal <a href="#cit/section_4.51">51</a> but not when the route was subcutaneous.<a href="#cit/section_4.52">52</a> Other differences between these two studies were the number of cells used in the Ehrlich <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45601&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045601&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">ascites</a> inoculum and the doses of IscadorM administered.</p><table id="_258" class="table-default expandable-container"><caption>Table 2.  <em><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46352&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046352&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">In Vivo</a></em> Studies<span class="sup">a</span></caption><colgroup><col width="32.91%"><col width="31.64%"><col width="35.44%"></colgroup><TFoot class="pdq-footer"><tr><td colspan="3">ALL = acute lymphoblastic leukemia; ME-A = mistletoe extracts (fir tree <em>Abies</em>); ME-M = mistletoe extracts (apple tree <em>Malus</em>); ML-1 = mistletoe extracts with mistletoe lectins I; ML-3 = mistletoe extracts with mistletoe lectins III; MT-A = mistletoe extracts obtained from fir trees; MT-P = mistletoe extracts obtained from pine trees; NK = natural killer.</td></tr><tr><td colspan="3"><span class="sup">a</span>Refer to text and the <a href="https://www.cancer.gov/publications/dictionaries/cancer-terms/" title="https://www.cancer.gov/publications/dictionaries/cancer-terms/">NCI Dictionary of Cancer Terms</a>   for additional information and definition of terms.</td></tr></TFoot><tbody><tr><td colspan="3"><strong>Iscador</strong></td></tr><tr><td align="Center" scope="col"><strong>Animal Model</strong></td><td align="Center" scope="col"><strong>Outcome</strong></td><td align="Center" scope="col"><strong>Reference</strong></td></tr><tr><td>Mice</td><td>Antiproliferative and antimetastatic effects in melanoma cell line MV3 were only achieved with low-dose ML-1 (30 ng/kg body weight) and not with higher doses (150 ng/kg and 500 ng/kg); increased number of infiltrating <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44948&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044948&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">dendritic cells</a> suggests stimulation of the immune system</td><td><a href="#cit/section_4.44">44</a></td></tr><tr><td>Mice</td><td>Viscum album extract (20 &#xB5;g/mouse/d) mediated inhibition of B16F1 melanoma cells tumor growth was associated with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=367426&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000367426&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">immunomodulation</a> via induction of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44418&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044418&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">IL-12</a> secretion leading to enhanced <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44928&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044928&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">T-cell</a> and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44439&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044439&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">NK-cell</a> functions</td><td><a href="#cit/section_4.45">45</a></td></tr><tr><td>Mice</td><td><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=257523&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000257523&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">Organ</a> colonization was investigated on day 14 after RAW 117 H 10 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44115&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044115&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">lymphosarcoma</a> cell and L-1 sarcoma cell  inoculation and demonstrated <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44167&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044167&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">statistically significant</a> (<em>P</em> &lt; .05) reductions of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44758&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044758&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">experimental</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46312&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046312&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">liver</a> and lung <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46710&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046710&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">metastases</a> for standardized <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43998&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043998&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">aqueous</a> mistletoe extract&#x2013;treated mice (2 &#xB5;g, 20 &#xB5;g, 100 &#xB5;g, and 500 &#xB5;g per  mouse)</td><td><a href="#cit/section_4.47">47</a></td></tr><tr><td>Mice (Nude and VMDk mice)</td><td>Glioblastoma tumor growth was reduced (cell lines LNT-229 and LN-308), the expression of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45693&amp;version=healthprofessional&amp;language=English&amp;dictionary=genetic" onclick="javascript:popWindow('defbyid','CDR0000045693&amp;version=healthprofessional&amp;language=English&amp;dictionary=genetic'); return(false);">genes</a> associated with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45669&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045669&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">tumor progression</a> was reduced, and  <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44439&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044439&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">NK cell</a> mediated glioblastoma cell <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44606&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044606&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">lysis</a> was enhanced when IscadorQ and IscadorM 100 &#xB5;g/mL was administered by an <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44603&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044603&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">intratumoral</a> injection</td><td><a href="#cit/section_4.41">41</a></td></tr><tr><td>BDF and Swiss albino mice</td><td>Treatment with IscadorM (50 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44213&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044213&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">mg</a>/kg/d and 100 mg/kg/d) increased the survival time of mice that had been implanted with Ehrlich ascites mouse cancer cells, but not L1210 leukemia or B16 melanoma cancer cells</td><td><a href="#cit/section_4.51">51</a></td></tr><tr><td>Swiss albino mice</td><td>No antitumor effect or improvement in survival was observed when IscadorM (15.75 mg, 750 mg, 10.5 mg, 500 mg) was used to treat rats bearing chemically induced mammary <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45963&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045963&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">carcinomas</a> or tumors formed from rat Walker 256 carcinosarcoma cells; IscadorM (5 mg, 200 mg, 150 mg, 3.75 mg) was also not effective in treating mice that had been injected with Ehrlich ascites cells; in addition, IscadorP (135 mg) was found ineffective in treating rats with tumors formed from rat L5222 leukemia cells</td><td><a href="#cit/section_4.52">52</a></td></tr><tr><td colspan="3" align="Left" scope="col"><strong>Helixor</strong></td></tr><tr><td align="Center" scope="col"><strong>Animal Model</strong></td><td align="Center" scope="col"><strong>Outcome</strong></td><td align="Center" scope="col"><strong>Reference</strong></td></tr><tr><td><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=615419&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000615419&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">SCID</a> mice</td><td>Despite a considerably lower ML-3 content, MT-A (50 mg/kg and 100 mg/kg)  was more effective and less <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43986&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043986&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">toxic</a> than MT-P (50 mg/kg) in a human <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45586&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045586&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">acute lymphoblastic leukemia</a>  cell line (NALM-6);  both were given intraperitoneally in mice inoculated with human ALL</td><td><a href="#cit/section_4.43">43</a></td></tr><tr><td>Human <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46441&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046441&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">ductal</a> breast carcinoma cell line BT474</td><td>As compared with tumors of control mice, tumors of the ME-A&#x2013; and ME-M&#x2013;treated groups (5 mg intratumoral injection) showed a decreased cell proliferation rate, as well as an increased cell <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44290&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044290&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">necrosis</a> and apoptosis rate</td><td><a href="#cit/section_4.46">46</a></td></tr><tr><td colspan="3"><strong>abnobaVISCUM</strong></td></tr><tr><td align="Center" scope="col"><strong>Animal Model</strong></td><td align="Center" scope="col"><strong>Outcome</strong></td><td align="Center" scope="col"><strong>Reference</strong></td></tr><tr><td>Nude mice</td><td>Intratumoral injections of mistletoe extract (abnobaVISCUM Fraxini-2, 8 mg/kg body weight and lectin at 5.3 &#xB5;g/kg body weight) demonstrated more antitumor activity than did <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46682&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046682&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">intravenous</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45347&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045347&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">gemcitabine</a> when injected into mice bearing xenografts of human <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44521&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044521&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">pancreatic adenocarcinoma cancer</a> (PAXF 736)</td><td><a href="#cit/section_4.53">53</a></td></tr><tr><td colspan="3"><strong>Isorel</strong></td></tr><tr><td align="Center" scope="col"><strong>Animal Model</strong></td><td align="Center" scope="col"><strong>Outcome</strong></td><td align="Center" scope="col"><strong>Reference</strong></td></tr><tr><td>Mice</td><td>In mice <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46631&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046631&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">transplanted</a> with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46403&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046403&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">fibrosarcoma</a> (CMC-2), when IsorelM (140 mg/kg)  was used alone, no effect on either tumor growth or animal survival was observed. When IsorelM (140 mg/kg)  was combined with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44302&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044302&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">x-ray therapy</a> of tumors, there was substantial improvements in survival of mice compared with survival of mice treated with x-ray therapy (43 Gy) alone</td><td><a href="#cit/section_4.54">54</a></td></tr><tr><td colspan="3"><strong>Eurixor</strong></td></tr><tr><td align="Center" scope="col"><strong>Animal Model</strong></td><td align="Center" scope="col"><strong>Outcome</strong></td><td align="Center" scope="col"><strong>Reference</strong></td></tr><tr><td>Mice</td><td>Aqueous mistletoe extract (30  ng/mL or 300 ng/mL)  showed antitumoral activity on <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44093&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044093&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">urinary</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46501&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046501&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">bladder</a> carcinoma (MB49)  in mice, which was considered to be mainly caused by the cytotoxic properties of mistletoe lectins</td><td><a href="#cit/section_4.6">6</a></td></tr><tr><td colspan="3"><strong>Lektinol</strong></td></tr><tr><td align="Center" scope="col"><strong>Animal Model</strong></td><td align="Center" scope="col"><strong>Outcome</strong></td><td align="Center" scope="col"><strong>Reference</strong></td></tr><tr><td>Mice</td><td>Treatment with Lektinol (0.3, 3, 30, or 300 ng/mL/kg/d) slowed the growth of tumors formed in mice from implants of three types of mouse cancers (<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46462&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046462&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">colon</a> adenocarcinoma 38, Renca <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=661352&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000661352&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">renal cell carcinoma</a>, and F9 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46611&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046611&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">testicular</a> carcinoma) but not from two other mouse cancers (B16 melanoma and Lewis lung carcinoma)</td><td><a href="#cit/section_4.7">7</a></td></tr></tbody></table><h6 do-not-show="toc">References</h6><ol><li id="section_4.1">Gabius HJ, Darro F, Remmelink M, et al.: Evidence for stimulation of tumor proliferation in cell lines and histotypic cultures by clinically relevant low doses of the galactoside-binding mistletoe lectin, a component of proprietary extracts. Cancer Invest 19 (2): 114-26, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11296616&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11296616&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.2">Lenartz D, Dott U, Menzel J, et al.: Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe. Anticancer Res 20 (3B): 2073-6, 2000 May-Jun.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10928154&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10928154&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.3">Steuer-Vogt MK, Bonkowsky V, Ambrosch P, et al.: The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. Eur J Cancer 37 (1): 23-31, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11165126&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11165126&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.4">Goebell PJ, Otto T, Suhr J, et al.: Evaluation of an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized phase II trial. J Urol 168 (1): 72-5, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12050495&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12050495&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.5">Kunze E, Schulz H, Adamek M, et al.: Long-term administration of galactoside-specific mistletoe lectin in an animal model: no protection against N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder carcinogenesis in rats and no induction of a relevant local cellular immune response. J Cancer Res Clin Oncol 126 (3): 125-38, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10741906&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10741906&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.6">Mengs U, Schwarz T, Bulitta M, et al.: Antitumoral effects of an intravesically applied aqueous mistletoe extract on urinary bladder carcinoma MB49 in mice. Anticancer Res 20 (5B): 3565-8, 2000 Sep- Oct.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11131663&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11131663&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.7">Burger AM, Mengs U, Sch&#xFC;ler JB, et al.: Anticancer activity of an aqueous mistletoe extract (AME) in syngeneic murine tumor models. Anticancer Res 21 (3B): 1965-8, 2001 May-Jun.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11497284&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11497284&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.8">Mengs U, G&#xF6;thel D, Leng-Peschlow E: Mistletoe extracts standardized to mistletoe lectins in oncology: review on current status of preclinical research. Anticancer Res 22 (3): 1399-407, 2002 May-Jun.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12168816&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12168816&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.9">Samtleben R, Hajto T, Hostanska K, et al.: Mistletoe lectins as immunostimulants (chemistry, pharmacology and clinic). In: Wagner H, ed.: Immunomodulatory Agents from Plants. Basel, Switzerland: Birkhauser Verlag, 1999, pp 223-41.</li><li id="section_4.10">Janssen O, Scheffler A, Kabelitz D: In vitro effects of mistletoe extracts and mistletoe lectins. Cytotoxicity towards tumor cells due to the induction of programmed cell death (apoptosis). Arzneimittelforschung 43 (11): 1221-7, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8292069&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8292069&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.11">Beuth J, Stoffel B, Ko HL, et al.: Immunomodulating ability of galactoside-specific lectin standardized and depleted mistletoe extract. Arzneimittelforschung 45 (11): 1240-2, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8929248&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8929248&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.12">Wagner H, Jordan E, Feil B: Studies on the standardization of mistletoe preparations. Oncology 43 (Suppl 1): 16-22, 1986.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3027640&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3027640&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.13">Mistletoe. In: Murray MT: The Healing Power of Herbs. Roseville, Calif: Prima Publishing, 1995, pp 253-9.</li><li id="section_4.14">J&#xE4;ggy C, Musielski H, Urech K, et al.: Quantitative determination of lectins in mistletoe preparations. Arzneimittelforschung 45 (8): 905-9, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7575759&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7575759&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.15">Stein GM, B&#xFC;ssing A, Schietzel M: Stimulation of the maturation of dendritic cells in vitro by a fermented mistletoe extract. Anticancer Res 22 (6C): 4215-9, 2002 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12553059&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12553059&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.16">Lyu SY, Kwon YJ, Joo HJ, et al.: Preparation of alginate/chitosan microcapsules and enteric coated granules of mistletoe lectin. Arch Pharm Res 27 (1): 118-26, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14969350&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14969350&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.17">Timoshenko AV, Gabius HJ: Efficient induction of superoxide release from human neutrophils by the galactoside-specific lectin from Viscum album. Biol Chem Hoppe Seyler 374 (4): 237-43, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8392351&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8392351&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.18">Dietrich JB, Rib&#xE9;reau-Gayon G, Jung ML, et al.: Identity of the N-terminal sequences of the three A chains of mistletoe (Viscum album L.) lectins: homology with ricin-like plant toxins and single-chain ribosome-inhibiting proteins. Anticancer Drugs 3 (5): 507-11, 1992.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1450445&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1450445&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.19">Wied&#x142;ocha A, Sandvig K, Walzel H, et al.: Internalization and action of an immunotoxin containing mistletoe lectin A-chain. Cancer Res 51 (3): 916-20, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1988131&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1988131&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.20">Tonevitsky AG, Toptygin AYu, Pfuller U, et al.: Immunotoxin with mistletoe lectin I A-chain and ricin A-chain directed against CD5 antigen of human T-lymphocytes; comparison of efficiency and specificity. Int J Immunopharmacol 13 (7): 1037-41, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1722193&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1722193&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.21">Bocci V: Mistletoe (viscum album) lectins as cytokine inducers and immunoadjuvant in tumor therapy. A review. J Biol Regul Homeost Agents 7 (1): 1-6, 1993 Jan-Mar.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8346712&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8346712&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.22">Habeck M: Mistletoe compound enters clinical trials. Drug Discov Today 8 (2): 52-3, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12565000&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12565000&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.23">M&#xFC;thing J, Meisen I, Kniep B, et al.: Tumor-associated CD75s gangliosides and CD75s-bearing glycoproteins with Neu5Acalpha2-6Galbeta1-4GlcNAc-residues are receptors for the anticancer drug rViscumin. FASEB J 19 (1): 103-5, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15520251&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15520251&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.24">Fritz P, Dippon J, Kierschke T, et al.: Impact of mistletoe lectin binding in breast cancer. Anticancer Res 24 (2C): 1187-92, 2004 Mar-Apr.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15154645&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15154645&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.25">Blonski K, Schumacher U, Burkholder I, et al.: Binding of recombinant mistletoe lectin (aviscumine) to resected human adenocarcinoma of the lung. Anticancer Res 25 (5): 3303-7, 2005 Sep-Oct.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16101142&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16101142&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.26">Timoshenko AV, Kayser K, Drings P, et al.: Modulation of lectin-triggered superoxide release from neutrophils of tumor patients with and without chemotherapy. Anticancer Res 13 (5C): 1789-92, 1993 Sep-Oct.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8267383&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8267383&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.27">Timoshenko AV, Gabius HJ: Influence of the galactoside-specific lectin from Viscum album and its subunits on cell aggregation and selected intracellular parameters of rat thymocytes. Planta Med 61 (2): 130-3, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7753919&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7753919&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.28">Timoshenko AV, Cherenkevich SN, Gabius HJ: Viscum album agglutinin-induced aggregation of blood cells and the lectin effects on neutrophil function. Biomed Pharmacother 49 (3): 153-8, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7647287&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7647287&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.29">Hostanska K, Hajto T, Spagnoli GC, et al.: A plant lectin derived from Viscum album induces cytokine gene expression and protein production in cultures of human peripheral blood mononuclear cells. Nat Immun 14 (5-6): 295-304, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8933823&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8933823&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.30">Fischer S, Scheffler A, Kabelitz D: Oligoclonal in vitro response of CD4 T cells to vesicles of mistletoe extracts in mistletoe-treated cancer patients. Cancer Immunol Immunother 44 (3): 150-6, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9191874&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9191874&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.31">Stein GM, Schaller G, Pf&#xFC;ller U, et al.: Characterisation of granulocyte stimulation by thionins from European mistletoe and from wheat. Biochim Biophys Acta 1426 (1): 80-90, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9878694&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9878694&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.32">Stein GM, Schaller G, Pf&#xFC;ller U, et al.: Thionins from Viscum album L: influence of the viscotoxins on the activation of granulocytes. Anticancer Res 19 (2A): 1037-42, 1999 Mar-Apr.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10368652&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10368652&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.33">Hallek M: Interleukin-6-mediated cell growth in multiple myeloma--a role for Viscum album extracts? Onkologie 28 (8-9): 387, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16160399&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16160399&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.34">Schaller G, Urech K, Giannattasio M: Cytotoxicity of different viscotoxins and extracts from the European subspecies Viscum album L. Phytother Res  10 (6): 473-7, 1996.</li><li id="section_4.35">Maier G, Fiebig HH: Absence of tumor growth stimulation in a panel of 16 human tumor cell lines by mistletoe extracts in vitro. Anticancer Drugs 13 (4): 373-9, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11984083&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11984083&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.36">Zarkovic N, Vukovic T, Loncaric I, et al.: An overview on anticancer activities of the Viscum album extract Isorel. Cancer Biother Radiopharm 16 (1): 55-62, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11279798&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11279798&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.37">Zuzak TJ, Rist L, Eggenschwiler J, et al.: Paediatric medulloblastoma cells are susceptible to Viscum album (Mistletoe) preparations. Anticancer Res 26 (5A): 3485-92, 2006 Sep-Oct.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17094471&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17094471&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.38">Kelter G, Fiebig HH: Absence of tumor growth stimulation in a panel of 26 human tumor cell lines by mistletoe (Viscum album L.) extracts Iscador in vitro. Arzneimittelforschung 56 (6A): 435-40, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16927523&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16927523&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.39">Kelter G, Schierholz JM, Fischer IU, et al.: Cytotoxic activity and absence of tumor growth stimulation of standardized mistletoe extracts in human tumor models in vitro. Anticancer Res 27 (1A): 223-33, 2007 Jan-Feb.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17352237&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17352237&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.40">Weissenstein U, Kunz M, Urech K, et al.: Interaction of standardized mistletoe (Viscum album) extracts with chemotherapeutic drugs regarding cytostatic and cytotoxic effects in vitro. BMC Complement Altern Med 14: 6, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24397864&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24397864&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.41">Podlech O, Harter PN, Mittelbronn M, et al.: Fermented mistletoe extract as a multimodal antitumoral agent in gliomas. Evid Based Complement Alternat Med 2012: 501796, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23133496&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23133496&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.42">Cebovi&#x107; T, Spasi&#x107; S, Popovi&#x107; M: Cytotoxic effects of the Viscum album L. extract on Ehrlich tumour cells in vivo. Phytother Res 22 (8): 1097-103, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18570233&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18570233&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.43">Seifert G, Jesse P, Laengler A, et al.: Molecular mechanisms of mistletoe plant extract-induced apoptosis in acute lymphoblastic leukemia in vivo and in vitro. Cancer Lett 264 (2): 218-28, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18314258&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18314258&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.44">Thies A, Dautel P, Meyer A, et al.: Low-dose mistletoe lectin-I reduces melanoma growth and spread in a scid mouse xenograft model. Br J Cancer 98 (1): 106-12, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18026191&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18026191&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.45">Van Huyen JP, Delignat S, Bayry J, et al.: Interleukin-12 is associated with the in vivo anti-tumor effect of mistletoe extracts in B16 mouse melanoma. Cancer Lett 243 (1): 32-7, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16412563&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16412563&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.46">Beuth J, Ko HL, Schneider H, et al.: Intratumoral application of standardized mistletoe extracts down regulates tumor weight via decreased cell proliferation, increased apoptosis and necrosis in a murine model. Anticancer Res 26 (6B): 4451-6, 2006 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17201168&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17201168&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.47">Braun JM, Ko HL, Schierholz JM, et al.: Standardized mistletoe extract augments immune response and down-regulates local and metastatic tumor growth in murine models. Anticancer Res 22 (6C): 4187-90, 2002 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12553054&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12553054&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.48">Pryme IF, Bardocz S, Pusztai A, et al.: Dietary mistletoe lectin supplementation and reduced growth of a murine non-Hodgkin lymphoma. Histol Histopathol 17 (1): 261-71, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11820217&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11820217&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.49">Els&#xE4;sser-Beile U, Ruhnau T, Freudenberg N, et al.: Antitumoral effect of recombinant mistletoe lectin on chemically induced urinary bladder carcinogenesis in a rat model. Cancer 91 (5): 998-1004, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11251952&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11251952&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.50">Stauder H, Kreuser ED: Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: current state of clinical research. Onkologie 25 (4): 374-80, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12232491&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12232491&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.51">Khwaja TA, Dias CB, Pentecost S: Recent studies on the anticancer activities of mistletoe (Viscum album) and its alkaloids. Oncology 43 (Suppl 1): 42-50, 1986.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3543783&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3543783&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.52">Berger M, Schm&#xE4;hl D: Studies on the tumor-inhibiting efficacy of Iscador in experimental animal tumors. J Cancer Res Clin Oncol 105 (3): 262-5, 1983.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6853588&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6853588&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.53">Rostock M, Huber R, Greiner T, et al.: Anticancer activity of a lectin-rich mistletoe extract injected intratumorally into human pancreatic cancer xenografts. Anticancer Res 25 (3B): 1969-75, 2005 May-Jun.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16158932&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16158932&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.54">Jurin M, Zarkovi&#x107; N, Hrzenjak M, et al.: Antitumorous and immunomodulatory effects of the Viscum album L. preparation Isorel. Oncology 50 (6): 393-8, 1993 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8233280&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8233280&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _35
      field_pdq_section_title:
        - format: plain_text
          value: 'Human/Clinical Studies'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_35" class="pdq-sections"><p id="_36" tabindex="-1"><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285939&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285939&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">Mistletoe</a> has been evaluated as a treatment for people with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45333&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045333&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cancer</a> in numerous <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44195&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044195&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">clinical studies</a>.<a href="#cit/section_5.1">1</a><a href="#cit/section_5.2">2</a><a href="#cit/section_5.3">3</a><a href="#cit/section_5.4">4</a><a href="#cit/section_5.5">5</a><a href="#cit/section_5.6">6</a><a href="#cit/section_5.7">7</a><a href="#cit/section_5.8">8</a><a href="#cit/section_5.9">9</a><a href="#cit/section_5.10">10</a><a href="#cit/section_5.11">11</a><a href="#cit/section_5.12">12</a><a href="#cit/section_5.13">13</a><a href="#cit/section_5.14">14</a><a href="#cit/section_5.15">15</a><a href="#cit/section_5.16">16</a><a href="#cit/section_5.17">17</a><a href="#cit/section_5.18">18</a><a href="#cit/section_5.19">19</a><a href="#cit/section_5.20">20</a>  </p><p id="_108" tabindex="-1">The mistletoe <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=407760&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000407760&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">extracts</a> and products studied in clinical trials were Iscador, Eurixor, Helixor, Lektinol, Isorel,  abnobaVISCUM,<a href="#cit/section_5.21">21</a> and recombinant <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44051&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044051&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">lectin</a> ML-1   (refer to  the appropriate sections and   tables  at the end of this section for more information).</p><p id="_197" tabindex="-1">The findings from more than 50 clinical trials of mistletoe extracts in patients with cancer have been published, and several systematic reviews and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=691484&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000691484&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">meta-analyses</a> of the results of these studies have been performed.  Three of the most recent systematic reviews addressed <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45417&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045417&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">quality of life</a> (QOL), survival, and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45022&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045022&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">symptom</a> relief in patients with various cancer types.<a href="#cit/section_5.18">18</a><a href="#cit/section_5.20">20</a><a href="#cit/section_5.22">22</a>  Most studies reported an improvement in QOL. </p><p id="_198" tabindex="-1">In one systematic review that examined 26 randomized controlled trials (RCTs), 22 trials reported an improvement in QOL. All 10 of the nonRCTs also reported the same benefit. Improvement in <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=321374&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000321374&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">fatigue</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=390302&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000390302&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">nausea</a> and vomiting, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=430479&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000430479&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">depression</a>, emotional well-being, and concentration were reported. Some of the studies were well designed, while others reported weaknesses.<a href="#cit/section_5.22">22</a></p><p id="_203" tabindex="-1">Tumor response, QOL, and psychological distress were measured in a review of 21 RCTs of various cancers in which  different mistletoe preparations were used either alone, with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45214&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045214&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">chemotherapy</a>, or with radiation therapy.<a href="#cit/section_5.18">18</a>  Survival times were included in 13 of the studies.  Most of the studies reported benefits for patients, although this review was limited by small sample size and methodological weaknesses. Thus, the authors were unable to suggest practice guidelines for the use of mistletoe.</p><p id="_204" tabindex="-1">The oldest of these three reviews investigated the results of 10 RCTs that used a variety of mistletoe extracts in patients with various malignancies. There was no difference in survival or other benefits for cancer patients who received mistletoe. Therefore, mistletoe was not recommended as a curative or supportive care therapy.<a href="#cit/section_5.20">20</a></p><p id="_37" tabindex="-1">A systematic review of all controlled clinical studies of mistletoe found consistent improvement in chemotherapy-associated fatigue as well as other QOL measures.<a href="#cit/section_5.22">22</a></p><p id="_38" tabindex="-1">Although mistletoe was found to be <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43985&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043985&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">therapeutically</a> effective in most of the reported studies, many of the studies had one or more major design weaknesses as mentioned above that raised doubts about the reliability of the findings. These weaknesses include registration of small numbers of patients; presence of large numbers of patients who either were not <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44029&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044029&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">evaluable</a> or were otherwise excluded from the analyses; failure to adequately document mistletoe use, mistletoe <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44664&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044664&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">dose</a>, and/or interruptions of mistletoe use; absence of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44149&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044149&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">control subjects</a> or use of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44596&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044596&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">historical control subjects</a>; use of inadequate <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=322881&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000322881&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">randomization</a> procedures; absence of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285982&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285982&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">treatment blinding</a>; extensive use of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285981&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285981&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">subset analysis</a>; and the measurement of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285973&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285973&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">mean</a> as opposed to <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44941&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044941&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">median</a> survival. (Note: In studies with small numbers of patients, the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285974&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285974&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">mean survival time</a> can be greatly exaggerated if one or more patients exhibit unusually long survival; <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=655249&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000655249&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">median survival</a>, therefore, is a less biased measure.) In addition, evaluation of the studies is often hindered by incomplete descriptions of the study design and by incomplete reporting of clinical data, including data about previous and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44011&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044011&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">concurrent therapies</a> received by the patients. A selection of studies is discussed below, organized by the type of mistletoe extract used. Eurixor, Isorel, and Vysorel are no longer available  on the market for sale.</p><section id="_125"><h3 id="_125_toc">Iscador</h3><p id="_219" tabindex="-1">An interim analysis of a randomized <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45833&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045833&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">phase III trial</a> reported on 220 patients with locally advanced or metastatic pancreatic cancer.<a href="#cit/section_5.23">23</a> Patients received best supportive care and were randomly assigned to receive either IscadorQu or no antineoplastic therapy (control). Patients were stratified according to tumor stage, age, and performance status. Iscador was administered <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45914&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045914&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">subcutaneously</a> in a dose-escalating manner from 0.01 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44213&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044213&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">mg</a> to 10 mg three times per week. Treatment with Iscador demonstrated a significant enhancement of overall survival (OS) (4.8 months vs. 2.7 months for IscadorQu patients vs. control patients, respectively; prognosis-adjusted hazard ratio [HR], 0.49; <em>P</em> &lt; .0001). </p><p id="_223" tabindex="-1">The independent data monitoring committee that reviewed the interim analysis results recommended termination of the trial because of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44167&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044167&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">statistically significant</a> superiority of survival in the treatment group compared with the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44149&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044149&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">control group</a>. Further analysis of a subset of the 220 patients enrolled demonstrated improved QOL symptoms (pain, fatigue, weight loss, nausea, diarrhea, and anxiety) in the treatment group compared with  the control group.<a href="#cit/section_5.24">24</a> </p><p id="_40" tabindex="-1">A three-arm, randomized phase III trial that involved 408 patients with previously untreated, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285970&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285970&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">inoperable</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45323&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045323&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">non-small cell lung cancer</a> was conducted between 1978 and 1987.<a href="#cit/section_5.25">25</a> Patients were randomly assigned to one of the following treatments:   </p><div class="pdq-content-list"><ul id="_224"><li>Subcutaneous <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44678&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044678&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">injection</a> 3 times a week with IscadorU or IscadorQu  (refer to the <a href="/about-cancer/treatment/cam/hp/mistletoe-pdq#link/_7">General Information</a> section of this summary for more information); the concentration of mistletoe was increased during a seven-injection sequence or cycle, followed by a 3-day pause, and then the process was repeated; IscadorU was administered for two cycles, followed by two cycles of IscadorQu; both mistletoe preparations contained <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285976&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285976&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">mercury</a>). </li><li><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44049&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044049&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">Intramuscular injection</a> once a week with Polyerga Neu, which is a sheep spleen <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285966&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285966&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">glycopeptide</a> that is reported to be an <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285968&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285968&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">immunostimulant</a> and an inhibitor of tumor cell <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44131&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044131&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">glycolysis</a>.</li><li>Intramuscular injection once a week with a <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44744&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044744&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">vitamin</a> B mixture, which served as a <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46688&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046688&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">placebo</a>.</li></ul></div><p id="_225" tabindex="-1">Complete follow-up information was available for 337 patients, and 312 patients (105 Iscador treated, 100 Polyerga Neu treated, and 107 placebo treated) were included in the survival analysis. No statistically significant differences in survival were found between the three groups. Median survival for the Iscador group was 9.1 months; for the Polyerga Neu group, it was 9.0 months; and for the placebo group, it was 7.6 months. The researchers reported that 11.5% of the patients in the Iscador group survived 2 years from the time they entered the trial; the corresponding survival values for the Polyerga Neu and the placebo groups were 13.9% and 10.1%, respectively. In addition, no differences were found between the three groups with respect to tumor response, median body weight, blood chemistry values, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44156&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044156&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">Karnofsky Performance Status</a>, and  QOL. However, more patients in the Iscador group than in the Polyerga Neu or the placebo groups reported subjective improvement in feelings of well-being (59.4% vs. 43.2% and 44.8%, respectively).<a href="#cit/section_5.25">25</a></p><p id="_78" tabindex="-1">Another randomized phase III trial of mistletoe as a treatment for people with cancer involved 830 patients with high-risk <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45135&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045135&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">melanoma</a> (i.e., a <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45847&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045847&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">primary tumor</a> &gt;3 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44215&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044215&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">mm</a> in <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44224&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044224&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">diameter</a> and no <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44312&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044312&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">regional lymph nodes</a> positive for cancer or a primary tumor of any size, one or   two regional lymph nodes positive for cancer, and no distant <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46710&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046710&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">metastases</a>) who were randomly assigned to one of the following four groups after potentially curative <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45570&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045570&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">surgery</a>: (1) treatment with low-dose <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45324&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045324&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">interferon</a>-alpha; (2) treatment with low-dose interferon-gamma; (3) treatment with IscadorM; or (4) no further treatment. Both types of interferon and IscadorM were administered by subcutaneous injection for a period of 1 year.<a href="#cit/section_5.5">5</a> The interferon injections were administered every other day, whereas IscadorM was administered 3 times a week for up to 1 year. After  8 years of follow-up, no increase in survival time or increase in  time until melanoma recurrence was demonstrated for mistletoe treatment or treatment with either
            type of interferon.  </p><p id="_199" tabindex="-1">In another retrospective <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44939&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044939&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">multicenter</a> cohort study that determined the safety and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=346517&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000346517&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">efficacy</a> of Iscador as an adjuvant long-term treatment after surgery for malignant melanoma, 686 patient records were examined (357 untreated controls and 329 treated with Iscador). Safety, efficacy, and a cluster of survival endpoints (tumor related, disease free, brain metastases free, and OS) were measured. The use of additional adjuvant chemotherapy was more frequent in the Iscador-treated  group, while the use of immunotherapy was more frequent in the control group. Only mild to intermediate adverse drug reactions were seen in the treated group. The tumor-related mortality rate was 8.9% in the Iscador group, compared with 10.7% in the control group (<em>P</em> = .017).<a href="#cit/section_5.26">26</a></p><p id="_43" tabindex="-1">Three other studies of mistletoe were described in a single published report.<a href="#cit/section_5.4">4</a> One of the three studies was a large cohort study on the effectiveness of Iscador as a treatment for people with rectal, colon, breast, stomach, or lung cancer.<a href="#cit/section_5.4">4</a> The second and third studies were small, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44079&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044079&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">prospective</a>, randomized, matched-pair studies (one randomized, one nonrandomized) that involved patients who were selected from a group of 8,475 individuals who had not been treated with mistletoe.<a href="#cit/section_5.4">4</a></p><p id="_44" tabindex="-1">These studies are summarized in <a href="/about-cancer/treatment/cam/hp/mistletoe-pdq#link/_194">Table 3</a>.  The overall conclusion of the authors in the report of these three studies was that Iscador treatment can produce a clinically significant increase in survival in cancer patients.  However, there were several weaknesses in the design and execution of these studies.  In a large cohort study, the investigators were unable to find matched cohorts for 61% of eligible patients, and even among the patients for whom matches were found, fewer than two-thirds  were judged to adhere strictly to the matching criteria;  thus, the final analysis contained fewer than 25% of eligible patients.  In the two small prospective studies, no records of the amount or duration of Iscador use were kept.</p><p id="_109" tabindex="-1">The use of Iscador as an adjuvant treatment has been examined in several studies.   In the following studies, Iscador proved safe and effective and also showed a significant survival advantage over untreated controls.</p><p id="_110" tabindex="-1">A retrospective multicenter cohort study of parallel groups examined Iscador as a <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43980&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043980&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">postoperative</a> adjuvant using safety and efficacy as the main endpoints. A total of 1,442 patient records (710 treated patients and 732 untreated controls) were randomly selected from medical institutions that provided both standard and alternative treatments.  Safety and efficacy were measured by the number and severity of adverse <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=348921&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000348921&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">drug</a> reactions.  The treatment group showed significantly less adverse reactions (confidence interval,  95%; <em>P</em> &lt;    .001) compared with the controls.<a href="#cit/section_5.27">27</a><a href="#cit/section_5.28">28</a></p><p id="_162" tabindex="-1"> A multicenter, controlled, retrospective observational cohort study that involved  nonmetastatic <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=444983&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000444983&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">colorectal cancer</a> patients treated between 1993 and 2002 was conducted to evaluate safety and efficacy measures with Iscador.  Eight hundred and four consecutive colorectal patients (429  treated with Iscador and 375  controls) from 26 hospitals and practices were included.  Iscador was well tolerated, with a significant reduction in adverse events, a higher rate of symptom relief, and improved <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44023&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044023&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">disease-free survival</a> compared with the control group.  The study concluded the use of Iscador has a beneficial effect as an <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45587&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045587&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">adjuvant therapy</a> and long-term treatment for patients with stage I to III colorectal cancer.<a href="#cit/section_5.29">29</a></p><p id="_200" tabindex="-1">A randomized phase II study of Iscador combined with carboplatin-containing regimens was conducted in chemotherapy-na&#xEF;ve patients with advanced non-small cell lung cancer.<a href="#cit/section_5.30">30</a> Seventy-two patients were randomly assigned to receive either chemotherapy alone with carboplatin combined with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45347&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045347&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">gemcitabine</a> or pemetrexed (39 patients) or chemotherapy plus Iscador (33 patients) 3 times a week until tumor progression. Time to progression (4.8 months vs. 6 months) and OS (11 months) were similar in both treatment groups. There were no differences in QOL observed between the treatment groups, although chemotherapy dose reductions, nonhematologic toxicities, and hospitalizations were less frequent in patients treated with Iscador in this nonblinded study.</p><p id="_201" tabindex="-1">Another U.S. trial (<a href="/clinicaltrials/NCT00283478">NCT00283478</a>) of the mistletoe extract Iscar with gemcitabine versus gemcitabine alone as a <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=346513&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000346513&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">second-line therapy</a> for non-small cell lung cancer patients who have failed one prior line of chemotherapy has been completed but not yet published.</p></section><table id="_194" class="table-default expandable-container"><caption>Table 3.  Use of Iscador in Cancer Treatment: Clinical Reports Describing Therapeutic Endpoints<span class="sup">a</span></caption><colgroup><col width="17.75%"><col width="12.77%"><col width="13.53%"><col width="13.92%"><col width="15.32%"><col width="13.66%"><col width="13.02%"></colgroup><THead><tr><th>Reference Citation(s) </th><th>Type of Study </th><th>Type(s) of Cancer </th><th>No. of Patients: Enrolled; Treated; Control<span class="sup">b</span> </th><th>Strongest Benefit Reported<span class="sup">c</span> </th><th>Concurrent Therapy<span class="sup">d</span></th><th>Level of Evidence Score<span class="sup">e</span></th></tr></THead><TFoot class="pdq-footer"><tr><td colspan="7">LN+ = lymph node&#x2013;positive disease; No. = number; QOL = quality of life.</td></tr><tr><td colspan="7"><span class="sup">a</span>Refer to text and the <a href="https://www.cancer.gov/publications/dictionaries/cancer-terms/" title="https://www.cancer.gov/publications/dictionaries/cancer-terms/">NCI Dictionary of Cancer Terms</a> for additional information and definition of terms.</td></tr><tr><td colspan="7"><span class="sup">b</span>Number of patients treated plus number of patients controlled may not equal number of patients enrolled; number of patients enrolled = number of patients initially recruited/considered by the researchers who conducted a study; number of patients treated = number of enrolled patients who were administered the treatment being studied and for whom results were reported; historical control subjects are not included in number of patients enrolled.</td></tr><tr><td colspan="7"><span class="sup">c</span>Strongest evidence reported that the treatment under study has anticancer activity or otherwise improves the well-being of cancer patients.</td></tr><tr><td colspan="7"><span class="sup">d</span>Chemotherapy, radiation therapy, hormonal therapy, or cytokine therapy administered/allowed at the same time as mistletoe therapy.</td></tr><tr><td colspan="7"><span class="sup">e</span>For information about levels of evidence analysis and an explanation of the level of evidence scores, refer to <a href="/publications/pdq/levels-evidence/cam">Levels of Evidence for Human Studies of Integrative, Alternative, and Complementary Therapies</a>.</td></tr><tr><td colspan="7"><span class="sup">f</span>Control patients were treated with a vitamin B mixture as a placebo; 100 additional evaluable patients were treated with Polyerga Neu, a sheep spleen glycopeptide reported to be an immunostimulant and an inhibitor of tumor cell glycolysis; treatment with Polyerga Neu was not found to be beneficial.</td></tr><tr><td colspan="7"><span class="sup">g</span>Radiation therapy for metastases distant from the site of the primary tumor was permitted; radiation therapy to the primary tumor site or use of other anticancer treatment was not permitted.</td></tr><tr><td colspan="7"><span class="sup">h</span>Among 10,226 cancer patients enrolled in a retrospective matched-pair, case-control study, 1,751 had been treated with Iscador or another mistletoe product and 8,475 had not been treated with mistletoe; from the 8,475 untreated patients, two sets of matched pairs were formed for prospective studies; in the prospective studies, one member of each pair was randomly assigned to be treated with Iscador and the other member served as a control subject.</td></tr><tr><td colspan="7"><span class="sup">i</span>Patients were strictly matched according to gender, year of birth &#xB1; 3 years, year of diagnosis &#xB1; 3 years, type of tumor, stage of disease, and conventional therapy received.</td></tr></TFoot><tbody><tr><td><a href="#cit/section_5.25">25</a></td><td>Randomized trial</td><td>Lung, non-small cell, inoperable</td><td>408; 105; 107<span class="sup">f</span></td><td>Subjective improvement in quality of life</td><td>Yes<span class="sup">g</span></td><td>1iiA</td></tr><tr><td><a href="#cit/section_5.31">31</a></td><td>Randomized trial</td><td>Lung, non-small cell, stages I&#x2013;IV </td><td>218; 87; 96</td><td>Improved median survival, LN+ patients only</td><td>No</td><td>1iiA</td></tr><tr><td><a href="#cit/section_5.5">5</a></td><td>Randomized trial</td><td>Melanoma, stages II&#x2013;III</td><td>204; 102; 102</td><td>None</td><td>No</td><td>1iiA</td></tr><tr><td><a href="#cit/section_5.23">23</a><a href="#cit/section_5.24">24</a></td><td>Randomized trial</td><td><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44521&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044521&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">Pancreatic</a>, advanced or metastatic</td><td>220; 110; 110</td><td>Improved survival and improved QOL</td><td>No</td><td>1iiA</td></tr><tr><td><a href="#cit/section_5.32">32</a></td><td>Randomized trial</td><td><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45395&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045395&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">Osteosarcoma,</a> second metastatic <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45866&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045866&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">relapse</a></td><td>20; 9 (viscum); 11 (<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45189&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045189&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">etoposide</a>)</td><td>Improved disease-free survival and QOL compared with etoposide group</td><td>No</td><td>1iiDii </td></tr><tr><td><a href="#cit/section_5.27">27</a></td><td>Comparative, retrolective, cohort study </td><td>Breast, stages I&#x2013;IV</td><td>1,442; 710; 732</td><td>Improved survival</td><td>Yes</td><td>2B</td></tr><tr><td><a href="#cit/section_5.26">26</a></td><td>Comparative, retrolective, cohort study </td><td>Melanoma, stages II&#x2013;III</td><td>686; 329; 357</td><td>Improved survival</td><td>Unknown</td><td>2A</td></tr><tr><td><a href="#cit/section_5.4">4</a></td><td>Cohort study</td><td>Breast, stage III</td><td>8,475<span class="sup">h</span>; 17<span class="sup">i</span>; 17<span class="sup">i</span> </td><td>Improved mean survival</td><td>Yes</td><td>None</td></tr><tr><td><a href="#cit/section_5.4">4</a></td><td>Cohort study </td><td>Various types, stages I&#x2013;IV</td><td>8,475<span class="sup">h</span>; 39<span class="sup">i</span>; 39<span class="sup">i</span></td><td>Improved mean survival</td><td>Yes</td><td>None</td></tr><tr><td><a href="#cit/section_5.4">4</a></td><td>Cohort study </td><td>Various types, stages I&#x2013;IV</td><td>10,226<span class="sup">h</span>; 396<span class="sup">i</span>; 396<span class="sup">i</span></td><td>Improved mean survival</td><td>Yes</td><td>None</td></tr><tr><td><a href="#cit/section_5.29">29</a></td><td>Retrospective, observational cohort study </td><td>Nonmetastatic colorectal</td><td>804; 429; 375</td><td>Lower incidence of diarrhea, nausea, loss of appetite, dermatitis, fatigue, and mucositis</td><td>Yes</td><td>2C</td></tr><tr><td><a href="#cit/section_5.33">33</a></td><td>Nonconsecutive case series </td><td>Pancreatic </td><td>292; 292; various historical controls</td><td>Improved median survival</td><td>Yes</td><td>3iiiA</td></tr></tbody></table><section id="_126"><h3 id="_126_toc">Other Mistletoe Preparations</h3><p id="_263" tabindex="-1">Studies on Eurixor, Helixor, Lektinol, Isorel, and abnobaVISCUM are summarized in <a href="/about-cancer/treatment/cam/hp/mistletoe-pdq#link/_71">Table 4.</a></p><section id="_182"><h4 id="_182_toc">Eurixor</h4><p id="_183" tabindex="-1">Five randomized controlled trials of Eurixor have been published as peer-reviewed articles. The largest of these studies involved 477 patients with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46595&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046595&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">squamous cell carcinoma</a> of the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=257519&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000257519&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">head and neck</a>.<a href="#cit/section_5.2">2</a><a href="#cit/section_5.15">15</a> These patients were randomly assigned to treatment with surgery or surgery and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44971&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044971&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">radiation therapy</a>, and they were randomly assigned again to either no additional treatment or treatment with Eurixor. This double randomization produced the following four groups: (1) 105 patients treated with surgery alone; (2) 97 patients treated with surgery and Eurixor; (3) 137 patients treated with surgery and radiation therapy; and (4) 138 patients treated with surgery, radiation therapy, and Eurixor. Eurixor was administered in four treatment cycles over a 60-week period. Each treatment cycle lasted 12 weeks and was followed by a 4-week break.  During each cycle, Eurixor was administered by subcutaneous injection twice a week. Each injection contained enough standardized mistletoe extract to yield a dose of 1 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285977&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285977&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">nanogram</a> of ML-1 lectin per <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44576&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044576&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">kilogram</a> of body weight. The results of this randomized trial showed that treatment with Eurixor did not improve either 5-year <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44023&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044023&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">disease-free survival</a> or 5-year <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44311&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044311&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">disease-specific survival</a>.  In addition, no stimulation of the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46356&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046356&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">immune system</a> or improvement in QOL was found with Eurixor treatment.</p><p id="_184" tabindex="-1">It has been suggested that a less-than-optimum dose of mistletoe was administered to patients in this trial.<a href="#cit/section_5.4">4</a> The same dose of Eurixor, however, has been used in other clinical studies, including studies in which benefit was reported.<a href="#cit/section_5.1">1</a><a href="#cit/section_5.34">34</a> In addition, both the dose and the duration of Eurixor treatment in this trial are consistent with those recommended by the manufacturer.<a href="#cit/section_5.2">2</a></p><p id="_185" tabindex="-1">A prospective, randomized phase II trial  involved 45 patients who had noninvasive <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=444968&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000444968&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">bladder cancer</a>.<a href="#cit/section_5.3">3</a> After surgery, the patients were randomly assigned to receive either three cycles of treatment with Eurixor or no further therapy. The goal of the study was to determine whether Eurixor treatment could reduce bladder cancer recurrence. Twenty-three patients were randomly  assigned to the treatment group, and 22 were randomly assigned to the control group. Each cycle of Eurixor treatment consisted of 3 months of subcutaneous injections, administered twice a week, followed by a 3-month break. One milliliter of Eurixor was administered at each injection. After 18 months of follow-up, 11 recurrences were observed in the treatment group, and 8 were observed in the control group. The average time of recurrence for the treatment group was 6.3 months; for the control group, it was 6.4 months. The median disease-free interval for the treatment group was 9 months; for the control group, it was 10.5 months. None of these differences was considered significant.</p><p id="_186" tabindex="-1">A major concern about this study, however, is that the dose of lectin ML-1 administered to patients was not adjusted for  body weight.      </p><p id="_226" tabindex="-1">Eurixor is no longer available  on the market for sale.</p></section><section id="_187"><h4 id="_187_toc">Isorel</h4><p id="_188" tabindex="-1">Only two trials of Isorel have been reported in the publicly available, online indexed peer-reviewed medical literature.  In one study, 64  patients with advanced colorectal cancer  (Dukes C and D)  were randomly assigned to three groups: (1) surgery and chemotherapy; (2) surgery and chemotherapy plus Isorel; and (3) surgery alone.  Patients receiving treatment with Isorel had a significantly better median survival advantage and a better cumulative survival advantage than patients in the other two groups.  In addition there were no side effects to treatment in the Isorel group.<a href="#cit/section_5.35">35</a></p><p id="_189" tabindex="-1">Another study showed that <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44076&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044076&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">perioperative</a> use of Isorel in patients with cancer of the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46447&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046447&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">digestive tract</a>  resulted in  an increase in <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45765&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045765&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">lymphocytes</a> through 14 days of drug <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=478733&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000478733&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">administration</a>. </p><p id="_227" tabindex="-1">Isorel is no longer available  on the market for sale.</p></section><section id="_190"><h4 id="_190_toc">Helixor</h4><p id="_264" tabindex="-1">                Most studies have been conducted in Europe, primarily in Germany and Austria.  One prospective, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45830&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045830&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">phase I</a>, dose-escalation trial studied  weekly <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46682&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046682&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">intravenous</a> pine mistletoe <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43998&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043998&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">aqueous</a> extract given alone. In the 21 patients evaluated, Helixor was well tolerated in doses up to 2,000 mg with mild to moderate <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=450108&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000450108&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">fever</a> noted.<a href="#cit/section_5.36">36</a> A subsequent study demonstrated improved median QOL in a group of patients receiving Helixor versus a control group receiving best supportive care.<a href="#cit/section_5.37">37</a></p><p id="_191" tabindex="-1">Other studies have explored the effects of administering Helixor to patients receiving chemotherapy and/or radiation therapy. The <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=454777&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000454777&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">National Center for Complementary and Integrative Health</a>   in cooperation with the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44266&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044266&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">National Cancer Institute</a> (NCI) conducted a   phase I trial (<a href="https://clinicaltrials.gov/ct2/show/NCT00049608" title="https://clinicaltrials.gov/ct2/show/NCT00049608">NCCAM-02-AT-260</a>) of  mistletoe (Helixor A) and gemcitabine in patients with advanced <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45301&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045301&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">solid tumors</a>. The Helixor A and gemcitabine combination showed limited <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=445093&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000445093&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">toxicity</a>, and no <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=367458&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000367458&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">botanical</a>-drug interactions were reported.<a href="#cit/section_5.38">38</a> (<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3944907/" title="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3944907/">Also available online.</a>) In a three-arm randomized trial,  breast cancer patients were randomly assigned to one of the following groups after surgery: Helixor, chemotherapy, or control. Some patients in each group were also treated with local radiation therapy.  The number of evaluable patients in the chemotherapy group was 177, with  survival in the chemotherapy group  superior to that in the control group and equivalent to that in the Helixor group.<a href="#cit/section_5.39">39</a>  The use of Helixor has also been examined in other studies.<a href="#cit/section_5.37">37</a><a href="#cit/section_5.40">40</a><a href="#cit/section_5.41">41</a><a href="#cit/section_5.42">42</a></p></section><section id="_192"><h4 id="_192_toc">abnobaVISCUM</h4><p id="_193" tabindex="-1">No tumor response was seen in any of the 25 patients in a phase ll trial that examined the effect of a mistletoe extract, known as abnobaVISCUM, in metastatic colorectal cancer resistant to standard treatment (5-<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46090&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046090&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">fluorouracil</a> and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45750&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045750&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">leucovorin</a> chemotherapy).    The endpoint of the study was objective tumor response.  Patients were administered a gradually increasing daily dose of 0.15 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44213&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044213&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">mg</a> to 15 mg. Treatment duration ranged from 4 weeks to 66 weeks.  Toxicity levels were mild.  Some patients reported relief of disease symptoms.<a href="#cit/section_5.43">43</a></p><p id="_248" tabindex="-1">A small, randomized, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44066&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044066&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">nonblinded</a>  trial of abnobaVISCUM, given postoperatively to 15 patients with resected stage IB or II gastric cancer, showed improved QOL among patients who received the mistletoe extract compared with 16 untreated controls.<a href="#cit/section_5.44">44</a> A small <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44092&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044092&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">uncontrolled</a> trial of  mistletoe plant extract from the same manufacturer (abnobaVISCUM) treated patients with non&#x2013;muscle-<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45741&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045741&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">invasive</a> bladder cancer; this trial showed the safety of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46340&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046340&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">intravesical</a> administration and had <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43983&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043983&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">response rates</a> of 56%, which was consistent with the published results of other treatments for bladder cancer (39%&#x2013;50%).<a href="#cit/section_5.45">45</a></p><p id="_249" tabindex="-1">A single-arm, multicenter, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285990&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285990&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">open-label</a> trial evaluated the efficacy and safety of chemical <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44294&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044294&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">pleurodesis</a> using abnobaVISCUM.<a href="#cit/section_5.46">46</a> Of the 62 patients in the study, 49 patients had a <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45652&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045652&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">complete response</a>, 11 patients had a partial response, and 2 patients had no response. The <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45981&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045981&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">observation</a> period was 4 weeks. There are no data on how <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285972&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285972&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">intrapleural</a> administration compared with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=346525&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000346525&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">standard of care</a>.</p></section></section><table id="_71" class="table-default expandable-container"><caption>Table 4.     Use of Other Mistletoe Products in Cancer Treatment: Clinical Reports Describing Therapeutic Endpoints<span class="sup">a</span></caption><colgroup><col width="11.37%"><col width="13.19%"><col width="16.91%"><col width="12.18%"><col width="12.08%"><col width="12.58%"><col width="10.07%"><col width="11.58%"></colgroup><THead><tr><th>Reference Citation(s)</th><th>Type of Study</th><th>Product Tested</th><th>Type(s) of  Cancer</th><th>No.  of Patients: Enrolled; Treated; Control<span class="sup">b</span></th><th>Strongest Benefit Reported<span class="sup">c</span></th><th>Concurrent Therapy<span class="sup">d</span></th><th>Level of Evidence Score<span class="sup">e</span></th></tr></THead><TFoot class="pdq-footer"><tr><td colspan="8">No. =  number; QOL = quality of life.</td></tr><tr><td colspan="8"><span class="sup">a</span>Refer to text and the <a href="https://www.cancer.gov/publications/dictionaries/cancer-terms/" title="https://www.cancer.gov/publications/dictionaries/cancer-terms/">NCI Dictionary     of Cancer Terms</a> for additional information and definition of terms.</td></tr><tr><td colspan="8"><span class="sup">b</span>Number of patients treated plus number of patients controlled may not equal number of patients enrolled; number of patients enrolled = number of patients initially  recruited/considered by the researchers who conducted a study; number of patients treated = number of enrolled patients who were administered the treatment being studied and for whom results were reported; historical control subjects are not included in number of patients enrolled.</td></tr><tr><td colspan="8"><span class="sup">c</span>Strongest evidence reported that the treatment under study has anticancer activity or otherwise improves the well-being of cancer patients.</td></tr><tr><td colspan="8"><span class="sup">d</span>Chemotherapy, radiation therapy, hormonal therapy, or cytokine therapy administered/allowed at the same time as mistletoe therapy.</td></tr><tr><td colspan="8"><span class="sup">e</span>For information about levels of evidence analysis and an explanation of the level of evidence scores, refer to <a href="/publications/pdq/levels-evidence/cam">Levels of Evidence for Human Studies of Integrative, Alternative, and Complementary Therapies</a>.</td></tr><tr><td colspan="8"><span class="sup"> f</span>This was a four-arm trial; patients were randomly assigned to surgery only or to surgery plus radiation therapy, followed by a second randomization to no mistletoe treatment or to treatment with Eurixor; the resulting treatment groups contained the following numbers of evaluable patients: surgery only  = 105, surgery plus Eurixor = 97, surgery plus radiation therapy = 137, and surgery plus radiation therapy plus
            Eurixor = 138; radiation therapy and Eurixor treatment overlapped; no treatment approach was superior in terms of disease-free survival, disease-specific survival, improvement in QOL, or stimulation of
            the immune system; in the table, mistletoe-treated and nontreated (control) patients were grouped (i.e., number treated = 97 + 138 = 235, and number control = 105 + 137 = 242).</td></tr></TFoot><tbody><tr><td><a href="#cit/section_5.3">3</a></td><td>Randomized trial</td><td>Eurixor</td><td>Bladder, noninvasive</td><td>45; 23; 22</td><td>None</td><td>No</td><td>1iiDi</td></tr><tr><td><a href="#cit/section_5.1">1</a><a href="#cit/section_5.34">34</a></td><td>Randomized trial</td><td>Eurixor</td><td>Brain, glioma; 74% of patients, stages III&#x2013;IV; 26% of
            patients,
            no stage
            information
            </td><td>47;        20; 18</td><td>Improved survival,
            stages
            III&#x2013;IV
            patients
            only
            </td><td>Yes</td><td>1iiA</td></tr><tr><td><a href="#cit/section_5.47">47</a><a href="#cit/section_5.48">48</a></td><td>Randomized trial</td><td>Eurixor</td><td>Colorectal, metastatic</td><td>107; 38; 41</td><td>Improved QOL</td><td>Yes</td><td>1iiA</td></tr><tr><td><a href="#cit/section_5.2">2</a></td><td>Randomized trial</td><td>Eurixor</td><td>Head and neck,
            squamous
            cell,
            stages
            I&#x2013;IV
            </td><td>495; 235<span class="sup">f</span>;  242<span class="sup">f</span></td><td>None</td><td>Yes<span class="sup">f</span></td><td>1iiA</td></tr><tr><td><a href="#cit/section_5.39">39</a></td><td>Randomized trial</td><td>Helixor</td><td>Breast, stages I&#x2013;III</td><td>692; 192 (Helixor) and 177 (chemotherapy); 274</td><td>Improved survival</td><td>Yes</td><td>1iiA</td></tr><tr><td><a href="#cit/section_5.49">49</a></td><td>Randomized trial</td><td>Helixor</td><td>Colorectal, metastatic</td><td>60; 20; 20</td><td>Improved mean survival</td><td>Yes</td><td>1iiA</td></tr><tr><td><a href="#cit/section_5.37">37</a></td><td>Randomized trial</td><td>Helixor</td><td>Breast, ovarian, and non-small cell lung </td><td>224; 115; 109</td><td>Improved QOL</td><td>Yes</td><td>1iiC</td></tr><tr><td><a href="#cit/section_5.13">13</a></td><td>Randomized controlled trial</td><td>PS76A (Lektin)</td><td>Breast</td><td>352; 176; 176</td><td>Improved QOL</td><td>Yes</td><td>1iC</td></tr><tr><td><a href="#cit/section_5.50">50</a></td><td>Randomized trial</td><td>Lektinol</td><td>Breast</td><td>261; 195; 66</td><td>Improved QOL</td><td>Yes</td><td>1iC</td></tr><tr><td><a href="#cit/section_5.51">51</a></td><td>Randomized trial</td><td>Lektinol</td><td>Breast</td><td>352; 176; 176</td><td>Improved QOL</td><td>Yes</td><td>1iC</td></tr><tr><td><a href="#cit/section_5.35">35</a></td><td>Randomized trial</td><td>Isorel</td><td>Colorectal</td><td>64; 50; 14 </td><td>Improved survival and tolerance to either adjuvant or palliative treatment</td><td>Yes</td><td>1iiA</td></tr><tr><td><a href="#cit/section_5.52">52</a></td><td>Nonrandomized controlled trial</td><td>Isorel</td><td>Digestive tract</td><td>70; 40; 30</td><td>Enhanced cellular immunity and improved QOL</td><td>No</td><td>2C</td></tr><tr><td><a href="#cit/section_5.43">43</a></td><td>Nonrandomized controlled trial</td><td>abnobaVISCUM <em>Quercus</em></td><td>Metastatic colorectal</td><td>25; 25; none</td><td>None</td><td>Yes</td><td>2Diii</td></tr><tr><td><a href="#cit/section_5.21">21</a></td><td>Nonrandomized controlled trial</td><td>Viscum fraxini-2</td><td>Hepatocellular carcinoma</td><td>23; 23; none</td><td>Improved survival </td><td>No</td><td>2Dii</td></tr></tbody></table><section id="_TrialSearch_35_sid_5"><h3 id="_TrialSearch_35_sid_5_toc">Current Clinical Trials</h3><p id="_TrialSearch_35_22" tabindex="-1">Use our <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search">advanced clinical trial search</a> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/">General information</a> about clinical trials is also available.</p></section><h6 do-not-show="toc">References</h6><ol><li id="section_5.1">Lenartz D, Dott U, Menzel J, et al.: Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe. Anticancer Res 20 (3B): 2073-6, 2000 May-Jun.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10928154&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10928154&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.2">Steuer-Vogt MK, Bonkowsky V, Ambrosch P, et al.: The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. Eur J Cancer 37 (1): 23-31, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11165126&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11165126&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.3">Goebell PJ, Otto T, Suhr J, et al.: Evaluation of an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized phase II trial. J Urol 168 (1): 72-5, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12050495&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12050495&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.4">Grossarth-Maticek R, Kiene H, Baumgartner SM, et al.: Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study. Altern Ther Health Med 7 (3): 57-66, 68-72, 74-6 passim, 2001 May-Jun.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11347286&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11347286&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.5">Kleeberg UR, Suciu S, Br&#xF6;cker EB, et al.: Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness &gt;3 mm) or regional lymph node metastasis. Eur J Cancer 40 (3): 390-402, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14746858&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14746858&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.6">Viscum album. In: Homoeopathic Pharmacopoeia Convention of the United States: Homoeopathic Pharmacopoeia of the United States. Washington, DC: 2002, Monograph 9444 Visc.</li><li id="section_5.7">Tr&#xF6;ger W, Jezdi&#x107; S, &#x17D;drale Z, et al.: Quality of life and neutropenia in patients with early stage breast cancer: a randomized pilot study comparing additional treatment with mistletoe extract to chemotherapy alone
            . Breast Cancer: Basic and Clinical Research  3: 35-45, 2009.</li><li id="section_5.8">Grossarth-Maticek R, Ziegler R: Prospective controlled cohort studies on long-term therapy of breast cancer patients with a mistletoe preparation (Iscador). Forsch Komplementmed 13 (5): 285-92, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17057389&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17057389&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.9">Grossarth-Maticek R, Ziegler R: Prospective controlled cohort studies on long-term therapy of cervical cancer patients with a mistletoe preparation (Iscador). Forsch Komplementmed 14 (3): 140-7, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17596694&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17596694&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.10">Grossarth-Maticek R, Ziegler R: Randomized and non-randomized prospective controlled cohort studies in matched pair design for the long-term therapy of corpus uteri cancer patients with a mistletoe preparation (Iscador). Eur J Med Res 13 (3): 107-20, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18499556&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18499556&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.11">Grossarth-Maticek R, Ziegler R: Prospective controlled cohort studies on long-term therapy of ovairian cancer patients with mistletoe (Viscum album L.) extracts iscador. Arzneimittelforschung 57 (10): 665-78, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18074761&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18074761&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.12">Bar-Sela G, Goldberg H, Beck D, et al.: Reducing malignant ascites accumulation by repeated intraperitoneal administrations of a Viscum album extract. Anticancer Res 26 (1B): 709-13, 2006 Jan-Feb.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16739342&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16739342&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.13">Wetzel D, Sch&#xE4;fer M: Results of a randomised placebo-controlled multicentre study with PS76A2 (standardised mistletoe preparation) in patients with breast cancer receiving adjuvant chemotherapy. [Abstract] Phytomedicine  7 (Suppl 2): A-SL-66, 2000.</li><li id="section_5.14">Sch&#xF6;ffski P, Riggert S, Fumoleau P, et al.: Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group. Ann Oncol 15 (12): 1816-24, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15550588&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15550588&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.15">Stauder H, Kreuser ED: Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: current state of clinical research. Onkologie 25 (4): 374-80, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12232491&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12232491&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.16">Kienle GS, Berrino F, B&#xFC;ssing A, et al.: Mistletoe in cancer - a systematic review on controlled clinical trials. Eur J Med Res 8 (3): 109-19, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12730032&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12730032&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.17">Kienle GS, Glockmann A, Schink M, et al.: Viscum album L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical research. J Exp Clin Cancer Res 28: 79, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19519890&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19519890&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.18">Horneber MA, Bueschel G, Huber R, et al.: Mistletoe therapy in oncology. Cochrane Database Syst Rev  (2): CD003297, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18425885&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18425885&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.19">Kienle GS, Kiene H: Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts. Eur J Med Res 12 (3): 103-19, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17507307&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17507307&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.20">Ernst E, Schmidt K, Steuer-Vogt MK: Mistletoe for cancer? A systematic review of randomised clinical trials. Int J Cancer 107 (2): 262-7, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12949804&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12949804&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.21">Mabed M, El-Helw L, Shamaa S: Phase II study of viscum fraxini-2 in patients with advanced hepatocellular carcinoma. Br J Cancer 90 (1): 65-9, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14710208&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14710208&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.22">Kienle GS, Kiene H: Review article: Influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies. Integr Cancer Ther 9 (2): 142-57, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20483874&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20483874&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.23">Tr&#xF6;ger W, Galun D, Reif M, et al.: Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: a randomised clinical trial on overall survival. Eur J Cancer 49 (18): 3788-97, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23890767&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23890767&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.24">Tr&#xF6;ger W, Galun D, Reif M, et al.: Quality of life of patients with advanced pancreatic cancer during treatment with mistletoe: a randomized controlled trial. Dtsch Arztebl Int 111 (29-30): 493-502, 33 p following 502, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25142075&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25142075&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.25">Dold U, Edler L, M&#xE4;urer HCh, et al., eds.: [Adjuvant Cancer Therapy in Advanced Non-Small Cell Bronchial Cancer: Multicentric Controlled Studies To Test the Efficacy of Iscador and Polyerga]. Stuttgart, Germany: Georg Thieme Verlag, 1991.</li><li id="section_5.26">Augustin M, Bock PR, Hanisch J, et al.: Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland. Arzneimittelforschung 55 (1): 38-49, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15727163&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15727163&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.27">Bock PR, Friedel WE, Hanisch J, et al.: Retrolective, comparative, epidemiological cohort study with parallel groups design for evaluation of efficacy and safety of drugs with "well-established use". Forsch Komplementarmed Klass Naturheilkd 11 (Suppl 1): 23-9, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15353899&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15353899&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.28">Bock PR, Friedel WE, Hanisch J, et al.: [Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland] Arzneimittelforschung 54 (8): 456-66, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15460213&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15460213&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.29">Friedel WE, Matthes H, Bock PR, et al.: Systematic evaluation of the clinical effects of supportive mistletoe treatment within chemo- and/or radiotherapy protocols and long-term mistletoe application in nonmetastatic colorectal carcinoma: multicenter, controlled, observational cohort study. J Soc Integr Oncol 7 (4): 137-45, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19883529&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19883529&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.30">Bar-Sela G, Wollner M, Hammer L, et al.: Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: a randomised phase II study. Eur J Cancer 49 (5): 1058-64, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23218588&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23218588&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.31">Salzer G, Danmayr E, Wutzholfer F, et al.: [Adjuvant Iscador&#xAE; treatment of non-small cell bronchial carcinoma. Results of a randomized study]. Dtsch Z Onkol  23 (4): 93-8, 1991.</li><li id="section_5.32">Longhi A, Reif M, Mariani E, et al.: A Randomized Study on Postrelapse Disease-Free Survival with Adjuvant Mistletoe versus Oral Etoposide in Osteosarcoma Patients. Evid Based Complement Alternat Med 2014: 210198, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24803944&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24803944&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.33">Schaefermeyer G, Schaefermeyer H: Treatment of pancreatic cancer with Viscum album (Iscador): a retrospective study of 292 patients 1986-1996. Complement Ther Med  6 (4): 172-7, 1998.</li><li id="section_5.34">Lenartz D, Stoffel B, Menzel J, et al.: Immunoprotective activity of the galactoside-specific lectin from mistletoe after tumor destructive therapy in glioma patients. Anticancer Res 16 (6B): 3799-802, 1996 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9042260&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9042260&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.35">Cazacu M, Oniu T, Lungoci C, et al.: The influence of isorel on the advanced colorectal cancer. Cancer Biother Radiopharm 18 (1): 27-34, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12667306&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12667306&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.36">Huber R, Schlodder D, Effertz C, et al.: Safety of intravenously applied mistletoe extract - results from a phase I dose escalation study in patients with advanced cancer. BMC Complement Altern Med 17 (1): 465, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28923036&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28923036&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.37">Piao BK, Wang YX, Xie GR, et al.: Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Res 24 (1): 303-9, 2004 Jan-Feb.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15015612&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15015612&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.38">Mansky PJ, Wallerstedt DB, Sannes TS, et al.: NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors. Evid Based Complement Alternat Med 2013: 964592, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24285980&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24285980&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.39">Gutsch J, Berger H, Scholz G, et al.: [Prospective study in radically operated breast cancer with polychemotherapy, Helixor&#xAE; and untreated controls]. Dtsch Z Onkol  21: 94-101, 1988.</li><li id="section_5.40">Auerbach L, Dostal V, V&#xE1;clavik-Fleck I, et al.: Signifikant h&#xF6;herer anteil aktivierter NK-Zellen durch additive misteltherapie bei chemotherapierten mamma-Ca-patientinnen in einer prospektiven randomisierten doppelblinden studie. In: Scheer R, Bauer R, Becker H, et al.: Fortschritte in der Misteltherapie. Aktueller Stand der Forschung und klinischen Anwendung. Essen, Germany: KCV-Verlag, 2005, pp 543-54.</li><li id="section_5.41">Matthes HF, Schad F, Buchwald D, et al.: Endoscopic ultrasound-guided fine-needle Injection of Viscum album L. (mistletoe; Helixor M) in the therapy of primary inoperable pancreas cancer:  a pilot study. [Abstract] Gastroenterology  128 (Suppl 2): A-T988, A433-A434, 2005.</li><li id="section_5.42">Beuth J, Schneider B, Schierholz JM: Impact of complementary treatment of breast cancer patients with standardized mistletoe extract during aftercare: a controlled multicenter comparative epidemiological cohort study. Anticancer Res 28 (1B): 523-7, 2008 Jan-Feb.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18383896&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18383896&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.43">Bar-Sela G, Haim N: Abnoba-viscum (mistletoe extract) in metastatic colorectal carcinoma resistant to 5-fluorouracil and leucovorin-based chemotherapy. Med Oncol 21 (3): 251-4, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15456952&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15456952&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.44">Kim KC, Yook JH, Eisenbraun J, et al.: Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma - a randomized, controlled pilot study. BMC Complement Altern Med 12: 172, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23033982&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23033982&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.45">Rose A, El-Leithy T, vom Dorp F, et al.: Mistletoe Plant Extract in Patients with Nonmuscle Invasive Bladder Cancer: Results of a Phase Ib/IIa Single Group Dose Escalation Study. J Urol 194 (4): 939-43, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25910967&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25910967&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.46">Cho JS, Na KJ, Lee Y, et al.: Chemical Pleurodesis Using Mistletoe Extraction (ABNOVAviscum(&#xAE;) Injection) for Malignant Pleural Effusion. Ann Thorac Cardiovasc Surg 22 (1): 20-6, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26639937&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26639937&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.47">Heiny BM, Albrecht V, Beuth J: Stabilization of quality of life with mistletoe lectin-1-standardized extract in advanced colorectal carcinoma. Onkologe  4 (Suppl 1): S35-9, 1998.</li><li id="section_5.48">Sauer H: Quality of life stabilization with mistletoe-1-standardized extract in advanced colorectal carcinoma [Letter]. Onkologe  4: 1180, 1998.</li><li id="section_5.49">Douwes FR, Wolfrum DI, Migeod F: [Results of a prospective randomized study: chemotherapy versus chemotherapy plus "biological response modifier" in metastasizing colorectal carcinoma]. Dtsch Z Onkol  18 (6): 155-64, 1986.</li><li id="section_5.50">Semiglasov VF, Stepula VV, Dudov A, et al.: The standardised mistletoe extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Res 24 (2C): 1293-302, 2004 Mar-Apr.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15154663&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15154663&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.51">Semiglazov VF, Stepula VV, Dudov A, et al.: Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Res 26 (2B): 1519-29, 2006 Mar-Apr.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16619567&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16619567&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.52">Enesel MB, Acalovschi I, Grosu V, et al.: Perioperative application of the Viscum album extract Isorel in digestive tract cancer patients. Anticancer Res 25 (6C): 4583-90, 2005 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16334146&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16334146&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _52
      field_pdq_section_title:
        - format: plain_text
          value: 'Adverse Effects'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_52" class="pdq-sections"><p id="_53" tabindex="-1">Although a number of different <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285939&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285939&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">mistletoe</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=407760&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000407760&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">extracts</a> have been used in <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44195&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044195&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">human studies</a>, the reported <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46580&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046580&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">side effects</a> have generally been minimal and not life threatening. Common side effects include soreness and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44042&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044042&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">inflammation</a> at <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44678&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044678&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">injection</a> sites, headache, fever, and chills.<a href="#cit/section_6.1">1</a><a href="#cit/section_6.2">2</a><a href="#cit/section_6.3">3</a><a href="#cit/section_6.4">4</a></p><p id="_205" tabindex="-1">One <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=691484&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000691484&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">meta-analysis</a> using <em>Viscum album L.</em> and isolated <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44994&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044994&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">mistletoe lectins</a> included both <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=454774&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000454774&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">animal</a> and human studies.  <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44664&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044664&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">Doses</a> and application forms varied. No <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44041&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044041&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">immunosuppressive</a> effects were reported. Side effects included local reactions at the injection site and flu-like symptoms such as <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=450108&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000450108&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">fever</a>, chills, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=321374&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000321374&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">fatigue</a>, mild <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45692&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045692&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">gastrointestinal</a> symptoms, and headache.  High doses of recombinantly-produced mistletoe lectins (not available in commercial products) resulted in reversible hepatotoxicity in some cases.<a href="#cit/section_6.5">5</a> Another review reported adverse reactions that included local reactions at the injection site, fever, increased intracerebral pressure, headache, circulatory problems, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46615&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046615&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">thrombophlebitis</a>, swelling of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45762&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045762&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">lymph nodes</a>, and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=443292&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000443292&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">allergic reactions</a>.<a href="#cit/section_6.6">6</a></p><p id="_206" tabindex="-1"> A few cases of severe allergic reactions, including <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285952&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285952&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">anaphylactic shock</a>, have been reported.<a href="#cit/section_6.2">2</a></p><h6 do-not-show="toc">References</h6><ol><li id="section_6.1">Kaegi E: Unconventional therapies for cancer: 3. Iscador. Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative. CMAJ 158 (9): 1157-9, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9597967&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9597967&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.2">Hutt N, Kopferschmitt-Kubler M, Cabalion J, et al.: Anaphylactic reactions after therapeutic injection of mistletoe (Viscum album L.). Allergol Immunopathol (Madr) 29 (5): 201-3, 2001 Sep-Oct.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11720654&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11720654&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.3">Stauder H, Kreuser ED: Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: current state of clinical research. Onkologie 25 (4): 374-80, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12232491&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12232491&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.4">Steele ML, Axtner J, Happe A, et al.: Safety of Intravenous Application of Mistletoe (Viscum album L.) Preparations in Oncology: An Observational Study. Evid Based Complement Alternat Med 2014: 236310, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24955100&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24955100&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.5">Kienle GS, Grugel R, Kiene H: Safety of higher dosages of Viscum album L. in animals and humans--systematic review of immune changes and safety parameters. BMC Complement Altern Med 11: 72, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21871125&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21871125&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.6">Ernst E, Schmidt K, Steuer-Vogt MK: Mistletoe for cancer? A systematic review of randomised clinical trials. Int J Cancer 107 (2): 262-7, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12949804&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12949804&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _55
      field_pdq_section_title:
        - format: plain_text
          value: 'Summary of the Evidence for Mistletoe Extracts'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_55" class="pdq-sections"><p id="_56" tabindex="-1"><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285939&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285939&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">Mistletoe</a> is one of the most widely studied <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44964&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044964&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">complementary and alternative medicine</a> therapies for <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45333&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045333&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cancer</a>. In certain European countries, the preparations made from European mistletoe (<em>Viscum album</em> L.) are among the most prescribed drugs offered to cancer patients. Mistletoe <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=407760&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000407760&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">extracts</a> have been evaluated in numerous <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44195&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044195&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">clinical studies</a> and improvements in survival, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45417&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045417&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">quality of life</a>, and/or stimulation of the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46356&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046356&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">immune system</a> have been frequently reported. However, most clinical studies conducted have had one or more major weaknesses that raise doubts about the reliability of the findings. In addition, no evidence exists to support the notion that stimulation of the immune system by mistletoe leads to an improved ability to fight cancer. Because all patients in the reported clinical studies appear to have been adults, no information is available about the use of mistletoe as a treatment for children with cancer. </p><p id="_94" tabindex="-1">Separate <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=446533&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000446533&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">levels of evidence</a> scores are assigned to qualifying human studies on the basis of statistical strength of the study design and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44724&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044724&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">scientific</a> strength of the treatment outcomes (i.e., <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=346519&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000346519&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">endpoints</a>) measured. The resulting two scores are then combined to produce an overall score.         For additional information about levels of evidence analysis, refer to <a href="/publications/pdq/levels-evidence/cam">Levels of Evidence for Human Studies of Integrative, Alternative, and Complementary Therapies</a>.</p></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _62
      field_pdq_section_title:
        - format: plain_text
          value: 'Changes to This Summary (10/05/2018)'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_62" class="pdq-sections"><p id="_63" tabindex="-1">The <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44271&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044271&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">PDQ</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45333&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045333&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cancer</a> information summaries are reviewed regularly and updated as
            new information becomes available.  This section describes the latest
            changes made to this summary as of the date above.</p><p id="_268" tabindex="-1">Editorial changes were made to this summary.</p><p id="_disclaimerHP_3" tabindex="-1">This summary is written and maintained by the <a href="https://www.cancer.gov/publications/pdq/editorial-boards/cam" title="https://www.cancer.gov/publications/pdq/editorial-boards/cam">PDQ Integrative, Alternative, and Complementary Therapies Editorial Board</a>, which is
            editorially independent of NCI.  The summary reflects an independent review of
            the literature and does not represent a policy statement of NCI or NIH.  More
            information about summary policies and the role of the PDQ Editorial Boards  in
            maintaining the PDQ summaries can be found on the <a href="/about-cancer/treatment/cam/hp/mistletoe-pdq#link/_AboutThis_1">About This PDQ Summary</a> and <a href="https://www.cancer.gov/publications/pdq" title="https://www.cancer.gov/publications/pdq">PDQ&#xAE; - NCI's Comprehensive Cancer Database</a> pages.
            </p></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _AboutThis_1
      field_pdq_section_title:
        - format: plain_text
          value: 'About This PDQ Summary'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_AboutThis_1" class="pdq-sections"><section id="_AboutThis_2"><h3 id="_AboutThis_2_toc">Purpose of This Summary</h3><p id="_AboutThis_3" tabindex="-1">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the use of mistletoe extracts in the treatment of people with cancer. It is intended as a resource to inform and assist clinicians who care for cancer patients.  It does not provide formal guidelines or recommendations for making health care decisions.</p></section><section id="_AboutThis_4"><h3 id="_AboutThis_4_toc">Reviewers and Updates</h3><p id="_AboutThis_5" tabindex="-1">This summary is reviewed regularly and updated as necessary by the <a href="https://www.cancer.gov/publications/pdq/editorial-boards/cam" title="https://www.cancer.gov/publications/pdq/editorial-boards/cam">PDQ Integrative, Alternative, and Complementary Therapies Editorial Board</a>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</p><p id="_AboutThis_22" tabindex="-1"> Board members review recently published articles each month to determine whether an article should:</p><div class="pdq-content-list"><ul id="_AboutThis_6"><li>be discussed at a meeting,</li><li>be cited with text, or</li><li>replace or update an existing article that is already cited.</li></ul></div><p id="_AboutThis_7" tabindex="-1">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</p><p id="" tabindex="-1">The lead reviewers for Mistletoe Extracts are:</p><div class="pdq-content-list"><ul id=""><li>John A. Beutler, PhD (National Cancer Institute)</li><li>Jinhui Dou, PhD (Yiling Pharmaceutical, Inc.)</li><li>Channing J Paller, MD (Johns Hopkins Hospital)</li></ul></div><p id="_AboutThis_9" tabindex="-1">Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's <a href="https://www.cancer.gov/contact/email-us" title="https://www.cancer.gov/contact/email-us">Email Us</a>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</p></section><section id="_AboutThis_10"><h3 id="_AboutThis_10_toc">Levels of Evidence</h3><p id="_AboutThis_11" tabindex="-1">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Integrative, Alternative, and Complementary Therapies Editorial Board uses a <a href="/publications/pdq/levels-evidence/cam">formal evidence ranking system</a> in developing its level-of-evidence designations.</p></section><section id="_AboutThis_12"><h3 id="_AboutThis_12_toc">Permission to Use This Summary</h3><p id="_AboutThis_13" tabindex="-1">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as &#x201C;NCI&#x2019;s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].&#x201D;</p><p id="_AboutThis_14" tabindex="-1">The preferred citation for this PDQ summary is:</p><p id="_AboutThis_15" tabindex="-1">PDQ&#xAE; Integrative, Alternative, and Complementary Therapies Editorial Board. PDQ Mistletoe Extracts. Bethesda, MD: National Cancer Institute. Updated  &lt;MM/DD/YYYY&gt;. Available at: <a href="https://www.cancer.gov/about-cancer/treatment/cam/hp/mistletoe-pdq" title="https://www.cancer.gov/about-cancer/treatment/cam/hp/mistletoe-pdq">https://www.cancer.gov/about-cancer/treatment/cam/hp/mistletoe-pdq</a>.  Accessed &lt;MM/DD/YYYY&gt;. [PMID: 26389489]</p><p id="_AboutThis_16" tabindex="-1">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <a href="https://visualsonline.cancer.gov/" title="https://visualsonline.cancer.gov/">Visuals Online</a>, a collection of over 2,000 scientific images.
            </p></section><section id="_AboutThis_17"><h3 id="_AboutThis_17_toc">Disclaimer</h3><p id="_AboutThis_19" tabindex="-1">The information in these summaries should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <a href="https://www.cancer.gov/about-cancer/managing-care" title="https://www.cancer.gov/about-cancer/managing-care">Managing Cancer Care</a> page.</p></section><section id="_AboutThis_20"><h3 id="_AboutThis_20_toc">Contact Us</h3><p id="_AboutThis_21" tabindex="-1">More information about contacting us or receiving help with the Cancer.gov website can be found on our <a href="https://www.cancer.gov/contact" title="https://www.cancer.gov/contact">Contact Us for Help</a> page. Questions can also be submitted to Cancer.gov through the website&#x2019;s <a href="https://www.cancer.gov/contact/email-us" title="https://www.cancer.gov/contact/email-us">Email Us</a>.</p></section></div>
  title__ES:
    value: 'Extractos de muérdago (PDQ®)–Versión para profesionales de salud'
  status__ES:
    value: 1
  langcode__ES:
    value: es
  moderation_state__ES:
    value: published
  field_pdq_url__ES:
    value: /cancer/tratamiento/mca/pro/muerdago-pdq
  field_pdq_cdr_id__ES:
    value: 778124
  field_pdq_audience__ES:
    value: Health Professionals
  field_pdq_summary_type__ES:
    value: Integrative, alternative, and complementary therapies
  field_date_posted__ES:
    value: '2016-01-22'
  field_date_updated__ES:
    value: '2018-11-14'
  field_short_title__ES:
    value: 'Extractos de muérdago'
  field_page_description__ES:
    value: 'Resumen de información revisada por expertos sobre el uso de los extractos de muérdago como tratamiento para personas con cáncer.'
  field_public_use__ES:
    value: 1
  field_summary_sections__ES:
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _1
      field_pdq_section_title:
        - format: plain_text
          value: 'Aspectos generales'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_1" class="pdq-sections"><div class="pdq-hp-patient-toggle"><a href="/espanol/cancer/tratamiento/mca/paciente/muerdago-pdq">Vaya a la versi&#xF3;n para pacientes</a></div><p id="_2" tabindex="-1">Este sumario de informaci&#xF3;n sobre <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45333&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045333&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer</a> proporciona una visi&#xF3;n general del uso del <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285939&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285939&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">mu&#xE9;rdago</a> para el tratamiento de personas con c&#xE1;ncer. En este sumario, se incluye una historia breve de la investigaci&#xF3;n sobre el mu&#xE9;rdago, los resultados de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45961&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045961&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">ensayos cl&#xED;nicos</a> y los posibles <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46580&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046580&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">efectos secundarios</a> del uso del mu&#xE9;rdago.</p><p id="_3" tabindex="-1">Este sumario contiene la siguiente informaci&#xF3;n clave:</p><div class="pdq-content-list"><ul id="_4"><li>El mu&#xE9;rdago es una planta <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44075&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044075&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">semiparasitaria</a> que se ha utilizado durante siglos para tratar numerosas dolencias humanas.</li><li>El mu&#xE9;rdago es de uso com&#xFA;n en Europa, donde se fabrica y comercializa una variedad de extractos diferentes como medicamentos <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44678&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044678&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">inyectables</a> de venta con receta. Estos medicamentos inyectables no est&#xE1;n disponibles comercialmente en los Estados Unidos y no est&#xE1;n aprobados como tratamiento para las personas con c&#xE1;ncer.</li><li>El mu&#xE9;rdago es uno de los tratamientos de MCA m&#xE1;s ampliamente estudiados para el c&#xE1;ncer. En algunos pa&#xED;ses europeos, las preparaciones hechas con mu&#xE9;rdago europeo (<em>Viscum album</em>, Loranthaceae) se encuentran entre los f&#xE1;rmacos m&#xE1;s recetados que se ofrecen a los pacientes de c&#xE1;ncer.</li><li>Aunque las plantas y las bayas de mu&#xE9;rdago se consideran t&#xF3;xicas para los seres humanos, el uso de extracto de mu&#xE9;rdago se ha relacionado con pocos efectos secundarios graves.       </li><li>
            El uso del mu&#xE9;rdago como tratamiento para las personas con c&#xE1;ncer se ha investigado en <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44195&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044195&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">estudios cl&#xED;nicos</a>. Los informes sobre mejora de la supervivencia o la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45417&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045417&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">calidad de vida</a> han sido comunes, pero muchos de los estudios ten&#xED;an  deficiencias importantes que plantean dudas acerca de la fiabilidad de los hallazgos.</li><li>En la actualidad, el uso del mu&#xE9;rdago no se puede recomendar fuera del contexto de ensayos cl&#xED;nicos bien dise&#xF1;ados. Tales ensayos ser&#xE1;n valiosos para determinar con mayor claridad si el mu&#xE9;rdago puede ser &#xFA;til para tratar subconjuntos espec&#xED;ficos de pacientes de c&#xE1;ncer.</li></ul></div><p id="_5" tabindex="-1">Muchos de los t&#xE9;rminos m&#xE9;dicos y cient&#xED;ficos en este sumario tienen un enlace  al <a href="https://www.cancer.gov/espanol/publicaciones/diccionario" title="https://www.cancer.gov/espanol/publicaciones/diccionario">Diccionario de c&#xE1;ncer del NCI</a> la primera vez que se mencionan en cada secci&#xF3;n. Este diccionario se orienta a personas sin conocimientos especializados. Al pulsar sobre un t&#xE9;rmino con un enlace, aparece la definici&#xF3;n en una ventana separada. </p><p id="_6" tabindex="-1">Las referencias bibliogr&#xE1;ficas citadas en los sumarios de informaci&#xF3;n sobre el c&#xE1;ncer del <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44271&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044271&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">PDQ</a> pueden tener enlaces a otros sitios de Internet gestionados por individuos u organizaciones con el prop&#xF3;sito de comercializar o promover el uso de tratamientos o productos espec&#xED;ficos. Estas referencias bibliogr&#xE1;ficas se ofrecen solo con fines informativos. Su inclusi&#xF3;n no se debe interpretar como aprobaci&#xF3;n del contenido de las p&#xE1;ginas de Internet ni de ning&#xFA;n tratamiento o producto por parte del Consejo editorial del PDQ sobre terapias integrales, alternativas y complementarias, o del <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44266&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044266&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">Instituto Nacional del C&#xE1;ncer</a>.</p></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _7
      field_pdq_section_title:
        - format: plain_text
          value: 'Información general'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_7" class="pdq-sections"><p id="_9" tabindex="-1">El <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285939&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285939&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">mu&#xE9;rdago</a> es una planta <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44075&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044075&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">semiparasitaria</a> que presenta inter&#xE9;s como un posible producto antineopl&#xE1;sico porque sus <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=407760&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000407760&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">extractos</a> derivados han mostrado que destruyen <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46476&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046476&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE9;lulas</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45333&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045333&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">cancerosas</a> <em><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45733&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045733&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">in vitro</a></em>,<a href="#cit/section_2.1">1</a><a href="#cit/section_2.2">2</a><a href="#cit/section_2.3">3</a><a href="#cit/section_2.4">4</a><a href="#cit/section_2.5">5</a><a href="#cit/section_2.6">6</a><a href="#cit/section_2.7">7</a><a href="#cit/section_2.8">8</a><a href="#cit/section_2.9">9</a><a href="#cit/section_2.10">10</a> para inhibir la expresi&#xF3;n de los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45693&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045693&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">genes</a> centrales que participan en la progresi&#xF3;n tumoral, la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45771&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045771&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">malignidad</a>, y la migraci&#xF3;n y la invasi&#xF3;n celular, como el TGF-&#x3B2; y las <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44211&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044211&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">metaloproteinasas de matriz</a>.<a href="#cit/section_2.11">11</a><a href="#cit/section_2.12">12</a> Se ha demostrado que los extractos de mu&#xE9;rdago imponen la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44606&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044606&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">lisis</a> celular tumoral mediada por <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44062&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044062&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">linfocitos linfoc&#xED;tico naturales</a>, reducen el potencial invasor y migratorio de las c&#xE9;lulas tumorales y estimulan las c&#xE9;lulas del <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46356&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046356&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">sistema inmunitario</a>, tanto <em>in vitro</em> como <em><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46352&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046352&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">in vivo</a></em>.<a href="#cit/section_2.10">10</a><a href="#cit/section_2.11">11</a><a href="#cit/section_2.12">12</a><a href="#cit/section_2.13">13</a><a href="#cit/section_2.14">14</a><a href="#cit/section_2.15">15</a><a href="#cit/section_2.16">16</a><a href="#cit/section_2.17">17</a><a href="#cit/section_2.18">18</a><a href="#cit/section_2.19">19</a><a href="#cit/section_2.20">20</a><a href="#cit/section_2.21">21</a><a href="#cit/section_2.22">22</a><a href="#cit/section_2.23">23</a><a href="#cit/section_2.24">24</a><a href="#cit/section_2.25">25</a><a href="#cit/section_2.26">26</a><a href="#cit/section_2.27">27</a><a href="#cit/section_2.28">28</a><a href="#cit/section_2.29">29</a><a href="#cit/section_2.30">30</a><a href="#cit/section_2.31">31</a> Es posible que tres componentes del mu&#xE9;rdago, a saber, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44094&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044094&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">viscotoxinas</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44162&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044162&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">polisac&#xE1;ridos</a> y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44051&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044051&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">lectinas</a>, sean ser responsables de estos efectos.<a href="#cit/section_2.10">10</a><a href="#cit/section_2.13">13</a><a href="#cit/section_2.14">14</a><a href="#cit/section_2.15">15</a><a href="#cit/section_2.19">19</a><a href="#cit/section_2.20">20</a><a href="#cit/section_2.21">21</a><a href="#cit/section_2.23">23</a><a href="#cit/section_2.24">24</a><a href="#cit/section_2.25">25</a><a href="#cit/section_2.32">32</a><a href="#cit/section_2.33">33</a><a href="#cit/section_2.34">34</a><a href="#cit/section_2.35">35</a><a href="#cit/section_2.36">36</a><a href="#cit/section_2.37">37</a><a href="#cit/section_2.38">38</a><a href="#cit/section_2.39">39</a> Las viscotoxinas son <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46092&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046092&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">prote&#xED;nas</a> peque&#xF1;as que muestran actividad citol&#xED;tica y posible actividad de estimulaci&#xF3;n del sistema inmunitario.<a href="#cit/section_2.1">1</a><a href="#cit/section_2.6">6</a><a href="#cit/section_2.20">20</a><a href="#cit/section_2.21">21</a><a href="#cit/section_2.40">40</a><a href="#cit/section_2.41">41</a> Las lectinas son <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45065&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045065&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">mol&#xE9;culas</a> complejas compuestas de prote&#xED;nas y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285960&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285960&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">carbohidratos</a> que se unen al exterior de las c&#xE9;lulas (por ejemplo, las c&#xE9;lulas del sistema inmunitario) e inducen cambios bioqu&#xED;micos en ellas.<a href="#cit/section_2.10">10</a><a href="#cit/section_2.42">42</a><a href="#cit/section_2.43">43</a><a href="#cit/section_2.44">44</a><a href="#cit/section_2.45">45</a> En vista de la capacidad de mu&#xE9;rdago para estimular el sistema inmunitario, se lo clasific&#xF3; como un tipo de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45616&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045616&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">modificador de la respuesta biol&#xF3;gica</a>.<a href="#cit/section_2.42">42</a> Los modificadores de respuesta biol&#xF3;gica constituyen un grupo diverso de mol&#xE9;culas <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44510&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044510&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">biol&#xF3;gicas</a> que se han utilizado individualmente o combinadas con otras sustancias para tratar el c&#xE1;ncer o para disminuir los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46580&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046580&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">efectos secundarios</a> de los medicamentos contra el c&#xE1;ncer. En entornos precl&#xED;nicos, se demostr&#xF3; que los extractos de mu&#xE9;rdago tienen otros mecanismos de acci&#xF3;n, como la angiog&#xE9;nesis.<a href="#cit/section_2.29">29</a></p><p id="_10" tabindex="-1">Las preparaciones de extractos de mu&#xE9;rdago se utilizan con mayor frecuencia para tratar pacientes de c&#xE1;ncer en los pa&#xED;ses de habla alemana.<a href="#cit/section_2.46">46</a> Los extractos disponibles para la venta se comercializan bajo una variedad de nombres de marca, incluso Iscador (ver explicaci&#xF3;n de sufijos a continuaci&#xF3;n), Eurixor, Helixor, Isorel, Iscucin, Plenosol y abnobaVISCUM. Algunos extractos se comercializan bajo m&#xE1;s de un nombre. Iscador, Isorel y Plenosol tambi&#xE9;n se venden como Iscar, Vysorel y Lektinol, respectivamente. Todos estos productos se preparan con  <em>Viscum album</em> (Loranthaceae) (<em>Viscum album</em> L. o mu&#xE9;rdago europeo). Ellos no se venden como medicamentos en los Estados Unidos. Eurixor, Isorel y Vysorel ya no est&#xE1;n disponibles para su venta en el mercado.</p><p id="_100" tabindex="-1">Adem&#xE1;s del mu&#xE9;rdago europeo, los extractos de un tipo de mu&#xE9;rdago coreano (<em>Viscum album</em> var. <em>coloratum</em> [Kom.] Ohwi) demostraron tener citotoxicidad en estudios de laboratorio realizados <em>in vitro</em> e  <em>in vivo</em>.<a href="#cit/section_2.47">47</a><a href="#cit/section_2.48">48</a><a href="#cit/section_2.49">49</a><a href="#cit/section_2.50">50</a><a href="#cit/section_2.51">51</a></p><p id="_11" tabindex="-1">El mu&#xE9;rdago crece en varios tipos de &#xE1;rboles y la composici&#xF3;n qu&#xED;mica de los extractos derivados de &#xE9;l depende de la especie del &#xE1;rbol anfitri&#xF3;n (por ejemplo, manzano, olmo, roble, pino, &#xE1;lamo y abeto), la &#xE9;poca del a&#xF1;o en que se cosecha, la forma de preparaci&#xF3;n de los extractos y el productor comercial.<a href="#cit/section_2.8">8</a><a href="#cit/section_2.43">43</a><a href="#cit/section_2.52">52</a><a href="#cit/section_2.53">53</a><a href="#cit/section_2.54">54</a><a href="#cit/section_2.55">55</a></p><p id="_12" tabindex="-1">Los extractos de mu&#xE9;rdago se preparan como soluciones <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43998&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043998&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">acuosas</a> o soluciones de agua y alcohol, y se pueden fermentar o no.<a href="#cit/section_2.4">4</a><a href="#cit/section_2.6">6</a><a href="#cit/section_2.22">22</a><a href="#cit/section_2.52">52</a><a href="#cit/section_2.53">53</a><a href="#cit/section_2.56">56</a><a href="#cit/section_2.57">57</a><a href="#cit/section_2.58">58</a><a href="#cit/section_2.59">59</a> Algunos extractos se preparan de acuerdo con principios <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45712&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045712&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">homeop&#xE1;ticos</a> y otros no. En consecuencia, como preparados homeop&#xE1;ticos, no son normalmente extractos estandarizados qu&#xED;micamente.<a href="#cit/section_2.10">10</a> <a href="#cit/section_2.60">60</a> Adem&#xE1;s, los productos comerciales se pueden subdividir de acuerdo con las especies de &#xE1;rbol anfitri&#xF3;n, que se indica normalmente en el nombre del producto por una letra sufijo. Iscador, un extracto acuoso fermentado de <em>Viscum album</em> L., que se prepara como medicamento homeop&#xE1;tico, se comercializa como IscadorM (de manzanos, <em>Malus domestica</em>), IscadorP (de pinos,  <em>Pinus sylvestris</em>), IscadorQu (de robles, <em>Quercus robur</em>) e IscadorU (de olmos,  <em>Ulmus minor</em>). Helixor, un extracto acuoso fermentado de  <em>Viscum album</em> L., que se estandariza por su efecto biol&#xF3;gico en las c&#xE9;lulas <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45343&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045343&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">leuc&#xE9;micas</a> <em>in vitro</em>, se comercializa como Helixor A (de abetos, <em>Picea abies</em>), HelixorM (de manzanos) y HelixorP (de pinos, <em>Pinus sylvestris</em>).<a href="#cit/section_2.57">57</a> Eurixor (que ya no est&#xE1; disponible para su venta comercial), un extracto acuoso sin fermentar de <em>Viscum album</em> L cosechado de &#xE1;lamos, se notifica que se estandariza para contener una cantidad espec&#xED;fica de una de las <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44994&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044994&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">lectinas de mu&#xE9;rdago</a> (es decir, la lectina ML-1; para obtener m&#xE1;s informaci&#xF3;n, consultar la secci&#xF3;n <a href="/espanol/cancer/tratamiento/mca/pro/muerdago-pdq#link/_17">Antecedentes</a> de este sumario).<a href="#cit/section_2.57">57</a> Algunos defensores sostienen que la elecci&#xF3;n del extracto debe depender del tipo de tumor y el sexo del paciente.<a href="#cit/section_2.55">55</a><a href="#cit/section_2.57">57</a><a href="#cit/section_2.61">61</a><a href="#cit/section_2.62">62</a></p><p id="_101" tabindex="-1">Un ML-1 recombinado de la bacteria <em>Escherichia coli</em>     conocido como rViscumin o aviscumina se ha estudiado en el laboratorio y en ensayos cl&#xED;nicos de fase I. Debido a que no es un extracto de mu&#xE9;rdago, no se incluye en este sumario.<a href="#cit/section_2.63">63</a></p><p id="_13" tabindex="-1">Por lo general, los extractos de mu&#xE9;rdago se administran mediante <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44678&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044678&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">inyecci&#xF3;n</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45914&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045914&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">subcut&#xE1;nea</a>, aunque se describi&#xF3; la administraci&#xF3;n por otras v&#xED;as (es decir, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44068&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044068&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">oral</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285972&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285972&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">intrapleural</a>, intratumoral e intravenosa).<a href="#cit/section_2.19">19</a><a href="#cit/section_2.22">22</a><a href="#cit/section_2.23">23</a><a href="#cit/section_2.24">24</a><a href="#cit/section_2.25">25</a><a href="#cit/section_2.26">26</a><a href="#cit/section_2.39">39</a><a href="#cit/section_2.43">43</a><a href="#cit/section_2.55">55</a><a href="#cit/section_2.57">57</a><a href="#cit/section_2.60">60</a><a href="#cit/section_2.64">64</a><a href="#cit/section_2.65">65</a><a href="#cit/section_2.66">66</a><a href="#cit/section_2.67">67</a><a href="#cit/section_2.68">68</a><a href="#cit/section_2.69">69</a><a href="#cit/section_2.70">70</a> En la mayor&#xED;a de los estudios notificados, se administraron inyecciones subcut&#xE1;neas 2 a 3 veces por semana, pero la duraci&#xF3;n total del tratamiento vari&#xF3; considerablemente.</p><p id="_14" tabindex="-1">El <em>Viscum album</em> se encuentra en la lista de la Homeopathic Pharmacopoeia de los Estados Unidos, que es el compendio de medicamentos homeop&#xE1;ticos reconocido oficialmente en este pa&#xED;s.<a href="#cit/section_2.71">71</a> Aunque la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=454785&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000454785&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">Administraci&#xF3;n de Alimentos y Medicamentos de los Estados Unidos</a> (FDA) es la autoridad que regula los medicamentos homeop&#xE1;ticos, habitualmente esta autoridad no se ejerce a menos que los medicamentos se formulen como inyectables o haya pruebas de que provocan <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43986&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043986&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">efectos t&#xF3;xicos</a> graves.</p><p id="_15" tabindex="-1">Antes de que los investigadores puedan realizar investigaciones cl&#xED;nicas de medicamentos en los Estados Unidos, deben presentar una solicitud de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=762975&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000762975&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">Investigational New Drug</a> (IND) ante la FDA. La aprobaci&#xF3;n de una IND tambi&#xE9;n se exige para la investigaci&#xF3;n cl&#xED;nica de medicamentos homeop&#xE1;ticos. La FDA no divulga informaci&#xF3;n sobre las solicitudes o aprobaciones de IND; solo los solicitantes pueden dar a conocer esta informaci&#xF3;n. Al menos dos <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44685&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044685&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">investigadores</a> estadounidenses recibieron la aprobaci&#xF3;n de un IND para estudiar el mu&#xE9;rdago como tratamiento para personas con c&#xE1;ncer (NCCAM-02-AT-260 y <a href="/clinicaltrials/NCT00052325">TJUH-01F.45</a>).</p><p id="_16" tabindex="-1">En este sumario, se especificar&#xE1; el extracto o producto de mu&#xE9;rdago utilizado en cada estudio toda vez que sea posible.</p><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_2.1">Jung ML, Baudino S, Rib&#xE9;reau-Gayon G, et al.: Characterization of cytotoxic proteins from mistletoe (Viscum album L.). Cancer Lett 51 (2): 103-8, 1990.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2344587&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2344587&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.2">Kuttan G, Vasudevan DM, Kuttan R: Effect of a preparation from Viscum album on tumor development in vitro and in mice. J Ethnopharmacol 29 (1): 35-41, 1990.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2345458&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2345458&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.3">Walzel H, Jonas L, Rosin T, et al.: Relationship between internalization kinetics and cytotoxicity of mistletoe lectin I to L1210 leukaemia cells. Folia Biol (Praha) 36 (3-4): 181-8, 1990.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2257937&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2257937&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.4">Janssen O, Scheffler A, Kabelitz D: In vitro effects of mistletoe extracts and mistletoe lectins. Cytotoxicity towards tumor cells due to the induction of programmed cell death (apoptosis). Arzneimittelforschung 43 (11): 1221-7, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8292069&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8292069&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.5">Jurin M, Zarkovi&#x107; N, Hrzenjak M, et al.: Antitumorous and immunomodulatory effects of the Viscum album L. preparation Isorel. Oncology 50 (6): 393-8, 1993 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8233280&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8233280&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.6">Schaller G, Urech K, Giannattasio M: Cytotoxicity of different viscotoxins and extracts from the European subspecies Viscum album L. Phytother Res  10 (6): 473-7, 1996.</li><li id="section_2.7">Gabius HJ, Darro F, Remmelink M, et al.: Evidence for stimulation of tumor proliferation in cell lines and histotypic cultures by clinically relevant low doses of the galactoside-binding mistletoe lectin, a component of proprietary extracts. Cancer Invest 19 (2): 114-26, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11296616&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11296616&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.8">Maier G, Fiebig HH: Absence of tumor growth stimulation in a panel of 16 human tumor cell lines by mistletoe extracts in vitro. Anticancer Drugs 13 (4): 373-9, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11984083&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11984083&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.9">Franz H: Mistletoe lectins and their A and B chains. Oncology 43 (Suppl 1): 23-34, 1986.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3543782&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3543782&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.10">Mengs U, G&#xF6;thel D, Leng-Peschlow E: Mistletoe extracts standardized to mistletoe lectins in oncology: review on current status of preclinical research. Anticancer Res 22 (3): 1399-407, 2002 May-Jun.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12168816&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12168816&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.11">Podlech O, Harter PN, Mittelbronn M, et al.: Fermented mistletoe extract as a multimodal antitumoral agent in gliomas. Evid Based Complement Alternat Med 2012: 501796, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23133496&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23133496&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.12">Sch&#xF6;tterl S, H&#xFC;bner M, Armento A, et al.: Viscumins functionally modulate cell motility-associated gene expression. Int J Oncol 50 (2): 684-696, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28101577&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28101577&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.13">Hostanska K, Hajto T, Spagnoli GC, et al.: A plant lectin derived from Viscum album induces cytokine gene expression and protein production in cultures of human peripheral blood mononuclear cells. Nat Immun 14 (5-6): 295-304, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8933823&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8933823&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.14">Beuth J, Stoffel B, Ko HL, et al.: Immunomodulating ability of galactoside-specific lectin standardized and depleted mistletoe extract. Arzneimittelforschung 45 (11): 1240-2, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8929248&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8929248&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.15">Lenartz D, Stoffel B, Menzel J, et al.: Immunoprotective activity of the galactoside-specific lectin from mistletoe after tumor destructive therapy in glioma patients. Anticancer Res 16 (6B): 3799-802, 1996 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9042260&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9042260&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.16">Fischer S, Scheffler A, Kabelitz D: Oligoclonal in vitro response of CD4 T cells to vesicles of mistletoe extracts in mistletoe-treated cancer patients. Cancer Immunol Immunother 44 (3): 150-6, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9191874&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9191874&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.17">Preisfeld A: Influence of aqueous mistletoe preparations on humoral immune parameters with emphasis on the cytotoxicity of human complement in breast cancer patients. Forsch Komplementarmed  4 (4): 224-8, 1997.</li><li id="section_2.18">Chernyshov VP, Omelchenko LI, Heusser P, et al.: Immunomodulatory actions of Viscum album (Iscador) in children with recurrent respiratory disease as a result of the Chernobyl nuclear accident. Complement Ther Med  5 (3): 141-6, 1997.</li><li id="section_2.19">Heiny BM, Albrecht V, Beuth J: Correlation of immune cell activities and beta-endorphin release in breast carcinoma patients treated with galactose-specific lectin standardized mistletoe extract. Anticancer Res 18 (1B): 583-6, 1998 Jan-Feb.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9568181&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9568181&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.20">Stein GM, Schaller G, Pf&#xFC;ller U, et al.: Characterisation of granulocyte stimulation by thionins from European mistletoe and from wheat. Biochim Biophys Acta 1426 (1): 80-90, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9878694&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9878694&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.21">Stein GM, Schaller G, Pf&#xFC;ller U, et al.: Thionins from Viscum album L: influence of the viscotoxins on the activation of granulocytes. Anticancer Res 19 (2A): 1037-42, 1999 Mar-Apr.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10368652&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10368652&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.22">Mistletoe. In: Murray MT: The Healing Power of Herbs. Roseville, Calif: Prima Publishing, 1995, pp 253-9.</li><li id="section_2.23">Lenartz D, Dott U, Menzel J, et al.: Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe. Anticancer Res 20 (3B): 2073-6, 2000 May-Jun.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10928154&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10928154&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.24">Steuer-Vogt MK, Bonkowsky V, Ambrosch P, et al.: The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. Eur J Cancer 37 (1): 23-31, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11165126&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11165126&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.25">Goebell PJ, Otto T, Suhr J, et al.: Evaluation of an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized phase II trial. J Urol 168 (1): 72-5, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12050495&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12050495&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.26">Stauder H, Kreuser ED: Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: current state of clinical research. Onkologie 25 (4): 374-80, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12232491&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12232491&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.27">Saha C, Das M, Stephen-Victor E, et al.: Differential Effects of Viscum album Preparations on the Maturation and Activation of Human Dendritic Cells and CD4&#x207A; T Cell Responses. Molecules 21 (7): , 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27428940&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27428940&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.28">Hegde P, Maddur MS, Friboulet A, et al.: Viscum album exerts anti-inflammatory effect by selectively inhibiting cytokine-induced expression of cyclooxygenase-2. PLoS One 6 (10): e26312, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22028854&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22028854&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.29">Elluru SR, VAN Huyen JP, Delignat S, et al.: Antiangiogenic properties of viscum album extracts are associated with endothelial cytotoxicity. Anticancer Res 29 (8): 2945-50, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19661299&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19661299&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.30">Elluru SR, Duong van Huyen JP, Delignat S, et al.: Induction of maturation and activation of human dendritic cells: a mechanism underlying the beneficial effect of Viscum album as complimentary therapy in cancer. BMC Cancer 8: 161, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18533025&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18533025&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.31">Elluru S, Duong Van Huyen JP, Delignat S, et al.: Molecular mechanisms underlying the immunomodulatory effects of mistletoe (Viscum album L.) extracts Iscador. Arzneimittelforschung 56 (6A): 461-6, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16927527&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16927527&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.32">Frohne D, Pfander HJ: Viscum album. In: Frohne D, Pfander HJ: Giftpflanzen: ein Handbuch f&#xFC;r Apotheker, &#xC4;rzte,
            Toxikologen und Biologen. 3rd rev. ed. Stuttgart, Germany: Wissenschaftliche Verlagsgesellschaft, 1987, pp 179-80.</li><li id="section_2.33">Pusztai A, Grant G, Pfuller U, et al.: Nutritional and metabolic effects of mistletoe lectin ML-1 (type 2 RIP) in the rat. In: European Cooperation in the Field of Scientific and Technical Research: COST 98: Effects of Antinutrients on the Nutritional Value of Legume Diets. Brussels, Belgium: European Commission, Directorate-General XII, Science, Research and Development, 1998, pp 164-7.</li><li id="section_2.34">Pusztai A, Grant G, Gelencs&#xE9;r E, et al.: Effects of an orally administered mistletoe (type-2 RIP) lectin on growth, body composition, small intestinal structure, and insulin levels in young rats. J Nutr Biochem  9 (1): 31-6, 1998.</li><li id="section_2.35">Ewen SWB, Bardocz S, Grant G, et al.: The effects of PHA and mistletoe lectin binding to epithelium of rat and mouse gut. In: European Cooperation in the Field of Scientific and Technical Research: COST 98: Effects of Antinutrients on the Nutritional Value of Legume Diets. Brussels, Belgium: European Commission, Directorate-General XII, Science, Research and Development, 1998, pp 221-5.</li><li id="section_2.36">Pryme IF, Bardocz S, Grant G, et al.: The plant lectins PHA and ML-1 suppress the growth of a lymphosarcoma tumour in mice. In: European Cooperation in the Field of Scientific and Technical Research: COST 98: Effects of Antinutrients on the Nutritional Value of Legume Diets. Brussels, Belgium: European Commission, Directorate-General XII, Science, Research and Development, 1998, pp 215-20.</li><li id="section_2.37">Tubeuf  KFv, Neckel G, Marzell H: Monographie der Mistel. Munchen, Berlin: R. Oldenbourg, 1923.</li><li id="section_2.38">Teuscher E: Viscum album. In: Hansel R, Keller K, Rimpler H, et al.: Hagers Handbuch der Pharmazeutischen Praxis, Vol. 6. 5th ed. Berlin, Germany: Springer-Verlag, 1994, pp 1160-83.</li><li id="section_2.39">Grossarth-Maticek R, Kiene H, Baumgartner SM, et al.: Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study. Altern Ther Health Med 7 (3): 57-66, 68-72, 74-6 passim, 2001 May-Jun.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11347286&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11347286&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.40">Capernaros Z: The golden bough: the case for mistletoe. Eur J Herbal Med  1 (1):19-24, 1994.</li><li id="section_2.41">Schrader G, Apel K: Isolation and characterization of cDNAs encoding viscotoxins of mistletoe (Viscum album). Eur J Biochem 198 (3): 549-53, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1710983&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1710983&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.42">Gabius HJ, Gabius S, Joshi SS, et al.: From ill-defined extracts to the immunomodulatory lectin: will there be a reason for oncological application of mistletoe? Planta Med 60 (1): 2-7, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8134410&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8134410&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.43">Samtleben R, Hajto T, Hostanska K, et al.: Mistletoe lectins as immunostimulants (chemistry, pharmacology and clinic). In: Wagner H, ed.: Immunomodulatory Agents from Plants. Basel, Switzerland: Birkhauser Verlag, 1999, pp 223-41.</li><li id="section_2.44">Abdullaev FI, de Mejia EG: Antitumor effect of plant lectins. Nat Toxins 5 (4): 157-63, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9407559&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9407559&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.45">Kilpatrick DC: Mechanisms and assessment of lectin-mediated mitogenesis. Mol Biotechnol 11 (1): 55-65, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10367282&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10367282&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.46">Horneber MA, Bueschel G, Huber R, et al.: Mistletoe therapy in oncology. Cochrane Database Syst Rev  (2): CD003297, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18425885&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18425885&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.47">Khil LY, Kim W, Lyu S, et al.: Mechanisms involved in Korean mistletoe lectin-induced apoptosis of cancer cells. World J Gastroenterol 13 (20): 2811-8, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17569116&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17569116&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.48">Kim MS, Lee J, Lee KM, et al.: Involvement of hydrogen peroxide in mistletoe lectin-II-induced apoptosis of myeloleukemic U937 cells. Life Sci 73 (10): 1231-43, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12850239&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12850239&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.49">Choi SH, Lyu SY, Park WB: Mistletoe lectin induces apoptosis and telomerase inhibition in human A253 cancer cells through dephosphorylation of Akt. Arch Pharm Res 27 (1): 68-76, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14969342&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14969342&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.50">Romagnoli S, Fogolari F, Catalano M, et al.: NMR solution structure of viscotoxin C1 from Viscum album species Coloratum ohwi: toward a structure-function analysis of viscotoxins. Biochemistry 42 (43): 12503-10, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14580196&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14580196&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.51">Yoon TJ, Yoo YC, Kang TB, et al.: Antitumor activity of the Korean mistletoe lectin is attributed to activation of macrophages and NK cells. Arch Pharm Res 26 (10): 861-7, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14609136&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14609136&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.52">Rib&#xE9;reau-Gayon G, Jung ML, Di Scala D, et al.: Comparison of the effects of fermented and unfermented mistletoe preparations on cultured tumor cells. Oncology 43 (Suppl 1): 35-41, 1986.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3808575&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3808575&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.53">J&#xE4;ggy C, Musielski H, Urech K, et al.: Quantitative determination of lectins in mistletoe preparations. Arzneimittelforschung 45 (8): 905-9, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7575759&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7575759&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.54">Zee-Cheng RK: Anticancer research on Loranthaceae plants. Drugs Future  22 (5): 519-30, 1997.</li><li id="section_2.55">Kaegi E: Unconventional therapies for cancer: 3. Iscador. Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative. CMAJ 158 (9): 1157-9, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9597967&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9597967&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.56">Stein G, Berg PA: Non-lectin component in a fermented extract from Viscum album L. grown on pines induces proliferation of lymphocytes from healthy and allergic individuals in vitro. Eur J Clin Pharmacol 47 (1): 33-8, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7988621&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7988621&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.57">Kleijnen J, Knipschild P: Mistletoe treatment for cancer: review of controlled trials in humans. Phytomedicine  1: 255-60, 1994.</li><li id="section_2.58">Wagner H, Jordan E, Feil B: Studies on the standardization of mistletoe preparations. Oncology 43 (Suppl 1): 16-22, 1986.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3027640&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3027640&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.59">Zarkovic N, Vukovic T, Loncaric I, et al.: An overview on anticancer activities of the Viscum album extract Isorel. Cancer Biother Radiopharm 16 (1): 55-62, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11279798&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11279798&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.60">Mellor D: Mistletoe in homoeopathic cancer treatment. Prof Nurse 4 (12): 605-7, 1989.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2813459&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2813459&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.61">Fellmer KE: A clinical trial of Iscador: follow-up treatment of irradiated genital carcinomata for the prevention of recurrences. Br Homeopath J  57: 43-7, 1968.</li><li id="section_2.62">Kjaer M: Mistletoe (Iscador) therapy in stage IV renal adenocarcinoma. A phase II study in patients with measurable lung metastases. Acta Oncol 28 (4): 489-94, 1989.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2477047&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2477047&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.63">Sch&#xF6;ffski P, Riggert S, Fumoleau P, et al.: Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group. Ann Oncol 15 (12): 1816-24, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15550588&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15550588&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.64">Matthes HF, Schad F, Buchwald D, et al.: Endoscopic ultrasound-guided fine-needle Injection of Viscum album L. (mistletoe; Helixor M) in the therapy of primary inoperable pancreas cancer:  a pilot study. [Abstract] Gastroenterology  128 (Suppl 2): A-T988, A433-A434, 2005.</li><li id="section_2.65">Matthes HF, Schad F, Schenk G: Viscum album in the therapy of primary inoperable hepatocellular carcinoma (HCC). [Abstract] Gastroenterology  126 (Suppl 2): A-755, A101-A102, 2004.</li><li id="section_2.66">Schaefermeyer G, Schaefermeyer H: Treatment of pancreatic cancer with Viscum album (Iscador): a retrospective study of 292 patients 1986-1996. Complement Ther Med  6 (4): 172-7, 1998.</li><li id="section_2.67">Kleeberg UR, Brocker EB, Lejeune F, et al.: Adjuvant trial in melanoma patients comparing rlFN-alpha to rlFN-gamma to Iscador to a control group after curative resection of high risk primary (&gt;=3mm) or regional lymphnode metastasis (EORTC 18871). [Abstract] Eur J Cancer  35 (Suppl 4): A-264, s82, 1999.</li><li id="section_2.68">Heiny BM, Albrecht V, Beuth J: Stabilization of quality of life with mistletoe lectin-1-standardized extract in advanced colorectal carcinoma. Onkologe  4 (Suppl 1): S35-9, 1998.</li><li id="section_2.69">Wetzel D, Sch&#xE4;fer M: Results of a randomised placebo-controlled multicentre study with PS76A2 (standardised mistletoe preparation) in patients with breast cancer receiving adjuvant chemotherapy. [Abstract] Phytomedicine  7 (Suppl 2): A-SL-66, 2000.</li><li id="section_2.70">Cho JS, Na KJ, Lee Y, et al.: Chemical Pleurodesis Using Mistletoe Extraction (ABNOVAviscum(&#xAE;) Injection) for Malignant Pleural Effusion. Ann Thorac Cardiovasc Surg 22 (1): 20-6, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26639937&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26639937&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.71">Viscum album. In: Homoeopathic Pharmacopoeia Convention of the United States: Homoeopathic Pharmacopoeia of the United States. Washington, DC: 2002, Monograph 9444 Visc.</li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _17
      field_pdq_section_title:
        - format: plain_text
          value: 'Antecedentes'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_17" class="pdq-sections"><p id="_18" tabindex="-1">El <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285939&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285939&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">mu&#xE9;rdago</a> se ha utilizado durante siglos por sus propiedades medicinales.<a href="#cit/section_3.1">1</a><a href="#cit/section_3.2">2</a><a href="#cit/section_3.3">3</a><a href="#cit/section_3.4">4</a><a href="#cit/section_3.5">5</a><a href="#cit/section_3.6">6</a> Seg&#xFA;n los informes, fue utilizado por los druidas y los antiguos griegos, y aparece en leyendas y tradiciones populares como una <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44073&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044073&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">panacea</a>. Se ha utilizado en varias formas para tratar el <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45333&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045333&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer</a>, la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44028&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044028&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">epilepsia</a>, la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46348&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046348&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">esterilidad</a>, los s&#xED;ntomas de la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46296&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046296&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">menopausia</a>, la tensi&#xF3;n nerviosa, el <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=440101&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000440101&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">asma</a>, la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44038&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044038&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">hipertensi&#xF3;n</a>, la cefalea y la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45667&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045667&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">dermatitis</a>. El uso del mu&#xE9;rdago para el tratamiento del c&#xE1;ncer se remonta a m&#xE1;s de 100 a&#xF1;os y su administraci&#xF3;n para el tratamiento de otras indicaciones es mucho m&#xE1;s antigua. El inter&#xE9;s moderno en el mu&#xE9;rdago como tratamiento del c&#xE1;ncer comenz&#xF3; en la d&#xE9;cada de 1920. La mayor&#xED;a de los resultados de estudios cl&#xED;nicos se han publicado exclusivamente en alem&#xE1;n. Para obtener m&#xE1;s informaci&#xF3;n, consultar la secci&#xF3;n de este sumario sobre <a href="/espanol/cancer/tratamiento/mca/pro/muerdago-pdq#link/_35">Estudios cl&#xED;nicos con seres humanos</a>.</p><p id="_19" tabindex="-1"> Otra actividad documentada sobre el mu&#xE9;rdago que puede ser importante para el funcionamiento &#xF3;ptimo del sistema inmunitario de personas con c&#xE1;ncer es la estabilizaci&#xF3;n del <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44393&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044393&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">ADN</a> en los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45993&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045993&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">gl&#xF3;bulos blancos</a>, incluso aquellos expuestos a medicamentos de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45214&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045214&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">quimioterapia</a> que da&#xF1;an el ADN.<a href="#cit/section_3.7">7</a><a href="#cit/section_3.8">8</a><a href="#cit/section_3.9">9</a><a href="#cit/section_3.10">10</a><a href="#cit/section_3.11">11</a></p><p id="_20" tabindex="-1">Se ha observado que el mu&#xE9;rdago estimula aumentos en el n&#xFA;mero y la actividad de diversos tipos de gl&#xF3;bulos blancos.<a href="#cit/section_3.2">2</a><a href="#cit/section_3.3">3</a><a href="#cit/section_3.9">9</a><a href="#cit/section_3.11">11</a><a href="#cit/section_3.12">12</a><a href="#cit/section_3.13">13</a><a href="#cit/section_3.14">14</a><a href="#cit/section_3.15">15</a><a href="#cit/section_3.16">16</a><a href="#cit/section_3.17">17</a><a href="#cit/section_3.18">18</a><a href="#cit/section_3.19">19</a><a href="#cit/section_3.20">20</a><a href="#cit/section_3.21">21</a><a href="#cit/section_3.22">22</a><a href="#cit/section_3.23">23</a><a href="#cit/section_3.24">24</a><a href="#cit/section_3.25">25</a><a href="#cit/section_3.26">26</a><a href="#cit/section_3.27">27</a><a href="#cit/section_3.28">28</a><a href="#cit/section_3.29">29</a><a href="#cit/section_3.30">30</a><a href="#cit/section_3.31">31</a><a href="#cit/section_3.32">32</a><a href="#cit/section_3.33">33</a><a href="#cit/section_3.34">34</a><a href="#cit/section_3.35">35</a><a href="#cit/section_3.36">36</a><a href="#cit/section_3.37">37</a><a href="#cit/section_3.38">38</a><a href="#cit/section_3.39">39</a><a href="#cit/section_3.40">40</a><a href="#cit/section_3.41">41</a><a href="#cit/section_3.42">42</a><a href="#cit/section_3.43">43</a><a href="#cit/section_3.44">44</a><a href="#cit/section_3.45">45</a><a href="#cit/section_3.46">46</a><a href="#cit/section_3.47">47</a><a href="#cit/section_3.48">48</a><a href="#cit/section_3.49">49</a><a href="#cit/section_3.50">50</a><a href="#cit/section_3.51">51</a><a href="#cit/section_3.52">52</a><a href="#cit/section_3.53">53</a> Las <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46130&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046130&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">citocinas</a>, que mejoran el sistema inmunitario, como la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=350231&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000350231&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">interleucina-1</a>, la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44045&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044045&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">interleucina-6</a> y el <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45290&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045290&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">factor de necrosis tumoral</a>-&#x3B1;, son liberadas por los gl&#xF3;bulos blancos despu&#xE9;s de la exposici&#xF3;n a <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=407760&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000407760&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">extractos</a> de mu&#xE9;rdago.<a href="#cit/section_3.1">1</a><a href="#cit/section_3.3">3</a><a href="#cit/section_3.7">7</a><a href="#cit/section_3.9">9</a><a href="#cit/section_3.10">10</a><a href="#cit/section_3.11">11</a><a href="#cit/section_3.14">14</a><a href="#cit/section_3.19">19</a><a href="#cit/section_3.29">29</a><a href="#cit/section_3.33">33</a><a href="#cit/section_3.37">37</a><a href="#cit/section_3.42">42</a><a href="#cit/section_3.43">43</a><a href="#cit/section_3.44">44</a><a href="#cit/section_3.45">45</a><a href="#cit/section_3.46">46</a><a href="#cit/section_3.48">48</a><a href="#cit/section_3.49">49</a><a href="#cit/section_3.50">50</a><a href="#cit/section_3.52">52</a><a href="#cit/section_3.53">53</a><a href="#cit/section_3.54">54</a> Otras pruebas indican que el mu&#xE9;rdago ejerce sus efectos <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44020&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044020&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">citot&#xF3;xicos</a> al interferir con la s&#xED;ntesis de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46092&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046092&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">prote&#xED;nas</a> en las c&#xE9;lulas afectadas <a href="#cit/section_3.3">3</a><a href="#cit/section_3.4">4</a><a href="#cit/section_3.8">8</a><a href="#cit/section_3.11">11</a><a href="#cit/section_3.33">33</a><a href="#cit/section_3.42">42</a><a href="#cit/section_3.43">43</a><a href="#cit/section_3.44">44</a><a href="#cit/section_3.45">45</a><a href="#cit/section_3.46">46</a><a href="#cit/section_3.52">52</a><a href="#cit/section_3.55">55</a><a href="#cit/section_3.56">56</a><a href="#cit/section_3.57">57</a><a href="#cit/section_3.58">58</a><a href="#cit/section_3.59">59</a><a href="#cit/section_3.60">60</a><a href="#cit/section_3.61">61</a><a href="#cit/section_3.62">62</a><a href="#cit/section_3.63">63</a> e inducir la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46524&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046524&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">apoptosis</a>.<a href="#cit/section_3.3">3</a><a href="#cit/section_3.11">11</a><a href="#cit/section_3.36">36</a><a href="#cit/section_3.42">42</a><a href="#cit/section_3.46">46</a><a href="#cit/section_3.52">52</a><a href="#cit/section_3.64">64</a><a href="#cit/section_3.65">65</a><a href="#cit/section_3.66">66</a> El mu&#xE9;rdago tambi&#xE9;n puede servir como puente funcional al reunir las <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44024&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044024&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE9;lulas efectoras</a> del sistema inmunitario con las c&#xE9;lulas tumorales.<a href="#cit/section_3.18">18</a><a href="#cit/section_3.67">67</a></p><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_3.1">Capernaros Z: The golden bough: the case for mistletoe. Eur J Herbal Med  1 (1):19-24, 1994.</li><li id="section_3.2">Mistletoe. In: Murray MT: The Healing Power of Herbs. Roseville, Calif: Prima Publishing, 1995, pp 253-9.</li><li id="section_3.3">Samtleben R, Hajto T, Hostanska K, et al.: Mistletoe lectins as immunostimulants (chemistry, pharmacology and clinic). In: Wagner H, ed.: Immunomodulatory Agents from Plants. Basel, Switzerland: Birkhauser Verlag, 1999, pp 223-41.</li><li id="section_3.4">Olsnes S, Stirpe F, Sandvig K, et al.: Isolation and characterization of viscumin, a toxic lectin from Viscum album L. (mistletoe). J Biol Chem 257 (22): 13263-70, 1982.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7142144&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7142144&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.5">Becker H: Botany of European mistletoe (Viscum album L.). Oncology 43 (Suppl 1): 2-7, 1986.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3808574&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3808574&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.6">Watkins D: A berry Christmas. Nurs Times 93 (51): 28-9, 1997 Dec 17-23.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9455311&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9455311&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.7">B&#xFC;ssing A, Azhari T, Ostendorp H, et al.: Viscum album L. extracts reduce sister chromatid exchanges in cultured peripheral blood mononuclear cells. Eur J Cancer 30A (12): 1836-41, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7880615&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7880615&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.8">B&#xFC;ssing A, Lehnert A, Schink M, et al.: Effect of Viscum album L. on rapidly proliferating amniotic fluid cells. Sister chromatid exchange frequency and proliferation index. Arzneimittelforschung 45 (1): 81-3, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7893276&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7893276&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.9">B&#xFC;ssing A, Regnery A, Schweizer K: Effects of Viscum album L. on cyclophosphamide-treated peripheral blood mononuclear cells in vitro: sister chromatid exchanges and activation/proliferation marker expression. Cancer Lett 94 (2): 199-205, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7634248&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7634248&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.10">Bussing A, Jungmann H, Suzart K, et al.: Suppression of sister chromatid exchange-inducing DNA lesions in cultured peripheral blood mononuclear cells by Viscum album L. J Exp Clin Cancer Res  15 (2): 107-14, 1996.</li><li id="section_3.11">B&#xFC;ssing A, Suzart K, Bergmann J, et al.: Induction of apoptosis in human lymphocytes treated with Viscum album L. is mediated by the mistletoe lectins. Cancer Lett 99 (1): 59-72, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8564930&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8564930&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.12">Rentea R, Lyon E, Hunter R: Biologic properties of iscador: a Viscum album preparation I. Hyperplasia of the thymic cortex and accelerated regeneration of hematopoietic cells following X-irradiation. Lab Invest 44 (1): 43-8, 1981.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7453129&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7453129&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.13">Bloksma N, Schmiermann P, de Reuver M, et al.: Stimulation of humoral and cellular immunity by Viscum preparations. Planta Med 46 (4): 221-7, 1982.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7163417&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7163417&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.14">Hajto T: Immunomodulatory effects of iscador: a Viscum album preparation. Oncology 43 (Suppl 1): 51-65, 1986.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2433654&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2433654&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.15">Hajto T, Lanzrein C: Natural killer and antibody-dependent cell-mediated cytotoxicity activities and large granular lymphocyte frequencies in Viscum album-treated breast cancer patients. Oncology 43 (2): 93-7, 1986.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3951791&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3951791&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.16">Hamprecht K, Handgretinger R, Voetsch W, et al.: Mediation of human NK-activity by components in extracts of Viscum album. Int J Immunopharmacol 9 (2): 199-209, 1987.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3583510&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3583510&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.17">Hajto T, Hostanska K, Gabius HJ: Modulatory potency of the beta-galactoside-specific lectin from mistletoe extract (Iscador) on the host defense system in vivo in rabbits and patients. Cancer Res 49 (17): 4803-8, 1989.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2758413&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2758413&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.18">Mueller EA, Hamprecht K, Anderer FA: Biochemical characterization of a component in extracts of Viscum album enhancing human NK cytotoxicity. Immunopharmacology 17 (1): 11-8, 1989 Jan-Feb.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2708032&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2708032&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.19">Hajto T, Hostanska K, Frei K, et al.: Increased secretion of tumor necrosis factors alpha, interleukin 1, and interleukin 6 by human mononuclear cells exposed to beta-galactoside-specific lectin from clinically applied mistletoe extract. Cancer Res 50 (11): 3322-6, 1990.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2334925&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2334925&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.20">Beuth J, Ko HL, Gabius HJ, et al.: Behavior of lymphocyte subsets and expression of activation markers in response to immunotherapy with galactoside-specific lectin from mistletoe in breast cancer patients. Clin Investig 70 (8): 658-61, 1992.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1392440&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1392440&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.21">Kuttan G, Kuttan R: Immunological mechanism of action of the tumor reducing peptide from mistletoe extract (NSC 635089) cellular proliferation. Cancer Lett 66 (2): 123-30, 1992.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1394116&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1394116&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.22">Kuttan G, Kuttan R: Immunomodulatory activity of a peptide isolated from Viscum album extract (NSC 635 089). Immunol Invest 21 (4): 285-96, 1992.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1398778&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1398778&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.23">Gabius HJ, Walzel H, Joshi SS, et al.: The immunomodulatory beta-galactoside-specific lectin from mistletoe: partial sequence analysis, cell and tissue binding, and impact on intracellular biosignalling of monocytic leukemia cells. Anticancer Res 12 (3): 669-75, 1992 May-Jun.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1622124&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1622124&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.24">Beuth J, Ko HL, Tunggal L, et al.: Thymocyte proliferation and maturation in response to galactoside-specific mistletoe lectin-1. In Vivo 7 (5): 407-10, 1993 Sep-Oct.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8110981&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8110981&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.25">Timoshenko AV, Gabius HJ: Efficient induction of superoxide release from human neutrophils by the galactoside-specific lectin from Viscum album. Biol Chem Hoppe Seyler 374 (4): 237-43, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8392351&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8392351&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.26">Timoshenko AV, Kayser K, Drings P, et al.: Modulation of lectin-triggered superoxide release from neutrophils of tumor patients with and without chemotherapy. Anticancer Res 13 (5C): 1789-92, 1993 Sep-Oct.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8267383&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8267383&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.27">Kuttan G: Tumoricidal activity of mouse peritoneal macrophages treated with Viscum album extract. Immunol Invest 22 (6-7): 431-40, 1993 Aug-Oct.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8262566&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8262566&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.28">Beuth J, Ko HL, Tunggal L, et al.: Immunoprotective activity of the galactoside-specific mistletoe lectin in cortisone-treated BALB/c-mice. In Vivo 8 (6): 989-92, 1994 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7772751&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7772751&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.29">Heiny BM, Beuth J: Mistletoe extract standardized for the galactoside-specific lectin (ML-1) induces beta-endorphin release and immunopotentiation in breast cancer patients. Anticancer Res 14 (3B): 1339-42, 1994 May-Jun.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8067703&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8067703&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.30">Stein G, Berg PA: Non-lectin component in a fermented extract from Viscum album L. grown on pines induces proliferation of lymphocytes from healthy and allergic individuals in vitro. Eur J Clin Pharmacol 47 (1): 33-8, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7988621&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7988621&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.31">Timoshenko AV, Gabius HJ: Influence of the galactoside-specific lectin from Viscum album and its subunits on cell aggregation and selected intracellular parameters of rat thymocytes. Planta Med 61 (2): 130-3, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7753919&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7753919&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.32">Timoshenko AV, Cherenkevich SN, Gabius HJ: Viscum album agglutinin-induced aggregation of blood cells and the lectin effects on neutrophil function. Biomed Pharmacother 49 (3): 153-8, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7647287&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7647287&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.33">Hostanska K, Hajto T, Spagnoli GC, et al.: A plant lectin derived from Viscum album induces cytokine gene expression and protein production in cultures of human peripheral blood mononuclear cells. Nat Immun 14 (5-6): 295-304, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8933823&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8933823&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.34">Beuth J, Stoffel B, Ko HL, et al.: Immunomodulating ability of galactoside-specific lectin standardized and depleted mistletoe extract. Arzneimittelforschung 45 (11): 1240-2, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8929248&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8929248&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.35">Lenartz D, Stoffel B, Menzel J, et al.: Immunoprotective activity of the galactoside-specific lectin from mistletoe after tumor destructive therapy in glioma patients. Anticancer Res 16 (6B): 3799-802, 1996 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9042260&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9042260&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.36">Fischer S, Scheffler A, Kabelitz D: Oligoclonal in vitro response of CD4 T cells to vesicles of mistletoe extracts in mistletoe-treated cancer patients. Cancer Immunol Immunother 44 (3): 150-6, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9191874&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9191874&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.37">Preisfeld A: Influence of aqueous mistletoe preparations on humoral immune parameters with emphasis on the cytotoxicity of human complement in breast cancer patients. Forsch Komplementarmed  4 (4): 224-8, 1997.</li><li id="section_3.38">Chernyshov VP, Omelchenko LI, Heusser P, et al.: Immunomodulatory actions of Viscum album (Iscador) in children with recurrent respiratory disease as a result of the Chernobyl nuclear accident. Complement Ther Med  5 (3): 141-6, 1997.</li><li id="section_3.39">Heiny BM, Albrecht V, Beuth J: Correlation of immune cell activities and beta-endorphin release in breast carcinoma patients treated with galactose-specific lectin standardized mistletoe extract. Anticancer Res 18 (1B): 583-6, 1998 Jan-Feb.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9568181&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9568181&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.40">Stein GM, Schaller G, Pf&#xFC;ller U, et al.: Characterisation of granulocyte stimulation by thionins from European mistletoe and from wheat. Biochim Biophys Acta 1426 (1): 80-90, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9878694&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9878694&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.41">Stein GM, Schaller G, Pf&#xFC;ller U, et al.: Thionins from Viscum album L: influence of the viscotoxins on the activation of granulocytes. Anticancer Res 19 (2A): 1037-42, 1999 Mar-Apr.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10368652&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10368652&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.42">Mengs U, G&#xF6;thel D, Leng-Peschlow E: Mistletoe extracts standardized to mistletoe lectins in oncology: review on current status of preclinical research. Anticancer Res 22 (3): 1399-407, 2002 May-Jun.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12168816&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12168816&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.43">Bocci V: Mistletoe (viscum album) lectins as cytokine inducers and immunoadjuvant in tumor therapy. A review. J Biol Regul Homeost Agents 7 (1): 1-6, 1993 Jan-Mar.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8346712&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8346712&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.44">Gabius HJ, Gabius S, Joshi SS, et al.: From ill-defined extracts to the immunomodulatory lectin: will there be a reason for oncological application of mistletoe? Planta Med 60 (1): 2-7, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8134410&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8134410&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.45">Zee-Cheng RK: Anticancer research on Loranthaceae plants. Drugs Future  22 (5): 519-30, 1997.</li><li id="section_3.46">Kaegi E: Unconventional therapies for cancer: 3. Iscador. Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative. CMAJ 158 (9): 1157-9, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9597967&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9597967&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.47">Lenartz D, Dott U, Menzel J, et al.: Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe. Anticancer Res 20 (3B): 2073-6, 2000 May-Jun.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10928154&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10928154&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.48">Goebell PJ, Otto T, Suhr J, et al.: Evaluation of an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized phase II trial. J Urol 168 (1): 72-5, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12050495&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12050495&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.49">Schaefermeyer G, Schaefermeyer H: Treatment of pancreatic cancer with Viscum album (Iscador): a retrospective study of 292 patients 1986-1996. Complement Ther Med  6 (4): 172-7, 1998.</li><li id="section_3.50">Kunze E, Schulz H, Gabius HJ: Inability of galactoside-specific mistletoe lectin to inhibit N-methyl-N-nitrosourea-induced tumor development in the urinary bladder of rats and to mediate a local cellular immune response after long-term administration. J Cancer Res Clin Oncol 124 (2): 73-87, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9654190&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9654190&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.51">Kunze E, Schulz H, Adamek M, et al.: Long-term administration of galactoside-specific mistletoe lectin in an animal model: no protection against N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder carcinogenesis in rats and no induction of a relevant local cellular immune response. J Cancer Res Clin Oncol 126 (3): 125-38, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10741906&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10741906&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.52">Mengs U, Schwarz T, Bulitta M, et al.: Antitumoral effects of an intravesically applied aqueous mistletoe extract on urinary bladder carcinoma MB49 in mice. Anticancer Res 20 (5B): 3565-8, 2000 Sep- Oct.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11131663&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11131663&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.53">Stauder H, Kreuser ED: Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: current state of clinical research. Onkologie 25 (4): 374-80, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12232491&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12232491&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.54">Kleijnen J, Knipschild P: Mistletoe treatment for cancer: review of controlled trials in humans. Phytomedicine  1: 255-60, 1994.</li><li id="section_3.55">Stirpe F, Sandvig K, Olsnes S, et al.: Action of viscumin, a toxic lectin from mistletoe, on cells in culture. J Biol Chem 257 (22): 13271-7, 1982.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7142145&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7142145&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.56">Walzel H, Jonas L, Rosin T, et al.: Relationship between internalization kinetics and cytotoxicity of mistletoe lectin I to L1210 leukaemia cells. Folia Biol (Praha) 36 (3-4): 181-8, 1990.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2257937&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2257937&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.57">Franz H: Mistletoe lectins and their A and B chains. Oncology 43 (Suppl 1): 23-34, 1986.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3543782&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3543782&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.58">Sweeney EC, Palmer RA, Pf&#xFC;ller U: Crystallization of the ribosome inactivating protein ML1 from Viscum album (mistletoe) complexed with beta-D-galactose. J Mol Biol 234 (4): 1279-81, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8263931&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8263931&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.59">Jung ML, Baudino S, Rib&#xE9;reau-Gayon G, et al.: Characterization of cytotoxic proteins from mistletoe (Viscum album L.). Cancer Lett 51 (2): 103-8, 1990.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2344587&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2344587&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.60">Gabius HJ, Darro F, Remmelink M, et al.: Evidence for stimulation of tumor proliferation in cell lines and histotypic cultures by clinically relevant low doses of the galactoside-binding mistletoe lectin, a component of proprietary extracts. Cancer Invest 19 (2): 114-26, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11296616&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11296616&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.61">Dietrich JB, Rib&#xE9;reau-Gayon G, Jung ML, et al.: Identity of the N-terminal sequences of the three A chains of mistletoe (Viscum album L.) lectins: homology with ricin-like plant toxins and single-chain ribosome-inhibiting proteins. Anticancer Drugs 3 (5): 507-11, 1992.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1450445&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1450445&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.62">J&#xE4;ggy C, Musielski H, Urech K, et al.: Quantitative determination of lectins in mistletoe preparations. Arzneimittelforschung 45 (8): 905-9, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7575759&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7575759&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.63">Burger AM, Mengs U, Sch&#xFC;ler JB, et al.: Anticancer activity of an aqueous mistletoe extract (AME) in syngeneic murine tumor models. Anticancer Res 21 (3B): 1965-8, 2001 May-Jun.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11497284&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11497284&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.64">Janssen O, Scheffler A, Kabelitz D: In vitro effects of mistletoe extracts and mistletoe lectins. Cytotoxicity towards tumor cells due to the induction of programmed cell death (apoptosis). Arzneimittelforschung 43 (11): 1221-7, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8292069&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8292069&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.65">Zarkovic N, Vukovic T, Loncaric I, et al.: An overview on anticancer activities of the Viscum album extract Isorel. Cancer Biother Radiopharm 16 (1): 55-62, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11279798&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11279798&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.66">Maier G, Fiebig HH: Absence of tumor growth stimulation in a panel of 16 human tumor cell lines by mistletoe extracts in vitro. Anticancer Drugs 13 (4): 373-9, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11984083&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11984083&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.67">Mueller EA, Anderer FA: Chemical specificity of effector cell/tumor cell bridging by a Viscum album rhamnogalacturonan enhancing cytotoxicity of human NK cells. Immunopharmacology 19 (1): 69-77, 1990 Jan-Feb.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2407685&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2407685&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _23
      field_pdq_section_title:
        - format: plain_text
          value: 'Estudios preclínicos de laboratorio o con animales'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_23" class="pdq-sections"><p id="_24" tabindex="-1">En <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44512&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044512&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">estudios de laboratorio</a> y con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=454774&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000454774&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">animales</a>, se han estudiado las propiedades estimulantes del <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46356&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046356&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">sistema inmunitario</a> y las propiedades <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44020&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044020&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">citot&#xF3;xicas</a> del <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285939&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285939&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">mu&#xE9;rdago</a>.</p><p id="_21" tabindex="-1">Se han investigado las <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44094&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044094&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">viscotoxinas</a> y las <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44051&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044051&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">lectinas</a> como componentes activos del mu&#xE9;rdago; la mayor parte de las investigaciones se concentraron en las lectinas.<a href="#cit/section_4.1">1</a><a href="#cit/section_4.2">2</a><a href="#cit/section_4.3">3</a><a href="#cit/section_4.4">4</a><a href="#cit/section_4.5">5</a><a href="#cit/section_4.6">6</a><a href="#cit/section_4.7">7</a><a href="#cit/section_4.8">8</a><a href="#cit/section_4.9">9</a> Las <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44994&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044994&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">lectinas de mu&#xE9;rdago</a> purificadas han demostrado actividad citot&#xF3;xica y estimulante del sistema inmunitario. Se identificaron cuatro lectinas diferentes en los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=407760&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000407760&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">extractos de mu&#xE9;rdago</a>: ML-1, ML-2, ML-3 y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285953&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285953&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">aglutinina</a> de uni&#xF3;n a <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285965&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285965&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">quitina</a> en <em>Viscum album</em>. La ML-1 (o viscumina) puede ser responsable de muchos de los efectos <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44510&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044510&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">biol&#xF3;gicos</a> del mu&#xE9;rdago. Cuando se utiliz&#xF3; un m&#xE9;todo de laboratorio para agotar selectivamente la ML-1 de los extractos de <em>Viscum album</em>, sus propiedades citot&#xF3;xicas y estimulantes del sistema inmunitario se redujeron notablemente.<a href="#cit/section_4.10">10</a><a href="#cit/section_4.11">11</a> Cabe se&#xF1;alar que la fermentaci&#xF3;n elimina la mayor parte del ML-1 en los extractos de mu&#xE9;rdago. Iscador y otros extractos fermentados de mu&#xE9;rdago solo contienen lectinas de mu&#xE9;rdago ML-2 y ML-3 y no contienen  <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46092&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046092&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">prote&#xED;nas</a> del complejo Ml-1.<a href="#cit/section_4.12">12</a><a href="#cit/section_4.13">13</a><a href="#cit/section_4.14">14</a> Se revisaron los componentes polisac&#xE1;ridos y oligosac&#xE1;ridos de los extractos de mu&#xE9;rdago con propiedades inmunitarias estimulante importantes.<a href="#cit/section_4.15">15</a><a href="#cit/section_4.16">16</a></p><p id="_61" tabindex="-1">La estructura molecular de ML-1 se compone de una cadena &#x3B1; y  una cadena &#x3B2; que se pueden separar entre s&#xED;.<a href="#cit/section_4.1">1</a><a href="#cit/section_4.6">6</a><a href="#cit/section_4.7">7</a><a href="#cit/section_4.8">8</a><a href="#cit/section_4.9">9</a><a href="#cit/section_4.13">13</a><a href="#cit/section_4.17">17</a><a href="#cit/section_4.18">18</a> Cada tipo de cadena parece mediar un subconjunto de las actividades descritas para la lectina intacta. La citotoxicidad se relaciona principalmente con la cadena &#x3B1;. En <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44512&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044512&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">estudios de laboratorio</a>, la cadena &#x3B1; de ML-1 se acopl&#xF3; a <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46066&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046066&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">anticuerpos monoclonales</a> para producir <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45730&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045730&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">inmunotoxinas</a> que se dirigen a tipos espec&#xED;ficos de c&#xE9;lulas y las destruyen.<a href="#cit/section_4.19">19</a><a href="#cit/section_4.20">20</a><a href="#cit/section_4.21">21</a></p><p id="_104" tabindex="-1">En estudios de laboratorio, la ML-1 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44619&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044619&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">recombinada</a>, rML (tambi&#xE9;n conocida como rViscumin o aviscumina) parece tener la misma <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=346517&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000346517&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">eficacia</a> que la ML-1 vegetal.<a href="#cit/section_4.22">22</a> Debido a que no es un extracto de mu&#xE9;rdago, est&#xE1; fuera del alcance de este sumario.</p><p id="_105" tabindex="-1">La cadena &#x3B2; de ML-1 es responsable por su uni&#xF3;n con la superficie de una c&#xE9;lula diana.<a href="#cit/section_4.23">23</a> En estudios de la lectina del mu&#xE9;rdago que se une a las c&#xE9;lulas cancerosas, se examin&#xF3; si el grado de uni&#xF3;n celular puede pronosticar el <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=467853&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000467853&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">desenlace</a> de la enfermedad o la supervivencia. En los estudios se observa que el valor pron&#xF3;stico de la capacidad de uni&#xF3;n de ML-1 depende del tipo de c&#xE1;ncer.<a href="#cit/section_4.24">24</a> Para las c&#xE9;lulas del <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=444971&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000444971&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer de mama</a> humano, la cantidad de c&#xE9;lulas de lectina unida se correlaciona de modo positivo con el desenlace de la enfermedad. Sin embargo, para el <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46216&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046216&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">adenocarcinoma</a> de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=270740&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000270740&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">pulm&#xF3;n</a> humano, no hay una correlaci&#xF3;n entre la cantidad de c&#xE9;lulas unidas a lectina y la supervivencia de la enfermedad.<a href="#cit/section_4.25">25</a> Aunque en la mayor parte de la investigaci&#xF3;n se ha analizado este aspecto en particular, no ha habido estudios que vinculen directamente la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=683342&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000683342&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">concentraci&#xF3;n</a> de ese componente con alguna actividad cl&#xED;nica del mu&#xE9;rdago.</p><p id="_25" tabindex="-1">En los estudios de laboratorio se observ&#xF3; que los extractos de mu&#xE9;rdago pueden estimular la actividad de los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45993&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045993&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">gl&#xF3;bulos blancos</a> <em><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45733&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045733&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">in vitro</a></em> y hacer que liberen <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45065&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045065&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">mol&#xE9;culas</a> que se consideran importantes para las <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45722&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045722&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">respuestas inmunitarias</a> ante el c&#xE1;ncer.<a href="#cit/section_4.4">4</a><a href="#cit/section_4.6">6</a><a href="#cit/section_4.8">8</a><a href="#cit/section_4.9">9</a><a href="#cit/section_4.17">17</a><a href="#cit/section_4.26">26</a><a href="#cit/section_4.27">27</a><a href="#cit/section_4.28">28</a><a href="#cit/section_4.29">29</a><a href="#cit/section_4.30">30</a><a href="#cit/section_4.31">31</a><a href="#cit/section_4.32">32</a><a href="#cit/section_4.33">33</a> Adem&#xE1;s, los extractos de mu&#xE9;rdago exhibieron actividad citot&#xF3;xica ante una variedad de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46476&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046476&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE9;lulas</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45333&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045333&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">cancerosas</a> <em>in vitro</em> de rat&#xF3;n, rata y humanas.<a href="#cit/section_4.1">1</a><a href="#cit/section_4.8">8</a><a href="#cit/section_4.23">23</a><a href="#cit/section_4.34">34</a><a href="#cit/section_4.35">35</a><a href="#cit/section_4.36">36</a><a href="#cit/section_4.37">37</a>   </p><p id="_118" tabindex="-1">Hay informes contradictorios referentes a la estimulaci&#xF3;n del crecimiento de c&#xE9;lulas cancerosas <em>in vitro</em>. En un estudio, se estimul&#xF3; el crecimiento <em>in vitro</em> de varios tipos de c&#xE9;lulas cancerosas humanas mediante el tratamiento con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44664&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044664&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">dosis</a> bajas de la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44051&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044051&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">lectina</a> purificada ML-1.<a href="#cit/section_4.1">1</a> Sin embargo, en varios otros estudios se encontr&#xF3; que la ML-1 y los extractos de mu&#xE9;rdago no indujeron la proliferaci&#xF3;n celular.<a href="#cit/section_4.38">38</a><a href="#cit/section_4.39">39</a></p><p id="_258" tabindex="-1">En el <a href="/espanol/cancer/tratamiento/mca/pro/muerdago-pdq#link/_259">Cuadro 1</a> y el  <a href="/espanol/cancer/tratamiento/mca/pro/muerdago-pdq#link/_261">Cuadro 2</a> se ofrece un resumen de los efectos biol&#xF3;gicos que se observaron en los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44517&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044517&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">estudios precl&#xED;nicos</a> de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=695994&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000695994&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">l&#xED;neas celulares cancerosas</a> y en  <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43996&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043996&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">modelos animales</a>.</p><table id="_259" class="table-default expandable-container"><caption>Cuadro 1.  Estudios <em>in vitro</em> <span class="sup">a</span></caption><colgroup><col align="Left" width="33.33%"><col width="33.33%"><col width="33.33%"></colgroup><TFoot class="pdq-footer"><tr><td colspan="3">IscadorQu =  IscadorQ; ML-1 = extracto de mu&#xE9;rdago con lectinas de mu&#xE9;rdago I.</td></tr><tr><td colspan="3"><span class="sup">a</span>Para obtener m&#xE1;s informaci&#xF3;n y la definici&#xF3;n de los t&#xE9;rminos, consultar el texto y el <a href="https://www.cancer.gov/espanol/publicaciones/diccionario" title="https://www.cancer.gov/espanol/publicaciones/diccionario">Diccionario de c&#xE1;ncer del NCI</a>.</td></tr></TFoot><tbody><tr><td colspan="3"><strong>Iscador</strong></td></tr><tr><td align="Center" scope="col"><strong>L&#xED;nea celular</strong></td><td align="Center" scope="col"><strong>Desenlace</strong></td><td align="Center" scope="col"><strong>Referencia</strong></td></tr><tr><td>Diferentes l&#xED;neas celulares cancerosas humanas</td><td>Hubo  &gt;70&#xA0;% de inhibici&#xF3;n del crecimiento en la l&#xED;nea celular cancerosa  <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44560&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044560&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">mamaria</a> (MAXF 401NL) con las preparaciones de Iscador que conten&#xED;an una concentraci&#xF3;n alta de lectina (15 &#x3BC;g/<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=655103&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000655103&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">ml</a>), en comparaci&#xF3;n con las c&#xE9;lulas de control que no recibieron tratamiento; 30&#x2013;70&#xA0;% de inhibici&#xF3;n del crecimiento en 3 l&#xED;neas celulares  <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46634&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046634&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">tumorales</a> (<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45343&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045343&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">leucemia</a> RPMI 8226, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45323&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045323&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">pulm&#xF3;n de c&#xE9;lulas no peque&#xF1;as</a> LXFE 66NL y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=445094&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000445094&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">uterino</a> UXF 1138L) para IscadorM  y en 7 l&#xED;neas celulares tumorales  (<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46481&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046481&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">sistema nervioso central</a> SF268, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=454513&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000454513&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">g&#xE1;strico</a> GXF 251L, c&#xE1;nceres de pulm&#xF3;n de c&#xE9;lulas no peque&#xF1;as LXFE 66NL y LXFL 529L, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=445079&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000445079&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">pr&#xF3;stata</a> PC3M, renal RXF 944L y uterino UXF 1138L)para IscadorQu.</td><td><a href="#cit/section_4.35">35</a></td></tr><tr><td>C&#xE9;lulas humanas de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45780&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045780&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">meduloblastoma</a> Daoy, D341,   D425 y UW 228-2</td><td>Hubo destrucci&#xF3;n celular por <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46524&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046524&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">apoptosis</a> con las preparaciones de <em>Viscum album</em> (0,1 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=306521&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000306521&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">&#xB5;g</a>/ml&#x2013;100 &#xB5;g/ml). La inhibici&#xF3;n del crecimiento se correlaciona con el contenido de lectina en la preparaci&#xF3;n. </td><td><a href="#cit/section_4.37">37</a></td></tr><tr><td>Diferentes l&#xED;neas celulares cancerosas humanas  (sistema nervioso central SF268; g&#xE1;strico GXF 251; pulm&#xF3;n H460, LXFA 629L, LXFE 66NL, LXFL 529L; leucemia y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45368&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045368&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">linfoma</a> CCRFCEM, MOLT-4, HL-60, K562, U937, RPMI 8226; mamaria MCF7, MAXF 401NL; <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45135&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045135&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">melanoma</a> HT144, MALME-3M, SK-MEL28, MEXF 462NL, MEXF 514L; pr&#xF3;stata PC3M; renal RXF 393NL, RXF 944L; <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45562&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045562&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">sarcoma</a> Hs729, SK-LMS-1, SK-UT-1B y &#xFA;tero UXF 1138L)</td><td>Hubo actividad <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=446109&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000446109&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">antitumoral</a> <em>in vitro</em>  cuando se usaron concentraciones altas (15&#x2013;150 &#xB5;g/ml) para las pruebas de IscadorM e IscadorQu con contenido alto de lectina.</td><td><a href="#cit/section_4.38">38</a></td></tr><tr><td>L&#xED;neas celulares humanas: HCC1937, HCC1143 (mama), PA-TU-8902 (<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46254&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046254&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">p&#xE1;ncreas</a>), DU145 (<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46539&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046539&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">pr&#xF3;stata</a>), NCI-H460 (pulm&#xF3;n)</td><td>La inhibici&#xF3;n de la proliferaci&#xF3;n celular se detect&#xF3; con una dosis de mu&#xE9;rdago de 100 &#x3BC;g/ml en las l&#xED;neas celulares PA-TU-8902 y NCI-H460, y con una dosis de &#x2265;10 &#x3BC;g/ml en las l&#xED;neas celulares HCC1937, HCC1143 y DU145.</td><td><a href="#cit/section_4.40">40</a></td></tr><tr><td>C&#xE9;lulas de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45698&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045698&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">glioblastoma</a>: LNT-229, LN-308</td><td>El crecimiento celular se redujo con IscadorQ y M en concentraciones de lectina de 100 &#xB5;g/ml.</td><td><a href="#cit/section_4.41">41</a></td></tr><tr><td colspan="3"><strong>Helixor</strong></td></tr><tr><td align="Center" scope="col"><strong>L&#xED;nea celular</strong> </td><td align="Center" scope="col"><strong>Desenlace</strong></td><td align="Center" scope="col"><strong>Referencia</strong></td></tr><tr><td>Diferentes l&#xED;neas celulares cancerosas humanas</td><td>No hubo proliferaci&#xF3;n celular con las preparaciones de mu&#xE9;rdago Helixor (15 &#xB5;g/ml&#x2013;150 &#xB5;g/ml) y ML-1 (10 ng/ml&#x2013;100 ng/ml).</td><td><a href="#cit/section_4.39">39</a></td></tr><tr><td colspan="3"><strong>abnobaVISCUM</strong></td></tr><tr><td align="Center" scope="col"><strong>L&#xED;nea celular</strong></td><td align="Center" scope="col"><strong>Desenlace</strong></td><td align="Center" scope="col"><strong>Referencia</strong></td></tr><tr><td>L&#xED;neas celulares tumorales humanas (hibridomas de  <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45611&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045611&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE9;lulas B</a>, P815, EL-4, Ke37, MOLT-4 y  U937)</td><td>Se detuvo la proliferaci&#xF3;n por apoptosis provocada  (50&#xA0;% de las c&#xE9;lulas  U937 en 100 ng/ml de ML-1 y 40&#xA0;% de los hibridomas de c&#xE9;lulas B y c&#xE9;lulas EL-4 a partir de concentraciones bajas de 1 ng/ml  de ML-1).</td><td><a href="#cit/section_4.10">10</a></td></tr></tbody></table><p id="_260" tabindex="-1">En los estudios sobre la capacidad del mu&#xE9;rdago para inhibir el crecimiento de c&#xE9;lulas cancerosas en animales, se obtuvieron resultados desiguales e incongruentes.<a href="#cit/section_4.5">5</a><a href="#cit/section_4.6">6</a><a href="#cit/section_4.7">7</a><a href="#cit/section_4.8">8</a><a href="#cit/section_4.9">9</a><a href="#cit/section_4.36">36</a><a href="#cit/section_4.42">42</a><a href="#cit/section_4.43">43</a><a href="#cit/section_4.44">44</a><a href="#cit/section_4.45">45</a><a href="#cit/section_4.46">46</a><a href="#cit/section_4.47">47</a><a href="#cit/section_4.48">48</a><a href="#cit/section_4.49">49</a><a href="#cit/section_4.50">50</a> En la mayor&#xED;a de estos estudios, los extractos de mu&#xE9;rdago se administraron por <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44678&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044678&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">inyecci&#xF3;n</a>  <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45914&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045914&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">subcut&#xE1;nea</a> o <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46339&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046339&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">intraperitoneal</a>; es posible que algunas variaciones en los resultados se deban a la v&#xED;a de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=478733&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000478733&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">administraci&#xF3;n</a>. Por ejemplo, la administraci&#xF3;n de IscadorM se relacion&#xF3; con una supervivencia prolongada de ratones hembras suizas cuando la administraci&#xF3;n  fue <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46339&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046339&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">intraperitoneal</a>.<a href="#cit/section_4.51">51</a> en lugar de subcut&#xE1;nea.<a href="#cit/section_4.52">52</a> Estos dos estudios tambi&#xE9;n se diferenciaron por el n&#xFA;mero de c&#xE9;lulas de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45601&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045601&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">ascitis</a> de Ehrlich inoculadas y las dosis de IscadorM administradas.</p><table id="_261" class="table-default expandable-container"><caption>Cuadro 2.  Estudios <em><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46352&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046352&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">in vivo</a></em><span class="sup">a</span></caption><colgroup><col width="33.33%"><col width="33.33%"><col width="33.33%"></colgroup><TFoot class="pdq-footer"><tr><td colspan="3">LLA = leucemia linfobl&#xE1;stica aguda; ME-A = extractos de mu&#xE9;rdago (de abetos, <em>Abies</em>); ME-M = extractos de mu&#xE9;rdago (de manzanos, <em>Malus</em>); ML-1 = extractos de mu&#xE9;rdago con lectinas de mu&#xE9;rdago I; ML-3 = extractos de mu&#xE9;rdago con lectinas de mu&#xE9;rdago III; MT-A = extractos de mu&#xE9;rdago (de abetos); MT-P = extractos de mu&#xE9;rdago (de pinos); CN = linfocito citol&#xED;tico natural.</td></tr><tr><td colspan="3"><span class="sup">a</span>Para obtener m&#xE1;s informaci&#xF3;n y la definici&#xF3;n de los t&#xE9;rminos, consultar el texto y el <a href="https://www.cancer.gov/espanol/publicaciones/diccionario" title="https://www.cancer.gov/espanol/publicaciones/diccionario">Diccionario de c&#xE1;ncer del NCI</a>.</td></tr></TFoot><tbody><tr><td colspan="3"><strong>Iscador</strong></td></tr><tr><td align="Center" scope="col"><strong>Modelo</strong></td><td align="Center" scope="col"><strong>Desenlace</strong></td><td align="Center" scope="col"><strong>Referencia</strong></td></tr><tr><td>Murino</td><td>Solo se lograron efectos antiproliferativos y antimetast&#xE1;sicos en la l&#xED;nea celular de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45135&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045135&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">melanoma</a> MV3 cuando se us&#xF3; una dosis baja de ML-1 (30 ng/kg de peso corporal) y no con dosis superiores (150 ng/kg y 500 ng/kg); el aumento en el n&#xFA;mero de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44948&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044948&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE9;lulas dendr&#xED;ticas</a>  infiltrantes  parece indicar que estimula el sistema inmunitario.</td><td><a href="#cit/section_4.44">44</a></td></tr><tr><td>Murino</td><td>Se relacion&#xF3; la inhibici&#xF3;n del crecimiento tumoral de las c&#xE9;lulas de melanoma B16F1 debido al uso del extracto <em>Viscum album</em> 20&#xB5;g/rat&#xF3;n/d) con la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=367426&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000367426&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">inmunomodulaci&#xF3;n</a> por inducci&#xF3;n de secreci&#xF3;n de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44418&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044418&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">IL-12</a>, que mejor&#xF3; el funcionamiento de los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44928&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044928&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">linfocitos T</a> y los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44439&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044439&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">linfocitos CN</a>.</td><td><a href="#cit/section_4.45">45</a></td></tr><tr><td>Murino</td><td>Se investig&#xF3; la diseminaci&#xF3;n a otros <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=257523&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000257523&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">&#xF3;rganos</a> el d&#xED;a 14 tras la inoculaci&#xF3;n con c&#xE9;lulas de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44115&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044115&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">linfosarcoma</a> RAW 117 H 10  y con c&#xE9;lulas de  <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45562&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045562&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">sarcoma</a> L-1; se observaron reducciones con  <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44167&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044167&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">significaci&#xF3;n estad&#xED;stica</a> (<em>P</em> &lt; 0,05) de  las <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46710&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046710&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">met&#xE1;stasis</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46312&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046312&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">hep&#xE1;ticas</a> y pulmonares en <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44758&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044758&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">experimentos</a>  con ratones que recibieron extracto de mu&#xE9;rdago <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43998&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043998&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">acuoso</a> estandarizado  (2 &#xB5;g, 20 &#xB5;g, 100 &#xB5;g y 500 &#xB5;g por rat&#xF3;n).</td><td><a href="#cit/section_4.47">47</a></td></tr><tr><td>Murino (ratones at&#xED;micos y VMDk)</td><td>Se redujo el crecimiento tumoral del glioblastoma (l&#xED;neas celulares LNT-229 and LN-308), se redujo la expresi&#xF3;n de los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45693&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045693&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">genes</a> vinculados a la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45669&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045669&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">progresi&#xF3;n del tumor</a> y mejor&#xF3; la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44606&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044606&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">lisis</a> celular del glioblastoma mediada por <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44439&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044439&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">linfocitos CN</a> cuando se administraron 100 &#xB5;g/ml de IscadorQ y M mediante inyecci&#xF3;n <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44603&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044603&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">intratumoral</a>.</td><td><a href="#cit/section_4.41">41</a></td></tr><tr><td>Murinos BDF y suizo albino</td><td> La terapia con IscadorM (50 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44213&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044213&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">mg</a>/kg/d y 100 mg/kg/d) prolong&#xF3; la supervivencia en los ratones con implantes de c&#xE9;lulas cancerosas murinas de ascitis de Ehrlich, pero no en los ratones con c&#xE9;lulas  <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45343&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045343&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">leuc&#xE9;micas</a> L1210  o c&#xE9;lulas de melanoma B16.</td><td><a href="#cit/section_4.51">51</a></td></tr><tr><td>Murino suizo albino</td><td>No se observ&#xF3; un efecto antitumoral ni una mejora en la supervivencia cuando se utiliz&#xF3; IscadorM (15,75 mg, 750 mg, 10,5 mg, 500 mg) para tratar ratas con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45963&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045963&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">carcinomas</a> mamarios provocados de forma qu&#xED;mica o tumores formados a partir de c&#xE9;lulas de carcinoma sarcomatoide murino Walker 256; IscadorM (5 mg, 200 mg, 150 mg, 3,75 mg) tampoco fue eficaz para tratar ratones inyectados con c&#xE9;lulas de ascitis de Ehrlich; adem&#xE1;s, IscadorP (135 mg) fue ineficaz para tratar ratas con tumores formados a partir de c&#xE9;lulas leuc&#xE9;micas murinas L5222.</td><td><a href="#cit/section_4.52">52</a></td></tr><tr><td colspan="3" align="Left" scope="col"><strong>Helixor</strong></td></tr><tr><td align="Center" scope="col"><strong>Modelo</strong></td><td align="Center" scope="col"><strong>Desenlace</strong></td><td align="Center" scope="col"><strong>Referencia</strong></td></tr><tr><td>Murino <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=615419&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000615419&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">SCID</a></td><td>A pesar de utilizar una concentraci&#xF3;n mucho m&#xE1;s baja de ML-3, MT-A  (50 mg/kg y 100 mg/kg) tuvo m&#xE1;s eficacia y menos <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43986&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043986&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">efectos t&#xF3;xicos</a> que MT-P  (50 mg/kg) en una l&#xED;nea celular humana de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45586&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045586&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">leucemia linfobl&#xE1;stica aguda</a>  (NALM-6); ambos se administraron por v&#xED;a intraperitoneal a ratones inoculados con LLA humana).</td><td><a href="#cit/section_4.43">43</a></td></tr><tr><td>L&#xED;nea celular de carcinoma <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46441&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046441&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">ductal</a> mamario humano, BT474</td><td>En comparaci&#xF3;n con los tumores de los controles murinos, se observ&#xF3; una disminuci&#xF3;n en la tasa de proliferaci&#xF3;n celular y un aumento en la tasa de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44290&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044290&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">necrosis</a> y apoptosis tumoral en los grupos tratados con ME-A y ME-M (5 mg mediante inyecci&#xF3;n intratumoral).</td><td><a href="#cit/section_4.46">46</a></td></tr><tr><td colspan="3"><strong>abnobaVISCUM</strong></td></tr><tr><td align="Center" scope="col"><strong>Modelo</strong></td><td align="Center" scope="col"><strong>Desenlace</strong></td><td align="Center" scope="col"><strong>Referencia</strong></td></tr><tr><td>Murino at&#xED;mico</td><td>Se observ&#xF3; una mayor actividad antitumoral con las inyecciones <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44603&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044603&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">intratumorales</a> de extracto de mu&#xE9;rdago (abnobaVISCUM Fraxini-2, 8 mg/kg de peso corporal y lectina en 5,3 &#xB5;g/kg de peso corporal) que con la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45347&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045347&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">gemcitabina</a> inyectada por v&#xED;a <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46682&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046682&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">intravenosa</a>  en los ratones con xenoinjertos de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44521&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044521&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">adenocarcinoma de c&#xE1;ncer de p&#xE1;ncreas</a> humano (PAXF 736).</td><td><a href="#cit/section_4.53">53</a></td></tr><tr><td colspan="3"><strong>Isorel</strong></td></tr><tr><td align="Center" scope="col"><strong>Modelo</strong></td><td align="Center" scope="col"><strong>Desenlace</strong></td><td align="Center" scope="col"><strong>Referencia</strong></td></tr><tr><td>Murino</td><td>En ratones <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46631&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046631&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">trasplantados</a> con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46403&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046403&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">fibrosarcoma</a> (CMC-2), cuando se emple&#xF3; solo IsorelM (140 mg/kg), no se observ&#xF3; efecto en el crecimiento tumoral ni en la supervivencia de los animales. Sin embargo, el uso combinado de IsorelM (140 mg/kg)  con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44302&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044302&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">terapia con rayos X</a> dirigida a los tumores, produjo mejoras importantes en la supervivencia de los ratones, en comparaci&#xF3;n con los ratones que solo recibieron terapia con rayos X (43 Gy).</td><td><a href="#cit/section_4.54">54</a></td></tr><tr><td colspan="3"><strong>Eurixor</strong></td></tr><tr><td align="Center" scope="col"><strong>Modelo</strong></td><td align="Center" scope="col"><strong>Desenlace</strong></td><td align="Center" scope="col"><strong>Referencia</strong></td></tr><tr><td>Murino</td><td>El extracto de mu&#xE9;rdago acuoso (30  ng/ml o 300 ng/ml)  exhibi&#xF3; actividad antitumoral en carcinoma de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46501&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046501&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">vejiga</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44093&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044093&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">urinaria</a> (MB49)  en los ratones; se consider&#xF3; que la causa principal fue la naturaleza citot&#xF3;xica de las lectinas de mu&#xE9;rdago.</td><td><a href="#cit/section_4.6">6</a></td></tr><tr><td colspan="3"><strong>Lektinol</strong></td></tr><tr><td align="Center" scope="col"><strong>Modelo</strong></td><td align="Center" scope="col"><strong>Desenlace</strong></td><td align="Center" scope="col"><strong>Referencia</strong></td></tr><tr><td>Murino</td><td>El tratamiento con Lektinol (0,3, 3, 30 o 300 ng/ml/kg/d) ralentiz&#xF3; el crecimiento de los tumores murinos originados a partir de implantes de tres tipos de c&#xE1;nceres murinos (adenocarcinoma <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46462&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046462&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">col&#xF3;nico</a> 38, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=661352&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000661352&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">carcinoma de c&#xE9;lulas renales</a> Renca y carcinoma <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46611&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046611&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">testicular</a> F9); pero no de otros dos tipos de c&#xE1;ncer murino (melanoma B16 y carcinoma pulmonar de  Lewis).</td><td><a href="#cit/section_4.7">7</a></td></tr></tbody></table><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_4.1">Gabius HJ, Darro F, Remmelink M, et al.: Evidence for stimulation of tumor proliferation in cell lines and histotypic cultures by clinically relevant low doses of the galactoside-binding mistletoe lectin, a component of proprietary extracts. Cancer Invest 19 (2): 114-26, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11296616&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11296616&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.2">Lenartz D, Dott U, Menzel J, et al.: Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe. Anticancer Res 20 (3B): 2073-6, 2000 May-Jun.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10928154&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10928154&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.3">Steuer-Vogt MK, Bonkowsky V, Ambrosch P, et al.: The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. Eur J Cancer 37 (1): 23-31, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11165126&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11165126&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.4">Goebell PJ, Otto T, Suhr J, et al.: Evaluation of an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized phase II trial. J Urol 168 (1): 72-5, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12050495&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12050495&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.5">Kunze E, Schulz H, Adamek M, et al.: Long-term administration of galactoside-specific mistletoe lectin in an animal model: no protection against N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder carcinogenesis in rats and no induction of a relevant local cellular immune response. J Cancer Res Clin Oncol 126 (3): 125-38, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10741906&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10741906&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.6">Mengs U, Schwarz T, Bulitta M, et al.: Antitumoral effects of an intravesically applied aqueous mistletoe extract on urinary bladder carcinoma MB49 in mice. Anticancer Res 20 (5B): 3565-8, 2000 Sep- Oct.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11131663&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11131663&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.7">Burger AM, Mengs U, Sch&#xFC;ler JB, et al.: Anticancer activity of an aqueous mistletoe extract (AME) in syngeneic murine tumor models. Anticancer Res 21 (3B): 1965-8, 2001 May-Jun.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11497284&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11497284&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.8">Mengs U, G&#xF6;thel D, Leng-Peschlow E: Mistletoe extracts standardized to mistletoe lectins in oncology: review on current status of preclinical research. Anticancer Res 22 (3): 1399-407, 2002 May-Jun.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12168816&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12168816&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.9">Samtleben R, Hajto T, Hostanska K, et al.: Mistletoe lectins as immunostimulants (chemistry, pharmacology and clinic). In: Wagner H, ed.: Immunomodulatory Agents from Plants. Basel, Switzerland: Birkhauser Verlag, 1999, pp 223-41.</li><li id="section_4.10">Janssen O, Scheffler A, Kabelitz D: In vitro effects of mistletoe extracts and mistletoe lectins. Cytotoxicity towards tumor cells due to the induction of programmed cell death (apoptosis). Arzneimittelforschung 43 (11): 1221-7, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8292069&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8292069&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.11">Beuth J, Stoffel B, Ko HL, et al.: Immunomodulating ability of galactoside-specific lectin standardized and depleted mistletoe extract. Arzneimittelforschung 45 (11): 1240-2, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8929248&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8929248&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.12">Wagner H, Jordan E, Feil B: Studies on the standardization of mistletoe preparations. Oncology 43 (Suppl 1): 16-22, 1986.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3027640&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3027640&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.13">Mistletoe. In: Murray MT: The Healing Power of Herbs. Roseville, Calif: Prima Publishing, 1995, pp 253-9.</li><li id="section_4.14">J&#xE4;ggy C, Musielski H, Urech K, et al.: Quantitative determination of lectins in mistletoe preparations. Arzneimittelforschung 45 (8): 905-9, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7575759&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7575759&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.15">Stein GM, B&#xFC;ssing A, Schietzel M: Stimulation of the maturation of dendritic cells in vitro by a fermented mistletoe extract. Anticancer Res 22 (6C): 4215-9, 2002 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12553059&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12553059&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.16">Lyu SY, Kwon YJ, Joo HJ, et al.: Preparation of alginate/chitosan microcapsules and enteric coated granules of mistletoe lectin. Arch Pharm Res 27 (1): 118-26, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14969350&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14969350&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.17">Timoshenko AV, Gabius HJ: Efficient induction of superoxide release from human neutrophils by the galactoside-specific lectin from Viscum album. Biol Chem Hoppe Seyler 374 (4): 237-43, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8392351&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8392351&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.18">Dietrich JB, Rib&#xE9;reau-Gayon G, Jung ML, et al.: Identity of the N-terminal sequences of the three A chains of mistletoe (Viscum album L.) lectins: homology with ricin-like plant toxins and single-chain ribosome-inhibiting proteins. Anticancer Drugs 3 (5): 507-11, 1992.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1450445&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1450445&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.19">Wied&#x142;ocha A, Sandvig K, Walzel H, et al.: Internalization and action of an immunotoxin containing mistletoe lectin A-chain. Cancer Res 51 (3): 916-20, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1988131&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1988131&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.20">Tonevitsky AG, Toptygin AYu, Pfuller U, et al.: Immunotoxin with mistletoe lectin I A-chain and ricin A-chain directed against CD5 antigen of human T-lymphocytes; comparison of efficiency and specificity. Int J Immunopharmacol 13 (7): 1037-41, 1991.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1722193&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1722193&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.21">Bocci V: Mistletoe (viscum album) lectins as cytokine inducers and immunoadjuvant in tumor therapy. A review. J Biol Regul Homeost Agents 7 (1): 1-6, 1993 Jan-Mar.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8346712&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8346712&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.22">Habeck M: Mistletoe compound enters clinical trials. Drug Discov Today 8 (2): 52-3, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12565000&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12565000&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.23">M&#xFC;thing J, Meisen I, Kniep B, et al.: Tumor-associated CD75s gangliosides and CD75s-bearing glycoproteins with Neu5Acalpha2-6Galbeta1-4GlcNAc-residues are receptors for the anticancer drug rViscumin. FASEB J 19 (1): 103-5, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15520251&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15520251&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.24">Fritz P, Dippon J, Kierschke T, et al.: Impact of mistletoe lectin binding in breast cancer. Anticancer Res 24 (2C): 1187-92, 2004 Mar-Apr.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15154645&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15154645&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.25">Blonski K, Schumacher U, Burkholder I, et al.: Binding of recombinant mistletoe lectin (aviscumine) to resected human adenocarcinoma of the lung. Anticancer Res 25 (5): 3303-7, 2005 Sep-Oct.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16101142&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16101142&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.26">Timoshenko AV, Kayser K, Drings P, et al.: Modulation of lectin-triggered superoxide release from neutrophils of tumor patients with and without chemotherapy. Anticancer Res 13 (5C): 1789-92, 1993 Sep-Oct.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8267383&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8267383&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.27">Timoshenko AV, Gabius HJ: Influence of the galactoside-specific lectin from Viscum album and its subunits on cell aggregation and selected intracellular parameters of rat thymocytes. Planta Med 61 (2): 130-3, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7753919&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7753919&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.28">Timoshenko AV, Cherenkevich SN, Gabius HJ: Viscum album agglutinin-induced aggregation of blood cells and the lectin effects on neutrophil function. Biomed Pharmacother 49 (3): 153-8, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7647287&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7647287&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.29">Hostanska K, Hajto T, Spagnoli GC, et al.: A plant lectin derived from Viscum album induces cytokine gene expression and protein production in cultures of human peripheral blood mononuclear cells. Nat Immun 14 (5-6): 295-304, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8933823&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8933823&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.30">Fischer S, Scheffler A, Kabelitz D: Oligoclonal in vitro response of CD4 T cells to vesicles of mistletoe extracts in mistletoe-treated cancer patients. Cancer Immunol Immunother 44 (3): 150-6, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9191874&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9191874&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.31">Stein GM, Schaller G, Pf&#xFC;ller U, et al.: Characterisation of granulocyte stimulation by thionins from European mistletoe and from wheat. Biochim Biophys Acta 1426 (1): 80-90, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9878694&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9878694&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.32">Stein GM, Schaller G, Pf&#xFC;ller U, et al.: Thionins from Viscum album L: influence of the viscotoxins on the activation of granulocytes. Anticancer Res 19 (2A): 1037-42, 1999 Mar-Apr.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10368652&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10368652&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.33">Hallek M: Interleukin-6-mediated cell growth in multiple myeloma--a role for Viscum album extracts? Onkologie 28 (8-9): 387, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16160399&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16160399&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.34">Schaller G, Urech K, Giannattasio M: Cytotoxicity of different viscotoxins and extracts from the European subspecies Viscum album L. Phytother Res  10 (6): 473-7, 1996.</li><li id="section_4.35">Maier G, Fiebig HH: Absence of tumor growth stimulation in a panel of 16 human tumor cell lines by mistletoe extracts in vitro. Anticancer Drugs 13 (4): 373-9, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11984083&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11984083&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.36">Zarkovic N, Vukovic T, Loncaric I, et al.: An overview on anticancer activities of the Viscum album extract Isorel. Cancer Biother Radiopharm 16 (1): 55-62, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11279798&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11279798&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.37">Zuzak TJ, Rist L, Eggenschwiler J, et al.: Paediatric medulloblastoma cells are susceptible to Viscum album (Mistletoe) preparations. Anticancer Res 26 (5A): 3485-92, 2006 Sep-Oct.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17094471&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17094471&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.38">Kelter G, Fiebig HH: Absence of tumor growth stimulation in a panel of 26 human tumor cell lines by mistletoe (Viscum album L.) extracts Iscador in vitro. Arzneimittelforschung 56 (6A): 435-40, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16927523&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16927523&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.39">Kelter G, Schierholz JM, Fischer IU, et al.: Cytotoxic activity and absence of tumor growth stimulation of standardized mistletoe extracts in human tumor models in vitro. Anticancer Res 27 (1A): 223-33, 2007 Jan-Feb.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17352237&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17352237&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.40">Weissenstein U, Kunz M, Urech K, et al.: Interaction of standardized mistletoe (Viscum album) extracts with chemotherapeutic drugs regarding cytostatic and cytotoxic effects in vitro. BMC Complement Altern Med 14: 6, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24397864&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24397864&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.41">Podlech O, Harter PN, Mittelbronn M, et al.: Fermented mistletoe extract as a multimodal antitumoral agent in gliomas. Evid Based Complement Alternat Med 2012: 501796, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23133496&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23133496&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.42">Cebovi&#x107; T, Spasi&#x107; S, Popovi&#x107; M: Cytotoxic effects of the Viscum album L. extract on Ehrlich tumour cells in vivo. Phytother Res 22 (8): 1097-103, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18570233&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18570233&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.43">Seifert G, Jesse P, Laengler A, et al.: Molecular mechanisms of mistletoe plant extract-induced apoptosis in acute lymphoblastic leukemia in vivo and in vitro. Cancer Lett 264 (2): 218-28, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18314258&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18314258&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.44">Thies A, Dautel P, Meyer A, et al.: Low-dose mistletoe lectin-I reduces melanoma growth and spread in a scid mouse xenograft model. Br J Cancer 98 (1): 106-12, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18026191&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18026191&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.45">Van Huyen JP, Delignat S, Bayry J, et al.: Interleukin-12 is associated with the in vivo anti-tumor effect of mistletoe extracts in B16 mouse melanoma. Cancer Lett 243 (1): 32-7, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16412563&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16412563&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.46">Beuth J, Ko HL, Schneider H, et al.: Intratumoral application of standardized mistletoe extracts down regulates tumor weight via decreased cell proliferation, increased apoptosis and necrosis in a murine model. Anticancer Res 26 (6B): 4451-6, 2006 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17201168&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17201168&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.47">Braun JM, Ko HL, Schierholz JM, et al.: Standardized mistletoe extract augments immune response and down-regulates local and metastatic tumor growth in murine models. Anticancer Res 22 (6C): 4187-90, 2002 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12553054&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12553054&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.48">Pryme IF, Bardocz S, Pusztai A, et al.: Dietary mistletoe lectin supplementation and reduced growth of a murine non-Hodgkin lymphoma. Histol Histopathol 17 (1): 261-71, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11820217&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11820217&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.49">Els&#xE4;sser-Beile U, Ruhnau T, Freudenberg N, et al.: Antitumoral effect of recombinant mistletoe lectin on chemically induced urinary bladder carcinogenesis in a rat model. Cancer 91 (5): 998-1004, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11251952&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11251952&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.50">Stauder H, Kreuser ED: Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: current state of clinical research. Onkologie 25 (4): 374-80, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12232491&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12232491&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.51">Khwaja TA, Dias CB, Pentecost S: Recent studies on the anticancer activities of mistletoe (Viscum album) and its alkaloids. Oncology 43 (Suppl 1): 42-50, 1986.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3543783&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3543783&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.52">Berger M, Schm&#xE4;hl D: Studies on the tumor-inhibiting efficacy of Iscador in experimental animal tumors. J Cancer Res Clin Oncol 105 (3): 262-5, 1983.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6853588&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6853588&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.53">Rostock M, Huber R, Greiner T, et al.: Anticancer activity of a lectin-rich mistletoe extract injected intratumorally into human pancreatic cancer xenografts. Anticancer Res 25 (3B): 1969-75, 2005 May-Jun.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16158932&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16158932&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.54">Jurin M, Zarkovi&#x107; N, Hrzenjak M, et al.: Antitumorous and immunomodulatory effects of the Viscum album L. preparation Isorel. Oncology 50 (6): 393-8, 1993 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8233280&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8233280&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _35
      field_pdq_section_title:
        - format: plain_text
          value: 'Estudios clínicos con seres humanos'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_35" class="pdq-sections"><p id="_36" tabindex="-1">El <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285939&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285939&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">mu&#xE9;rdago</a> se evalu&#xF3; como tratamiento de personas con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45333&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045333&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer</a> en numerosos <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44195&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044195&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">estudios cl&#xED;nicos</a>.<a href="#cit/section_5.1">1</a><a href="#cit/section_5.2">2</a><a href="#cit/section_5.3">3</a><a href="#cit/section_5.4">4</a><a href="#cit/section_5.5">5</a><a href="#cit/section_5.6">6</a><a href="#cit/section_5.7">7</a><a href="#cit/section_5.8">8</a><a href="#cit/section_5.9">9</a><a href="#cit/section_5.10">10</a><a href="#cit/section_5.11">11</a><a href="#cit/section_5.12">12</a><a href="#cit/section_5.13">13</a><a href="#cit/section_5.14">14</a><a href="#cit/section_5.15">15</a><a href="#cit/section_5.16">16</a><a href="#cit/section_5.17">17</a><a href="#cit/section_5.18">18</a><a href="#cit/section_5.19">19</a><a href="#cit/section_5.20">20</a>  </p><p id="_108" tabindex="-1">Los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=407760&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000407760&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">extractos</a> y productos de mu&#xE9;rdago estudiados en ensayos cl&#xED;nicos fueron Iscador, Eurixor, Helixor, Lektinol, Isorel, abnobaVISCUM <a href="#cit/section_5.21">21</a> y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44051&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044051&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">lectina</a> ML-1 recombinada (para obtener m&#xE1;s informaci&#xF3;n, consultar las secciones y cuadros correspondientes al final de esta secci&#xF3;n).</p><p id="_197" tabindex="-1">Se publicaron los hallazgos de m&#xE1;s de 50 ensayos cl&#xED;nicos de extractos de mu&#xE9;rdago en pacientes de c&#xE1;ncer y se realizaron varias revisiones sistem&#xE1;ticas y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=691484&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000691484&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">metan&#xE1;lisis</a> de los resultados de estos estudios. Las tres revisiones sistem&#xE1;ticas m&#xE1;s recientes se enfocaron en la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45417&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045417&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">calidad de vida</a> (CV), la supervivencia y el alivio de los s&#xED;ntomas de pacientes con diversos tipos de c&#xE1;ncer.<a href="#cit/section_5.18">18</a><a href="#cit/section_5.20">20</a><a href="#cit/section_5.22">22</a> En la mayor&#xED;a de los estudios se notific&#xF3; una mejora de la CV. </p><p id="_198" tabindex="-1">En una revisi&#xF3;n sistem&#xE1;tica en la que se analizaron 26 ensayos controlados aleatorizados (ECA), en 22 ensayos se notific&#xF3; una mejora de la CV. En los 10 ECnA tambi&#xE9;n se notific&#xF3; el mismo beneficio. Se notificaron mejoras en <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=321374&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000321374&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">fatiga</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=390302&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000390302&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">n&#xE1;useas</a> y v&#xF3;mitos, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=430479&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000430479&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">depresi&#xF3;n</a>, bienestar emocional y concentraci&#xF3;n. Si bien algunos de los estudios estuvieron bien dise&#xF1;ados, en otros se notificaron debilidades.<a href="#cit/section_5.22">22</a></p><p id="_203" tabindex="-1">En una revisi&#xF3;n de 21 ECA de varios tipos de c&#xE1;ncer en los que se utilizaron diferentes preparaciones de mu&#xE9;rdago ya sea solo, con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45214&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045214&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">quimioterapia</a> o con radioterapia, se midieron la respuesta tumoral, la CV y el sufrimiento psicol&#xF3;gico.<a href="#cit/section_5.18">18</a> En 13 de los estudios se incluy&#xF3; la duraci&#xF3;n de la supervivencia. En la mayor&#xED;a de los estudios se notificaron beneficios para los pacientes, aunque esta revisi&#xF3;n fue limitada debido al tama&#xF1;o peque&#xF1;o de la muestra y a debilidades metodol&#xF3;gicas. En consecuencia, los autores no pudieron indicar directrices pr&#xE1;cticas para el uso del mu&#xE9;rdago.</p><p id="_204" tabindex="-1">En la m&#xE1;s antigua de estas tres revisiones, se investigaron los resultados de 10 ECA en los que se utiliz&#xF3; una variedad de extractos de mu&#xE9;rdago en pacientes con diversas neoplasias malignas. No hubo diferencia en la supervivencia u otros beneficios para los pacientes de c&#xE1;ncer que recibieron mu&#xE9;rdago. Por lo tanto, el mu&#xE9;rdago no se recomienda como tratamiento curativo o de apoyo.<a href="#cit/section_5.20">20</a></p><p id="_37" tabindex="-1">En una revisi&#xF3;n sistem&#xE1;tica de todos los estudios cl&#xED;nicos controlados de mu&#xE9;rdago, se encontr&#xF3; una mejor&#xED;a constante de la fatiga relacionada con la quimioterapia, as&#xED; como en otras mediciones de la CV.<a href="#cit/section_5.22">22</a></p><p id="_38" tabindex="-1"> Aunque se encontr&#xF3; que el mu&#xE9;rdago fue <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43985&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043985&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">terap&#xE9;uticamente</a> eficaz en la mayor&#xED;a de los estudios notificados, como muchos de los estudios ten&#xED;an una o m&#xE1;s debilidades importantes de dise&#xF1;o, como se mencion&#xF3; anteriormente, se plantearon dudas acerca de la fiabilidad de los hallazgos. Estas debilidades incluyen la participaci&#xF3;n de un n&#xFA;mero peque&#xF1;o de pacientes; la presencia de grandes n&#xFA;meros de pacientes que no se pod&#xED;an <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44029&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044029&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">evaluar</a> o que se excluyeron de los an&#xE1;lisis; la falla en documentar adecuadamente el uso, la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44664&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044664&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">dosis</a> de mu&#xE9;rdago o las interrupciones del uso del mu&#xE9;rdago; la ausencia de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44149&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044149&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">controles</a> o el uso de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44596&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044596&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">controles hist&#xF3;ricos</a>; el uso de procedimientos inadecuados de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=322881&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000322881&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">aleatorizaci&#xF3;n</a>; la ausencia de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285982&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285982&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">enmascaramiento del tratamiento</a>; el uso extensivo de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285981&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285981&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">an&#xE1;lisis de subgrupo</a> y la medici&#xF3;n de la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285973&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285973&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">media</a> de supervivencia en comparaci&#xF3;n con la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44941&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044941&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">mediana</a> de supervivencia. (Nota: en estudios con n&#xFA;meros peque&#xF1;os de pacientes, la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285974&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285974&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">media de tiempo de supervivencia</a> se puede exagerar mucho si uno o m&#xE1;s pacientes exhiben una supervivencia m&#xE1;s larga que la habitual; en consecuencia, la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=655249&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000655249&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">mediana de supervivencia</a> es una medida menos sesgada). Adem&#xE1;s, la evaluaci&#xF3;n de los estudios a menudo se ve obstaculizada por descripciones incompletas del dise&#xF1;o del estudio y por la informaci&#xF3;n incompleta de los datos cl&#xED;nicos, incluso los datos sobre tratamientos previos y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44011&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044011&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">tratamientos simult&#xE1;neos</a> recibidos por los pacientes. A continuaci&#xF3;n, se presenta una selecci&#xF3;n de los estudios organizados por el tipo de extracto de mu&#xE9;rdago utilizado. Eurixor, Isorel y Vysorel ya no est&#xE1;n disponibles para su venta en el mercado.</p><section id="_125"><h3 id="_125_toc">Iscador</h3><p id="_219" tabindex="-1">En un an&#xE1;lisis intermedio de un <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45833&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045833&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">ensayo de fase III</a> aleatorizado, se inform&#xF3; sobre 220 pacientes de c&#xE1;ncer de p&#xE1;ncreas localmente avanzado o metast&#xE1;sico.<a href="#cit/section_5.23">23</a> Los pacientes recibieron los mejores cuidados de apoyo y se asignaron al azar para recibir IscadorQu o ning&#xFA;n tratamiento antineopl&#xE1;sico (control). Los pacientes se estratificaron de acuerdo con el estadio del tumor, la edad y el estado funcional. El Iscador se administr&#xF3; por v&#xED;a <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45914&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045914&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">subcut&#xE1;nea</a> con un aumento de la dosis de 0,01 a 10 mg 3 veces por semana. Con el tratamiento con Iscador, se demostr&#xF3; una mejora significativa de la supervivencia general (SG) (4,8 vs. 2,7 meses para los pacientes que recibieron IscadorQu vs. los pacientes del grupo de control, respectivamente; cociente de riesgos instant&#xE1;neos ajustado al pron&#xF3;stico [CRI], 0,49; <em>P</em> &lt;0,0001).</p><p id="_223" tabindex="-1">El comit&#xE9; independiente de control de datos que revis&#xF3; los resultados de los an&#xE1;lisis intermedios recomend&#xF3; la terminaci&#xF3;n del ensayo debido a la superioridad <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44167&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044167&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">estad&#xED;sticamente significativa</a> de la supervivencia en el grupo de tratamiento en comparaci&#xF3;n con el <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44149&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044149&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">grupo de control</a>. En un an&#xE1;lisis adicional de un subconjunto de 220 pacientes inscritos, se demostraron mejoras de los s&#xED;ntomas de CV (dolor, fatiga, p&#xE9;rdida de peso, n&#xE1;useas, diarrea y ansiedad) en el grupo de tratamiento en comparaci&#xF3;n con el grupo de control.<a href="#cit/section_5.24">24</a></p><p id="_40" tabindex="-1"> Entre 1978 y 1987, se llev&#xF3; a cabo un ensayo aleatorizado de fase III con 408 pacientes de c&#xE1;ncer de pulm&#xF3;n de c&#xE9;lulas no peque&#xF1;as <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285970&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285970&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">inoperable</a> sin tratamiento previo.<a href="#cit/section_5.25">25</a> Los pacientes se asignaron al azar a uno de los siguientes tratamientos:   </p><div class="pdq-content-list"><ul id="_224"><li><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44678&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044678&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">Inyecci&#xF3;n</a> subcut&#xE1;nea de IscadorU o IscadorQu tres veces por semana (para obtener m&#xE1;s informaci&#xF3;n consultar la secci&#xF3;n <a href="/espanol/cancer/tratamiento/mca/pro/muerdago-pdq#link/_7">Informaci&#xF3;n general</a> de este sumario); la concentraci&#xF3;n de mu&#xE9;rdago se increment&#xF3; durante una secuencia o ciclo de 7 inyecciones, seguidos de una pausa de 3 d&#xED;as; luego, se repiti&#xF3; el proceso; IscadorU se administr&#xF3; durante 2 ciclos, seguido de 2 ciclos de IscadorQu; ambos preparados de mu&#xE9;rdago conten&#xED;an <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285976&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285976&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">mercurio</a>). </li><li><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44049&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044049&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">Inyecci&#xF3;n intramuscular</a> una vez por semana con Polyerga Neu, que es un <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285966&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285966&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">glucop&#xE9;ptido</a> del bazo de ovejas que se inform&#xF3; que es un <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285968&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285968&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">inmunoestimulante</a> y un inhibidor de la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44131&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044131&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">gluc&#xF3;lisis</a> de las c&#xE9;lulas tumorales.</li><li>Inyecci&#xF3;n intramuscular una vez por semana con una mezcla de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44744&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044744&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">vitamina</a> B, que sirvi&#xF3; como <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46688&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046688&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">placebo</a>.</li></ul></div><p id="_225" tabindex="-1">Para el an&#xE1;lisis de supervivencia, se dispuso de informaci&#xF3;n completa de seguimiento de 337 pacientes y se incluy&#xF3; a 312 pacientes (105 tratados con Iscador, 100 tratados con Polyerga Neu y 107 tratados con placebo). No se encontraron diferencias estad&#xED;sticamente significativas en la supervivencia entre los tres grupos. La mediana de supervivencia para el grupo de Iscador fue de 9,1 meses; para el grupo de Polyerga Neu, 9,0 meses y para el grupo de placebo, 7,6 meses. Los investigadores informaron que el 11,5&#xA0;% de los pacientes del grupo de Iscador sobrevivi&#xF3; 2 a&#xF1;os desde el momento en que entraron en el ensayo; los valores de supervivencia correspondientes para el grupo de Polyerga Neu y el grupo de placebo fueron de 13,9 y 10,1&#xA0;%, respectivamente. Adem&#xE1;s, no se encontraron diferencias entre los tres grupos con respecto a la respuesta del tumor, la mediana de peso corporal, los valores qu&#xED;micos de la sangre, la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44156&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044156&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">escala de rendimiento de Karnofsky</a> y la CV. Sin embargo, hubo m&#xE1;s pacientes del grupo de Iscador que del grupo de Polyerga Neu o los grupos de placebo que informaron de una mejora subjetiva en la sensaci&#xF3;n de bienestar (59,4 vs. 43,2 y 44,8&#xA0;%, respectivamente).<a href="#cit/section_5.25">25</a></p><p id="_78" tabindex="-1">En otro ensayo de fase III aleatorizado de mu&#xE9;rdago como tratamiento para personas con c&#xE1;ncer, participaron 830 pacientes de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45135&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045135&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">melanoma</a> de riesgo alto (es decir, un <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45847&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045847&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">tumor primario</a> de &gt; 3 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44215&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044215&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">mm</a> de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44224&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044224&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">di&#xE1;metro</a> y sin <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44312&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044312&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">ganglios linf&#xE1;ticos regionales</a> positivos para c&#xE1;ncer, o un tumor primario de cualquier tama&#xF1;o, uno o dos ganglios linf&#xE1;ticos regionales positivos para c&#xE1;ncer, y sin <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46710&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046710&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">met&#xE1;stasis</a> a distancia) que se asignaron al azar a uno de los siguientes cuatro grupos despu&#xE9;s de una <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45570&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045570&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">cirug&#xED;a</a> posiblemente curativa: 1) tratamiento con dosis bajas de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45324&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045324&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">interfer&#xF3;n</a>-&#x3B1;, 2) tratamiento con dosis bajas de interfer&#xF3;n-&#x3B3;, 3) tratamiento con IscadorM o 4) ning&#xFA;n tratamiento adicional. Ambos tipos de interfer&#xF3;n e IscadorM se administraron por inyecci&#xF3;n subcut&#xE1;nea durante un periodo de 1 a&#xF1;o.<a href="#cit/section_5.5">5</a> Las inyecciones de interfer&#xF3;n se administraron cada 2 d&#xED;as, mientras que IscadorM se administr&#xF3; 3 veces por semana durante un m&#xE1;ximo de 1 a&#xF1;o. Despu&#xE9;s de 8 a&#xF1;os de seguimiento, no se demostr&#xF3; ning&#xFA;n aumento del tiempo de supervivencia o del tiempo hasta la recidiva del melanoma debido al tratamiento con mu&#xE9;rdago o el tratamiento con cualquier tipo de interfer&#xF3;n.  </p><p id="_199" tabindex="-1">En otro estudio <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44939&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044939&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">multic&#xE9;ntrico</a> retrospectivo de cohortes que se llev&#xF3; a cabo para determinar la inocuidad y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=346517&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000346517&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">eficacia</a> de Iscador como tratamiento adyuvante a largo plazo despu&#xE9;s de la cirug&#xED;a por un melanoma maligno, se examinaron los registros de 686 pacientes (357 controles sin tratar y 329 tratados con Iscador). Se midieron la inocuidad, la eficacia y un conjunto de criterios de valoraci&#xF3;n de supervivencia (relacionados con el tumor, sin enfermedad, sin met&#xE1;stasis cerebrales y SG). El uso de quimioterapia adyuvante adicional fue m&#xE1;s frecuente en el grupo tratado con Iscador, mientras que el uso de inmunoterapia fue m&#xE1;s frecuente en el grupo de control. Solo se observaron reacciones adversas leves o intermedias a los f&#xE1;rmacos en el grupo de tratamiento. La tasa de mortalidad relacionada con el tumor fue de 8,9&#xA0;% en el grupo de Iscador, en comparaci&#xF3;n con 10,7&#xA0;% en el grupo de control (<em>P</em> = 0,017).<a href="#cit/section_5.26">26</a></p><p id="_43" tabindex="-1">En un &#xFA;nico informe publicado se describieron otros tres estudios sobre mu&#xE9;rdago.<a href="#cit/section_5.4">4</a> Uno de los tres estudios fue un estudio grande de cohortes sobre la eficacia de Iscador como tratamiento para personas con c&#xE1;nceres de recto, colon, mama, est&#xF3;mago o pulm&#xF3;n.<a href="#cit/section_5.4">4</a> El segundo y tercer estudios fueron peque&#xF1;os, prospectivos, aleatorizados, emparejados (uno aleatorizado, uno sin aleatorizaci&#xF3;n) en el que participaron pacientes seleccionados de un grupo de 8475 personas que no se hab&#xED;an tratado con mu&#xE9;rdago.<a href="#cit/section_5.4">4</a></p><p id="_44" tabindex="-1">Estos tres estudios se resumen en el <a href="/espanol/cancer/tratamiento/mca/pro/muerdago-pdq#link/_194">Cuadro 3</a>. La conclusi&#xF3;n general de los autores del informe de estos tres estudios fue que el tratamiento con Iscador puede producir un aumento cl&#xED;nicamente significativo de la supervivencia en pacientes de c&#xE1;ncer. Sin embargo, hubo varias debilidades en el dise&#xF1;o y ejecuci&#xF3;n de estos estudios. En un estudio grande de cohortes, los investigadores no pudieron encontrar cohortes emparejadas de 61&#xA0;% de los pacientes aptos; incluso entre los pacientes para quienes se encontraron testigos emparejados, se juzg&#xF3; que menos de dos tercios se adher&#xED;an estrictamente a los criterios de emparejamiento; en consecuencia, el an&#xE1;lisis final contuvo menos de 25&#xA0;% de los pacientes aptos. En los dos estudios prospectivos peque&#xF1;os, no se mantuvieron registros de la cantidad o la duraci&#xF3;n del uso Iscador.</p><p id="_109" tabindex="-1">El uso de Iscador como tratamiento adyuvante se examin&#xF3; en varios estudios. En los siguientes estudios, Iscador result&#xF3; inocuo y eficaz; tambi&#xE9;n mostr&#xF3; una ventaja significativa de supervivencia en comparaci&#xF3;n con los controles no tratados.</p><p id="_110" tabindex="-1">En un estudio multic&#xE9;ntrico retrospectivo de cohortes de grupos paralelos, se examin&#xF3; Iscador como adyuvante <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43980&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043980&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">posoperatorio</a> utilizando la inocuidad y la eficacia como los criterios principales de valoraci&#xF3;n. Se seleccion&#xF3; al azar a un total de 1442 registros de pacientes (710 pacientes tratados y 732 controles no tratados) de instituciones m&#xE9;dicas que proporcionaron tratamientos est&#xE1;ndar y alternativos. Se midieron la inocuidad y eficacia por el n&#xFA;mero y la gravedad de reacciones adversas a los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=348921&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000348921&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">medicamentos</a>. En el grupo de tratamiento se observaron significativamente menos reacciones adversas (intervalo de confianza, 95&#xA0;%; <em>P</em> &lt;0,001) en comparaci&#xF3;n con los controles.<a href="#cit/section_5.27">27</a><a href="#cit/section_5.28">28</a></p><p id="_162" tabindex="-1"> Se realiz&#xF3; un estudio multic&#xE9;ntrico retrospectivo de observaci&#xF3;n de cohortes controlado, que incluy&#xF3; a pacientes de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=444983&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000444983&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer colorrectal</a> no metast&#xE1;sico tratados entre 1993 y 2002, para evaluar las medidas de inocuidad y eficacia de Iscador. Se incluy&#xF3; a 804 pacientes consecutivos de c&#xE1;ncer colorrectal (429 tratados con Iscador y 375 controles) de 26 hospitales y consultorios. Iscador se toler&#xF3; bien, con una reducci&#xF3;n significativa de episodios adversos, una tasa m&#xE1;s alta de alivio de los s&#xED;ntomas y una mejora de la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44023&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044023&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">supervivencia sin enfermedad</a> en comparaci&#xF3;n con el <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44149&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044149&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">grupo de control</a>. En el estudio se concluy&#xF3; que el uso de Iscador tiene un efecto beneficioso como <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45587&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045587&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">terapia adyuvante</a> y tratamiento a largo plazo para pacientes de c&#xE1;ncer colorrectal en estadios I a III.<a href="#cit/section_5.29">29</a></p><p id="_200" tabindex="-1">Se llev&#xF3; a cabo un estudio de fase II aleatorizado de Iscador combinado con reg&#xED;menes con carboplatino en pacientes de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45323&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045323&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer de pulm&#xF3;n de c&#xE9;lulas no peque&#xF1;as</a> en estadio avanzado que no hab&#xED;an recibido antes quimioterapia.<a href="#cit/section_5.30">30</a> Se asign&#xF3; al azar a 72 pacientes para recibir quimioterapia sola con carboplatino combinado con gemcitabina o pemetrexed (39 pacientes), o quimioterapia e Iscador (33 pacientes) 3 veces por semana hasta la progresi&#xF3;n del tumor. El tiempo transcurrido hasta la progresi&#xF3;n (4,8 vs. 6 meses) y la SG (11 meses) fueron similares en ambos grupos de tratamiento. No hubo diferencias en la CV observada entre los grupos de tratamiento, aunque las reducciones de dosis de quimioterapia, las reacciones adversas no hematol&#xF3;gicas y las hospitalizaciones fueron menos frecuentes entre los pacientes tratados con Iscador en este estudio sin enmascaramiento.</p><p id="_201" tabindex="-1">Se complet&#xF3; otro ensayo de los Estados Unidos (<a href="/clinicaltrials/NCT00283478">NCT00283478</a>) del extracto de mu&#xE9;rdago Iscar con gemcitabina versus gemcitabina sola como <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=346513&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000346513&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">terapia de segunda l&#xED;nea</a> para pacientes de c&#xE1;ncer de pulm&#xF3;n de c&#xE9;lulas no peque&#xF1;as que no mejoraron con una l&#xED;nea de quimioterapia previa, pero todav&#xED;a no se public&#xF3;.</p></section><table id="_194" class="table-default expandable-container"><caption>Cuadro 3.  Uso de Iscador para el tratamiento del c&#xE1;ncer: informes cl&#xED;nicos que describen criterios de valoraci&#xF3;n terap&#xE9;uticos<span class="sup">a</span></caption><colgroup><col width="17.27%"><col width="10.16%"><col width="17.17%"><col width="13.92%"><col width="14.93%"><col width="13.92%"><col width="12.60%"></colgroup>
            <THead>
            <tr>
            <th>Cita(s) bibliogr&#xE1;fica(s) </th>
            <th>Tipo de estudio </th>
            <th>Tipo(s) de c&#xE1;ncer </th>
            <th>N&#xFA;mero de pacientes: inscritos, tratados, de control<span class="sup">b</span> </th>
            <th>Beneficio m&#xE1;s importante notificado<span class="sup">c</span> </th>
            <th>Tratamiento simult&#xE1;neo<span class="sup">d</span></th>
            <th>Puntaje de grado de comprobaci&#xF3;n cient&#xED;fica<span class="sup">e</span></th>
            </tr>
            </THead>
            <TFoot class="pdq-footer">
            <tr>
            <td colspan="7">CV = calidad de vida; GL+ = enfermedad con ganglio linf&#xE1;tico positivo.20; 9 (viscum); 11 (<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45189&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045189&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">etop&#xF3;sido</a>).</td>
            </tr>
            <tr>
            <td colspan="7"><span class="sup">a</span>Para obtener m&#xE1;s informaci&#xF3;n y la definici&#xF3;n de los t&#xE9;rminos, consultar el texto y el <a href="https://www.cancer.gov/espanol/publicaciones/diccionario" title="https://www.cancer.gov/espanol/publicaciones/diccionario">Diccionario de c&#xE1;ncer del NCI</a>.</td>
            </tr>
            <tr>
            <td colspan="7"><span class="sup">b</span>El n&#xFA;mero de pacientes tratados m&#xE1;s el n&#xFA;mero de pacientes controlados puede ser distinto del n&#xFA;mero de pacientes inscritos; n&#xFA;mero de pacientes inscritos = n&#xFA;mero de pacientes inicialmente preseleccionados o considerados por los investigadores que condujeron el estudio; n&#xFA;mero de pacientes tratados = n&#xFA;mero de pacientes inscritos que se sometieron al tratamiento en estudio y de quienes se notificaron los resultados; los sujetos hist&#xF3;ricos de referencia no se incluyeron en el n&#xFA;mero de pacientes inscritos.</td>
            </tr>
            <tr>
            <td colspan="7"><span class="sup">c</span>Las pruebas m&#xE1;s s&#xF3;lidas notificaron que el tratamiento tiene eficacia antineopl&#xE1;sica o que mejora de otra manera el bienestar de los pacientes de c&#xE1;ncer.</td>
            </tr>
            <tr>
            <td colspan="7"><span class="sup">d</span>Se administr&#xF3; o permiti&#xF3; la administraci&#xF3;n de quimioterapia, radioterapia, hormonoterapia o terapia con citocinas al mismo tiempo que la terapia con mu&#xE9;rdago.</td>
            </tr>
            <tr>
            <td colspan="7"><span class="sup">e</span>Para obtener m&#xE1;s informaci&#xF3;n sobre el an&#xE1;lisis de los grados de comprobaci&#xF3;n cient&#xED;fica y una explicaci&#xF3;n de los puntajes de dichos grados, consultar <a href="/publications/pdq/levels-evidence/cam">Grados de comprobaci&#xF3;n cient&#xED;fica de los estudios de terapias integrales, alternativas y complementarias en seres humanos con c&#xE1;ncer</a>.</td>
            </tr>
            <tr>
            <td colspan="7"><span class="sup">f</span>Los pacientes del grupo de control se trataron con una mezcla de vitamina B como placebo; 100 pacientes m&#xE1;s que se pod&#xED;an evaluar se trataron con Polyerga Neu, un glucop&#xE9;ptido de bazo ovino que se inform&#xF3; que era un estimulante inmunitario y un inhibidor de la gluc&#xF3;lisis de las c&#xE9;lulas tumorales; no se encontr&#xF3; que Polyerga Neu fuera beneficioso.</td>
            </tr>
            <tr>
            <td colspan="7"><span class="sup">g</span>Se permiti&#xF3; la administraci&#xF3;n de radioterapia para las met&#xE1;stasis distantes del sitio del tumor primario; no se permiti&#xF3; la administraci&#xF3;n de radioterapia dirigida al sitio del tumor primario ni el uso de otro tratamiento contra el c&#xE1;ncer.</td>
            </tr>
            <tr>
            <td colspan="7"><span class="sup">h</span>De 10 226 pacientes de c&#xE1;ncer incluidos en un estudio retrospectivo de casos y controles emparejados, 1751 se hab&#xED;an tratado con Iscador u otro producto de mu&#xE9;rdago y 8475 no se hab&#xED;an tratado con mu&#xE9;rdago; a partir de los 8475 pacientes no tratados, se formaron dos grupos de pares emparejados para realizar estudios prospectivos; en los estudios prospectivos, un miembro de cada pareja se asign&#xF3; al azar para ser tratado con Iscador y el otro miembro sirvi&#xF3; como sujeto de control.</td>
            </tr>
            <tr>
            <td colspan="7"><span class="sup">i</span>Los pacientes se emparejaron estrictamente por sexo, a&#xF1;o de nacimiento &#xB1; 3 a&#xF1;os, a&#xF1;o del diagn&#xF3;stico &#xB1; 3 a&#xF1;os, tipo de tumor, estadio de la enfermedad y terapia convencional recibida.</td>
            </tr>
            </TFoot>
            <tbody>
            <tr>
            <td>
            <a href="#cit/section_5.25">25</a>
            </td>
            <td>Ensayo aleatorizado</td>
            <td>Pulm&#xF3;n, c&#xE9;lulas no peque&#xF1;as, inoperable</td>
            <td>408; 105; 107<span class="sup">f</span></td>
            <td>Mejora subjetiva de la calidad de vida</td>
            <td>S&#xED;<span class="sup">g</span></td>
            <td>1iiA</td>
            </tr>
            <tr>
            <td>
            <a href="#cit/section_5.31">31</a>
            </td>
            <td>Ensayo aleatorizado</td>
            <td>Pulm&#xF3;n, c&#xE9;lulas no peque&#xF1;as, estadios I&#x2013;IV </td>
            <td>218; 87; 96</td>
            <td>Mejora de la mediana de supervivencia, solo pacientes con GL+ </td>
            <td>No</td>
            <td>1iiA</td>
            </tr>
            <tr>
            <td>
            <a href="#cit/section_5.5">5</a>
            </td>
            <td>Ensayo aleatorizado</td>
            <td>Melanoma, estadios II&#x2013;III</td>
            <td>204; 102; 102</td>
            <td>Ninguno</td>
            <td>No</td>
            <td>1iiA</td>
            </tr>
            <tr>
            <td>
            <a href="#cit/section_5.23">23</a><a href="#cit/section_5.24">24</a>
            </td>
            <td>Ensayo aleatorizado</td>
            <td><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44521&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044521&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">P&#xE1;ncreas</a>, avanzado o metast&#xE1;sico</td>
            <td>220; 110; 110</td>
            <td>Mejora de la supervivencia y mejora de la CV</td>
            <td>No</td>
            <td>1iiA</td>
            </tr><tr><td><a href="#cit/section_5.32">32</a></td><td>Ensayo aleatorizado</td><td><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45395&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045395&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">Osteosarcoma,</a> segunda <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45866&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045866&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">reca&#xED;da</a> metast&#xE1;sica </td><td>20, 9 (viscum); 11 (<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45189&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045189&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">etop&#xF3;sido</a></td><td>Mejora de la supervivencia sin enfermedad y CV en comparaci&#xF3;n con el grupo de etop&#xF3;sido</td><td>No</td><td>1iiDii</td></tr>
            <tr>
            <td>
            <a href="#cit/section_5.27">27</a>
            </td>
            <td>Estudio comparativo, retrolectivo, de cohorte </td>
            <td>Mama, estadios I&#x2013;IV</td>
            <td>1442; 710; 732</td>
            <td>Mejora de la supervivencia</td>
            <td>S&#xED;</td>
            <td>2B</td>
            </tr>
            <tr>
            <td>
            <a href="#cit/section_5.26">26</a>
            </td>
            <td>Estudio comparativo, retrolectivo, de cohorte </td>
            <td>Melanoma, estadios II&#x2013;III</td>
            <td>686; 329; 357</td>
            <td>Mejora de la supervivencia</td>
            <td>No se sabe</td>
            <td>2A</td>
            </tr>
            <tr>
            <td>
            <a href="#cit/section_5.4">4</a>
            </td>
            <td>Estudio de cohorte</td>
            <td>Mama, estadio III</td>
            <td>8475<span class="sup">h</span>; 17<span class="sup">i</span>; 17<span class="sup">i</span> </td>
            <td>Mejora de la media de supervivencia</td>
            <td>S&#xED;</td>
            <td>Ninguno</td>
            </tr>
            <tr>
            <td>
            <a href="#cit/section_5.4">4</a>
            </td>
            <td>Estudio de cohorte </td>
            <td>Varios tipos, estadios I&#x2013;IV</td>
            <td>8475<span class="sup">h</span>; 39<span class="sup">i</span>; 39<span class="sup">i</span></td>
            <td>Mejora de la media de supervivencia</td>
            <td>S&#xED;</td>
            <td>Ninguno</td>
            </tr>
            <tr>
            <td>
            <a href="#cit/section_5.4">4</a>
            </td>
            <td>Estudio de cohorte </td>
            <td>Varios tipos, estadios I&#x2013;IV</td>
            <td>10 226<span class="sup">h</span>; 396<span class="sup">i</span>; 396<span class="sup">i</span></td>
            <td>Mejora de la media de supervivencia</td>
            <td>S&#xED;</td>
            <td>Ninguno</td>
            </tr>
            <tr>
            <td>
            <a href="#cit/section_5.29">29</a>
            </td>
            <td>Estudio de cohorte retrospectivo de observaci&#xF3;n </td>
            <td>Colorrectal no metast&#xE1;sico</td>
            <td>804; 429; 375</td>
            <td>Incidencia m&#xE1;s baja de diarrea, n&#xE1;useas, p&#xE9;rdida de apetito, dermatitis, fatiga y mucositis</td>
            <td>S&#xED;</td>
            <td>2C</td>
            </tr>
            <tr>
            <td>
            <a href="#cit/section_5.33">33</a>
            </td>
            <td>Serie de casos no consecutivos </td>
            <td>P&#xE1;ncreas</td>
            <td>292; 292; diversos controles hist&#xF3;ricos</td>
            <td>Mejora de la mediana de supervivencia</td>
            <td>S&#xED;</td>
            <td>3iiiA</td>
            </tr>
            </tbody>
            </table><section id="_126"><h3 id="_126_toc">Otras preparaciones con mu&#xE9;rdago</h3><p id="_264" tabindex="-1">Los estudios sobre Eurixor, Helixor, Lektinol, Isorel y abnobaVISCUM se resumen en el <a href="/espanol/cancer/tratamiento/mca/pro/muerdago-pdq#link/_71">Cuadro 4</a>.</p><section id="_182"><h4 id="_182_toc">Eurixor</h4><p id="_183" tabindex="-1">Se publicaron cinco ensayos controlados aleatorizados sobre Eurixor como art&#xED;culos de revisi&#xF3;n arbitrada. El mayor de estos estudios incluy&#xF3; a 477 pacientes de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46595&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046595&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">carcinoma de c&#xE9;lulas escamosas</a> de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=257519&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000257519&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">cabeza y cuello</a>.<a href="#cit/section_5.2">2</a><a href="#cit/section_5.15">15</a> Estos pacientes se asignaron al azar para ser tratados con cirug&#xED;a, o cirug&#xED;a y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44971&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044971&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">radioterapia</a>, y se volvieron a asignar al azar para no recibir m&#xE1;s tratamiento o recibir tratamiento con Eurixor. Esta aleatorizaci&#xF3;n doble produjo los cuatro grupos siguientes: 1) 105 pacientes tratados con cirug&#xED;a sola; 2) 97 pacientes tratados con cirug&#xED;a y Eurixor; 3) 137 pacientes tratados con cirug&#xED;a y radioterapia, y 4) 138 pacientes tratados con cirug&#xED;a, radioterapia y Eurixor. Eurixor se administr&#xF3; en 4 ciclos de tratamiento durante un per&#xED;odo de 60 semanas. Cada ciclo de tratamiento dur&#xF3; 12 semanas y fue seguido por un descanso de 4 semanas. Durante cada ciclo, se administr&#xF3; Eurixor por inyecci&#xF3;n subcut&#xE1;nea 2 veces por semana. Cada inyecci&#xF3;n conten&#xED;a suficiente extracto de mu&#xE9;rdago estandarizado para rendir una dosis de 1 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285977&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285977&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">nanogramo</a> de lectina ML-1 por <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44576&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044576&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">kilogramo</a> de peso corporal. Los resultados de este ensayo aleatorizado mostraron que Eurixor no mejor&#xF3; la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44023&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044023&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">supervivencia sin enfermedad</a> a 5 a&#xF1;os ni la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44311&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044311&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">supervivencia por una enfermedad espec&#xED;fica</a> a 5 a&#xF1;os. Adem&#xE1;s, no se encontr&#xF3; que el tratamiento con Eurixor estimulara el <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46356&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046356&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">sistema inmunitario</a> o mejorara la CV.</p><p id="_184" tabindex="-1">Se indic&#xF3; que, en este ensayo, la dosis de mu&#xE9;rdago administrada a los pacientes fue menor que &#xF3;ptima.<a href="#cit/section_5.4">4</a> Sin embargo, se ha utilizado la misma dosis de Eurixor en otros estudios cl&#xED;nicos, incluso en estudios de los que se notificaron beneficios.<a href="#cit/section_5.1">1</a><a href="#cit/section_5.34">34</a> Por otra parte, tanto la dosis como la duraci&#xF3;n del tratamiento con Eurixor en este ensayo concuerdan con los recomendados por el fabricante.<a href="#cit/section_5.2">2</a></p><p id="_185" tabindex="-1">En un ensayo prospectivo aleatorizado de fase II participaron 45 pacientes de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=444968&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000444968&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer de vejiga</a> sin infiltraci&#xF3;n.<a href="#cit/section_5.3">3</a> Despu&#xE9;s de la cirug&#xED;a, se asign&#xF3; al azar a los pacientes a recibir 3 ciclos de tratamiento con Eurixor o a no recibir m&#xE1;s tratamiento. El objetivo del estudio fue determinar si el tratamiento con Eurixor podr&#xED;a reducir la recidiva del c&#xE1;ncer de vejiga. Se asign&#xF3; al azar a 23 pacientes al grupo de tratamiento y a 22 pacientes al grupo de control. Cada ciclo de tratamiento con Eurixor const&#xF3; de 3 meses de inyecciones subcut&#xE1;neas administradas 2 veces por semana, seguidas de un descanso de 3 meses. Cada inyecci&#xF3;n conten&#xED;a 1 ml de Eurixor. Despu&#xE9;s de 18 meses de seguimiento, se observaron 11 recidivas en el grupo de tratamiento y 8 recidivas en el grupo de control. El promedio de tiempo hasta la recidiva en el grupo de tratamiento fue de 6,3 meses y de 6,4 meses en el grupo de control. La mediana del intervalo sin enfermedad en el grupo de tratamiento fue de 9 meses y de 10,5 meses en el grupo de control. Ninguna de estas diferencias se consider&#xF3; significativa.</p><p id="_186" tabindex="-1">No obstante, una preocupaci&#xF3;n importante relacionada con este estudio es que la dosis de lectina ML-1 administrada a los pacientes no se ajust&#xF3; de acuerdo con el peso corporal.      </p><p id="_226" tabindex="-1">Eurixor ya no est&#xE1; disponible para su venta en el mercado.</p></section><section id="_187"><h4 id="_187_toc">Isorel</h4><p id="_188" tabindex="-1">Solo se notificaron dos ensayos con Isorel en la bibliograf&#xED;a m&#xE9;dica con revisi&#xF3;n arbitrada e indizada disponible p&#xFA;blicamente en l&#xED;nea. En un estudio, se asign&#xF3; al azar a 64 pacientes de c&#xE1;ncer colorrectal en estadio avanzado (C y D de Dukes) a tres grupos: 1) cirug&#xED;a y quimioterapia; 2) cirug&#xED;a y quimioterapia e Isorel, y 3) cirug&#xED;a sola. Los pacientes sometidos a tratamiento con Isorel tuvieron una ventaja en la mediana de supervivencia significativamente mejor y una ventaja de supervivencia acumulada mejor que los pacientes de los otros dos grupos. Adem&#xE1;s, no se presentaron efectos secundarios del tratamiento en el grupo de Isorel.<a href="#cit/section_5.35">35</a></p><p id="_189" tabindex="-1">En otro estudio, se observ&#xF3; que la administraci&#xF3;n <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44076&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044076&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">perioperatoria</a> de Isorel a pacientes de c&#xE1;ncer del <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46447&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046447&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">tubo digestivo</a> produjo un aumento de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45765&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045765&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">linfocitos</a> durante los 14 d&#xED;as de la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=478733&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000478733&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">administraci&#xF3;n</a> del f&#xE1;rmaco. </p><p id="_227" tabindex="-1">Isorel ya no est&#xE1; disponible para su venta en el mercado.</p></section><section id="_190"><h4 id="_190_toc">Helixor</h4><p id="_265" tabindex="-1">La mayor&#xED;a de los estudios se condujeron en Europa, principalmente en Alemania y Austria. En un estudio prospectivo de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45830&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045830&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">fase I</a> con aumento gradual de la dosis, se estudi&#xF3; la administraci&#xF3;n semanal <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46682&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046682&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">intravenosa</a> de extracto de mu&#xE9;rdago de pino <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43998&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043998&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">acuoso</a> solo. En 21 pacientes evaluados, Helixor se toler&#xF3; bien en dosis de hasta 2000 mg y se not&#xF3; <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=450108&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000450108&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">fiebre</a> baja a moderada.<a href="#cit/section_5.36">36</a> En un estudio posterior, se observ&#xF3; una mejora de la CV en un grupo de pacientes que recibieron Helixor en comparaci&#xF3;n con un grupo de control que recibi&#xF3; los mejores cuidados de apoyo.<a href="#cit/section_5.37">37</a></p><p id="_191" tabindex="-1">En otros estudios se exploraron los efectos de la administraci&#xF3;n de Helixor a pacientes sometidos a quimioterapia o radioterapia. El <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=454777&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000454777&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">National Center for Complementary and Integrative Health</a>   en cooperaci&#xF3;n con el <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44266&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044266&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">Instituto Nacional del C&#xE1;ncer</a> (NCI) condujeron un ensayo de fase I (<a href="https://clinicaltrials.gov/ct2/show/NCT00049608" title="https://clinicaltrials.gov/ct2/show/NCT00049608">NCCAM-02-AT-260</a>) de extracto de mu&#xE9;rdago (Helixor A) y gemcitabina administrados a pacientes de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45301&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045301&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">tumores s&#xF3;lidos</a> en estadio avanzado. La combinaci&#xF3;n de Helixor A y gemcitabina produjo <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=445093&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000445093&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">efectos t&#xF3;xicos</a> limitados y no se notificaron interacciones entre las <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=367458&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000367458&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">sustancias bot&#xE1;nicas</a> y los medicamentos.<a href="#cit/section_5.38">38</a> (<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3944907/" title="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3944907/">Tambi&#xE9;n disponible en l&#xED;nea, en ingl&#xE9;s</a>). En un ensayo aleatorizado de tres grupos, se asign&#xF3; al azar a pacientes de c&#xE1;ncer de mama a uno de los siguientes grupos despu&#xE9;s de la cirug&#xED;a: Helixor, quimioterapia o control. Algunos pacientes de cada grupo tambi&#xE9;n se trataron con radioterapia local. El n&#xFA;mero de pacientes evaluables en el grupo de quimioterapia fue de 177, con una supervivencia superior en el grupo de quimioterapia que en el de control y equivalente a la del grupo de Helixor.<a href="#cit/section_5.39">39</a> El uso de Helixor tambi&#xE9;n se examin&#xF3; en otros estudios.<a href="#cit/section_5.37">37</a><a href="#cit/section_5.40">40</a><a href="#cit/section_5.41">41</a><a href="#cit/section_5.42">42</a></p></section><section id="_192"><h4 id="_192_toc">abnobaVISCUM</h4><p id="_193" tabindex="-1">No se observ&#xF3; reacci&#xF3;n del tumor en ninguno de los 25 pacientes en un ensayo de fase II en el que se examin&#xF3; el efecto de un extracto de mu&#xE9;rdago, conocido como abnobaVISCUM, en el c&#xE1;ncer colorrectal metast&#xE1;sico resistente al tratamiento est&#xE1;ndar (quimioterapia con 5-<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46090&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046090&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">fluorouracilo</a> y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45750&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045750&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">leucovorina</a>). El criterio de valoraci&#xF3;n del estudio fue la respuesta objetiva del tumor. Los pacientes recibieron una dosis diaria aumentada gradualmente de 0,15 a 15 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44213&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044213&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">mg</a>. La duraci&#xF3;n del tratamiento oscil&#xF3; entre 4 y 66 semanas. Los efectos secundarios fueron leves. Algunos pacientes notificaron de alivio de los s&#xED;ntomas de la enfermedad.<a href="#cit/section_5.43">43</a></p><p id="_252" tabindex="-1"> En un ensayo aleatorizado peque&#xF1;o <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44066&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044066&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">sin enmascaramiento</a> de abnobaVISCUM posoperatorio administrado a 15 pacientes de c&#xE1;ncer de est&#xF3;mago resecado en estadios IB o II, se observ&#xF3; una mejor CV entre quienes recibieron el extracto de mu&#xE9;rdago que en los 16 controles que no se trataron.<a href="#cit/section_5.44">44</a> En un ensayo  <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44092&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044092&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">no controlado</a> peque&#xF1;o del extracto de la planta de mu&#xE9;rdago del mismo fabricante  (abnobaVISCUM),  se trat&#xF3; a pacientes de c&#xE1;ncer de vejiga sin <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45741&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045741&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">invasi&#xF3;n</a> muscular; en este ensayo se observ&#xF3; la inocuidad de la administraci&#xF3;n <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46340&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046340&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">intravesical</a> y hubo <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43983&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043983&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">tasas de respuesta</a> de 56&#xA0;%, lo cual concuerda con los resultados publicados de otros tratamientos para el c&#xE1;ncer de vejiga (39&#x2013;50&#xA0;%).<a href="#cit/section_5.45">45</a></p><p id="_253" tabindex="-1">En un ensayo  multic&#xE9;ntrico <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285990&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285990&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">sin anonimato</a> de un solo grupo, se evalu&#xF3; la eficacia e inocuidad de la  <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44294&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044294&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">pleurodesis</a> qu&#xED;mica con abnobaVISCUM.<a href="#cit/section_5.46">46</a> De los 62 pacientes del estudio, 49 presentaron una <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45652&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045652&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">respuesta completa</a>, 11 presentaron una respuesta parcial y 2 pacientes no obtuvieron respuesta.  El per&#xED;odo de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45981&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045981&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">observaci&#xF3;n</a> fue de 4 semanas. No hay datos sobre el m&#xE9;todo de comparaci&#xF3;n de la administraci&#xF3;n  <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285972&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285972&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">intrapleural</a> con el <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=346525&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000346525&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">est&#xE1;ndar de atenci&#xF3;n</a>.</p></section></section><table id="_71" class="table-default expandable-container"><caption>Cuadro 4.     Uso de otros productos de mu&#xE9;rdago para el tratamiento del c&#xE1;ncer: informes cl&#xED;nicos que describen criterios de valoraci&#xF3;n terap&#xE9;uticos<span class="sup">a</span></caption><colgroup><col width="11.37%"><col width="13.19%"><col width="16.91%"><col width="12.18%"><col width="12.08%"><col width="12.58%"><col width="10.07%"><col width="11.58%"></colgroup>
            <THead>
            <tr>
            <th>Cita(s) bibliogr&#xE1;fica(s)</th>
            <th>Tipo de estudio</th>
            <th>Producto probado</th>
            <th>Tipo(s) de c&#xE1;ncer</th>
            <th>N&#xFA;mero de pacientes: inscritos, tratados, de control<span class="sup">b</span></th>
            <th>Beneficio m&#xE1;s importante notificado<span class="sup">c</span></th>
            <th>Tratamiento simult&#xE1;neo<span class="sup">d</span></th>
            <th>Puntaje de grado de comprobaci&#xF3;n cient&#xED;fica<span class="sup">e</span></th>
            </tr>
            </THead>
            <TFoot class="pdq-footer">
            <tr>
            <td colspan="8"><span class="sup">a</span>Para obtener m&#xE1;s  informaci&#xF3;n y la definici&#xF3;n de los t&#xE9;rminos, consultar el texto y el <a href="https://www.cancer.gov/espanol/publicaciones/diccionario" title="https://www.cancer.gov/espanol/publicaciones/diccionario">Diccionario de c&#xE1;ncer del NCI</a>.</td>
            </tr>
            <tr>
            <td colspan="8"><span class="sup">b</span>El n&#xFA;mero de pacientes tratados m&#xE1;s el n&#xFA;mero de pacientes controlados puede ser distinto del n&#xFA;mero de pacientes inscritos; n&#xFA;mero de pacientes inscritos = n&#xFA;mero de pacientes inicialmente inscritos o considerados por los investigadores que condujeron el estudio; n&#xFA;mero de pacientes tratados = n&#xFA;mero de pacientes inscritos que se sometieron al tratamiento en estudio y de quienes se notificaron los resultados; los sujetos hist&#xF3;ricos de referencia no se incluyeron en el n&#xFA;mero de pacientes inscritos.</td>
            </tr>
            <tr>
            <td colspan="8"><span class="sup">c</span>Pruebas m&#xE1;s s&#xF3;lidas notificadas de que el tratamiento en estudio es activo contra el c&#xE1;ncer o que mejora de otra manera el bienestar de los pacientes de c&#xE1;ncer.</td>
            </tr>
            <tr>
            <td colspan="8"><span class="sup">d</span>Se administr&#xF3; o permiti&#xF3; la administraci&#xF3;n de quimioterapia, radioterapia, hormonoterapia o terapia con citocinas al mismo tiempo que la terapia con mu&#xE9;rdago.</td>
            </tr>
            <tr>
            <td colspan="8"><span class="sup">e</span>Para obtener informaci&#xF3;n sobre el an&#xE1;lisis de los grados de comprobaci&#xF3;n cient&#xED;fica y una explicaci&#xF3;n de los puntajes de dichos grados, consultar <a href="/publications/pdq/levels-evidence/cam">Grados de comprobaci&#xF3;n cient&#xED;fica de los estudios de terapias integrales, alternativas y complementarias en seres humanos con c&#xE1;ncer</a>.</td>
            </tr>
            <tr>
            <td colspan="8"><span class="sup"> f</span>En este ensayo hubo cuatro grupos; los pacientes se asignaron al azar para someterse a cirug&#xED;a sola o a cirug&#xED;a y radioterapia; a continuaci&#xF3;n, se realiz&#xF3; una segunda aleatorizaci&#xF3;n en la que se asign&#xF3; a los pacientes a no recibir tratamiento con mu&#xE9;rdago o a tratamiento con Eurixor; los grupos de tratamiento formados incluyeron el siguiente n&#xFA;mero de pacientes evaluables: cirug&#xED;a sola = 105; cirug&#xED;a y Eurixor = 97; cirug&#xED;a y radioterapia = 137; y cirug&#xED;a, radioterapia y Eurixor = 138; se superpusieron la radioterapia y el tratamiento con Eurixor; ning&#xFA;n enfoque de tratamiento fue superior en t&#xE9;rminos de supervivencia sin enfermedad, supervivencia por una enfermedad espec&#xED;fica, mejora de la CV o estimulaci&#xF3;n del sistema inmunitario; en el cuadro, se agruparon los pacientes tratados con mu&#xE9;rdago y los pacientes de control sin tratamiento (es decir, n&#xFA;mero de tratados = 97 + 138 = 235; n&#xFA;mero de control = 105 + 137 = 242).</td>
            </tr>
            </TFoot>
            <tbody>
            <tr>
            <td>
            <a href="#cit/section_5.3">3</a>
            </td>
            <td>Ensayo aleatorizado</td>
            <td>Eurixor</td>
            <td>Vejiga, sin infiltraci&#xF3;n</td>
            <td>45; 23; 22</td>
            <td>Ninguno</td>
            <td>No</td>
            <td>1iiDi</td>
            </tr>
            <tr>
            <td>
            <a href="#cit/section_5.34">34</a>
            <a href="#cit/section_5.1">1</a>
            </td>
            <td>Ensayo aleatorizado</td>
            <td>Eurixor</td>
            <td>Enc&#xE9;falo, glioma; 74&#xA0;% de los pacientes en estadios III&#x2013;IV; 26&#xA0;% de los pacientes sin informaci&#xF3;n sobre el estadio
            </td>
            <td>47; 20; 18</td>
            <td>Mejora de la supervivencia: solo en pacientes en estadios III&#x2013;IV
            </td>
            <td>S&#xED;</td>
            <td>1iiA</td>
            </tr>
            <tr>
            <td>
            <a href="#cit/section_5.47">47</a>
            <a href="#cit/section_5.48">48</a>
            </td>
            <td>Ensayo aleatorizado</td>
            <td>Eurixor</td>
            <td>Colorrectal, metast&#xE1;sico</td>
            <td>107; 38; 41</td>
            <td>Mejora de la CV</td>
            <td>S&#xED;</td>
            <td>1iiA</td>
            </tr>
            <tr>
            <td>
            <a href="#cit/section_5.2">2</a>
            </td>
            <td>Ensayo aleatorizado</td>
            <td>Eurixor</td>
            <td>Cabeza y cuello, c&#xE9;lulas escamosas, estadios I&#x2013;IV
            </td>
            <td>495; 235<span class="sup">f</span>; 242<span class="sup">f</span></td>
            <td>Ninguno</td>
            <td>S&#xED;<span class="sup">f</span></td>
            <td>1iiA</td>
            </tr>
            <tr>
            <td>
            <a href="#cit/section_5.39">39</a>
            </td>
            <td>Ensayo aleatorizado</td>
            <td>Helixor</td>
            <td>Mama, estadios I&#x2013;III</td>
            <td>692; 192 (Helixor) y 177 (quimioterapia); 274 </td>
            <td>Mejora de la supervivencia</td>
            <td>S&#xED;</td>
            <td>1iiA</td>
            </tr>
            <tr>
            <td>
            <a href="#cit/section_5.49">49</a>
            </td>
            <td>Ensayo aleatorizado</td>
            <td>Helixor</td>
            <td>Colorrectal, metast&#xE1;sico</td>
            <td>60; 20; 20</td>
            <td>Mejora de la media de supervivencia</td>
            <td>S&#xED;</td>
            <td>1iiA</td>
            </tr><tr><td><a href="#cit/section_5.37">37</a></td><td>Ensayo aleatorizado</td><td>Helixor</td><td>Mama, ovario y pulm&#xF3;n de c&#xE9;lulas no peque&#xF1;as</td><td>224; 115; 109</td><td>Mejora de la CV</td><td>S&#xED;</td><td>1iiC</td></tr>
            <tr>
            <td>
            <a href="#cit/section_5.13">13</a>
            </td>
            <td>Ensayo controlado aleatorizado</td>
            <td>PS76A (Lektin)</td>
            <td>Mama</td>
            <td>352; 176; 176</td>
            <td>Mejora de la CV</td>
            <td>S&#xED;</td>
            <td>1iC</td>
            </tr><tr><td><a href="#cit/section_5.50">50</a></td><td>Ensayo aleatorizado</td><td>Lektinol</td><td>Mama</td><td>261; 195; 66</td><td>Mejora de la CV</td><td>S&#xED;</td><td>1iC</td></tr><tr><td><a href="#cit/section_5.51">51</a></td><td>Ensayo aleatorizado</td><td>Lektinol</td><td>Mama</td><td>352; 176; 176</td><td>Mejora de la CV</td><td>S&#xED;</td><td>1iC</td></tr>
            <tr>
            <td>
            <a href="#cit/section_5.35">35</a>
            </td>
            <td>Ensayo aleatorizado</td>
            <td>Isorel</td>
            <td>Colorrectal</td>
            <td>64; 50; 14 </td>
            <td>Mejora de la supervivencia y tolerancia al tratamiento adyuvante o paliativo</td>
            <td>S&#xED;</td>
            <td>1iiA</td>
            </tr>
            <tr>
            <td>
            <a href="#cit/section_5.52">52</a>
            </td>
            <td>Ensayo controlado no aleatorizado</td>
            <td>Isorel</td>
            <td>Tubo digestivo</td>
            <td>70; 40; 30</td>
            <td>Realce de la inmunidad celular y mejora de la CV</td>
            <td>No</td>
            <td>2C</td>
            </tr>
            <tr>
            <td>
            <a href="#cit/section_5.43">43</a>
            </td>
            <td>Ensayo controlado no aleatorizado</td>
            <td>abnobaVISCUM <em>Quercus</em></td>
            <td>Colorrectal metast&#xE1;sico</td>
            <td>25; 25; ninguno</td>
            <td>Ninguno</td>
            <td>S&#xED;</td>
            <td>2Diii</td>
            </tr>
            <tr>
            <td>
            <a href="#cit/section_5.21">21</a>
            </td>
            <td>Ensayo controlado no aleatorizado</td>
            <td>Viscum fraxini-2</td>
            <td>Carcinoma hepatocelular</td>
            <td>23; 23; ninguno</td>
            <td>Mejora de la supervivencia </td>
            <td>No</td>
            <td>2Dii</td>
            </tr><tr><td colspan="2">CV = calidad de vida.</td><td>&#xA0;</td><td>&#xA0;</td><td>&#xA0;</td><td>&#xA0;</td><td>&#xA0;</td><td>&#xA0;</td></tr>
            </tbody>
            </table><section id="_TrialSearch_35_sid_5"><h3 id="_TrialSearch_35_sid_5_toc">Ensayos cl&#xED;nicos en curso</h3><p id="_TrialSearch_35_25" tabindex="-1">Realizar una <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search">b&#xFA;squeda avanzada</a> en ingl&#xE9;s de los ensayos cl&#xED;nicos sobre c&#xE1;ncer auspiciados por el NCI que ahora aceptan pacientes. La b&#xFA;squeda se puede simplificar por ubicaci&#xF3;n del ensayo, tipo de tratamiento, nombre del f&#xE1;rmaco y otros criterios. Tambi&#xE9;n se dispone de <a href="https://www.cancer.gov/espanol/cancer/tratamiento/estudios-clinicos" title="https://www.cancer.gov/espanol/cancer/tratamiento/estudios-clinicos">informaci&#xF3;n general</a> sobre los ensayos cl&#xED;nicos. </p></section><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_5.1">Lenartz D, Dott U, Menzel J, et al.: Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe. Anticancer Res 20 (3B): 2073-6, 2000 May-Jun.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10928154&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10928154&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.2">Steuer-Vogt MK, Bonkowsky V, Ambrosch P, et al.: The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. Eur J Cancer 37 (1): 23-31, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11165126&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11165126&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.3">Goebell PJ, Otto T, Suhr J, et al.: Evaluation of an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized phase II trial. J Urol 168 (1): 72-5, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12050495&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12050495&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.4">Grossarth-Maticek R, Kiene H, Baumgartner SM, et al.: Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study. Altern Ther Health Med 7 (3): 57-66, 68-72, 74-6 passim, 2001 May-Jun.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11347286&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11347286&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.5">Kleeberg UR, Suciu S, Br&#xF6;cker EB, et al.: Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness &gt;3 mm) or regional lymph node metastasis. Eur J Cancer 40 (3): 390-402, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14746858&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14746858&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.6">Viscum album. In: Homoeopathic Pharmacopoeia Convention of the United States: Homoeopathic Pharmacopoeia of the United States. Washington, DC: 2002, Monograph 9444 Visc.</li><li id="section_5.7">Tr&#xF6;ger W, Jezdi&#x107; S, &#x17D;drale Z, et al.: Quality of life and neutropenia in patients with early stage breast cancer: a randomized pilot study comparing additional treatment with mistletoe extract to chemotherapy alone
            . Breast Cancer: Basic and Clinical Research  3: 35-45, 2009.</li><li id="section_5.8">Grossarth-Maticek R, Ziegler R: Prospective controlled cohort studies on long-term therapy of breast cancer patients with a mistletoe preparation (Iscador). Forsch Komplementmed 13 (5): 285-92, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17057389&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17057389&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.9">Grossarth-Maticek R, Ziegler R: Prospective controlled cohort studies on long-term therapy of cervical cancer patients with a mistletoe preparation (Iscador). Forsch Komplementmed 14 (3): 140-7, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17596694&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17596694&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.10">Grossarth-Maticek R, Ziegler R: Randomized and non-randomized prospective controlled cohort studies in matched pair design for the long-term therapy of corpus uteri cancer patients with a mistletoe preparation (Iscador). Eur J Med Res 13 (3): 107-20, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18499556&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18499556&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.11">Grossarth-Maticek R, Ziegler R: Prospective controlled cohort studies on long-term therapy of ovairian cancer patients with mistletoe (Viscum album L.) extracts iscador. Arzneimittelforschung 57 (10): 665-78, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18074761&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18074761&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.12">Bar-Sela G, Goldberg H, Beck D, et al.: Reducing malignant ascites accumulation by repeated intraperitoneal administrations of a Viscum album extract. Anticancer Res 26 (1B): 709-13, 2006 Jan-Feb.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16739342&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16739342&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.13">Wetzel D, Sch&#xE4;fer M: Results of a randomised placebo-controlled multicentre study with PS76A2 (standardised mistletoe preparation) in patients with breast cancer receiving adjuvant chemotherapy. [Abstract] Phytomedicine  7 (Suppl 2): A-SL-66, 2000.</li><li id="section_5.14">Sch&#xF6;ffski P, Riggert S, Fumoleau P, et al.: Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group. Ann Oncol 15 (12): 1816-24, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15550588&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15550588&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.15">Stauder H, Kreuser ED: Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: current state of clinical research. Onkologie 25 (4): 374-80, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12232491&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12232491&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.16">Kienle GS, Berrino F, B&#xFC;ssing A, et al.: Mistletoe in cancer - a systematic review on controlled clinical trials. Eur J Med Res 8 (3): 109-19, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12730032&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12730032&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.17">Kienle GS, Glockmann A, Schink M, et al.: Viscum album L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical research. J Exp Clin Cancer Res 28: 79, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19519890&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19519890&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.18">Horneber MA, Bueschel G, Huber R, et al.: Mistletoe therapy in oncology. Cochrane Database Syst Rev  (2): CD003297, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18425885&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18425885&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.19">Kienle GS, Kiene H: Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts. Eur J Med Res 12 (3): 103-19, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17507307&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17507307&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.20">Ernst E, Schmidt K, Steuer-Vogt MK: Mistletoe for cancer? A systematic review of randomised clinical trials. Int J Cancer 107 (2): 262-7, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12949804&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12949804&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.21">Mabed M, El-Helw L, Shamaa S: Phase II study of viscum fraxini-2 in patients with advanced hepatocellular carcinoma. Br J Cancer 90 (1): 65-9, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14710208&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14710208&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.22">Kienle GS, Kiene H: Review article: Influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies. Integr Cancer Ther 9 (2): 142-57, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20483874&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20483874&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.23">Tr&#xF6;ger W, Galun D, Reif M, et al.: Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: a randomised clinical trial on overall survival. Eur J Cancer 49 (18): 3788-97, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23890767&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23890767&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.24">Tr&#xF6;ger W, Galun D, Reif M, et al.: Quality of life of patients with advanced pancreatic cancer during treatment with mistletoe: a randomized controlled trial. Dtsch Arztebl Int 111 (29-30): 493-502, 33 p following 502, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25142075&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25142075&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.25">Dold U, Edler L, M&#xE4;urer HCh, et al., eds.: [Adjuvant Cancer Therapy in Advanced Non-Small Cell Bronchial Cancer: Multicentric Controlled Studies To Test the Efficacy of Iscador and Polyerga]. Stuttgart, Germany: Georg Thieme Verlag, 1991.</li><li id="section_5.26">Augustin M, Bock PR, Hanisch J, et al.: Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland. Arzneimittelforschung 55 (1): 38-49, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15727163&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15727163&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.27">Bock PR, Friedel WE, Hanisch J, et al.: Retrolective, comparative, epidemiological cohort study with parallel groups design for evaluation of efficacy and safety of drugs with "well-established use". Forsch Komplementarmed Klass Naturheilkd 11 (Suppl 1): 23-9, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15353899&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15353899&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.28">Bock PR, Friedel WE, Hanisch J, et al.: [Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland] Arzneimittelforschung 54 (8): 456-66, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15460213&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15460213&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.29">Friedel WE, Matthes H, Bock PR, et al.: Systematic evaluation of the clinical effects of supportive mistletoe treatment within chemo- and/or radiotherapy protocols and long-term mistletoe application in nonmetastatic colorectal carcinoma: multicenter, controlled, observational cohort study. J Soc Integr Oncol 7 (4): 137-45, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19883529&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19883529&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.30">Bar-Sela G, Wollner M, Hammer L, et al.: Mistletoe as complementary treatment in patients with advanced non-small-cell lung cancer treated with carboplatin-based combinations: a randomised phase II study. Eur J Cancer 49 (5): 1058-64, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23218588&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23218588&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.31">Salzer G, Danmayr E, Wutzholfer F, et al.: [Adjuvant Iscador&#xAE; treatment of non-small cell bronchial carcinoma. Results of a randomized study]. Dtsch Z Onkol  23 (4): 93-8, 1991.</li><li id="section_5.32">Longhi A, Reif M, Mariani E, et al.: A Randomized Study on Postrelapse Disease-Free Survival with Adjuvant Mistletoe versus Oral Etoposide in Osteosarcoma Patients. Evid Based Complement Alternat Med 2014: 210198, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24803944&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24803944&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.33">Schaefermeyer G, Schaefermeyer H: Treatment of pancreatic cancer with Viscum album (Iscador): a retrospective study of 292 patients 1986-1996. Complement Ther Med  6 (4): 172-7, 1998.</li><li id="section_5.34">Lenartz D, Stoffel B, Menzel J, et al.: Immunoprotective activity of the galactoside-specific lectin from mistletoe after tumor destructive therapy in glioma patients. Anticancer Res 16 (6B): 3799-802, 1996 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9042260&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9042260&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.35">Cazacu M, Oniu T, Lungoci C, et al.: The influence of isorel on the advanced colorectal cancer. Cancer Biother Radiopharm 18 (1): 27-34, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12667306&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12667306&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.36">Huber R, Schlodder D, Effertz C, et al.: Safety of intravenously applied mistletoe extract - results from a phase I dose escalation study in patients with advanced cancer. BMC Complement Altern Med 17 (1): 465, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28923036&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28923036&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.37">Piao BK, Wang YX, Xie GR, et al.: Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial. Anticancer Res 24 (1): 303-9, 2004 Jan-Feb.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15015612&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15015612&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.38">Mansky PJ, Wallerstedt DB, Sannes TS, et al.: NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors. Evid Based Complement Alternat Med 2013: 964592, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24285980&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24285980&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.39">Gutsch J, Berger H, Scholz G, et al.: [Prospective study in radically operated breast cancer with polychemotherapy, Helixor&#xAE; and untreated controls]. Dtsch Z Onkol  21: 94-101, 1988.</li><li id="section_5.40">Auerbach L, Dostal V, V&#xE1;clavik-Fleck I, et al.: Signifikant h&#xF6;herer anteil aktivierter NK-Zellen durch additive misteltherapie bei chemotherapierten mamma-Ca-patientinnen in einer prospektiven randomisierten doppelblinden studie. In: Scheer R, Bauer R, Becker H, et al.: Fortschritte in der Misteltherapie. Aktueller Stand der Forschung und klinischen Anwendung. Essen, Germany: KCV-Verlag, 2005, pp 543-54.</li><li id="section_5.41">Matthes HF, Schad F, Buchwald D, et al.: Endoscopic ultrasound-guided fine-needle Injection of Viscum album L. (mistletoe; Helixor M) in the therapy of primary inoperable pancreas cancer:  a pilot study. [Abstract] Gastroenterology  128 (Suppl 2): A-T988, A433-A434, 2005.</li><li id="section_5.42">Beuth J, Schneider B, Schierholz JM: Impact of complementary treatment of breast cancer patients with standardized mistletoe extract during aftercare: a controlled multicenter comparative epidemiological cohort study. Anticancer Res 28 (1B): 523-7, 2008 Jan-Feb.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18383896&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18383896&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.43">Bar-Sela G, Haim N: Abnoba-viscum (mistletoe extract) in metastatic colorectal carcinoma resistant to 5-fluorouracil and leucovorin-based chemotherapy. Med Oncol 21 (3): 251-4, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15456952&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15456952&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.44">Kim KC, Yook JH, Eisenbraun J, et al.: Quality of life, immunomodulation and safety of adjuvant mistletoe treatment in patients with gastric carcinoma - a randomized, controlled pilot study. BMC Complement Altern Med 12: 172, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23033982&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23033982&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.45">Rose A, El-Leithy T, vom Dorp F, et al.: Mistletoe Plant Extract in Patients with Nonmuscle Invasive Bladder Cancer: Results of a Phase Ib/IIa Single Group Dose Escalation Study. J Urol 194 (4): 939-43, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25910967&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25910967&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.46">Cho JS, Na KJ, Lee Y, et al.: Chemical Pleurodesis Using Mistletoe Extraction (ABNOVAviscum(&#xAE;) Injection) for Malignant Pleural Effusion. Ann Thorac Cardiovasc Surg 22 (1): 20-6, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26639937&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26639937&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.47">Heiny BM, Albrecht V, Beuth J: Stabilization of quality of life with mistletoe lectin-1-standardized extract in advanced colorectal carcinoma. Onkologe  4 (Suppl 1): S35-9, 1998.</li><li id="section_5.48">Sauer H: Quality of life stabilization with mistletoe-1-standardized extract in advanced colorectal carcinoma [Letter]. Onkologe  4: 1180, 1998.</li><li id="section_5.49">Douwes FR, Wolfrum DI, Migeod F: [Results of a prospective randomized study: chemotherapy versus chemotherapy plus "biological response modifier" in metastasizing colorectal carcinoma]. Dtsch Z Onkol  18 (6): 155-64, 1986.</li><li id="section_5.50">Semiglasov VF, Stepula VV, Dudov A, et al.: The standardised mistletoe extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Res 24 (2C): 1293-302, 2004 Mar-Apr.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15154663&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15154663&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.51">Semiglazov VF, Stepula VV, Dudov A, et al.: Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial. Anticancer Res 26 (2B): 1519-29, 2006 Mar-Apr.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16619567&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16619567&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.52">Enesel MB, Acalovschi I, Grosu V, et al.: Perioperative application of the Viscum album extract Isorel in digestive tract cancer patients. Anticancer Res 25 (6C): 4583-90, 2005 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16334146&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16334146&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _52
      field_pdq_section_title:
        - format: plain_text
          value: 'Efectos adversos'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_52" class="pdq-sections"><p id="_53" tabindex="-1">Aunque se ha usado una cantidad diferente de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=407760&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000407760&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">extractos</a> de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285939&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285939&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">mu&#xE9;rdago</a> en <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44195&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044195&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">estudios con seres humanos</a>, los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46580&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046580&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">efectos secundarios</a> notificados generalmente han sido m&#xED;nimos y no pusieron en peligro la vida. Los efectos secundarios comunes incluyeron escozor e <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44042&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044042&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">inflamaci&#xF3;n</a> en los sitios de la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44678&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044678&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">inyecci&#xF3;n</a>, cefalea, fiebre y escalofr&#xED;os.<a href="#cit/section_6.1">1</a><a href="#cit/section_6.2">2</a><a href="#cit/section_6.3">3</a><a href="#cit/section_6.4">4</a></p><p id="_205" tabindex="-1">En un <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=691484&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000691484&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">metan&#xE1;lisis</a> en el que se usaron <em>Viscum album L.</em> y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44994&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044994&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">lectinas de mu&#xE9;rdago</a> aisladas, se incluyeron estudios con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=454774&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000454774&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">animales</a> y seres humanos. Las <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44664&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044664&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">dosis</a> y formas de aplicaci&#xF3;n fueron variadas. No se notificaron efectos <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44041&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044041&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">inmunodepresores</a>. Los efectos secundarios incluyeron reacciones locales en el sitio de la inyecci&#xF3;n y s&#xED;ntomas pseudogripales como <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=450108&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000450108&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">fiebre</a>, escalofr&#xED;os, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=321374&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000321374&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">fatiga</a>, s&#xED;ntomas <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45692&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045692&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">gastrointestinales</a> leves y cefalea. En algunos casos, las dosis altas de lectinas de mu&#xE9;rdago elaboradas por recombinaci&#xF3;n (no disponibles en productos comerciales) produjeron una hepatotoxicidad reversible.<a href="#cit/section_6.5">5</a> En otra revisi&#xF3;n, se notificaron reacciones adversas que incluyeron reacciones locales en el sitio de la inyecci&#xF3;n, fiebre, aumento de la presi&#xF3;n intracraneal, cefalea, problemas circulatorios, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46615&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046615&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">tromboflebitis</a>, inflamaci&#xF3;n de los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45762&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045762&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">ganglios linf&#xE1;ticos</a> y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=443292&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000443292&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">reacciones al&#xE9;rgicas</a>.<a href="#cit/section_6.6">6</a></p><p id="_206" tabindex="-1"> Se notificaron algunos casos de reacciones al&#xE9;rgicas graves como <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285952&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285952&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">choque anafil&#xE1;ctico</a>.<a href="#cit/section_6.2">2</a></p><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_6.1">Kaegi E: Unconventional therapies for cancer: 3. Iscador. Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative. CMAJ 158 (9): 1157-9, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9597967&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9597967&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.2">Hutt N, Kopferschmitt-Kubler M, Cabalion J, et al.: Anaphylactic reactions after therapeutic injection of mistletoe (Viscum album L.). Allergol Immunopathol (Madr) 29 (5): 201-3, 2001 Sep-Oct.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11720654&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11720654&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.3">Stauder H, Kreuser ED: Mistletoe extracts standardised in terms of mistletoe lectins (ML I) in oncology: current state of clinical research. Onkologie 25 (4): 374-80, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12232491&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12232491&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.4">Steele ML, Axtner J, Happe A, et al.: Safety of Intravenous Application of Mistletoe (Viscum album L.) Preparations in Oncology: An Observational Study. Evid Based Complement Alternat Med 2014: 236310, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24955100&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24955100&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.5">Kienle GS, Grugel R, Kiene H: Safety of higher dosages of Viscum album L. in animals and humans--systematic review of immune changes and safety parameters. BMC Complement Altern Med 11: 72, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21871125&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21871125&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.6">Ernst E, Schmidt K, Steuer-Vogt MK: Mistletoe for cancer? A systematic review of randomised clinical trials. Int J Cancer 107 (2): 262-7, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12949804&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12949804&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _55
      field_pdq_section_title:
        - format: plain_text
          value: 'Resumen de las pruebas de extractos de muérdago'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_55" class="pdq-sections"><p id="_56" tabindex="-1">El <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=285939&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000285939&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">mu&#xE9;rdago</a> es una de las sustancias de tratamientos de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44964&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044964&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">medicina complementaria y alternativa</a> para el <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45333&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045333&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer</a> m&#xE1;s ampliamente estudiadas. En algunos pa&#xED;ses europeos, las preparaciones hechas de mu&#xE9;rdago europeo (<em>Viscum album</em>, Loranthaceae) se encuentran entre los f&#xE1;rmacos m&#xE1;s recetados que se ofrecen a los pacientes de c&#xE1;ncer. Los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=407760&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000407760&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">extractos</a> de mu&#xE9;rdago fueron evaluados en numerosos <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44195&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044195&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">estudios cl&#xED;nicos</a> y frecuentemente se notificaron mejoras en la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45417&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045417&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">calidad de vida</a> o la estimulaci&#xF3;n del <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46356&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046356&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">sistema inmunitario</a>. Sin embargo, la mayor&#xED;a de los estudios cl&#xED;nicos conducidos tuvieron una o m&#xE1;s debilidades que despiertan dudas acerca de la fiabilidad de los hallazgos. Adem&#xE1;s, no hay pruebas que apoyen la noci&#xF3;n de que la estimulaci&#xF3;n del sistema inmunitario con mu&#xE9;rdago conduzca a una mejora de la capacidad de luchar contra el c&#xE1;ncer. Debido a que todos los pacientes de los que se informa en los estudios cl&#xED;nicos son adultos, no se dispone de informaci&#xF3;n acerca del uso del mu&#xE9;rdago para el tratamiento de ni&#xF1;os con c&#xE1;ncer. </p><p id="_94" tabindex="-1">Para calificar los estudios en humanos sobre la base de la solidez estad&#xED;stica de su dise&#xF1;o y la rigurosidad <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44724&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044724&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">cient&#xED;fica</a> de los resultados del tratamiento (es decir, los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=346519&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000346519&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">criterios de valoraci&#xF3;n</a>) medidos, se asignan puntajes separados de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=446533&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000446533&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">grados de comprobaci&#xF3;n cient&#xED;fica</a>. Los dos puntajes resultantes se combinan luego para obtener un puntaje general. Para obtener m&#xE1;s informaci&#xF3;n sobre el an&#xE1;lisis de los grados de comprobaci&#xF3;n cient&#xED;fica y una explicaci&#xF3;n de los puntajes de dichos grados, consultar <a href="/publications/pdq/levels-evidence/cam">Grados de comprobaci&#xF3;n cient&#xED;fica de los estudios de terapias integrales, alternativas y complementarias en seres humanos con c&#xE1;ncer</a>.</p></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _245
      field_pdq_section_title:
        - format: plain_text
          value: 'Modificaciones a este sumario (11/14/2018)'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_245" class="pdq-sections"><p id="_246" tabindex="-1">Los sumarios del <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44271&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044271&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">PDQ</a> con informaci&#xF3;n sobre el <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45333&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045333&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer</a> se revisan con regularidad y se actualizan a medida que se obtiene nueva informaci&#xF3;n. Esta secci&#xF3;n describe los cambios m&#xE1;s recientes introducidos en este sumario a partir de la fecha arriba indicada.</p><p id="_266" tabindex="-1">Este sumario fue objeto de amplia revisi&#xF3;n.</p><p id="_267" tabindex="-1"><strong><a href="/espanol/cancer/tratamiento/mca/pro/muerdago-pdq#link/_23">Estudios precl&#xED;nicos de laboratorio o con animales</a></strong></p><p id="_268" tabindex="-1">Se revis&#xF3; el <a href="/espanol/cancer/tratamiento/mca/pro/muerdago-pdq#link/_259">Cuadro 1</a> y el <a href="/espanol/cancer/tratamiento/mca/pro/muerdago-pdq#link/_261">Cuadro 2</a> para incluir informaci&#xF3;n sobre ratones at&#xED;micos y VMDk como modelos animales (se cit&#xF3; a Podlech et al. como referencia 41).</p><p id="_disclaimerHP_3" tabindex="-1">Este sumario est&#xE1; redactado y mantenido por el <a href="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/medicina-complementaria-alternativa" title="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/medicina-complementaria-alternativa">Consejo editorial del PDQ&#xAE; sobre las terapias integrales, alternativas y complementarias</a>, que es editorialmente independiente del NCI. El sumario refleja una revisi&#xF3;n independiente de la bibliograf&#xED;a y no representa una declaraci&#xF3;n de pol&#xED;ticas del NCI o de los NIH. Para mayor informaci&#xF3;n sobre las pol&#xED;ticas de los sumarios y la funci&#xF3;n de los  consejos editoriales  del PDQ que mantienen los sumarios del PDQ, consultar en <a href="/espanol/cancer/tratamiento/mca/pro/muerdago-pdq#link/_AboutThis_1">Informaci&#xF3;n sobre este sumario del PDQ</a> y  la p&#xE1;gina sobre <a href="https://www.cancer.gov/espanol/publicaciones/pdq" title="https://www.cancer.gov/espanol/publicaciones/pdq">Banco de datos de informaci&#xF3;n de c&#xE1;ncer - PDQ&#xAE;</a>.
            </p></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _AboutThis_1
      field_pdq_section_title:
        - format: plain_text
          value: 'Información sobre este sumario del PDQ'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_AboutThis_1" class="pdq-sections"><section id="_AboutThis_2"><h3 id="_AboutThis_2_toc">Prop&#xF3;sito de este sumario</h3><p id="_AboutThis_3" tabindex="-1">Este sumario del PDQ con informaci&#xF3;n sobre el c&#xE1;ncer para profesionales de la salud proporciona informaci&#xF3;n integral revisada por expertos y con fundamento en datos probatorios sobre el uso de los extractos de mu&#xE9;rdago en el tratamiento de personas con c&#xE1;ncer. El prop&#xF3;sito es servir como fuente de informaci&#xF3;n y ayuda para los m&#xE9;dicos que atienden a pacientes de c&#xE1;ncer. No  ofrece pautas ni recomendaciones formales para tomar decisiones relacionadas con la atenci&#xF3;n sanitaria.</p></section><section id="_AboutThis_21"><h3 id="_AboutThis_21_toc">Revisores y actualizaciones</h3><p id="_AboutThis_22" tabindex="-1">El  <a href="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/medicina-complementaria-alternativa" title="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/medicina-complementaria-alternativa">Consejo editorial del PDQ&#xAE; sobre las terapias integrales, alternativas y complementarias</a>, cuya funci&#xF3;n editorial es independiente del Instituto Nacional del C&#xE1;ncer (NCI), revisa con regularidad este sumario y, en caso necesario,   lo actualiza. Este sumario refleja una revisi&#xF3;n bibliogr&#xE1;fica independiente y no constituye una declaraci&#xF3;n de la pol&#xED;tica del Instituto Nacional del C&#xE1;ncer ni de los Institutos Nacionales de la Salud (NIH).</p><p id="_AboutThis_26" tabindex="-1">Cada mes, los miembros de este Consejo  examinan art&#xED;culos  publicados recientemente para determinar si se deben:</p><div class="pdq-content-list"><ul id="_AboutThis_23"><li>tratar en una reuni&#xF3;n,</li><li>citar textualmente, o</li><li>sustituir o actualizar, si ya se citaron con anterioridad.</li></ul></div><p id="_AboutThis_24" tabindex="-1">Los cambios en los sumarios se deciden mediante consenso, una vez que  los integrantes del Consejo eval&#xFA;an la solidez de los datos probatorios en los art&#xED;culos publicados y determinan la forma en que se incorporar&#xE1;n al sumario.</p><p id="" tabindex="-1">Los revisores principales del sumario sobre Extractos de mu&#xE9;rdago son:</p><div class="pdq-content-list"><ul id=""><li>John A. Beutler, PhD (National Cancer Institute)</li><li>Jinhui Dou, PhD (Yiling Pharmaceutical, Inc.)</li><li>Channing J Paller, MD (Johns Hopkins Hospital)</li></ul></div><p id="_AboutThis_25" tabindex="-1">Cualquier comentario o pregunta sobre el contenido de este sumario se debe enviar mediante el   <a href="https://www.cancer.gov/espanol/contactenos/correo-electronico" title="https://www.cancer.gov/espanol/contactenos/correo-electronico">formulario de comunicaci&#xF3;n</a> en Cancer.gov/espanol del NCI.  No comunicarse con los miembros del Consejo para enviar preguntas o comentarios sobre los sumarios.  Los miembros del Consejo no responder&#xE1;n a preguntas del p&#xFA;blico. </p></section><section id="_AboutThis_9"><h3 id="_AboutThis_9_toc">Grados de comprobaci&#xF3;n cient&#xED;fica</h3><p id="_AboutThis_10" tabindex="-1">En algunas referencias bibliogr&#xE1;ficas de este sumario se indica el grado de comprobaci&#xF3;n cient&#xED;fica. El prop&#xF3;sito de estas designaciones es ayudar al lector a evaluar la solidez de los datos probatorios que sustentan el uso de  ciertas intervenciones  o enfoques. El Consejo editorial del PDQ&#xAE; sobre las terapias integrales, alternativas y complementarias emplea un <a href="/espanol/publicaciones/pdq/grados-comprobacion/cam">sistema de jerarquizaci&#xF3;n formal</a> para establecer  las designaciones del grado de comprobaci&#xF3;n cient&#xED;fica.</p></section><section id="_AboutThis_11"><h3 id="_AboutThis_11_toc">Permisos para el uso de este sumario</h3><p id="_AboutThis_12" tabindex="-1">PDQ (Physician Data Query) es una marca registrada. Se autoriza el libre uso del texto  de los documentos del PDQ. Sin embargo, no se podr&#xE1; identificar como un sumario de informaci&#xF3;n sobre c&#xE1;ncer del PDQ del  NCI,  salvo que se reproduzca en su totalidad y se actualice con regularidad. Por otra parte, se permitir&#xE1; que un autor  escriba una oraci&#xF3;n como &#x201C;En el sumario del PDQ  del NCI de informaci&#xF3;n sobre la prevenci&#xF3;n del c&#xE1;ncer de mama se describen, en breve, los siguientes riesgos: [incluir fragmento del sumario]&#x201D;.</p><p id="_AboutThis_13" tabindex="-1">Se sugiere citar la referencia bibliogr&#xE1;fica de este sumario del PDQ de la siguiente forma:</p><p id="_AboutThis_14" tabindex="-1">PDQ&#xAE; . PDQ Extractos de mu&#xE9;rdago. Bethesda, MD: National Cancer Institute. Actualizaci&#xF3;n:  &lt;MM/DD/YYYY&gt;. Disponible en: <a href="https://www.cancer.gov/espanol/cancer/tratamiento/mca/pro/muerdago-pdq" title="https://www.cancer.gov/espanol/cancer/tratamiento/mca/pro/muerdago-pdq">https://www.cancer.gov/espanol/cancer/tratamiento/mca/pro/muerdago-pdq</a>.  Fecha de acceso: &lt;MM/DD/YYYY&gt;. </p><p id="_AboutThis_15" tabindex="-1">Las im&#xE1;genes  en este sumario se reproducen  con el permiso del autor, el artista o la  editorial para uso exclusivo en los sumarios del PDQ. La utilizaci&#xF3;n de las im&#xE1;genes fuera del  PDQ requiere la autorizaci&#xF3;n del propietario, que el Instituto Nacional del C&#xE1;ncer no  puede otorgar. Para obtener m&#xE1;s informaci&#xF3;n sobre el uso de las ilustraciones de este sumario o de  otras im&#xE1;genes relacionadas con el c&#xE1;ncer, consultar <a href="https://visualsonline.cancer.gov/" title="https://visualsonline.cancer.gov/">Visuals Online</a>, una colecci&#xF3;n de m&#xE1;s de 2000 im&#xE1;genes cient&#xED;ficas.</p></section><section id="_AboutThis_16"><h3 id="_AboutThis_16_toc">Cl&#xE1;usula sobre el descargo de responsabilidad</h3><p id="_AboutThis_18" tabindex="-1">La informaci&#xF3;n en estos sumarios  no se debe utilizar como base para determinar reembolsos por parte de las aseguradoras. Para obtener m&#xE1;s informaci&#xF3;n  sobre la cobertura de seguros, consultar la p&#xE1;gina <a href="https://www.cancer.gov/espanol/cancer/manejo-del-cancer" title="https://www.cancer.gov/espanol/cancer/manejo-del-cancer">Manejo de la atenci&#xF3;n del c&#xE1;ncer</a> disponible en Cancer.gov/espanol.</p></section><section id="_AboutThis_19"><h3 id="_AboutThis_19_toc">Para obtener m&#xE1;s informaci&#xF3;n</h3><p id="_AboutThis_20" tabindex="-1">En Cancer.gov/espanol,  se ofrece m&#xE1;s informaci&#xF3;n sobre c&#xF3;mo comunicarse o recibir ayuda en  <a href="https://www.cancer.gov/espanol/contactenos" title="https://www.cancer.gov/espanol/contactenos">&#xBF;En qu&#xE9; podemos ayudarle?</a>.
            Tambi&#xE9;n se puede enviar un mensaje de  correo electr&#xF3;nico  mediante este  <a href="https://www.cancer.gov/espanol/contactenos/correo-electronico" title="https://www.cancer.gov/espanol/contactenos/correo-electronico">formulario</a>.</p></section></div>

- entity: node
  type: pdq_cancer_information_summary
  title: 'Cartilage (Bovine and Shark) (PDQ®)–Health Professional Version'
  status: 1
  langcode: en
  moderation_state:
    value: published
  field_pdq_url:
    value: /about-cancer/treatment/cam/hp/cartilage-pdq
  field_pdq_cdr_id:
    value: 62974
  field_pdq_audience:
    value: Health Professionals
  field_pdq_summary_type:
    value: Integrative, alternative, and complementary therapies
  field_date_posted:
    value: '2019-02-13'
  field_date_updated:
    value: '2018-08-23'
  field_short_title:
    value: 'Cartilage (Bovine and Shark)'
  field_page_description:
    value: 'Cartilage (bovine and shark) has been studied as a treatment for people with cancer and other conditions for more than 30 years. Few human studies of cartilage in cancer have been reported to date, and the results are inconclusive. Get detailed information in this clinician summary.'
  field_public_use:
    value: 1
  field_summary_sections:
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _1
      field_pdq_section_title:
        - format: plain_text
          value: 'Overview'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_1" class="pdq-sections"><div class="pdq-hp-patient-toggle"><a href="/about-cancer/treatment/cam/patient/cartilage-pdq">Go to Patient Version</a></div><p id="_160" tabindex="-1"><strong>NOTE: The information in this summary is no longer being updated and is provided for reference purposes only.</strong></p><p id="_2" tabindex="-1">This <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45333&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045333&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cancer</a> information summary provides an overview of
            the use of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44190&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044190&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cartilage</a> as a treatment
            for people with  cancer.  The summary includes a brief history of cartilage research, the
            results of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44195&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044195&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">clinical studies</a>, and
            possible <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46580&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046580&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">side effects</a> of cartilage use.</p><p id="_3" tabindex="-1">This summary contains the following key information:</p><div class="pdq-content-list"><ul id="_4"><li>Bovine (cow) cartilage and shark cartilage have been studied as
            treatments for people with cancer and other medical conditions for more than 30
            years.</li><li>Numerous cartilage products are sold commercially in the United States
            as <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=373932&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000373932&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">dietary supplements</a>.</li><li>Three principal mechanisms of action have been proposed to explain the
            <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=446109&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000446109&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">antitumor</a> potential of cartilage: (1) it kills cancer <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46476&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046476&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cells</a> directly; (2) it
            stimulates the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46356&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046356&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">immune system</a>; and (3) it blocks the formation of new <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45020&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045020&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">blood vessels</a>
            (<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46529&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046529&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">angiogenesis</a>), which <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46634&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046634&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">tumors</a> need
            for unrestricted growth.</li><li>At least three different inhibitors of angiogenesis have been identified
            in bovine cartilage, and two <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46739&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046739&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">angiogenesis inhibitors</a>
            have been purified from shark cartilage.</li><li>Few human studies  of cartilage as a treatment for people with cancer have been reported, and the results
            are inconclusive.</li><li>Additional <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45961&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045961&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">clinical trials</a>
            of cartilage as a treatment for people with cancer are now being conducted.</li></ul></div><p id="_61" tabindex="-1">Many of the medical and scientific terms used in this summary are hypertext linked (at first use in each section) to the <a href="https://www.cancer.gov/publications/dictionaries/cancer-terms/" title="https://www.cancer.gov/publications/dictionaries/cancer-terms/">NCI  Dictionary of Cancer Terms</a>, which is oriented toward nonexperts. When a linked term is clicked, a definition will appear in a separate window. </p><p id="_62" tabindex="-1">Reference citations in some <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44271&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044271&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">PDQ</a> cancer information summaries may include links to external websites that are operated by individuals or organizations for the purpose of marketing or advocating the use of specific treatments or products. These reference citations are included for informational purposes only. Their inclusion should not be viewed as an endorsement of the content of the websites, or of any treatment or product, by the PDQ Integrative, Alternative, and Complementary Therapies Editorial Board or the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44266&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044266&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">National Cancer Institute</a>.</p></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _5
      field_pdq_section_title:
        - format: plain_text
          value: 'General Information'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_5" class="pdq-sections"><p id="_6" tabindex="-1">Bovine (cow) <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44190&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044190&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cartilage</a> and shark cartilage have been investigated as treatments
            for people with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45333&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045333&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cancer</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44219&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044219&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">psoriasis</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44188&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044188&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">arthritis</a>, and a number of other medical
            conditions for more than 30 years.<a href="#cit/section_2.1">1</a><a href="#cit/section_2.2">2</a><a href="#cit/section_2.3">3</a><a href="#cit/section_2.4">4</a><a href="#cit/section_2.5">5</a><a href="#cit/section_2.6">6</a><a href="#cit/section_2.7">7</a><a href="#cit/section_2.8">8</a><a href="#cit/section_2.9">9</a><a href="#cit/section_2.10">10</a><a href="#cit/section_2.11">11</a><a href="#cit/section_2.12">12</a><a href="#cit/section_2.13">13</a><a href="#cit/section_2.14">14</a><a href="#cit/section_2.15">15</a><a href="#cit/section_2.16">16</a><a href="#cit/section_2.17">17</a><a href="#cit/section_2.18">18</a><a href="#cit/section_2.19">19</a> At least some of
            the interest in cartilage as a treatment for people with cancer arose from the mistaken
            belief that sharks, whose <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44221&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044221&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">skeletons</a> are
            made primarily of cartilage, are not affected by this disease.<a href="#cit/section_2.16">16</a><a href="#cit/section_2.20">20</a><a href="#cit/section_2.21">21</a>  Although reports of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45772&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045772&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">malignant</a>
            tumors in sharks are rare, a variety of cancers have been detected in these
            animals.<a href="#cit/section_2.20">20</a><a href="#cit/section_2.21">21</a><a href="#cit/section_2.22">22</a><a href="#cit/section_2.23">23</a>  Nonetheless, several substances that have
            antitumor activity have been identified in cartilage.<a href="#cit/section_2.2">2</a><a href="#cit/section_2.3">3</a><a href="#cit/section_2.4">4</a><a href="#cit/section_2.7">7</a><a href="#cit/section_2.15">15</a><a href="#cit/section_2.16">16</a><a href="#cit/section_2.17">17</a><a href="#cit/section_2.18">18</a><a href="#cit/section_2.19">19</a><a href="#cit/section_2.24">24</a><a href="#cit/section_2.25">25</a><a href="#cit/section_2.26">26</a><a href="#cit/section_2.27">27</a><a href="#cit/section_2.28">28</a><a href="#cit/section_2.29">29</a><a href="#cit/section_2.30">30</a><a href="#cit/section_2.31">31</a><a href="#cit/section_2.32">32</a><a href="#cit/section_2.33">33</a><a href="#cit/section_2.34">34</a><a href="#cit/section_2.35">35</a><a href="#cit/section_2.36">36</a><a href="#cit/section_2.37">37</a><a href="#cit/section_2.38">38</a><a href="#cit/section_2.39">39</a><a href="#cit/section_2.40">40</a><a href="#cit/section_2.41">41</a><a href="#cit/section_2.42">42</a><a href="#cit/section_2.43">43</a><a href="#cit/section_2.44">44</a><a href="#cit/section_2.45">45</a><a href="#cit/section_2.46">46</a><a href="#cit/section_2.47">47</a><a href="#cit/section_2.48">48</a><a href="#cit/section_2.49">49</a>  More than half a dozen <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44195&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044195&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">clinical studies</a> of cartilage as a
            treatment for people with cancer have already been conducted.<a href="#cit/section_2.2">2</a><a href="#cit/section_2.3">3</a><a href="#cit/section_2.4">4</a><a href="#cit/section_2.6">6</a><a href="#cit/section_2.7">7</a><a href="#cit/section_2.8">8</a><a href="#cit/section_2.9">9</a><a href="#cit/section_2.15">15</a><a href="#cit/section_2.16">16</a><a href="#cit/section_2.17">17</a><a href="#cit/section_2.18">18</a><a href="#cit/section_2.49">49</a><a href="#cit/section_2.50">50</a> Additional clinical studies, <a href="/clinicaltrials/NCT00005838">MDA-ID-99303</a> and <a href="/clinicaltrials/NCT00022282">AETERNA-AE-MM-00-02</a> have been completed.<a href="#cit/section_2.6">6</a><a href="#cit/section_2.15">15</a><a href="#cit/section_2.50">50</a></p><p id="_7" tabindex="-1">The absence of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45020&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045020&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">blood vessels</a> in cartilage led to the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44209&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044209&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">hypothesis</a> that cartilage <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46476&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046476&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cells</a> (also
            known as <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44191&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044191&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">chondrocytes</a>) produce one
            or more substances that inhibit blood vessel formation.<a href="#cit/section_2.27">27</a><a href="#cit/section_2.28">28</a><a href="#cit/section_2.29">29</a><a href="#cit/section_2.30">30</a><a href="#cit/section_2.35">35</a><a href="#cit/section_2.36">36</a><a href="#cit/section_2.48">48</a>  The formation of new blood vessels or <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46529&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046529&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">angiogenesis</a> is
            necessary for <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46634&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046634&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">tumors</a> to grow larger than a few <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44215&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044215&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">millimeters</a> in <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44224&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044224&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">diameter</a> (i.e., larger than approximately
            100,000 to 1,000,000 cells) because tumors, like normal tissues, must obtain
            most of their oxygen and nutrients from blood.<a href="#cit/section_2.33">33</a><a href="#cit/section_2.34">34</a><a href="#cit/section_2.41">41</a><a href="#cit/section_2.51">51</a><a href="#cit/section_2.52">52</a><a href="#cit/section_2.53">53</a><a href="#cit/section_2.54">54</a>  A
            developing tumor, therefore, cannot continue to grow unless it establishes
            connections to the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44194&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044194&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">circulatory
            system</a> of its host.  It has been reported that tumors can initiate the
            process of angiogenesis when they contain as few as 100 cells.<a href="#cit/section_2.53">53</a>  Inhibition
            of angiogenesis at this early <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45885&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045885&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">stage</a> may,
            in some instances, lead to complete tumor <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46039&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046039&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">regression</a>.<a href="#cit/section_2.53">53</a>  The possibility that
            cartilage could be a source of one or more types of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46739&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046739&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">angiogenesis inhibitors</a>
            for the treatment of cancer has prompted much research.</p><p id="_8" tabindex="-1">The major structural components of cartilage include several types of the
            <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46092&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046092&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">protein</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44196&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044196&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">collagen</a> and several types of
            <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44206&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044206&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">glycosaminoglycans</a>, which are
            <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44162&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044162&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">polysaccharides</a>.<a href="#cit/section_2.19">19</a><a href="#cit/section_2.29">29</a><a href="#cit/section_2.30">30</a><a href="#cit/section_2.39">39</a><a href="#cit/section_2.48">48</a><a href="#cit/section_2.54">54</a><a href="#cit/section_2.55">55</a>          <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44192&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044192&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">Chondroitin sulfate</a> is the
            major glycosaminoglycan in cartilage.<a href="#cit/section_2.39">39</a><a href="#cit/section_2.54">54</a>  Although there is no
            evidence that the collagens in cartilage, or their breakdown products, can
            inhibit angiogenesis, there is evidence that shark cartilage contains at least
            one angiogenesis inhibitor that has a glycosaminoglycan component (refer to the <a href="/about-cancer/treatment/cam/hp/cartilage-pdq#link/_23">Laboratory/Animal/Preclinical Studies</a> section of this summary for more information).<a href="#cit/section_2.46">46</a>  Other data indicate that
            most of the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44186&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044186&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">antiangiogenic</a>
            activity in cartilage is not associated with the major structural components.<a href="#cit/section_2.26">26</a><a href="#cit/section_2.30">30</a><a href="#cit/section_2.48">48</a></p><p id="_9" tabindex="-1">Some glycosaminoglycans in cartilage reportedly have <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44187&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044187&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">anti-inflammatory</a> and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46356&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046356&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">immune-system</a>-stimulating properties,<a href="#cit/section_2.1">1</a><a href="#cit/section_2.2">2</a><a href="#cit/section_2.14">14</a><a href="#cit/section_2.16">16</a><a href="#cit/section_2.56">56</a><a href="#cit/section_2.57">57</a> and it has been
            suggested that either they or some of their breakdown products are toxic to
            tumor cells.<a href="#cit/section_2.2">2</a><a href="#cit/section_2.3">3</a><a href="#cit/section_2.24">24</a>  Thus, the antitumor potential of cartilage
            may involve more than one mechanism of action.</p><p id="_10" tabindex="-1">Cartilage products are sold commercially in the United States as <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=373932&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000373932&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">dietary
            supplements</a>.  More than 40 different brand names of shark cartilage alone are
            available to consumers.<a href="#cit/section_2.17">17</a>  In the United States, dietary
            supplements are regulated as foods, not drugs.  Therefore, premarket
            evaluation and approval by the U.S. Food and Drug Administration (FDA) are not
            required unless specific disease prevention or treatment claims are made.
            Because manufacturers of cartilage products are not required to show evidence
            of anticancer or other biologic effects, it is unclear whether
            any of these products have <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43985&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043985&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">therapeutic</a> potential.  In addition,
            individual products may vary considerably from lot to lot because standard
            manufacturing processes do not exist, and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44189&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044189&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">binding agents</a> and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44205&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044205&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">fillers</a> may be added during
            production.<a href="#cit/section_2.17">17</a>     The FDA has not approved the use of cartilage as a treatment for people with cancer or any other medical condition. The FDA is notifying consumers of a refund program for purchasers of Lane Labs-USA, Inc.'s shark cartilage product, BeneFin. Consumers are eligible for a partial refund of the purchase price and any shipping and handling costs if this  product was purchased between September 22, 1999 and July 12, 2004.</p><p id="_11" tabindex="-1">To conduct clinical drug research in the United States, researchers must
            file an <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44763&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044763&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">Investigational</a> New Drug (IND) application with the FDA.  IND
            status has been granted to at least four groups of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44685&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044685&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">investigators</a>  to study
            cartilage as a treatment for people with cancer; one of these trials, MDA-ID-99303, is now completed.<a href="#cit/section_2.7">7</a><a href="#cit/section_2.18">18</a><a href="#cit/section_2.58">58</a>  Because the
            IND application process is confidential and because the existence of an IND
            can be disclosed only by the applicants, it is not known whether other
            applications have been made.</p><p id="_12" tabindex="-1">In <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=454774&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000454774&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">animal studies</a>, cartilage products have been administered in a variety
            of ways.  In some studies, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44068&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044068&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">oral</a>
            administration of either liquid or powdered forms has been
            used.<a href="#cit/section_2.19">19</a><a href="#cit/section_2.39">39</a><a href="#cit/section_2.40">40</a><a href="#cit/section_2.43">43</a><a href="#cit/section_2.44">44</a><a href="#cit/section_2.59">59</a> <a href="#cit/section_2.15">15</a><a href="#cit/section_2.47">47</a>  In other studies, cartilage
            products have been given by <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44678&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044678&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">injection</a> (<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46682&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046682&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">intravenous</a> or <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46339&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046339&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">intraperitoneal</a>), applied <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45927&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045927&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">topically</a>, or placed in slow-release
            plastic pellets that were <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45570&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045570&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">surgically</a> implanted.<a href="#cit/section_2.26">26</a><a href="#cit/section_2.27">27</a><a href="#cit/section_2.28">28</a><a href="#cit/section_2.32">32</a><a href="#cit/section_2.33">33</a><a href="#cit/section_2.35">35</a><a href="#cit/section_2.38">38</a><a href="#cit/section_2.40">40</a><a href="#cit/section_2.42">42</a><a href="#cit/section_2.44">44</a><a href="#cit/section_2.46">46</a><a href="#cit/section_2.48">48</a>    Most of the latter studies investigated the effects of
            cartilage products on the development of blood vessels in the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44193&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044193&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">chorioallantoic membrane</a>
            of chicken <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44202&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044202&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">embryos</a>, the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44199&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044199&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cornea</a> of rabbits, or the  <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44197&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044197&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">conjunctiva</a> of
            mice.<a href="#cit/section_2.26">26</a><a href="#cit/section_2.27">27</a><a href="#cit/section_2.28">28</a><a href="#cit/section_2.32">32</a><a href="#cit/section_2.35">35</a><a href="#cit/section_2.38">38</a><a href="#cit/section_2.40">40</a><a href="#cit/section_2.42">42</a><a href="#cit/section_2.44">44</a><a href="#cit/section_2.46">46</a><a href="#cit/section_2.48">48</a></p><p id="_13" tabindex="-1">In human studies (MDA-ID-99303, AETERNA-AE-MM-00-02, and <a href="/clinicaltrials/NCT00026117">NCCTG-971151</a>),         cartilage products have been administered topically or
            orally, or they have been given by <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44204&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044204&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">enema</a>
            or <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45914&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045914&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">subcutaneous</a>
            injection.<a href="#cit/section_2.2">2</a><a href="#cit/section_2.3">3</a><a href="#cit/section_2.4">4</a><a href="#cit/section_2.6">6</a><a href="#cit/section_2.7">7</a><a href="#cit/section_2.8">8</a><a href="#cit/section_2.9">9</a><a href="#cit/section_2.15">15</a><a href="#cit/section_2.16">16</a><a href="#cit/section_2.18">18</a><a href="#cit/section_2.60">60</a>  For oral
            administration, liquid, powdered, and pill forms have been
            used as described in the following completed trials:  MDA-ID-99303, NCCTG-971151, <a href="/clinicaltrials/NCT00005995">AETERNA-AE-RC-99-02</a>, and AETERNA-AE-MM-00-02.<a href="#cit/section_2.2">2</a><a href="#cit/section_2.3">3</a><a href="#cit/section_2.4">4</a><a href="#cit/section_2.6">6</a><a href="#cit/section_2.7">7</a><a href="#cit/section_2.8">8</a><a href="#cit/section_2.9">9</a><a href="#cit/section_2.15">15</a><a href="#cit/section_2.16">16</a><a href="#cit/section_2.18">18</a>  The <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44664&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044664&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">dose</a> and duration of
            cartilage treatment have varied in human studies, in part because different
            types of products have been tested.</p><p id="_14" tabindex="-1">In this summary, the brand name (i.e., registered or trademarked name) of
            the cartilage product(s) used in individual studies will be identified
            wherever possible.</p><h6 do-not-show="toc">References</h6><ol><li id="section_2.1">Prudden JF, Balassa LL: The biological activity of bovine cartilage preparations. Clinical demonstration of their potent anti-inflammatory capacity with supplementary notes on certain relevant fundamental supportive studies. Semin Arthritis Rheum 3 (4): 287-321, 1974 Summer.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4275322&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4275322&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.2">Prudden JF: The treatment of human cancer with agents prepared from bovine cartilage. J Biol Response Mod 4 (6): 551-84, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4087031&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4087031&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.3">Romano CF, Lipton A, Harvey HA, et al.: A phase II study of Catrix-S in solid tumors. J Biol Response Mod 4 (6): 585-9, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3878861&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3878861&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.4">Puccio C, Mittelman A, Chun P, et al.: Treatment of metastatic renal cell carcinoma with Catrix. [Abstract] Proceedings of the American Society of Clinical Oncology  13: A-769, 246, 1994.</li><li id="section_2.5">Dupont E, Savard PE, Jourdain C, et al.: Antiangiogenic properties of a novel shark cartilage extract: potential role in the treatment of psoriasis. J Cutan Med Surg 2 (3): 146-52, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9479080&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9479080&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.6">Falardeau P, Champagne P, Poyet P, et al.: Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol 28 (6): 620-5, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11740820&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11740820&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.7">Miller DR, Anderson GT, Stark JJ, et al.: Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. J Clin Oncol 16 (11): 3649-55, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9817287&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9817287&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.8">Leitner SP, Rothkopf MM, Haverstick L, et al.: Two phase II studies of oral dry shark cartilage powder (SCP) with either metastatic breast or prostate cancer refractory to standard treatment. [Abstract] Proceedings of the American Society of Clinical Oncology  17: A-240, 1998.</li><li id="section_2.9">Rosenbluth RJ, Jennis AA, Cantwell S, et al.: Oral shark cartilage in the treatment of patients with advanced primary brain tumors. [Abstract] Proceedings of the American Society of Clinical Oncology  18: A-554, 1999.</li><li id="section_2.10">Iandoli R: Shark cartilage in the treatment of psoriasis. Dermatologia Clinica  21 (part 1): 39-42, 2001.</li><li id="section_2.11">Milner M: A guide to the use of shark cartilage in the treatment of arthritis and other inflammatory joint diseases. American Chiropractor  21 (4): 40-2, 1999.</li><li id="section_2.12">Himmel PB, Seligman TM: Treatment of systemic sclerosis with shark cartilage extract. Journal of Orthomolecular Medicine   14 (2): 73-7, 1999. <a href="http://orthomolecular.org/library/jom/1999/pdf/1999-v14n02-p073.pdf" title="http://orthomolecular.org/library/jom/1999/pdf/1999-v14n02-p073.pdf">Also available online</a>. Last accessed April 8, 2016.</li><li id="section_2.13">Sorbera LA, Casta&#xF1;er RM, Leeson PA: AE-941. Oncolytic, antipsoriatic, treatment of age-related macular degeneration, angiogenesis inhibitor. Drugs Future  25 (6): 551-7, 2000.</li><li id="section_2.14">Prudden JF, Migel P, Hanson P, et al.: The discovery of a potent pure chemical wound-healing accelerator. Am J Surg 119 (5): 560-4, 1970.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=5441746&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=5441746&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.15">AE 941--Neovastat. Drugs R D 1 (2): 135-6, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10566006&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10566006&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.16">Cassileth BR: Shark and bovine cartilage therapies. In: Cassileth BR, ed.: The Alternative Medicine Handbook: The Complete Reference Guide to Alternative and Complementary Therapies. New York, NY: WW Norton &amp; Company, 1998, pp 197-200.</li><li id="section_2.17">Holt S: Shark cartilage and nutriceutical update. Altern Complement Ther  1 (6): 414-16, 1995.</li><li id="section_2.18">Hunt TJ, Connelly JF: Shark cartilage for cancer treatment. Am J Health Syst Pharm 52 (16): 1756, 1760, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8528831&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8528831&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.19">Fontenele JB, Ara&#xFA;jo GB, de Alencar JW, et al.: The analgesic and anti-inflammatory effects of shark cartilage are due to a peptide molecule and are nitric oxide (NO) system dependent. Biol Pharm Bull 20 (11): 1151-4, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9401722&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9401722&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.20">Ostrander GK, Cheng KC, Wolf JC, et al.: Shark cartilage, cancer and the growing threat of pseudoscience. Cancer Res 64 (23): 8485-91, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15574750&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15574750&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.21">Finkelstein JB: Sharks do get cancer: few surprises in cartilage research. J Natl Cancer Inst 97 (21): 1562-3, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16264172&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16264172&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.22">Schlumberger HG, Lucke B: Tumors of fishes, amphibians, and reptiles. Cancer Res  8 (12): 657-754, 1948.</li><li id="section_2.23">Wellings SR: Neoplasia and primitive vertebrate phylogeny: echinoderms, prevertebrates, and fishes--A review. Natl Cancer Inst Monogr 31: 59-128, 1969.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4315900&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4315900&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.24">Durie BG, Soehnlen B, Prudden JF: Antitumor activity of bovine cartilage extract (Catrix-S) in the human tumor stem cell assay. J Biol Response Mod 4 (6): 590-5, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4087032&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4087032&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.25">Murray JB, Allison K, Sudhalter J, et al.: Purification and partial amino acid sequence of a bovine cartilage-derived collagenase inhibitor. J Biol Chem 261 (9): 4154-9, 1986.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3005321&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3005321&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.26">Moses MA, Sudhalter J, Langer R: Identification of an inhibitor of neovascularization from cartilage. Science 248 (4961): 1408-10, 1990.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1694043&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1694043&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.27">Moses MA, Sudhalter J, Langer R: Isolation and characterization of an inhibitor of neovascularization from scapular chondrocytes. J Cell Biol 119 (2): 475-82, 1992.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1383232&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1383232&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.28">Moses MA: A cartilage-derived inhibitor of neovascularization and metalloproteinases. Clin Exp Rheumatol 11 (Suppl 8): S67-9, 1993 Mar-Apr.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7686834&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7686834&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.29">Takigawa M, Pan HO, Enomoto M, et al.: A clonal human chondrosarcoma cell line produces an anti-angiogenic antitumor factor. Anticancer Res 10 (2A): 311-5, 1990 Mar-Apr.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1693264&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1693264&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.30">Ohba Y, Goto Y, Kimura Y, et al.: Purification of an angiogenesis inhibitor from culture medium conditioned by a human chondrosarcoma-derived chondrocytic cell line, HCS-2/8. Biochim Biophys Acta 1245 (1): 1-8, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7544625&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7544625&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.31">Sadove AM, Kuettner KE: Inhibition of mammary carcinoma invasiveness with cartilage-derived inhibitor. Surg Forum 28: 499-501, 1977.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=214885&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=214885&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.32">Langer R, Brem H, Falterman K, et al.: Isolations of a cartilage factor that inhibits tumor neovascularization. Science 193 (4247): 70-2, 1976.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=935859&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=935859&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.33">Langer R, Conn H, Vacanti J, et al.: Control of tumor growth in animals by infusion of an angiogenesis inhibitor. Proc Natl Acad Sci U S A 77 (7): 4331-5, 1980.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6159628&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6159628&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.34">Takigawa M, Shirai E, Enomoto M, et al.: Cartilage-derived anti-tumor factor (CATF) inhibits the proliferation of endothelial cells in culture. Cell Biol Int Rep 9 (7): 619-25, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4028190&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4028190&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.35">Takigawa M, Shirai E, Enomoto M, et al.: A factor in conditioned medium of rabbit costal chondrocytes inhibits the proliferation of cultured endothelial cells and angiogenesis induced by B16 melanoma: its relation with cartilage-derived anti-tumor factor (CATF). Biochem Int 14 (2): 357-63, 1987.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2437926&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2437926&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.36">Hiraki Y, Inoue H, Iyama K, et al.: Identification of chondromodulin I as a novel endothelial cell growth inhibitor. Purification and its localization in the avascular zone of epiphyseal cartilage. J Biol Chem 272 (51): 32419-26, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9405451&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9405451&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.37">Pauli BU, Memoli VA, Kuettner KE: Regulation of tumor invasion by cartilage-derived anti-invasion factor in vitro. J Natl Cancer Inst 67 (1): 65-73, 1981.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7019530&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7019530&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.38">Lee A, Langer R: Shark cartilage contains inhibitors of tumor angiogenesis. Science 221 (4616): 1185-7, 1983.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6193581&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6193581&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.39">Davis PF, He Y, Furneaux RH, et al.: Inhibition of angiogenesis by oral ingestion of powdered shark cartilage in a rat model. Microvasc Res 54 (2): 178-82, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9327389&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9327389&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.40">Sheu JR, Fu CC, Tsai ML, et al.: Effect of U-995, a potent shark cartilage-derived angiogenesis inhibitor, on anti-angiogenesis and anti-tumor activities. Anticancer Res 18 (6A): 4435-41, 1998 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9891506&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9891506&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.41">McGuire TR, Kazakoff PW, Hoie EB, et al.: Antiproliferative activity of shark cartilage with and without tumor necrosis factor-alpha in human umbilical vein endothelium. Pharmacotherapy 16 (2): 237-44, 1996 Mar-Apr.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8820467&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8820467&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.42">Oikawa T, Ashino-Fuse H, Shimamura M, et al.: A novel angiogenic inhibitor derived from Japanese shark cartilage (I). Extraction and estimation of inhibitory activities toward tumor and embryonic angiogenesis. Cancer Lett 51 (3): 181-6, 1990.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1693543&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1693543&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.43">Morris GM, Coderre JA, Micca PL, et al.: Boron neutron capture therapy of the rat 9L gliosarcoma: evaluation of the effects of shark cartilage. Br J Radiol 73 (868): 429-34, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10844870&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10844870&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.44">Dupont E, Falardeau P, Mousa SA, et al.: Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue. Clin Exp Metastasis 19 (2): 145-53, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11964078&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11964078&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.45">B&#xE9;liveau R, Gingras D, Kruger EA, et al.: The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects. Clin Cancer Res 8 (4): 1242-50, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11948139&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11948139&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.46">Liang JH, Wong KP: The characterization of angiogenesis inhibitor from shark cartilage. Adv Exp Med Biol 476: 209-23, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10949667&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10949667&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.47">Wojtowicz-Praga S: Clinical potential of matrix metalloprotease inhibitors. Drugs R D 1 (2): 117-29, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10566004&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10566004&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.48">Suzuki F: Cartilage-derived growth factor and antitumor factor: past, present, and future studies. Biochem Biophys Res Commun 259 (1): 1-7, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10334906&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10334906&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.49">Batist G, Champagne P, Hariton C, et al.: Dose-survival relationship in a phase II study of Neovastat in refractory renal cell carcinoma patients. [Abstract] Proceedings of the American Society of Clinical Oncology  21: A-1907, 2002.</li><li id="section_2.50">Loprinzi CL, Levitt R, Barton DL, et al.: Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial. Cancer 104 (1): 176-82, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15912493&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15912493&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.51">Folkman J: The role of angiogenesis in tumor growth. Semin Cancer Biol 3 (2): 65-71, 1992.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1378311&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1378311&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.52">Sipos EP, Tamargo RJ, Weingart JD, et al.: Inhibition of tumor angiogenesis. Ann N Y Acad Sci 732: 263-72, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7526758&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7526758&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.53">Li CY, Shan S, Huang Q, et al.: Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst 92 (2): 143-7, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10639516&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10639516&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.54">Alberts B, Bray D, Lewis J, et al.: Molecular Biology of the Cell. 3rd ed. New York, NY: Garland Publishing, 1994.</li><li id="section_2.55">Cremer MA, Rosloniec EF, Kang AH: The cartilage collagens: a review of their structure, organization, and role in the pathogenesis of experimental arthritis in animals and in human rheumatic disease. J Mol Med 76 (3-4): 275-88, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9535561&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9535561&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.56">Rosen J, Sherman WT, Prudden JF, et al.: Immunoregulatory effects of catrix. J Biol Response Mod 7 (5): 498-512, 1988.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2846789&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2846789&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.57">Houck JC, Jacob RA, Deangelo L, et al.: The inhibition of inflammation and the acceleration of tissue repair by cartilage powder. Surgery 51: 632-8, 1962.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14449250&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14449250&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.58">Simone CB, Simone NL, Simone CB 2nd: Shark cartilage for cancer. Lancet 351 (9113): 1440, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9593449&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9593449&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.59">Horsman MR, Alsner J, Overgaard J: The effect of shark cartilage extracts on the growth and metastatic spread of the SCCVII carcinoma. Acta Oncol 37 (5): 441-5, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9831372&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9831372&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.60">Gingras D, Batist G, B&#xE9;liveau R: AE-941 (Neovastat): a novel multifunctional antiangiogenic compound. Expert Rev Anticancer Ther 1 (3): 341-7, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12113101&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12113101&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _15
      field_pdq_section_title:
        - format: plain_text
          value: 'History'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_15" class="pdq-sections"><p id="_16" tabindex="-1">The <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43985&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043985&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">therapeutic</a> potential of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44190&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044190&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cartilage</a> has been investigated for more than
            30 years.  As noted previously (refer to the <a href="/about-cancer/treatment/cam/hp/cartilage-pdq#link/_5">General Information</a> section of this summary for more information),
            cartilage products have been tested as treatments for people with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45333&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045333&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cancer</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44219&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044219&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">psoriasis</a>, and
            <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44188&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044188&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">arthritis</a>.  Cartilage products have also been studied as enhancers of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=441269&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000441269&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">wound</a>
            repair and as treatments for people with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45371&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045371&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">osteoporosis</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45493&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045493&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">ulcerative colitis</a>,  <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44220&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044220&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">regional enteritis</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44183&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044183&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">acne</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44142&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044142&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">scleroderma</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44207&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044207&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">hemorrhoids</a>, severe <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44185&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044185&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">anal</a> itching, and the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45667&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045667&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">dermatitis</a> caused by poison oak and
            poison ivy.<a href="#cit/section_3.1">1</a><a href="#cit/section_3.2">2</a><a href="#cit/section_3.3">3</a><a href="#cit/section_3.4">4</a><a href="#cit/section_3.5">5</a></p><p id="_17" tabindex="-1">Early <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44195&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044195&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">studies</a> of cartilage&#x2019;s therapeutic potential utilized extracts of bovine
            (cow) cartilage.  The ability of these extracts to suppress <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44042&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044042&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">inflammation</a> was first described in
            the early 1960s.<a href="#cit/section_3.1">1</a>  The first report that bovine cartilage contains at least
            one <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46739&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046739&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">angiogenesis inhibitor</a> was published in the mid-1970s.<a href="#cit/section_3.6">6</a>  The use of
            bovine cartilage extracts to treat patients with cancer and the ability of
            these extracts to kill cancer <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46476&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046476&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cells</a> directly and to stimulate animal <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46356&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046356&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">immune
            systems</a> were first described in the mid- to late-1980s.<a href="#cit/section_3.7">7</a><a href="#cit/section_3.8">8</a><a href="#cit/section_3.9">9</a><a href="#cit/section_3.10">10</a></p><p id="_18" tabindex="-1">The first report that shark cartilage contains at least one angiogenesis inhibitor was published in the early 1980s,<a href="#cit/section_3.11">11</a> and the only
            published report of a clinical trial of shark cartilage as a treatment
            for people with cancer appeared in the late 1990s.<a href="#cit/section_3.12">12</a>  The more recent interest in shark
            cartilage is due, in part, to the greater abundance of cartilage in this
            animal and its apparently higher level of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44186&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044186&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">antiangiogenic</a> activity.  Approximately 6% of the body weight of a shark is composed of cartilage,
            compared with less than 1% of the body weight of a cow.<a href="#cit/section_3.13">13</a>  In
            addition,  on a weight-for-weight basis, shark
            cartilage contains approximately 1,000 times more antiangiogenic activity than bovine
            cartilage.<a href="#cit/section_3.11">11</a></p><p id="_19" tabindex="-1">As indicated previously (refer to  the <a href="/about-cancer/treatment/cam/hp/cartilage-pdq#link/_1">Overview</a> and <a href="/about-cancer/treatment/cam/hp/cartilage-pdq#link/_5">General Information</a> sections of this summary for more information), at
            least three different mechanisms of action have been proposed to explain the
            anticancer potential of cartilage: 1) it is <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43986&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043986&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">toxic</a> to cancer cells; 2) it
            stimulates the immune system; and 3) it inhibits <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46529&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046529&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">angiogenesis</a>.   Only
            limited evidence is available to support the first two mechanisms of action; however, the
            evidence in favor of the third mechanism is more substantial (refer to the
            <a href="/about-cancer/treatment/cam/hp/cartilage-pdq#link/_23">Laboratory/Animal/Preclinical Studies</a> section of this summary for more information).</p><p id="_20" tabindex="-1">The process of angiogenesis requires at least four coordinated steps, each
            of which may be a target for inhibition.  First, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46634&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046634&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">tumors</a> must communicate with
            the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44203&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044203&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">endothelial cells</a> that line
            the inside of nearby <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45020&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045020&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">blood vessels</a>.  This communication takes place, in part,
            through the secretion of angiogenesis factors such as <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44222&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044222&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">
            vascular endothelial growth factor</a>.<a href="#cit/section_3.14">14</a><a href="#cit/section_3.15">15</a><a href="#cit/section_3.16">16</a><a href="#cit/section_3.17">17</a><a href="#cit/section_3.18">18</a>  Second,
            the activated endothelial cells must divide to produce new endothelial
            cells, which will be used to make the new blood vessels.<a href="#cit/section_3.15">15</a><a href="#cit/section_3.17">17</a><a href="#cit/section_3.18">18</a><a href="#cit/section_3.19">19</a><a href="#cit/section_3.20">20</a>  Third, the dividing endothelial cells must migrate toward the
            tumor.<a href="#cit/section_3.15">15</a><a href="#cit/section_3.16">16</a><a href="#cit/section_3.17">17</a><a href="#cit/section_3.18">18</a><a href="#cit/section_3.19">19</a><a href="#cit/section_3.20">20</a>  To accomplish this, they must produce <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46081&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046081&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">enzymes</a> called <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44211&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044211&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">matrix metalloproteinases</a>,
            which will help them carve a pathway through the tissue elements that separate
            them from the tumor.<a href="#cit/section_3.18">18</a><a href="#cit/section_3.19">19</a><a href="#cit/section_3.20">20</a><a href="#cit/section_3.21">21</a><a href="#cit/section_3.22">22</a>  Fourth, the new endothelial cells
            must form the hollow tubes that will become the new blood vessels.<a href="#cit/section_3.17">17</a><a href="#cit/section_3.18">18</a>  Some angiogenesis inhibitors may be able to
            block more than one step in this process.</p><p id="_21" tabindex="-1">Cartilage is relatively resistant to invasion
            by tumor cells,<a href="#cit/section_3.23">23</a><a href="#cit/section_3.24">24</a><a href="#cit/section_3.25">25</a><a href="#cit/section_3.26">26</a><a href="#cit/section_3.27">27</a><a href="#cit/section_3.28">28</a><a href="#cit/section_3.29">29</a><a href="#cit/section_3.30">30</a> and  tumor cells use
            matrix metalloproteinases when they migrate during the process of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46710&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046710&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">metastasis</a>.<a href="#cit/section_3.21">21</a><a href="#cit/section_3.25">25</a><a href="#cit/section_3.31">31</a><a href="#cit/section_3.32">32</a> Therefore, if the angiogenesis inhibitors in cartilage are also inhibitors of
            matrix metalloproteinases, then the same <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45065&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045065&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">molecules</a> may be able to block both
            angiogenesis and metastasis.   Shark tissues other
            than cartilage have also been reported to produce <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=446109&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000446109&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">antitumor</a> substances.<a href="#cit/section_3.33">33</a><a href="#cit/section_3.34">34</a><a href="#cit/section_3.35">35</a><a href="#cit/section_3.36">36</a></p><h6 do-not-show="toc">References</h6><ol><li id="section_3.1">Houck JC, Jacob RA, Deangelo L, et al.: The inhibition of inflammation and the acceleration of tissue repair by cartilage powder. Surgery 51: 632-8, 1962.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14449250&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14449250&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.2">Prudden JF, Balassa LL: The biological activity of bovine cartilage preparations. Clinical demonstration of their potent anti-inflammatory capacity with supplementary notes on certain relevant fundamental supportive studies. Semin Arthritis Rheum 3 (4): 287-321, 1974 Summer.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4275322&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4275322&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.3">Prudden JF, Migel P, Hanson P, et al.: The discovery of a potent pure chemical wound-healing accelerator. Am J Surg 119 (5): 560-4, 1970.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=5441746&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=5441746&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.4">Cassileth BR: Shark and bovine cartilage therapies. In: Cassileth BR, ed.: The Alternative Medicine Handbook: The Complete Reference Guide to Alternative and Complementary Therapies. New York, NY: WW Norton &amp; Company, 1998, pp 197-200.</li><li id="section_3.5">Fontenele JB, Ara&#xFA;jo GB, de Alencar JW, et al.: The analgesic and anti-inflammatory effects of shark cartilage are due to a peptide molecule and are nitric oxide (NO) system dependent. Biol Pharm Bull 20 (11): 1151-4, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9401722&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9401722&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.6">Langer R, Brem H, Falterman K, et al.: Isolations of a cartilage factor that inhibits tumor neovascularization. Science 193 (4247): 70-2, 1976.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=935859&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=935859&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.7">Prudden JF: The treatment of human cancer with agents prepared from bovine cartilage. J Biol Response Mod 4 (6): 551-84, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4087031&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4087031&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.8">Romano CF, Lipton A, Harvey HA, et al.: A phase II study of Catrix-S in solid tumors. J Biol Response Mod 4 (6): 585-9, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3878861&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3878861&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.9">Durie BG, Soehnlen B, Prudden JF: Antitumor activity of bovine cartilage extract (Catrix-S) in the human tumor stem cell assay. J Biol Response Mod 4 (6): 590-5, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4087032&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4087032&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.10">Rosen J, Sherman WT, Prudden JF, et al.: Immunoregulatory effects of catrix. J Biol Response Mod 7 (5): 498-512, 1988.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2846789&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2846789&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.11">Lee A, Langer R: Shark cartilage contains inhibitors of tumor angiogenesis. Science 221 (4616): 1185-7, 1983.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6193581&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6193581&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.12">Miller DR, Anderson GT, Stark JJ, et al.: Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. J Clin Oncol 16 (11): 3649-55, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9817287&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9817287&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.13">Hunt TJ, Connelly JF: Shark cartilage for cancer treatment. Am J Health Syst Pharm 52 (16): 1756, 1760, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8528831&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8528831&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.14">Folkman J: The role of angiogenesis in tumor growth. Semin Cancer Biol 3 (2): 65-71, 1992.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1378311&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1378311&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.15">Sipos EP, Tamargo RJ, Weingart JD, et al.: Inhibition of tumor angiogenesis. Ann N Y Acad Sci 732: 263-72, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7526758&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7526758&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.16">Li CY, Shan S, Huang Q, et al.: Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst 92 (2): 143-7, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10639516&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10639516&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.17">Alberts B, Bray D, Lewis J, et al.: Molecular Biology of the Cell. 3rd ed. New York, NY: Garland Publishing, 1994.</li><li id="section_3.18">Moses MA: The regulation of neovascularization of matrix metalloproteinases and their inhibitors. Stem Cells 15 (3): 180-9, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9170209&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9170209&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.19">Stetler-Stevenson WG: Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 103 (9): 1237-41, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10225966&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10225966&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.20">Haas TL, Madri JA: Extracellular matrix-driven matrix metalloproteinase production in endothelial cells: implications for angiogenesis. Trends Cardiovasc Med 9 (3-4): 70-7, 1999 Apr-May.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10578520&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10578520&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.21">McCawley LJ, Matrisian LM: Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today 6 (4): 149-56, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10740253&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10740253&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.22">Mandal M, Mandal A, Das S, et al.: Clinical implications of matrix metalloproteinases. Mol Cell Biochem 252 (1-2): 305-29, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14577606&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14577606&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.23">Takigawa M, Pan HO, Enomoto M, et al.: A clonal human chondrosarcoma cell line produces an anti-angiogenic antitumor factor. Anticancer Res 10 (2A): 311-5, 1990 Mar-Apr.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1693264&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1693264&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.24">Ohba Y, Goto Y, Kimura Y, et al.: Purification of an angiogenesis inhibitor from culture medium conditioned by a human chondrosarcoma-derived chondrocytic cell line, HCS-2/8. Biochim Biophys Acta 1245 (1): 1-8, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7544625&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7544625&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.25">Sadove AM, Kuettner KE: Inhibition of mammary carcinoma invasiveness with cartilage-derived inhibitor. Surg Forum 28: 499-501, 1977.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=214885&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=214885&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.26">Takigawa M, Shirai E, Enomoto M, et al.: Cartilage-derived anti-tumor factor (CATF) inhibits the proliferation of endothelial cells in culture. Cell Biol Int Rep 9 (7): 619-25, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4028190&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4028190&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.27">Takigawa M, Shirai E, Enomoto M, et al.: A factor in conditioned medium of rabbit costal chondrocytes inhibits the proliferation of cultured endothelial cells and angiogenesis induced by B16 melanoma: its relation with cartilage-derived anti-tumor factor (CATF). Biochem Int 14 (2): 357-63, 1987.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2437926&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2437926&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.28">Pauli BU, Memoli VA, Kuettner KE: Regulation of tumor invasion by cartilage-derived anti-invasion factor in vitro. J Natl Cancer Inst 67 (1): 65-73, 1981.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7019530&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7019530&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.29">Liang JH, Wong KP: The characterization of angiogenesis inhibitor from shark cartilage. Adv Exp Med Biol 476: 209-23, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10949667&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10949667&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.30">Suzuki F: Cartilage-derived growth factor and antitumor factor: past, present, and future studies. Biochem Biophys Res Commun 259 (1): 1-7, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10334906&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10334906&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.31">Murray JB, Allison K, Sudhalter J, et al.: Purification and partial amino acid sequence of a bovine cartilage-derived collagenase inhibitor. J Biol Chem 261 (9): 4154-9, 1986.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3005321&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3005321&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.32">Wojtowicz-Praga S: Clinical potential of matrix metalloprotease inhibitors. Drugs R D 1 (2): 117-29, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10566004&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10566004&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.33">Pettit GR, Ode RH: Antineoplastic agents L: isolation and characterization of sphyrnastatins 1 and 2 from the hammerhead shark Sphyrna lewini. J Pharm Sci 66 (5): 757-8, 1977.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=874772&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=874772&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.34">Sigel MM, Fugmann RA: Studies on immunoglobulins reactive with tumor cells and antigens. Cancer Res 28 (7): 1457-9, 1968.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4174343&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4174343&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.35">Snodgrass MJ, Burke JD, Meetz GD: Inhibitory effect of shark serum on the Lewis lung carcinoma. J Natl Cancer Inst 56 (5): 981-4, 1976.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=994208&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=994208&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.36">Pugliese PT, Heinerman J: Devour Disease with Shark Liver Oil. Green Bay, Wis: Impakt Communications, 1999.</li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _23
      field_pdq_section_title:
        - format: plain_text
          value: 'Laboratory/Animal/Preclinical Studies'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_23" class="pdq-sections"><p id="_24" tabindex="-1"> The <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=446109&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000446109&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">antitumor</a> potential of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44190&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044190&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cartilage</a> has been investigated extensively in
            <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44512&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044512&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">laboratory</a> and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=454774&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000454774&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">animal studies</a>.  Some of these studies have assessed the
            toxicity of cartilage products toward <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45333&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045333&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cancer</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46476&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046476&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cells</a> <em><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45733&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045733&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">in vitro</a></em>.<a href="#cit/section_4.1">1</a><a href="#cit/section_4.2">2</a><a href="#cit/section_4.3">3</a><a href="#cit/section_4.4">4</a><a href="#cit/section_4.5">5</a></p><section id="_142"><h3 id="_142_toc">Powdered Cartilage Products</h3><p id="_25" tabindex="-1">In one study, cells from 22 freshly isolated human <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46634&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046634&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">tumors</a> (nine <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46687&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046687&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">ovary</a>,
            three <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=270740&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000270740&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">lung</a>, two brain, two <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=304766&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000304766&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">breast</a>, and one each of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45562&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045562&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">sarcoma</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45135&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045135&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">melanoma</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46462&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046462&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">colon</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46254&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046254&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">pancreas</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46133&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046133&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cervix</a>, and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=367406&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000367406&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">testis</a>) and three human <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44016&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044016&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cultured cell lines</a> (<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=444971&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000444971&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">breast
            cancer</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44237&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044237&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">colon cancer</a>, and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45795&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045795&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">myeloma</a>) were
            treated with Catrix, which is a commercially available powdered preparation of
            bovine (cow) cartilage.<a href="#cit/section_4.1">1</a> <a href="#cit/section_4.3">3</a><a href="#cit/section_4.4">4</a>  In the study, the growth of all
            three  cultured cell lines and cells from approximately 70% of the tumor
            specimens were inhibited by 50% or more when Catrix was used at high
            concentrations (1&#x2013;5 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44213&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044213&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">mg</a>/<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44214&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044214&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">mL</a> of culture fluid).  However, it is
            unclear whether the inhibitory effect of Catrix in this study was
            specific to the growth of cancer cells because  the preparation&#x2019;s   effect on the growth of
            normal cells was not tested.  In addition, the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44020&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044020&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cytotoxic</a> component of Catrix has
            not been identified, and it has not been shown that equivalent inhibitory
            concentrations of this component can be achieved in the bloodstreams of
            patients who may be treated with either <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44678&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044678&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">injected</a> or <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44068&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044068&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">oral</a> formulations of this
            product. (Refer to the  <a href="/about-cancer/treatment/cam/hp/cartilage-pdq#link/_36">Human/Clinical Studies</a> section of this summary for more information.)</p><p id="_27" tabindex="-1"> A commercially available preparation of powdered shark
            cartilage (no brand name given) was reported to have no effect on the growth
            of human <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45602&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045602&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">astrocytoma</a> cells <em>in
            vitro</em>.<a href="#cit/section_4.2">2</a>      The shark cartilage product   tested in this study, however, was  examined at
            only one concentration (0.75 mg/mL).<a href="#cit/section_4.2">2</a></p><p id="_28" tabindex="-1">The <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46356&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046356&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">immune system</a>&#x2013;stimulating potential of cartilage has also been
            investigated in laboratory and animal studies.<a href="#cit/section_4.6">6</a>  In one study,
            Catrix was shown to stimulate the production of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44918&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044918&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">antibodies</a> by mouse <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45611&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045611&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">B cells</a> (B <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45765&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045765&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">lymphocytes</a>) both <em>in vitro</em> and <em><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46352&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046352&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">in vivo</a></em>.   However, increased antibody
            production <em>in vivo</em> was observed only when Catrix was administered by <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46339&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046339&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">intraperitoneal</a>
            or <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46682&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046682&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">intravenous</a> injection.  It was not observed when oral formulations of
            Catrix were used.<a href="#cit/section_4.6">6</a>  In most experiments, the
            proliferation of mouse B cells (i.e., normal, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44217&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044217&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">nonmalignant</a> cells) <em>in vitro</em> was
            increasingly inhibited as the concentration of Catrix was increased (tested
            concentration range, 1&#x2013;20 mg/mL).  Catrix has also been
            reported to stimulate the activity of mouse <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44054&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044054&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">macrophages</a> <em>in vivo</em>,<a href="#cit/section_4.3">3</a>
            but results demonstrating this effect have not been published.</p><p id="_115" tabindex="-1">The effects of shark cartilage on the immune system were also reported in two studies that used the same purified protein fraction that had exhibited the most immunostimulatory effects when tested.<a href="#cit/section_4.7">7</a><a href="#cit/section_4.8">8</a> One study explored the effects of this fraction on tumor immune response by observing the infiltration of this fraction on CD4 and CD8 lymphocytes in a murine tumor model. An increase in the ratio of CD4/CD8 lymphocytes was seen in tumor-infiltrating lymphocytes but not in peripheral blood lymphocytes.<a href="#cit/section_4.8">8</a> The second study exploring immune system response measured antibody response, cytotoxic assay, lymphocyte transformation, and intratumor T-cell ratio in mice. The fraction exhibited the ability to augment delayed-type hypersensitivity response against sheep red blood cells in mice and to decrease the cytotoxic activity of natural killer cells. In addition, this fraction showed a strong inhibitory effect on human brain microvascular endothelial cell proliferation and migration in the fibrin matrix.<a href="#cit/section_4.7">7</a></p><p id="_35" tabindex="-1">Additional <em>in vivo</em> studies of the antitumor potential of shark cartilage
            have been published in the peer-reviewed scientific literature.<a href="#cit/section_4.9">9</a><a href="#cit/section_4.10">10</a><a href="#cit/section_4.11">11</a>  In
            one study, oral administration of powdered shark cartilage (no brand name
            given) was shown to inhibit chemically induced angiogenesis in the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44212&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044212&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">mesenteric membrane</a> of
            rats.<a href="#cit/section_4.9">9</a>  In another study, oral administration of powdered shark cartilage
            (no brand name given) was shown to reduce the growth of GS-9L
            <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45701&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045701&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">gliosarcomas</a> in rats.<a href="#cit/section_4.10">10</a>  It was reported in a third study that oral administration of two powdered shark cartilage products, Sharkilage and MIA Shark Powder, did not
            inhibit the growth or the metastasis of SCCVII <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46595&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046595&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">squamous cell carcinomas</a> in
            mice.<a href="#cit/section_4.11">11</a></p><p id="_29" tabindex="-1">A large number of laboratory and animal studies concerning the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44186&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044186&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">antiangiogenic</a> potential of cartilage have been published.<a href="#cit/section_4.2">2</a><a href="#cit/section_4.9">9</a><a href="#cit/section_4.12">12</a><a href="#cit/section_4.13">13</a><a href="#cit/section_4.14">14</a><a href="#cit/section_4.15">15</a><a href="#cit/section_4.16">16</a><a href="#cit/section_4.17">17</a><a href="#cit/section_4.18">18</a><a href="#cit/section_4.19">19</a><a href="#cit/section_4.20">20</a><a href="#cit/section_4.21">21</a><a href="#cit/section_4.22">22</a><a href="#cit/section_4.23">23</a><a href="#cit/section_4.24">24</a><a href="#cit/section_4.25">25</a><a href="#cit/section_4.26">26</a><a href="#cit/section_4.27">27</a><a href="#cit/section_4.28">28</a><a href="#cit/section_4.29">29</a><a href="#cit/section_4.30">30</a><a href="#cit/section_4.31">31</a><a href="#cit/section_4.32">32</a> Overall, these studies have revealed the presence of at least three <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46739&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046739&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">angiogenesis inhibitors</a> in bovine cartilage <a href="#cit/section_4.13">13</a><a href="#cit/section_4.14">14</a><a href="#cit/section_4.16">16</a><a href="#cit/section_4.17">17</a><a href="#cit/section_4.18">18</a><a href="#cit/section_4.21">21</a><a href="#cit/section_4.23">23</a><a href="#cit/section_4.33">33</a> and at least two in shark cartilage.<a href="#cit/section_4.2">2</a><a href="#cit/section_4.9">9</a><a href="#cit/section_4.25">25</a><a href="#cit/section_4.26">26</a></p></section><section id="_146"><h3 id="_146_toc">Aqueous Extracts of Cartilage</h3><p id="_147" tabindex="-1">A liquid (i.e., <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43998&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043998&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">aqueous</a>) extract of
            shark cartilage called AE-941/Neovastat has also been reported to inhibit
            the growth of a variety of cancer cell types <em>in vitro</em>.<a href="#cit/section_4.5">5</a>
            These results have not been published in a peer-reviewed scientific
            journal  and are not consistent with other results obtained by the same group of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44685&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044685&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">investigators</a>.<a href="#cit/section_4.27">27</a><a href="#cit/section_4.34">34</a></p><p id="_148" tabindex="-1">Three angiogenesis inhibitors in bovine cartilage have been very well
            characterized.<a href="#cit/section_4.13">13</a><a href="#cit/section_4.14">14</a><a href="#cit/section_4.16">16</a><a href="#cit/section_4.17">17</a><a href="#cit/section_4.18">18</a><a href="#cit/section_4.21">21</a><a href="#cit/section_4.23">23</a><a href="#cit/section_4.33">33</a>  They are relatively
            small <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46092&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046092&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">proteins</a> with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44216&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044216&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">molecular
            masses</a> that range from 23,000 to 28,000.<a href="#cit/section_4.13">13</a><a href="#cit/section_4.14">14</a><a href="#cit/section_4.16">16</a><a href="#cit/section_4.23">23</a>  These
            proteins, called cartilage-derived inhibitor (CDI), cartilage-derived
            antitumor factor (CATF), and cartilage-derived <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44249&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044249&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">collagenase</a> inhibitor (CDCI) by the
            researchers who purified them,<a href="#cit/section_4.13">13</a><a href="#cit/section_4.14">14</a><a href="#cit/section_4.21">21</a> have been shown to block <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44203&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044203&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">endothelial
            cell</a> proliferation <em>in vitro</em> and new <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45020&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045020&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">blood vessel</a> formation in the
            <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44193&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044193&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">chorioallantoic membrane</a> of chicken <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44202&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044202&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">embryos</a>.<a href="#cit/section_4.14">14</a><a href="#cit/section_4.16">16</a><a href="#cit/section_4.17">17</a><a href="#cit/section_4.18">18</a><a href="#cit/section_4.21">21</a><a href="#cit/section_4.23">23</a><a href="#cit/section_4.33">33</a>  Two of the proteins (CDI and CDCI) have been shown to inhibit <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44211&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044211&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">matrix
            metalloproteinase</a> activity <em>in vitro</em>,<a href="#cit/section_4.13">13</a><a href="#cit/section_4.14">14</a><a href="#cit/section_4.16">16</a><a href="#cit/section_4.18">18</a> and one (CDI)
            has been shown to inhibit endothelial cell migration <em>in vitro</em>.<a href="#cit/section_4.14">14</a><a href="#cit/section_4.16">16</a>  These proteins do not block the proliferation of normal cells or of tumor
            cells <em>in vitro</em>.<a href="#cit/section_4.14">14</a><a href="#cit/section_4.16">16</a><a href="#cit/section_4.17">17</a><a href="#cit/section_4.21">21</a><a href="#cit/section_4.33">33</a>  When the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44184&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044184&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">amino acid sequences</a> of CDI,
            CATF, and CDCI were determined, it was discovered that they were the same as
            those of proteins known otherwise as tissue inhibitor of matrix
            metalloproteinases 1 (TIMP-1), chondromodulin I, and  TIMP-2, respectively.<a href="#cit/section_4.13">13</a><a href="#cit/section_4.14">14</a><a href="#cit/section_4.18">18</a><a href="#cit/section_4.23">23</a><a href="#cit/section_4.33">33</a></p><p id="_149" tabindex="-1">A possible fourth angiogenesis inhibitor in bovine cartilage has been
            purified not from cartilage but from the culture fluid of bovine <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44191&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044191&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">chondrocytes</a>
            grown in the laboratory.<a href="#cit/section_4.15">15</a>  This inhibitor, which has been named
            chondrocyte-derived inhibitor (ChDI), is a protein that has a molecular mass
            of approximately 36,000.  It has been reported that ChDI and CDI/TIMP-1
            have similar antiangiogenic activities,<a href="#cit/section_4.15">15</a><a href="#cit/section_4.16">16</a><a href="#cit/section_4.33">33</a> but the
            relationship between these proteins is unclear because amino acid sequence
            information for ChDI is not available.  Thus, whether CDI/TIMP-1 is a
            breakdown product of ChDI or whether ChDI is truly the fourth angiogenesis
            inhibitor identified in bovine cartilage is unknown.</p><p id="_150" tabindex="-1">As indicated previously, shark cartilage, like bovine cartilage, contains
            more than one type of angiogenesis inhibitor.  One shark cartilage inhibitor,
            named U-995, reportedly contains two small proteins, one with a molecular mass
            of approximately 14,000 and the other with a molecular mass of approximately
            10,000.<a href="#cit/section_4.25">25</a>  Both proteins have shown antiangiogenic activity when tested
            individually.  The exact relationship between these two proteins and their relationship to the larger bovine angiogenesis inhibitors are not
            known because amino acid sequence information for U-995 is not available.
            U-995 has been reported to inhibit endothelial cell proliferation, endothelial
            cell migration,  matrix metalloproteinase activity <em>in vitro</em>, and the
            formation of new blood vessels in the chorioallantoic membrane of chicken
            embryos.<a href="#cit/section_4.25">25</a>  It does not appear to inhibit the proliferation of other types
            of normal cells or of cancer cells <em>in vitro</em>. Intraperitoneal but not
            oral administration of U-995 has been shown to inhibit the growth of mouse
            sarcoma-180 tumors implanted <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45914&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045914&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">subcutaneously</a> on the backs of mice and the
            formation of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45315&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045315&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">lung metastases</a> of mouse B16-F10 melanoma cells injected into the
            tail veins of mice.<a href="#cit/section_4.25">25</a></p><p id="_151" tabindex="-1">The second angiogenesis inhibitor identified in shark cartilage appears to
            have been studied independently by three groups of investigators.<a href="#cit/section_4.2">2</a><a href="#cit/section_4.26">26</a><a href="#cit/section_4.35">35</a>
            This inhibitor, which was named SCF2 by one of the groups,<a href="#cit/section_4.35">35</a> is a
            <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44218&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044218&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">proteoglycan</a> that has a molecular
            mass of  about 10,000.  Proteoglycans are combinations of
            <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44206&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044206&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">glycosaminoglycans</a> and protein.<a href="#cit/section_4.30">30</a>  The principal
            glycosaminoglycan in SCF2 is <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44210&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044210&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">keratan
            sulfate</a>.<a href="#cit/section_4.35">35</a>  SCF2 has been shown to block endothelial cell proliferation
            <em>in vitro</em>,<a href="#cit/section_4.2">2</a><a href="#cit/section_4.26">26</a><a href="#cit/section_4.35">35</a> the formation of new blood vessels in the chorioallantoic
            membrane of chicken embryos,<a href="#cit/section_4.2">2</a><a href="#cit/section_4.26">26</a> and tumor-induced angiogenesis in the
            <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44199&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044199&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">corneas</a> of rabbits.<a href="#cit/section_4.2">2</a><a href="#cit/section_4.26">26</a></p><p id="_152" tabindex="-1">Other studies have  demonstrated that AE-941/Neovastat, the previously
            mentioned aqueous extract of shark cartilage, has antiangiogenic activity,<a href="#cit/section_4.12">12</a><a href="#cit/section_4.27">27</a><a href="#cit/section_4.28">28</a><a href="#cit/section_4.34">34</a><a href="#cit/section_4.36">36</a><a href="#cit/section_4.37">37</a><a href="#cit/section_4.38">38</a><a href="#cit/section_4.39">39</a> but the molecular basis for this activity has not been
            defined.  Therefore, whether AE-941/Neovastat contains U-995 and/or SCF2 or
            some other angiogenesis inhibitor is not known.  It has been reported that
            AE-941/Neovastat inhibits endothelial cell proliferation and matrix
            metalloproteinase activity <em>in vitro</em> and the formation of new blood vessels in
            the chorioallantoic membrane of chicken embryos.<a href="#cit/section_4.12">12</a><a href="#cit/section_4.27">27</a><a href="#cit/section_4.31">31</a>  In addition, AE-941/Neovastat has been shown to induce endothelial cell <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46524&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046524&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">apoptosis</a> by activating caspases, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46081&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046081&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">enzymes</a> important in the promotion and regulation of apoptosis.<a href="#cit/section_4.32">32</a><a href="#cit/section_4.34">34</a><a href="#cit/section_4.38">38</a> It
            also appears to inhibit the action of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44222&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044222&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">vascular endothelial growth factor</a>, thus
            interfering with the communication between tumor cells and nearby blood
            vessels.<a href="#cit/section_4.28">28</a><a href="#cit/section_4.34">34</a><a href="#cit/section_4.37">37</a><a href="#cit/section_4.38">38</a>  AE-941/Neovastat may also inhibit angiogenesis through promotion of tissue plasminogen activator (tPA) activity. Neovastat stimulates tPA expression in endothelial cells through an increase in the transcription of the tPA gene.<a href="#cit/section_4.40">40</a> This transcriptional activation is associated with activation of c-Jun N-terminal kinase (JNK) and nuclear factor-kappa B (NF-kappa B) signaling pathways to an extent similar to tumor necrosis factor-alpha (TNF-alpha).<a href="#cit/section_4.40">40</a> Furthermore,  AE-941/Neovastat has been reported to inhibit the growth of
            DA3 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44560&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044560&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">mammary</a>          <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46216&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046216&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">adenocarcinoma</a> cells and the
            <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46710&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046710&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">metastasis</a> of Lewis lung <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45963&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045963&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">carcinoma</a>
            cells <em>in vivo</em> in mice.<a href="#cit/section_4.5">5</a><a href="#cit/section_4.27">27</a><a href="#cit/section_4.34">34</a><a href="#cit/section_4.41">41</a> In the Lewis lung
            carcinoma experiments, AE-941/Neovastat  enhanced the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44058&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044058&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">antimetastatic</a> effect of the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45214&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045214&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">chemotherapy</a> drug <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45230&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045230&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cisplatin</a>.<a href="#cit/section_4.5">5</a><a href="#cit/section_4.27">27</a><a href="#cit/section_4.34">34</a><a href="#cit/section_4.41">41</a> All the aspects of preclinical development have been reviewed.<a href="#cit/section_4.42">42</a></p><p id="_153" tabindex="-1">The cartilage-derived antiangiogenic substance troponin I (TnI) has been isolated from human cartilage and has been produced by the cloning and expression of cDNA of human cartilage. It has been shown to specifically inhibit angiogenesis <em>in vivo</em> and <em>in vitro</em>   and tumor metastasis <em>in vivo</em>.<a href="#cit/section_4.43">43</a> The active site of  Tnl has been located in the amino acid residues of 96 to 116. The synthetic peptide Glu94-Leu123 (pTnl) has been shown to be a potent inhibitor of endothelial cell tube formation and endothelial cell division and to inhibit pancreatic cancer metastases in an <em>in vivo</em> liver metastases model.<a href="#cit/section_4.44">44</a></p></section><h6 do-not-show="toc">References</h6><ol><li id="section_4.1">Durie BG, Soehnlen B, Prudden JF: Antitumor activity of bovine cartilage extract (Catrix-S) in the human tumor stem cell assay. J Biol Response Mod 4 (6): 590-5, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4087032&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4087032&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.2">McGuire TR, Kazakoff PW, Hoie EB, et al.: Antiproliferative activity of shark cartilage with and without tumor necrosis factor-alpha in human umbilical vein endothelium. Pharmacotherapy 16 (2): 237-44, 1996 Mar-Apr.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8820467&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8820467&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.3">Prudden JF: The treatment of human cancer with agents prepared from bovine cartilage. J Biol Response Mod 4 (6): 551-84, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4087031&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4087031&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.4">Romano CF, Lipton A, Harvey HA, et al.: A phase II study of Catrix-S in solid tumors. J Biol Response Mod 4 (6): 585-9, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3878861&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3878861&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.5">AE 941--Neovastat. Drugs R D 1 (2): 135-6, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10566006&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10566006&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.6">Rosen J, Sherman WT, Prudden JF, et al.: Immunoregulatory effects of catrix. J Biol Response Mod 7 (5): 498-512, 1988.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2846789&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2846789&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.7">Hassan ZM, Feyzi R, Sheikhian A, et al.: Low molecular weight fraction of shark cartilage can modulate immune responses and abolish angiogenesis. Int Immunopharmacol 5 (6): 961-70, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15829412&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15829412&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.8">Feyzi R, Hassan ZM, Mostafaie A: Modulation of CD(4)(+) and CD(8)(+) tumor infiltrating lymphocytes by a fraction isolated from shark cartilage: shark cartilage modulates anti-tumor immunity. Int Immunopharmacol 3 (7): 921-6, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12810349&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12810349&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.9">Davis PF, He Y, Furneaux RH, et al.: Inhibition of angiogenesis by oral ingestion of powdered shark cartilage in a rat model. Microvasc Res 54 (2): 178-82, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9327389&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9327389&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.10">Morris GM, Coderre JA, Micca PL, et al.: Boron neutron capture therapy of the rat 9L gliosarcoma: evaluation of the effects of shark cartilage. Br J Radiol 73 (868): 429-34, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10844870&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10844870&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.11">Horsman MR, Alsner J, Overgaard J: The effect of shark cartilage extracts on the growth and metastatic spread of the SCCVII carcinoma. Acta Oncol 37 (5): 441-5, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9831372&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9831372&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.12">Dupont E, Savard PE, Jourdain C, et al.: Antiangiogenic properties of a novel shark cartilage extract: potential role in the treatment of psoriasis. J Cutan Med Surg 2 (3): 146-52, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9479080&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9479080&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.13">Murray JB, Allison K, Sudhalter J, et al.: Purification and partial amino acid sequence of a bovine cartilage-derived collagenase inhibitor. J Biol Chem 261 (9): 4154-9, 1986.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3005321&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3005321&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.14">Moses MA, Sudhalter J, Langer R: Identification of an inhibitor of neovascularization from cartilage. Science 248 (4961): 1408-10, 1990.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1694043&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1694043&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.15">Moses MA, Sudhalter J, Langer R: Isolation and characterization of an inhibitor of neovascularization from scapular chondrocytes. J Cell Biol 119 (2): 475-82, 1992.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1383232&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1383232&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.16">Moses MA: A cartilage-derived inhibitor of neovascularization and metalloproteinases. Clin Exp Rheumatol 11 (Suppl 8): S67-9, 1993 Mar-Apr.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7686834&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7686834&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.17">Takigawa M, Pan HO, Enomoto M, et al.: A clonal human chondrosarcoma cell line produces an anti-angiogenic antitumor factor. Anticancer Res 10 (2A): 311-5, 1990 Mar-Apr.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1693264&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1693264&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.18">Ohba Y, Goto Y, Kimura Y, et al.: Purification of an angiogenesis inhibitor from culture medium conditioned by a human chondrosarcoma-derived chondrocytic cell line, HCS-2/8. Biochim Biophys Acta 1245 (1): 1-8, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7544625&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7544625&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.19">Langer R, Brem H, Falterman K, et al.: Isolations of a cartilage factor that inhibits tumor neovascularization. Science 193 (4247): 70-2, 1976.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=935859&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=935859&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.20">Langer R, Conn H, Vacanti J, et al.: Control of tumor growth in animals by infusion of an angiogenesis inhibitor. Proc Natl Acad Sci U S A 77 (7): 4331-5, 1980.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6159628&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6159628&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.21">Takigawa M, Shirai E, Enomoto M, et al.: Cartilage-derived anti-tumor factor (CATF) inhibits the proliferation of endothelial cells in culture. Cell Biol Int Rep 9 (7): 619-25, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4028190&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4028190&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.22">Takigawa M, Shirai E, Enomoto M, et al.: A factor in conditioned medium of rabbit costal chondrocytes inhibits the proliferation of cultured endothelial cells and angiogenesis induced by B16 melanoma: its relation with cartilage-derived anti-tumor factor (CATF). Biochem Int 14 (2): 357-63, 1987.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2437926&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2437926&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.23">Hiraki Y, Inoue H, Iyama K, et al.: Identification of chondromodulin I as a novel endothelial cell growth inhibitor. Purification and its localization in the avascular zone of epiphyseal cartilage. J Biol Chem 272 (51): 32419-26, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9405451&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9405451&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.24">Lee A, Langer R: Shark cartilage contains inhibitors of tumor angiogenesis. Science 221 (4616): 1185-7, 1983.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6193581&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6193581&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.25">Sheu JR, Fu CC, Tsai ML, et al.: Effect of U-995, a potent shark cartilage-derived angiogenesis inhibitor, on anti-angiogenesis and anti-tumor activities. Anticancer Res 18 (6A): 4435-41, 1998 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9891506&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9891506&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.26">Oikawa T, Ashino-Fuse H, Shimamura M, et al.: A novel angiogenic inhibitor derived from Japanese shark cartilage (I). Extraction and estimation of inhibitory activities toward tumor and embryonic angiogenesis. Cancer Lett 51 (3): 181-6, 1990.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1693543&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1693543&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.27">Dupont E, Falardeau P, Mousa SA, et al.: Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue. Clin Exp Metastasis 19 (2): 145-53, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11964078&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11964078&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.28">B&#xE9;liveau R, Gingras D, Kruger EA, et al.: The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects. Clin Cancer Res 8 (4): 1242-50, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11948139&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11948139&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.29">Cho J, Kim Y: Sharks: a potential source of antiangiogenic factors and tumor treatments. Mar Biotechnol (NY) 4 (6): 521-5, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14961226&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14961226&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.30">Alberts B, Bray D, Lewis J, et al.: Molecular Biology of the Cell. 3rd ed. New York, NY: Garland Publishing, 1994.</li><li id="section_4.31">Gingras D, Renaud A, Mousseau N, et al.: Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound. Anticancer Res 21 (1A): 145-55, 2001 Jan-Feb.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11299728&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11299728&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.32">Boivin D, Gendron S, Beaulieu E, et al.: The antiangiogenic agent Neovastat (AE-941) induces endothelial cell apoptosis. Mol Cancer Ther 1 (10): 795-802, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12492112&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12492112&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.33">Suzuki F: Cartilage-derived growth factor and antitumor factor: past, present, and future studies. Biochem Biophys Res Commun 259 (1): 1-7, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10334906&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10334906&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.34">Falardeau P, Champagne P, Poyet P, et al.: Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol 28 (6): 620-5, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11740820&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11740820&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.35">Liang JH, Wong KP: The characterization of angiogenesis inhibitor from shark cartilage. Adv Exp Med Biol 476: 209-23, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10949667&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10949667&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.36">Bukowski RM: AE-941, a multifunctional antiangiogenic compound: trials in renal cell carcinoma. Expert Opin Investig Drugs 12 (8): 1403-11, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12882625&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12882625&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.37">Gingras D, Batist G, B&#xE9;liveau R: AE-941 (Neovastat): a novel multifunctional antiangiogenic compound. Expert Rev Anticancer Ther 1 (3): 341-7, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12113101&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12113101&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.38">Gingras D, Boivin D, Deckers C, et al.: Neovastat--a novel antiangiogenic drug for cancer therapy. Anticancer Drugs 14 (2): 91-6, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12569294&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12569294&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.39">Ryoo JJ, Cole CE, Anderson KC: Novel therapies for multiple myeloma. Blood Rev 16 (3): 167-74, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12163002&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12163002&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.40">Gingras D, Nyalendo C, Di Tomasso G, et al.: Activation of tissue plasminogen activator gene transcription by Neovastat, a multifunctional antiangiogenic agent. Biochem Biophys Res Commun 320 (1): 205-12, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15207722&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15207722&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.41">Wojtowicz-Praga S: Clinical potential of matrix metalloprotease inhibitors. Drugs R D 1 (2): 117-29, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10566004&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10566004&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.42">Dredge K: AE-941 (AEterna). Curr Opin Investig Drugs 5 (6): 668-77, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15242256&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15242256&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.43">Moses MA, Wiederschain D, Wu I, et al.: Troponin I is present in human cartilage and inhibits angiogenesis. Proc Natl Acad Sci U S A 96 (6): 2645-50, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10077564&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10077564&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.44">Kern BE, Balcom JH, Antoniu BA, et al.: Troponin I peptide (Glu94-Leu123), a cartilage-derived angiogenesis inhibitor: in vitro and in vivo effects on human endothelial cells and on pancreatic cancer. J Gastrointest Surg 7 (8): 961-8; discussion 969, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14675705&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14675705&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _36
      field_pdq_section_title:
        - format: plain_text
          value: 'Human/Clinical Studies'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_36" class="pdq-sections"><p id="_96" tabindex="-1">Since the early 1970s,    at least a dozen clinical trials<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44195&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044195&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);"></a> (<a href="/clinicaltrials/NCT00005838">MDA-ID-99303</a>, <a href="/clinicaltrials/NCT00026117">NCCTG-971151</a>, and <a href="/clinicaltrials/NCT00022282">AETERNA-AE-MM-00-02</a>) of  <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44190&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044190&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cartilage</a> as a treatment for  people with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45333&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045333&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cancer
            </a> have been (or are being) conducted;<a href="#cit/section_5.1">1</a><a href="#cit/section_5.2">2</a><a href="#cit/section_5.3">3</a><a href="#cit/section_5.4">4</a><a href="#cit/section_5.5">5</a><a href="#cit/section_5.6">6</a><a href="#cit/section_5.7">7</a><a href="#cit/section_5.8">8</a><a href="#cit/section_5.9">9</a><a href="#cit/section_5.10">10</a><a href="#cit/section_5.11">11</a><a href="#cit/section_5.12">12</a><a href="#cit/section_5.13">13</a><a href="#cit/section_5.14">14</a><a href="#cit/section_5.15">15</a>   (refer to the <a href="/about-cancer/treatment/cam/hp/cartilage-pdq#link/_82">table</a> at the end of this section) however, results
            from only    seven studies have been published in peer-reviewed scientific
            journals.<a href="#cit/section_5.1">1</a><a href="#cit/section_5.2">2</a><a href="#cit/section_5.4">4</a><a href="#cit/section_5.8">8</a><a href="#cit/section_5.9">9</a><a href="#cit/section_5.16">16</a> It is not clear whether any of the patients in these
            studies were children.   </p><p id="_97" tabindex="-1">In the first randomized trial published in a peer-reviewed scientific journal, 83 incurable <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=444971&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000444971&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">breast cancer</a> and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=444983&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000444983&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">colorectal cancer</a> patients were randomly assigned to receive either shark cartilage or <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46688&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046688&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">placebo</a>, in addition to standard care. No difference was observed in survival or <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45417&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045417&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">quality of life</a> between those receiving shark cartilage and those receiving placebo.<a href="#cit/section_5.8">8</a> Additional clinical studies are under way; however,  the cumulative
            evidence is inconclusive regarding the effectiveness of cartilage as a
            treatment for people with cancer.</p><section id="_144"><h3 id="_144_toc">Powdered Cartilage Products</h3><p id="_38" tabindex="-1">Two of the three published clinical studies evaluated the use of Catrix,
            the previously mentioned (refer to the <a href="/about-cancer/treatment/cam/hp/cartilage-pdq#link/_23">Laboratory/Animal/Preclinical Studies</a> section of this summary for more information)
            powdered preparation of bovine (cow) cartilage, as a treatment for various <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45301&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045301&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">solid
            tumors</a>.<a href="#cit/section_5.1">1</a><a href="#cit/section_5.2">2</a>  One of these studies was a <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44006&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044006&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">case series</a> that included 31
            patients;<a href="#cit/section_5.1">1</a> the other was a <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45831&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045831&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">phase II clinical trial</a> that
            included 9    patients.<a href="#cit/section_5.2">2</a></p><p id="_39" tabindex="-1">In the case series,<a href="#cit/section_5.1">1</a> all patients were treated with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45914&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045914&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">subcutaneously</a>
            <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44678&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044678&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">injected</a> and/or <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44068&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044068&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">oral</a> Catrix; however, three patients (one with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46595&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046595&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">squamous cell
            carcinoma</a> of the skin and two with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46515&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046515&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">basal cell carcinoma</a> of the
            skin) were also treated with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45927&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045927&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">topical</a> preparations.  The individual <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44664&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044664&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">dose</a>,
            the total dose, and the duration of Catrix treatment in this series varied
            from patient to patient; however, the minimum treatment duration was 7 months,
            and the maximum duration was more than 10 years.  Eighteen patients had been
            treated with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44198&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044198&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">conventional therapy</a> (<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45570&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045570&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">surgery</a>,
            <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45214&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045214&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">chemotherapy</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44971&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044971&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">radiation
            therapy</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46367&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046367&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">hormonal therapy</a>)
            within 1 year of the start of Catrix treatment; nine patients received
            conventional therapy concurrently with Catrix treatment;
            and seven patients received conventional therapy both prior to and during
            Catrix treatment.  It was reported that 19 patients had a <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45652&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045652&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">complete response</a>, 10 patients
            had a <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45819&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045819&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">partial response</a>, and 1 patient had <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45884&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045884&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">stable disease</a>
            following Catrix treatment.  The remaining patient did not respond to
            cartilage therapy.  Eight of the patients with a complete response received no
            prior or concurrent conventional therapy.  Approximately half of the patients
            with a complete response eventually experienced <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45862&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045862&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">recurrent cancer</a>.</p><p id="_40" tabindex="-1">This clinical study had several weaknesses that could have affected its
            outcome, including the absence of a <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44149&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044149&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">control group</a> and the receipt of
            prior and/or concurrent conventional therapy by most patients.</p><p id="_42" tabindex="-1">Partial results of a third clinical study of Catrix are described in an
            abstract submitted for presentation at a scientific conference,<a href="#cit/section_5.3">3</a> but
            complete results of this study have not been published in a peer-reviewed
            scientific journal.  In the study, 35 patients with metastatic renal cell
            carcinoma were divided into four  groups, and the individuals in each group
            were treated with identical doses of subcutaneously injected and/or oral
            Catrix.  Three partial responses and no complete responses were observed among
            22  <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44029&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044029&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">evaluable patients</a> who
            were treated with Catrix for more than 3 months.  Following Catrix therapy, 2 of the 22 evaluable
            patients were reported to have stable disease, and 17 were reported to have
            progressive disease.  No relationship between Catrix dose and tumor <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44085&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044085&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">response</a> could be
            established in this study.</p><p id="_43" tabindex="-1">The third published study of cartilage as a treatment for people with cancer was a
            <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45832&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045832&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">phase I/II trial</a> that tested
            the safety and the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=346517&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000346517&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">efficacy</a> of orally administered Cartilade, a commercially
            available powdered preparation of shark cartilage, in 60 patients with various
            types of advanced solid tumors.<a href="#cit/section_5.4">4</a>  All but one patient in this trial had
            been treated previously with conventional therapy.  According to the design of
            the study, no additional anticancer treatment could be given concurrently with
            Cartilade therapy.  No complete responses or partial responses were observed
            among 50 evaluable patients who were treated with Cartilade for at least 6
            weeks.  However, stable disease that lasted 12 weeks or more was reported for
            10 of the 50 patients.  All ten of these patients eventually experienced
            progressive disease.</p><p id="_44" tabindex="-1">Partial results of three other clinical studies of powdered shark cartilage
            are described in two abstracts submitted for presentation at scientific
            conferences,<a href="#cit/section_5.5">5</a><a href="#cit/section_5.6">6</a> but complete results of these studies have not been
            published in peer-reviewed scientific journals.  All three studies were phase
            II clinical trials that involved patients with advanced disease; two of the
            studies were conducted by the same group of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44685&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044685&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">investigators</a>.<a href="#cit/section_5.5">5</a>  These three
            studies enrolled 20 patients with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=444971&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000444971&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">breast cancer</a>,<a href="#cit/section_5.5">5</a> 12 patients with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=445079&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000445079&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">prostate
            cancer</a>,<a href="#cit/section_5.5">5</a> and 12 patients with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45847&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045847&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">primary</a> brain tumors.<a href="#cit/section_5.6">6</a>  All patients had
            been treated previously with conventional therapy.  No other anticancer
            treatment was allowed concurrently with cartilage therapy.  In two of the
            studies,<a href="#cit/section_5.5">5</a> the name of the cartilage product was not identified; however, in
            the third study,<a href="#cit/section_5.6">6</a> the commercially available product BeneFin was used.  Ten
            patients in each study completed at least 8 weeks of treatment and therefore  were considered evaluable for response.  No complete responses or
            partial responses were observed in any of the studies.  Two evaluable patients
            in the breast cancer study were reported to have stable disease that lasted 8
            weeks or more; two evaluable patients in the brain tumor study had stable
            disease that lasted 20 weeks or more; and three evaluable patients in the
            prostate cancer study had stable disease that also lasted 20 weeks or
            more.</p></section><section id="_145"><h3 id="_145_toc">Aqueous Extracts of Cartilage</h3><p id="_41" tabindex="-1">In the phase II trial,<a href="#cit/section_5.2">2</a> Catrix was administered by subcutaneous injection
            only.  All patients in this trial had <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45850&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045850&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">progressive disease</a> following
            radiation therapy and/or chemotherapy.  Identical individual doses of Catrix
            were administered to each patient, but the duration of treatment and the total
            delivered dose varied because of disease progression or death.  The minimum
            duration of Catrix treatment in this study was 4 weeks.  One patient (with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44058&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044058&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">metastatic</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44988&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044988&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">renal cell carcinoma</a>) reportedly had a
            complete response that lasted more than 39 weeks.  The remaining eight
            patients did not respond to Catrix treatment.  The researchers in this trial
            also investigated whether Catrix had an effect on <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46356&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046356&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">immune system</a> function in
            these patients.  No consistent trend or change in the numbers, percentages, or
            ratios of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45993&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045993&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">white blood cells</a>
            (i.e., total <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45765&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045765&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">lymphocyte</a> counts, total <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44928&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044928&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">T cell</a> counts, total <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45611&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045611&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">B cell</a> counts,
            percentage of T cells, percentage of B cells, and ratio of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44594&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044594&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">helper T cells</a>  to
            <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45664&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045664&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cytotoxic T cells</a>) was
            observed, though increased numbers of T cells were found in three
            patients.</p><p id="_46" tabindex="-1">The safety and the efficacy of AE-941/Neovastat, the previously mentioned
            <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43998&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043998&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">aqueous</a> extract of shark cartilage, has also been examined in clinical
            studies.<a href="#cit/section_5.9">9</a><a href="#cit/section_5.10">10</a><a href="#cit/section_5.11">11</a><a href="#cit/section_5.15">15</a><a href="#cit/section_5.17">17</a> It has been reported that AE-941/Neovastat has little <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43986&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043986&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">toxicity</a>.<a href="#cit/section_5.10">10</a><a href="#cit/section_5.11">11</a><a href="#cit/section_5.15">15</a>  In addition, there is evidence from a randomized clinical trial that examined the effect of AE-941/Neovastat on <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46529&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046529&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">angiogenesis</a> associated with surgical wound repair that  this product contains at least  one <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44186&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044186&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">antiangiogenic</a> component that is orally <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44225&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044225&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">bioavailable</a>.<a href="#cit/section_5.17">17</a></p><p id="_83" tabindex="-1">AE-941/Neovastat was administered to 331 patients with advanced solid tumors (including lung, prostate, breast, and kidney tumors) in two phase I/II trials.<a href="#cit/section_5.10">10</a>    The results of these trials, however, have not been fully reported. A <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44120&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044120&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">retrospective</a>     analysis involving a subgroup of patients with advanced <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45323&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045323&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">non-small cell lung cancer</a> (NSCLC) suggests that AE-941/Neovastat is able to lengthen the survival of patients with this disease.<a href="#cit/section_5.10">10</a>  Furthermore, in a  <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44079&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044079&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">prospective</a>     analysis involving 22  patients with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45863&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045863&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">refractory</a>   renal cell carcinoma, survival was longer in patients treated with 240 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44214&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044214&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">mL</a>/day AE-941/Neovastat than in patients treated with only 60 mL/day.<a href="#cit/section_5.7">7</a><a href="#cit/section_5.10">10</a><a href="#cit/section_5.16">16</a></p><p id="_121" tabindex="-1">In 2003, the results of a phase I/II trial of AE-941/Neovastat in 80 patients with advanced  NSCLC  reported that there was a significant survival advantage for patients receiving the highest doses (2.6 mL/kg/day) of AE-941/Neovastat. A survival analysis of 48 patients with unresectable stage IIIA, IIIB, or IV NSCLC showed a median survival advantage of <em>P</em> = .0026 in patients receiving the highest doses. The trial was principally conducted to explore the safety and efficacy of orally administered AE-941/Neovastat when administered in escalating doses (30, 60, 120, and 240 mL/day). No dose-limiting toxicity was found, and no tumor response was observed.<a href="#cit/section_5.9">9</a></p><p id="_47" tabindex="-1">In 2001, a phase II trial (AETERNA-AE-MM-00-02) of AE-941/Neovastat was initiated in patients with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45866&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045866&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">relapsed</a> or refractory <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45793&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045793&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">multiple myeloma</a>. This trial closed approximately 1 year later, and no results have been reported.<a href="#cit/section_5.18">18</a></p><p id="_48" tabindex="-1">Two randomized phase III trials of AE-941/Neovastat in patients
            with advanced cancer have been approved by the U.S. Food and Drug Administration (FDA).   In one trial (MDA-ID-99303),  which is completed,  treatment
            with oral AE-941/Neovastat plus chemotherapy and radiation therapy
            was compared with treatment with placebo plus the same chemotherapy and radiation
            therapy in patients with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45367&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045367&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">
            stage III NSCLC</a>.                   In the second  trial, which closed to patient recruitment in 2002, treatment
            with oral AE-941/Neovastat was compared with treatment with placebo in
            patients with metastatic renal cell carcinoma. Results from this second phase III trial have not been reported in the peer-reviewed scientific literature.<a href="#cit/section_5.19">19</a> Despite AE-941/Neovastat being granted orphan drug status by the FDA in 2002 for use  in the treatment of renal cell carcinoma, the company that produces AE-941/Neovastat,   Aeterna Laboratories, announced in early 2004 that this application would be discontinued in favor of a focus on the treatment of NSCLC.<a href="#cit/section_5.19">19</a><a href="#cit/section_5.20">20</a> </p><p id="_154" tabindex="-1">In 2010, the results of a randomized, double-blind, placebo-controlled phase III trial aimed at assessing the effect of adding AE-941 to chemotherapy and radiation
            therapy on the overall survival of patients with nonresectable stage III NSCLC were reported.  A total of 379 eligible patients received induction chemotherapy followed by concurrent chemotherapy with chest radiation
            therapy; participating centers used one of two chemotherapy regimens, either carboplatin and paclitaxel, or cisplatin and vinorelbine.  No statistically significant difference in overall survival was observed between the group (n = 188) receiving chemotherapy and radiation
            therapy plus AE-941 (120 mL administered orally twice daily) and the group receiving chemotherapy and radiation
            therapy plus placebo (n = 191).  Both AE-941 and placebo were well tolerated.<a href="#cit/section_5.21">21</a></p></section><table id="_82" class="table-default expandable-container"><caption>Cartilage Use in Cancer Treatment: Clinical Studies With Therapeutic Endpoints<span class="sup">a,b</span></caption><colgroup><col width="12.50%"><col width="12.50%"><col width="12.50%"><col width="12.50%"><col width="12.50%"><col width="12.50%"><col width="12.50%"><col width="12.50%"></colgroup><THead><tr><th>Reference  Citation(s)           </th><th>Type  of  Study           </th><th>Type(s)  of  Cancer</th><th>Cartilage
            Product (Source)</th><th>No. of Patients: Treated; Control</th><th>Strongest Benefit Reported<span class="sup">c</span></th><th>Concurrent Therapy<span class="sup">d</span></th><th>Level
            of Evidence Score<span class="sup">e</span></th></tr></THead><TFoot class="pdq-footer"><tr><td colspan="8">No. = number; NSCLC =  non-small cell lung cancer; wk = week.</td></tr><tr><td colspan="8"><span class="sup">a</span>See text and the <a href="https://www.cancer.gov/publications/dictionaries/cancer-terms/" title="https://www.cancer.gov/publications/dictionaries/cancer-terms/">NCI Dictionary     of Cancer Terms</a> for additional information and definition of
            terms. </td></tr><tr><td colspan="8"><span class="sup">b</span>Other clinical studies have been conducted, but no results have been
            reported.</td></tr><tr><td colspan="8"><span class="sup">c</span>Strongest evidence reported that the treatment under study has
            anticancer activity or otherwise improves the well-being of cancer patients. </td></tr><tr><td colspan="8"><span class="sup">d</span>Chemotherapy, radiation therapy, hormonal therapy, or cytokine therapy
            given/allowed at the same time as cartilage therapy. </td></tr><tr><td colspan="8"><span class="sup">e</span>For information about Levels of Evidence analysis and an explanation of
            the level of evidence scores, see <a href="/publications/pdq/levels-evidence/cam">Levels of Evidence for Human Studies of Integrative, Alternative, and Complementary Therapies</a>.  </td></tr><tr><td colspan="8"><span class="sup">f</span>Study results reported in review article or abstract form only; insufficient information presented for Level of Evidence analysis.</td></tr><tr><td colspan="8"><span class="sup">g</span>Insufficient information available to describe these studies separately.</td></tr></TFoot><tbody><tr><td><a href="#cit/section_5.8">8</a></td><td>Phase III randomized, placebo-controlled, double-blind trial (2 arms)</td><td>Breast and colorectal </td><td>BeneFin (shark)</td><td>42; 41 </td><td>No statistically significant difference</td><td>No</td><td>1i</td></tr><tr><td><a href="#cit/section_5.21">21</a></td><td>Randomized controlled phase III trial</td><td>NSCLC</td><td>AE-941 (shark)</td><td>188; 191</td><td>None</td><td>Cisplatin and vinorelbine; carboplatin and paclitaxel </td><td>1iA</td></tr><tr><td><a href="#cit/section_5.1">1</a></td><td><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44575&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044575&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">
            Nonconsecutive case series</a></td><td>Various advanced or recurrent          </td><td>Catrix (bovine)</td><td>31;
            None</td><td>Complete response, 19 patients          </td><td>Yes          </td><td>3iiiDiii          </td></tr><tr><td><a href="#cit/section_5.2">2</a></td><td>Phase II trial          </td><td>Various metastatic          </td><td>Catrix (bovine)</td><td>9;
            None</td><td>Complete response, 1
            patient, metastatic renal cell carcinoma          </td><td>No          </td><td>3iiiDiii          </td></tr><tr><td><a href="#cit/section_5.3">3</a></td><td>Phase II trial          </td><td>Metastatic renal cell          </td><td>Catrix (bovine)</td><td>35;
            None</td><td>Partial response, 3 of
            22 evaluable patients</td><td>Unknown</td><td>None<span class="sup">f</span></td></tr><tr><td><a href="#cit/section_5.10">10</a><a href="#cit/section_5.16">16</a></td><td>Two phase I/II trials<span class="sup">g</span></td><td>Various advanced, refractory solid tumors</td><td>AE-941/ Neovastat (shark)          </td><td>331;
            None          </td><td>Improved survival, higher versus lower
            doses, patients with stage III/IV non-small cell lung cancer (unplanned retrospective analysis), and patients with refractory renal cell carcinoma (prospective analysis)</td><td>Unknown</td><td>None<span class="sup">f</span></td></tr><tr><td><a href="#cit/section_5.9">9</a></td><td>Phase I/II trial</td><td>Advanced non-small cell lung cancer
            </td><td>AT-941/Neovastat (shark)
            </td><td>80; None
            </td><td>No dose-limiting toxicity found. Improved survival time in patients receiving the highest doses when survival analysis was conducted, and stable disease for greater number of patients receiving higher doses. No tumor response observed.</td><td>Yes or refused standard therapy</td><td>None</td></tr><tr><td><a href="#cit/section_5.4">4</a></td><td>Phase I/II trial          </td><td>Various advanced solid tumors</td><td>Cartilade (shark)</td><td>60;
            None          </td><td>Stable disease for 12 wk or more, 10 of
            50 evaluable patients</td><td>No          </td><td>3iiiDiii</td></tr><tr><td><a href="#cit/section_5.5">5</a></td><td>Phase II trial</td><td>Metastatic, refractory breast          </td><td>Unknown (shark)          </td><td>20;
            None          </td><td>Stable disease for 8 wk or more, 2 of
            10 evaluable patients         </td><td>No          </td><td>None<span class="sup">f</span></td></tr><tr><td><a href="#cit/section_5.5">5</a></td><td>Phase II trial          </td><td>Metastatic, hormone- refractory prostate</td><td>Unknown (shark)</td><td>12;
            None          </td><td>Stable disease for 20 wk or more, 3 of
            10 evaluable patients          </td><td>No          </td><td>None<span class="sup">f</span></td></tr><tr><td><a href="#cit/section_5.6">6</a></td><td>Phase II trial          </td><td>Various advanced brain          </td><td>BeneFin (shark)          </td><td>12;
            None          </td><td>Stable disease for 20 wk or more, 2 of
            10 evaluable patients</td><td>No          </td><td>None<span class="sup">f</span></td></tr></tbody></table><h6 do-not-show="toc">References</h6><ol><li id="section_5.1">Prudden JF: The treatment of human cancer with agents prepared from bovine cartilage. J Biol Response Mod 4 (6): 551-84, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4087031&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4087031&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.2">Romano CF, Lipton A, Harvey HA, et al.: A phase II study of Catrix-S in solid tumors. J Biol Response Mod 4 (6): 585-9, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3878861&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3878861&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.3">Puccio C, Mittelman A, Chun P, et al.: Treatment of metastatic renal cell carcinoma with Catrix. [Abstract] Proceedings of the American Society of Clinical Oncology  13: A-769, 246, 1994.</li><li id="section_5.4">Miller DR, Anderson GT, Stark JJ, et al.: Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. J Clin Oncol 16 (11): 3649-55, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9817287&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9817287&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.5">Leitner SP, Rothkopf MM, Haverstick L, et al.: Two phase II studies of oral dry shark cartilage powder (SCP) with either metastatic breast or prostate cancer refractory to standard treatment. [Abstract] Proceedings of the American Society of Clinical Oncology  17: A-240, 1998.</li><li id="section_5.6">Rosenbluth RJ, Jennis AA, Cantwell S, et al.: Oral shark cartilage in the treatment of patients with advanced primary brain tumors. [Abstract] Proceedings of the American Society of Clinical Oncology  18: A-554, 1999.</li><li id="section_5.7">Batist G, Champagne P, Hariton C, et al.: Dose-survival relationship in a phase II study of Neovastat in refractory renal cell carcinoma patients. [Abstract] Proceedings of the American Society of Clinical Oncology  21: A-1907, 2002.</li><li id="section_5.8">Loprinzi CL, Levitt R, Barton DL, et al.: Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial. Cancer 104 (1): 176-82, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15912493&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15912493&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.9">Latreille J, Batist G, Laberge F, et al.: Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer. Clin Lung Cancer 4 (4): 231-6, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14624712&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14624712&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.10">Falardeau P, Champagne P, Poyet P, et al.: Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol 28 (6): 620-5, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11740820&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11740820&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.11">AE 941--Neovastat. Drugs R D 1 (2): 135-6, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10566006&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10566006&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.12">Cassileth BR: Shark and bovine cartilage therapies. In: Cassileth BR, ed.: The Alternative Medicine Handbook: The Complete Reference Guide to Alternative and Complementary Therapies. New York, NY: WW Norton &amp; Company, 1998, pp 197-200.</li><li id="section_5.13">Holt S: Shark cartilage and nutriceutical update. Altern Complement Ther  1 (6): 414-16, 1995.</li><li id="section_5.14">Hunt TJ, Connelly JF: Shark cartilage for cancer treatment. Am J Health Syst Pharm 52 (16): 1756, 1760, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8528831&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8528831&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.15">AE 941. Drugs R D 5 (2): 83-9, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15293867&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15293867&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.16">Batist G, Patenaude F, Champagne P, et al.: Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. Ann Oncol 13 (8): 1259-63, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12181250&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12181250&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.17">Berbari P, Thibodeau A, Germain L, et al.: Antiangiogenic effects of the oral administration of liquid cartilage extract in humans. J Surg Res 87 (1): 108-13, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10527711&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10527711&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.18">Ryoo JJ, Cole CE, Anderson KC: Novel therapies for multiple myeloma. Blood Rev 16 (3): 167-74, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12163002&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12163002&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.19">Bukowski RM: AE-941, a multifunctional antiangiogenic compound: trials in renal cell carcinoma. Expert Opin Investig Drugs 12 (8): 1403-11, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12882625&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12882625&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.20">New treatment option for postmenopausal women with early breast cancer. Expert Rev Anticancer Ther 2 (6): 617, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12503198&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12503198&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.21">Lu C, Lee JJ, Komaki R, et al.: Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. J Natl Cancer Inst 102 (12): 859-65, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20505152&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20505152&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _57
      field_pdq_section_title:
        - format: plain_text
          value: 'Adverse Effects'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_57" class="pdq-sections"><p id="_58" tabindex="-1">The <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46580&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046580&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">side effects</a> associated with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44190&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044190&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cartilage</a> therapy are generally described
            as mild to moderate in severity.  <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44042&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044042&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">Inflammation</a> at <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44678&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044678&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">injection</a> sites, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44201&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044201&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">dysgeusia</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=321374&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000321374&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">fatigue</a>, nausea, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44200&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044200&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">dyspepsia</a>, fever, dizziness, and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45676&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045676&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">edema</a> of the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46573&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046573&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">scrotum</a> have been reported after treatment
            with the bovine (cow) cartilage product Catrix.<a href="#cit/section_6.1">1</a><a href="#cit/section_6.2">2</a><a href="#cit/section_6.3">3</a>  Nausea, vomiting, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46684&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046684&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">abdominal</a> cramping and/or bloating,
            constipation, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44039&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044039&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">hypotension</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44208&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044208&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">hyperglycemia</a>, generalized weakness,
            and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45363&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045363&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">hypercalcemia</a> have been
            associated with the use of powdered shark cartilage.<a href="#cit/section_6.4">4</a><a href="#cit/section_6.5">5</a><a href="#cit/section_6.6">6</a>  The high level of
            <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45632&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045632&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">calcium</a> in shark cartilage may contribute to the development of
            hypercalcemia.<a href="#cit/section_6.5">5</a><a href="#cit/section_6.7">7</a>  In addition, one case of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46371&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046371&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">hepatitis</a> has been associated with the
            use of powdered shark cartilage.<a href="#cit/section_6.8">8</a>  Nausea,  vomiting, and dyspepsia  are the most
            commonly reported side effects following treatment with AE-941/Neovastat, the
            <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43998&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043998&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">aqueous</a> extract of shark cartilage.<a href="#cit/section_6.9">9</a></p><h6 do-not-show="toc">References</h6><ol><li id="section_6.1">Prudden JF: The treatment of human cancer with agents prepared from bovine cartilage. J Biol Response Mod 4 (6): 551-84, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4087031&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4087031&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.2">Romano CF, Lipton A, Harvey HA, et al.: A phase II study of Catrix-S in solid tumors. J Biol Response Mod 4 (6): 585-9, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3878861&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3878861&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.3">Puccio C, Mittelman A, Chun P, et al.: Treatment of metastatic renal cell carcinoma with Catrix. [Abstract] Proceedings of the American Society of Clinical Oncology  13: A-769, 246, 1994.</li><li id="section_6.4">Miller DR, Anderson GT, Stark JJ, et al.: Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. J Clin Oncol 16 (11): 3649-55, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9817287&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9817287&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.5">Leitner SP, Rothkopf MM, Haverstick L, et al.: Two phase II studies of oral dry shark cartilage powder (SCP) with either metastatic breast or prostate cancer refractory to standard treatment. [Abstract] Proceedings of the American Society of Clinical Oncology  17: A-240, 1998.</li><li id="section_6.6">Rosenbluth RJ, Jennis AA, Cantwell S, et al.: Oral shark cartilage in the treatment of patients with advanced primary brain tumors. [Abstract] Proceedings of the American Society of Clinical Oncology  18: A-554, 1999.</li><li id="section_6.7">Jungi WF: Dangerous nutrition. Support Care Cancer 11 (4): 197-8, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12673456&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12673456&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.8">Ashar B, Vargo E: Shark cartilage-induced hepatitis. Ann Intern Med 125 (9): 780-1, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8929024&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8929024&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.9">Falardeau P, Champagne P, Poyet P, et al.: Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol 28 (6): 620-5, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11740820&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11740820&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _59
      field_pdq_section_title:
        - format: plain_text
          value: 'Summary of the Evidence for Cartilage'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_59" class="pdq-sections"><p id="_60" tabindex="-1">Although  at least a dozen <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44195&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044195&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">clinical studies</a> of <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44190&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044190&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cartilage</a> as a treatment for
            people with <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45333&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045333&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cancer</a> have been conducted since the early 1970s, relatively few results have
            been reported in the  peer-reviewed  scientific  literature. There are small amounts of reported data
            from <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45833&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045833&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">phase III clinical  trials</a>. Additional clinical studies are  now under
            way. At present,  the use of cartilage (bovine [cow] or shark) as a
            treatment for people with cancer cannot be recommended outside the context of
            well-designed clinical trials.</p><p id="_123" tabindex="-1">Separate <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=446533&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000446533&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">levels of evidence</a> scores are assigned to qualifying human studies on the basis of statistical strength of the study design and <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44724&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044724&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">scientific</a> strength of the treatment outcomes (i.e., <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=346519&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000346519&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">endpoints</a>) measured. The resulting two scores are then combined to produce an overall score.     For additional information about levels of evidence analysis, refer to <a href="/publications/pdq/levels-evidence/cam">Levels of Evidence for Human Studies of Integrative, Alternative, and Complementary Therapies</a>.
            </p></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _63
      field_pdq_section_title:
        - format: plain_text
          value: 'Changes to This Summary (08/23/2018)'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_63" class="pdq-sections"><p id="_64" tabindex="-1">The <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44271&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044271&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">PDQ</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45333&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045333&amp;version=healthprofessional&amp;language=English&amp;dictionary=Cancer.gov'); return(false);">cancer</a> information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.</p><p id="_163" tabindex="-1">Editorial changes were made to this summary.</p><p id="_disclaimerHP_3" tabindex="-1">This summary is written and maintained by the <a href="https://www.cancer.gov/publications/pdq/editorial-boards/cam" title="https://www.cancer.gov/publications/pdq/editorial-boards/cam">PDQ Integrative, Alternative, and Complementary Therapies Editorial Board</a>, which is
            editorially independent of NCI.  The summary reflects an independent review of
            the literature and does not represent a policy statement of NCI or NIH.  More
            information about summary policies and the role of the PDQ Editorial Boards  in
            maintaining the PDQ summaries can be found on the <a href="/about-cancer/treatment/cam/hp/cartilage-pdq#link/_AboutThis_1">About This PDQ Summary</a> and <a href="https://www.cancer.gov/publications/pdq" title="https://www.cancer.gov/publications/pdq">PDQ&#xAE; - NCI's Comprehensive Cancer Database</a> pages.
            </p></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _AboutThis_1
      field_pdq_section_title:
        - format: plain_text
          value: 'About This PDQ Summary'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_AboutThis_1" class="pdq-sections"><section id="_AboutThis_2"><h3 id="_AboutThis_2_toc">Purpose of This Summary</h3><p id="_AboutThis_3" tabindex="-1">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the use of cartilage (bovine and shark) in the treatment of people with cancer. It is intended as a resource to inform and assist clinicians who care for cancer patients.  It does not provide formal guidelines or recommendations for making health care decisions.</p></section><section id="_AboutThis_4"><h3 id="_AboutThis_4_toc">Reviewers and Updates</h3><p id="_AboutThis_5" tabindex="-1">This summary is reviewed regularly and updated as necessary by the <a href="https://www.cancer.gov/publications/pdq/editorial-boards/cam" title="https://www.cancer.gov/publications/pdq/editorial-boards/cam">PDQ Integrative, Alternative, and Complementary Therapies Editorial Board</a>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</p><p id="_AboutThis_22" tabindex="-1"> Board members review recently published articles each month to determine whether an article should:</p><div class="pdq-content-list"><ul id="_AboutThis_6"><li>be discussed at a meeting,</li><li>be cited with text, or</li><li>replace or update an existing article that is already cited.</li></ul></div><p id="_AboutThis_7" tabindex="-1">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</p><p id="" tabindex="-1">The lead reviewers for Cartilage (Bovine and Shark) are:</p><div class="pdq-content-list"><ul id=""><li>John A. Beutler, PhD (National Cancer Institute)</li><li>Keith I. Block, MD (Block Center for Integrative Cancer Treatment &amp; University of Illinois College of Medicine)</li></ul></div><p id="_AboutThis_9" tabindex="-1">Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's <a href="https://www.cancer.gov/contact/email-us" title="https://www.cancer.gov/contact/email-us">Email Us</a>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</p></section><section id="_AboutThis_10"><h3 id="_AboutThis_10_toc">Levels of Evidence</h3><p id="_AboutThis_11" tabindex="-1">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Integrative, Alternative, and Complementary Therapies Editorial Board uses a <a href="/publications/pdq/levels-evidence/cam">formal evidence ranking system</a> in developing its level-of-evidence designations.</p></section><section id="_AboutThis_12"><h3 id="_AboutThis_12_toc">Permission to Use This Summary</h3><p id="_AboutThis_13" tabindex="-1">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as &#x201C;NCI&#x2019;s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].&#x201D;</p><p id="_AboutThis_14" tabindex="-1">The preferred citation for this PDQ summary is:</p><p id="_AboutThis_15" tabindex="-1">PDQ&#xAE; Integrative, Alternative, and Complementary Therapies Editorial Board. PDQ Cartilage (Bovine and Shark). Bethesda, MD: National Cancer Institute. Updated  &lt;MM/DD/YYYY&gt;. Available at: <a href="https://www.cancer.gov/about-cancer/treatment/cam/hp/cartilage-pdq" title="https://www.cancer.gov/about-cancer/treatment/cam/hp/cartilage-pdq">https://www.cancer.gov/about-cancer/treatment/cam/hp/cartilage-pdq</a>.  Accessed &lt;MM/DD/YYYY&gt;. [PMID: 26389205]</p><p id="_AboutThis_16" tabindex="-1">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <a href="https://visualsonline.cancer.gov/" title="https://visualsonline.cancer.gov/">Visuals Online</a>, a collection of over 2,000 scientific images.
            </p></section><section id="_AboutThis_17"><h3 id="_AboutThis_17_toc">Disclaimer</h3><p id="_AboutThis_19" tabindex="-1">The information in these summaries should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <a href="https://www.cancer.gov/about-cancer/managing-care" title="https://www.cancer.gov/about-cancer/managing-care">Managing Cancer Care</a> page.</p></section><section id="_AboutThis_20"><h3 id="_AboutThis_20_toc">Contact Us</h3><p id="_AboutThis_21" tabindex="-1">More information about contacting us or receiving help with the Cancer.gov website can be found on our <a href="https://www.cancer.gov/contact" title="https://www.cancer.gov/contact">Contact Us for Help</a> page. Questions can also be submitted to Cancer.gov through the website&#x2019;s <a href="https://www.cancer.gov/contact/email-us" title="https://www.cancer.gov/contact/email-us">Email Us</a>.</p></section></div>
  title__ES:
    value: 'Cartílago (bovino y de tiburón) (PDQ®)–Versión para profesionales de salud'
  status__ES:
    value: 1
  langcode__ES:
    value: es
  moderation_state__ES:
    value: published
  field_pdq_url__ES:
    value: /cancer/tratamiento/mca/pro/cartilago-pdq
  field_pdq_cdr_id__ES:
    value: 789591
  field_pdq_audience__ES:
    value: Health Professionals
  field_pdq_summary_type__ES:
    value: Integrative, alternative, and complementary therapies
  field_date_posted__ES:
    value: '2017-07-10'
  field_date_updated__ES:
    value: '2017-07-10'
  field_short_title__ES:
    value: 'Cartílago (bovino y de tiburón)'
  field_page_description__ES:
    value: 'Resumen de información revisada por expertos sobre el uso de cartílago bovino y de tiburón como tratamiento para personas con cáncer. Nota: la información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta.'
  field_public_use__ES:
    value: 1
  field_summary_sections__ES:
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _1
      field_pdq_section_title:
        - format: plain_text
          value: 'Aspectos generales'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_1" class="pdq-sections"><div class="pdq-hp-patient-toggle"><a href="/espanol/cancer/tratamiento/mca/paciente/cartilago-pdq">Vaya a la versi&#xF3;n para pacientes</a></div><p id="_160" tabindex="-1">
            <strong>NOTA: La informaci&#xF3;n contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta.</strong>
            </p><p id="_2" tabindex="-1">En este sumario de informaci&#xF3;n sobre <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45333&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045333&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer</a> se proporciona una descripci&#xF3;n general del uso del <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44190&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044190&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">cart&#xED;lago</a> como tratamiento para personas con c&#xE1;ncer. El sumario incluye antecedentes breves de la investigaci&#xF3;n sobre el cart&#xED;lago, los resultados de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44195&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044195&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">estudios cl&#xED;nicos</a> y los posibles <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46580&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046580&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">efectos secundarios</a> relacionados con su uso.</p><p id="_3" tabindex="-1">Este sumario contiene la siguiente informaci&#xF3;n clave:</p><div class="pdq-content-list"><ul id="_4"><li>El cart&#xED;lago bovino (vacuno) y el cart&#xED;lago de tibur&#xF3;n se han estudiado como tratamiento para personas con c&#xE1;ncer y otras afecciones durante m&#xE1;s de 30 a&#xF1;os.</li><li>Hay numerosos productos de cart&#xED;lago que se venden en los comercios de los Estados Unidos como <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=373932&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000373932&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">suplementos alimentarios</a>.</li><li>Se propusieron tres mecanismos principales para explicar el potencial <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=446109&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000446109&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">antitumoral</a> del cart&#xED;lago: 1) destruye de forma directa las <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46476&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046476&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE9;lulas</a> cancerosas; 2) estimula el <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46356&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046356&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">sistema inmunitario</a>; 3) impide la formaci&#xF3;n de los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45020&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045020&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">vasos sangu&#xED;neos</a> nuevos (<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46529&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046529&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">angiog&#xE9;nesis</a>) que los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46634&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046634&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">tumores</a> necesitan para crecer sin restricciones.</li><li>En el cart&#xED;lago bovino se identificaron por lo menos tres inhibidores diferentes de la angiog&#xE9;nesis y en el cart&#xED;lago de tibur&#xF3;n se purificaron dos <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46739&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046739&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">inhibidores de la angiog&#xE9;nesis</a>.</li><li>Hasta la fecha, se realizaron pocos estudios del cart&#xED;lago como tratamiento para personas con c&#xE1;ncer; adem&#xE1;s, los resultados no son concluyentes.</li><li>En la actualidad, se est&#xE1;n realizando otros <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45961&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045961&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">ensayos cl&#xED;nicos</a> con cart&#xED;lago como tratamiento para personas con c&#xE1;ncer.</li></ul></div><p id="_61" tabindex="-1">Muchos de los t&#xE9;rminos m&#xE9;dicos y cient&#xED;ficos utilizados en este sumario tienen un enlace al <a href="http://www.cancer.gov/publications/dictionaries/cancer-terms/" title="http://www.cancer.gov/publications/dictionaries/cancer-terms/">Diccionario de c&#xE1;ncer del NCI</a> la primera vez que se mencionan en cada secci&#xF3;n. Este diccionario se orienta a personas sin conocimientos especializados. Al pulsar sobre un t&#xE9;rmino con un enlace, aparece la definici&#xF3;n en una ventana separada. </p><p id="_62" tabindex="-1">Las referencias bibliogr&#xE1;ficas citadas en algunos sumarios de informaci&#xF3;n sobre el c&#xE1;ncer del <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44271&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044271&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">PDQ</a> pueden incluir enlaces a otros sitios de Internet gestionados por individuos u organizaciones con el prop&#xF3;sito de comercializar o promover el uso de tratamientos o productos espec&#xED;ficos. Estas referencias bibliogr&#xE1;ficas se ofrecen solo con fines informativos. Su inclusi&#xF3;n no se debe interpretar como aprobaci&#xF3;n del contenido de esos sitios ni de ning&#xFA;n tratamiento o producto por parte del Consejo editorial del PDQ sobre las terapias integrales, alternativas y complementarias, o del <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44266&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044266&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">Instituto Nacional del C&#xE1;ncer</a>.</p></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _5
      field_pdq_section_title:
        - format: plain_text
          value: 'Información general'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_5" class="pdq-sections"><p id="_6" tabindex="-1">El <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44190&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044190&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">cart&#xED;lago</a> bovino (vacuno) y el cart&#xED;lago de tibur&#xF3;n se han investigado para el tratamiento de personas con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45333&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045333&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44219&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044219&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">psoriasis</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44188&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044188&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">artritis</a> y otras afecciones durante m&#xE1;s de 30 a&#xF1;os.<a href="#cit/section_2.1">1</a><a href="#cit/section_2.2">2</a><a href="#cit/section_2.3">3</a><a href="#cit/section_2.4">4</a><a href="#cit/section_2.5">5</a><a href="#cit/section_2.6">6</a><a href="#cit/section_2.7">7</a><a href="#cit/section_2.8">8</a><a href="#cit/section_2.9">9</a><a href="#cit/section_2.10">10</a><a href="#cit/section_2.11">11</a><a href="#cit/section_2.12">12</a><a href="#cit/section_2.13">13</a><a href="#cit/section_2.14">14</a><a href="#cit/section_2.15">15</a><a href="#cit/section_2.16">16</a><a href="#cit/section_2.17">17</a><a href="#cit/section_2.18">18</a><a href="#cit/section_2.19">19</a> Por lo menos parte del inter&#xE9;s en el cart&#xED;lago para el tratamiento de personas con c&#xE1;ncer surgi&#xF3; de la creencia err&#xF3;nea de que los tiburones, cuyos <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44221&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044221&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">esqueletos</a> se componen principalmente de cart&#xED;lago, no se ven afectados por esta enfermedad.<a href="#cit/section_2.16">16</a><a href="#cit/section_2.20">20</a><a href="#cit/section_2.21">21</a> Aunque es infrecuente que se informe sobre tumores <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45772&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045772&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">malignos</a> en los tiburones, se ha detectado una variedad de tumores en estos animales.<a href="#cit/section_2.20">20</a><a href="#cit/section_2.21">21</a><a href="#cit/section_2.22">22</a><a href="#cit/section_2.23">23</a> No obstante, se han identificado varias sustancias en el cart&#xED;lago que tienen actividad antitumoral.<a href="#cit/section_2.2">2</a><a href="#cit/section_2.3">3</a><a href="#cit/section_2.4">4</a><a href="#cit/section_2.7">7</a><a href="#cit/section_2.15">15</a><a href="#cit/section_2.16">16</a><a href="#cit/section_2.17">17</a><a href="#cit/section_2.18">18</a><a href="#cit/section_2.19">19</a><a href="#cit/section_2.24">24</a><a href="#cit/section_2.25">25</a><a href="#cit/section_2.26">26</a><a href="#cit/section_2.27">27</a><a href="#cit/section_2.28">28</a><a href="#cit/section_2.29">29</a><a href="#cit/section_2.30">30</a><a href="#cit/section_2.31">31</a><a href="#cit/section_2.32">32</a><a href="#cit/section_2.33">33</a><a href="#cit/section_2.34">34</a><a href="#cit/section_2.35">35</a><a href="#cit/section_2.36">36</a><a href="#cit/section_2.37">37</a><a href="#cit/section_2.38">38</a><a href="#cit/section_2.39">39</a><a href="#cit/section_2.40">40</a><a href="#cit/section_2.41">41</a><a href="#cit/section_2.42">42</a><a href="#cit/section_2.43">43</a><a href="#cit/section_2.44">44</a><a href="#cit/section_2.45">45</a><a href="#cit/section_2.46">46</a><a href="#cit/section_2.47">47</a><a href="#cit/section_2.48">48</a><a href="#cit/section_2.49">49</a> Ya se llevaron a cabo m&#xE1;s de media docena de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44195&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044195&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">estudios cl&#xED;nicos</a> de cart&#xED;lago para el tratamiento de personas con c&#xE1;ncer.<a href="#cit/section_2.2">2</a><a href="#cit/section_2.3">3</a><a href="#cit/section_2.4">4</a><a href="#cit/section_2.6">6</a><a href="#cit/section_2.7">7</a><a href="#cit/section_2.8">8</a><a href="#cit/section_2.9">9</a><a href="#cit/section_2.15">15</a><a href="#cit/section_2.16">16</a><a href="#cit/section_2.17">17</a><a href="#cit/section_2.18">18</a><a href="#cit/section_2.49">49</a><a href="#cit/section_2.50">50</a> Los estudios cl&#xED;nicos  <a href="/clinicaltrials/NCT00005838">MDA-ID-99303</a> y  <a href="/clinicaltrials/NCT00022282">AETERNA-AE-MM-00-02 </a> ya se completaron.<a href="#cit/section_2.6">6</a><a href="#cit/section_2.15">15</a><a href="#cit/section_2.50">50</a></p><p id="_7" tabindex="-1">La ausencia de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45020&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045020&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">vasos sangu&#xED;neos</a> en el cart&#xED;lago condujo a la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44209&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044209&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">hip&#xF3;tesis</a> de que las <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46476&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046476&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE9;lulas</a> del cart&#xED;lago (tambi&#xE9;n conocidas como <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44191&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044191&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">condrocitos</a>) producen una o m&#xE1;s sustancias que inhiben la formaci&#xF3;n de vasos sangu&#xED;neos.<a href="#cit/section_2.27">27</a><a href="#cit/section_2.28">28</a><a href="#cit/section_2.29">29</a><a href="#cit/section_2.30">30</a><a href="#cit/section_2.35">35</a><a href="#cit/section_2.36">36</a><a href="#cit/section_2.48">48</a> La formaci&#xF3;n de vasos sangu&#xED;neos nuevos o <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46529&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046529&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">angiog&#xE9;nesis</a> es necesaria para que los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46634&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046634&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">tumores</a> crezcan m&#xE1;s de unos pocos <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44215&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044215&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">mil&#xED;metros</a> de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44224&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044224&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">di&#xE1;metro</a> (es decir, que contengan m&#xE1;s de alrededor de 100&#xA0;000 a 1 000 000 de c&#xE9;lulas) porque los tumores, como los tejidos normales, deben obtener la mayor parte de su ox&#xED;geno y nutrientes de la sangre.<a href="#cit/section_2.33">33</a><a href="#cit/section_2.34">34</a><a href="#cit/section_2.41">41</a><a href="#cit/section_2.51">51</a><a href="#cit/section_2.52">52</a><a href="#cit/section_2.53">53</a><a href="#cit/section_2.54">54</a> En consecuencia, un tumor en desarrollo no puede continuar creciendo a menos que establezca conexiones con el <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44194&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044194&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">sistema circulatorio</a> de su hu&#xE9;sped. Se notific&#xF3; que los tumores pueden iniciar el proceso de angiog&#xE9;nesis con tan solo 100 c&#xE9;lulas.<a href="#cit/section_2.53">53</a> En algunos casos, es posible que la inhibici&#xF3;n de la angiog&#xE9;nesis en este <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45885&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045885&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">estadio</a> temprano lleve a la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46039&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046039&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">regresi&#xF3;n</a> completa del tumor.<a href="#cit/section_2.53">53</a> La posibilidad de que el cart&#xED;lago sea una fuente de uno o m&#xE1;s tipos de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46739&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046739&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">inhibidores de la angiog&#xE9;nesis</a> para el tratamiento del c&#xE1;ncer ha impulsado muchas investigaciones.</p><p id="_8" tabindex="-1">Los principales componentes estructurales del cart&#xED;lago incluyen varios tipos de la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46092&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046092&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">prote&#xED;na</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44196&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044196&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">col&#xE1;geno</a> y varios tipos de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44206&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044206&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">glucosaminoglucanos</a>, que son <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44162&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044162&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">polisac&#xE1;ridos</a>.<a href="#cit/section_2.19">19</a><a href="#cit/section_2.29">29</a><a href="#cit/section_2.30">30</a><a href="#cit/section_2.39">39</a><a href="#cit/section_2.48">48</a><a href="#cit/section_2.54">54</a><a href="#cit/section_2.55">55</a> El <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44192&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044192&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">sulfato de condroitina</a> es el glucosaminoglucano principal en el cart&#xED;lago.<a href="#cit/section_2.39">39</a><a href="#cit/section_2.54">54</a> Aunque no hay datos probatorios de que los col&#xE1;genos en el cart&#xED;lago o sus productos de descomposici&#xF3;n puedan inhibir la angiog&#xE9;nesis, hay pruebas de que el cart&#xED;lago de tibur&#xF3;n contiene por lo menos un inhibidor de la angiog&#xE9;nesis con un componente glucosaminoglucano (para obtener m&#xE1;s informaci&#xF3;n, consultar la secci&#xF3;n de este sumario sobre <a href="/about-cancer/treatment/cam/hp/cartilage-pdq#link/_23">Estudios precl&#xED;nicos de laboratorio o con animales</a>).<a href="#cit/section_2.46">46</a> Otros datos indican que la mayor parte de la actividad <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44186&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044186&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">antiangiog&#xE9;nica</a> del cart&#xED;lago no se vincula con los componentes estructurales m&#xE1;s importantes.<a href="#cit/section_2.26">26</a><a href="#cit/section_2.30">30</a><a href="#cit/section_2.48">48</a></p><p id="_9" tabindex="-1">Seg&#xFA;n se informa, algunos glucosaminoglucanos en el cart&#xED;lago tienen propiedades <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44187&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044187&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">antinflamatorias</a> y estimulantes del <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46356&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046356&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">sistema inmunitario</a>.<a href="#cit/section_2.1">1</a><a href="#cit/section_2.2">2</a><a href="#cit/section_2.14">14</a><a href="#cit/section_2.16">16</a><a href="#cit/section_2.56">56</a><a href="#cit/section_2.57">57</a> Asimismo, se indic&#xF3; que cualesquiera de ellos o algunos de sus productos de descomposici&#xF3;n producen efectos t&#xF3;xicos en las c&#xE9;lulas tumorales.<a href="#cit/section_2.2">2</a><a href="#cit/section_2.3">3</a><a href="#cit/section_2.24">24</a> As&#xED;, es posible que el potencial antitumoral del cart&#xED;lago incluya m&#xE1;s de un mecanismo de acci&#xF3;n.</p><p id="_10" tabindex="-1">Los productos de cart&#xED;lago se venden en los comercios de los Estados Unidos como <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=373932&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000373932&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">suplementos alimentarios</a>. Hay m&#xE1;s de 40 marcas comerciales disponibles para los consumidores.<a href="#cit/section_2.17">17</a> En los Estados Unidos, los suplementos alimentarios se reglamentan como alimentos, no como medicamentos. Por lo tanto, no se exige la evaluaci&#xF3;n y la aprobaci&#xF3;n de la Administraci&#xF3;n de Alimentos y Medicamentos  de los Estados Unidos (FDA) antes de la comercializaci&#xF3;n, a menos que se presente informaci&#xF3;n espec&#xED;fica de que sirven para prevenir o tratar una determinada enfermedad. Debido a que no se exige que los fabricantes de productos de cart&#xED;lago exhiban pruebas de efectos anticancer&#xED;genos u otros efectos biol&#xF3;gicos, no est&#xE1; claro si alguno de estos productos tiene potencial <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43985&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043985&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">terap&#xE9;utico</a>. Adem&#xE1;s, es posible que haya variaciones considerables de cada producto entre un lote y otro porque no hay procesos est&#xE1;ndar de fabricaci&#xF3;n y, a veces, se a&#xF1;aden <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44189&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044189&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">aglutinantes</a> y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44205&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044205&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">excipientes</a> durante la producci&#xF3;n.<a href="#cit/section_2.17">17</a> La FDA no ha aprobado el uso del cart&#xED;lago para el tratamiento de pacientes de c&#xE1;ncer o pacientes de cualquier otra afecci&#xF3;n m&#xE9;dica. La FDA est&#xE1; notificando a los consumidores sobre un programa de rembolso para quienes compraron el producto de cart&#xED;lago de tibur&#xF3;n BeneFin de Lane Labs-USA, Inc. Los consumidores que compraron este producto entre el 22 de septiembre y el 12 de julio de 2004 pueden solicitar un rembolso parcial del precio de compra y cualquier costo de env&#xED;o y manipulaci&#xF3;n.</p><p id="_11" tabindex="-1">Para llevar a cabo una investigaci&#xF3;n cl&#xED;nica de medicamentos en los Estados Unidos, los investigadores deben presentar una solicitud de un nuevo <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44763&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044763&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">producto en fase de investigaci&#xF3;n cl&#xED;nica</a> (IND) a la FDA. Hasta la fecha, se aprobaron las solicitudes de IND de por lo menos cuatro grupos de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44685&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044685&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">investigadores</a>, uno de los cuales corresponde al ensayo MDA-ID-99303, ya concluido, para estudiar el cart&#xED;lago como tratamiento para personas con c&#xE1;ncer.<a href="#cit/section_2.7">7</a><a href="#cit/section_2.18">18</a><a href="#cit/section_2.58">58</a> Debido a que el proceso de solicitud del IND es confidencial y porque la existencia de un IND solo la pueden revelar los solicitantes, no se sabe si se presentaron otras solicitudes.</p><p id="_12" tabindex="-1">En <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=454774&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000454774&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">estudios con animales</a>, los productos de cart&#xED;lago se administraron en varias formas. En algunos estudios, se administraron por v&#xED;a <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44068&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044068&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">oral</a> en l&#xED;quido o en polvo.<a href="#cit/section_2.19">19</a><a href="#cit/section_2.39">39</a><a href="#cit/section_2.40">40</a><a href="#cit/section_2.43">43</a><a href="#cit/section_2.44">44</a><a href="#cit/section_2.59">59</a> <a href="#cit/section_2.15">15</a><a href="#cit/section_2.47">47</a> En otros estudios, los productos de cart&#xED;lago se administraron por <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44678&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044678&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">inyecci&#xF3;n</a> (<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46682&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046682&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">intravenosa</a> o <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46339&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046339&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">intraperitoneal</a>), por aplicaci&#xF3;n <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45927&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045927&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">t&#xF3;pica</a> o implantaci&#xF3;n <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45570&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045570&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">quir&#xFA;rgica</a> de gr&#xE1;nulos de pl&#xE1;stico de liberaci&#xF3;n lenta.<a href="#cit/section_2.26">26</a><a href="#cit/section_2.27">27</a><a href="#cit/section_2.28">28</a><a href="#cit/section_2.32">32</a><a href="#cit/section_2.33">33</a><a href="#cit/section_2.35">35</a><a href="#cit/section_2.38">38</a><a href="#cit/section_2.40">40</a><a href="#cit/section_2.42">42</a><a href="#cit/section_2.44">44</a><a href="#cit/section_2.46">46</a><a href="#cit/section_2.48">48</a> En la mayor&#xED;a de estos &#xFA;ltimos estudios, se investigaron los efectos de los productos de cart&#xED;lago en la formaci&#xF3;n de vasos sangu&#xED;neos en la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44193&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044193&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">membrana corioalantoica</a> de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44202&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044202&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">embriones</a> de pollo, la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44199&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044199&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xF3;rnea</a> de conejos o la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44197&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044197&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">conjuntiva</a> de ratones.<a href="#cit/section_2.26">26</a><a href="#cit/section_2.27">27</a><a href="#cit/section_2.28">28</a><a href="#cit/section_2.32">32</a><a href="#cit/section_2.35">35</a><a href="#cit/section_2.38">38</a><a href="#cit/section_2.40">40</a><a href="#cit/section_2.42">42</a><a href="#cit/section_2.44">44</a><a href="#cit/section_2.46">46</a><a href="#cit/section_2.48">48</a></p><p id="_13" tabindex="-1">En estudios con seres humanos (MDA-ID-99303, AETERNA-AE-MM-00-02 y <a href="/clinicaltrials/NCT00026117">NCCTG-971151</a>), los productos de cart&#xED;lago se administraron en forma oral o t&#xF3;pica, o mediante <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44204&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044204&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">enema</a> o inyecci&#xF3;n <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45914&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045914&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">subcut&#xE1;nea</a>.<a href="#cit/section_2.2">2</a><a href="#cit/section_2.3">3</a><a href="#cit/section_2.4">4</a><a href="#cit/section_2.6">6</a><a href="#cit/section_2.7">7</a><a href="#cit/section_2.8">8</a><a href="#cit/section_2.9">9</a><a href="#cit/section_2.15">15</a><a href="#cit/section_2.16">16</a><a href="#cit/section_2.18">18</a><a href="#cit/section_2.60">60</a> Para la administraci&#xF3;n oral, se usaron formas l&#xED;quidas, en polvo o pastillas, como se describen en los siguientes ensayos finalizados: MDA-ID-99303, NCCTG-971151, <a href="/clinicaltrials/NCT00005995">AETERNA-AE-RC-99-02</a> y AETERNA-AE-MM-00-02.<a href="#cit/section_2.2">2</a><a href="#cit/section_2.3">3</a><a href="#cit/section_2.4">4</a><a href="#cit/section_2.6">6</a><a href="#cit/section_2.7">7</a><a href="#cit/section_2.8">8</a><a href="#cit/section_2.9">9</a><a href="#cit/section_2.15">15</a><a href="#cit/section_2.16">16</a><a href="#cit/section_2.18">18</a> En los estudios con seres humanos, hubo variaciones en la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44664&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044664&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">dosis</a> y la duraci&#xF3;n del tratamiento con cart&#xED;lago; en parte, porque se probaron distintos tipos de productos.</p><p id="_14" tabindex="-1">En este sumario y siempre que sea posible, se identificar&#xE1; el nombre de la marca (es decir, el nombre comercial o registrado) de los productos de cart&#xED;lago usados en cada estudio.</p><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_2.1">Prudden JF, Balassa LL: The biological activity of bovine cartilage preparations. Clinical demonstration of their potent anti-inflammatory capacity with supplementary notes on certain relevant fundamental supportive studies. Semin Arthritis Rheum 3 (4): 287-321, 1974 Summer.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4275322&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4275322&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.2">Prudden JF: The treatment of human cancer with agents prepared from bovine cartilage. J Biol Response Mod 4 (6): 551-84, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4087031&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4087031&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.3">Romano CF, Lipton A, Harvey HA, et al.: A phase II study of Catrix-S in solid tumors. J Biol Response Mod 4 (6): 585-9, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3878861&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3878861&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.4">Puccio C, Mittelman A, Chun P, et al.: Treatment of metastatic renal cell carcinoma with Catrix. [Abstract] Proceedings of the American Society of Clinical Oncology  13: A-769, 246, 1994.</li><li id="section_2.5">Dupont E, Savard PE, Jourdain C, et al.: Antiangiogenic properties of a novel shark cartilage extract: potential role in the treatment of psoriasis. J Cutan Med Surg 2 (3): 146-52, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9479080&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9479080&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.6">Falardeau P, Champagne P, Poyet P, et al.: Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol 28 (6): 620-5, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11740820&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11740820&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.7">Miller DR, Anderson GT, Stark JJ, et al.: Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. J Clin Oncol 16 (11): 3649-55, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9817287&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9817287&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.8">Leitner SP, Rothkopf MM, Haverstick L, et al.: Two phase II studies of oral dry shark cartilage powder (SCP) with either metastatic breast or prostate cancer refractory to standard treatment. [Abstract] Proceedings of the American Society of Clinical Oncology  17: A-240, 1998.</li><li id="section_2.9">Rosenbluth RJ, Jennis AA, Cantwell S, et al.: Oral shark cartilage in the treatment of patients with advanced primary brain tumors. [Abstract] Proceedings of the American Society of Clinical Oncology  18: A-554, 1999.</li><li id="section_2.10">Iandoli R: Shark cartilage in the treatment of psoriasis. Dermatologia Clinica  21 (part 1): 39-42, 2001.</li><li id="section_2.11">Milner M: A guide to the use of shark cartilage in the treatment of arthritis and other inflammatory joint diseases. American Chiropractor  21 (4): 40-2, 1999.</li><li id="section_2.12">Himmel PB, Seligman TM: Treatment of systemic sclerosis with shark cartilage extract. Journal of Orthomolecular Medicine   14 (2): 73-7, 1999. <a href="http://orthomolecular.org/library/jom/1999/pdf/1999-v14n02-p073.pdf" title="http://orthomolecular.org/library/jom/1999/pdf/1999-v14n02-p073.pdf">Also available online</a>. Last accessed April 8, 2016.</li><li id="section_2.13">Sorbera LA, Casta&#xF1;er RM, Leeson PA: AE-941. Oncolytic, antipsoriatic, treatment of age-related macular degeneration, angiogenesis inhibitor. Drugs Future  25 (6): 551-7, 2000.</li><li id="section_2.14">Prudden JF, Migel P, Hanson P, et al.: The discovery of a potent pure chemical wound-healing accelerator. Am J Surg 119 (5): 560-4, 1970.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=5441746&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=5441746&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.15">AE 941--Neovastat. Drugs R D 1 (2): 135-6, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10566006&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10566006&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.16">Cassileth BR: Shark and bovine cartilage therapies. In: Cassileth BR, ed.: The Alternative Medicine Handbook: The Complete Reference Guide to Alternative and Complementary Therapies. New York, NY: WW Norton &amp; Company, 1998, pp 197-200.</li><li id="section_2.17">Holt S: Shark cartilage and nutriceutical update. Altern Complement Ther  1 (6): 414-16, 1995.</li><li id="section_2.18">Hunt TJ, Connelly JF: Shark cartilage for cancer treatment. Am J Health Syst Pharm 52 (16): 1756, 1760, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8528831&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8528831&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.19">Fontenele JB, Ara&#xFA;jo GB, de Alencar JW, et al.: The analgesic and anti-inflammatory effects of shark cartilage are due to a peptide molecule and are nitric oxide (NO) system dependent. Biol Pharm Bull 20 (11): 1151-4, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9401722&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9401722&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.20">Ostrander GK, Cheng KC, Wolf JC, et al.: Shark cartilage, cancer and the growing threat of pseudoscience. Cancer Res 64 (23): 8485-91, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15574750&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15574750&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.21">Finkelstein JB: Sharks do get cancer: few surprises in cartilage research. J Natl Cancer Inst 97 (21): 1562-3, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16264172&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16264172&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.22">Schlumberger HG, Lucke B: Tumors of fishes, amphibians, and reptiles. Cancer Res  8 (12): 657-754, 1948.</li><li id="section_2.23">Wellings SR: Neoplasia and primitive vertebrate phylogeny: echinoderms, prevertebrates, and fishes--A review. Natl Cancer Inst Monogr 31: 59-128, 1969.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4315900&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4315900&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.24">Durie BG, Soehnlen B, Prudden JF: Antitumor activity of bovine cartilage extract (Catrix-S) in the human tumor stem cell assay. J Biol Response Mod 4 (6): 590-5, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4087032&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4087032&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.25">Murray JB, Allison K, Sudhalter J, et al.: Purification and partial amino acid sequence of a bovine cartilage-derived collagenase inhibitor. J Biol Chem 261 (9): 4154-9, 1986.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3005321&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3005321&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.26">Moses MA, Sudhalter J, Langer R: Identification of an inhibitor of neovascularization from cartilage. Science 248 (4961): 1408-10, 1990.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1694043&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1694043&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.27">Moses MA, Sudhalter J, Langer R: Isolation and characterization of an inhibitor of neovascularization from scapular chondrocytes. J Cell Biol 119 (2): 475-82, 1992.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1383232&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1383232&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.28">Moses MA: A cartilage-derived inhibitor of neovascularization and metalloproteinases. Clin Exp Rheumatol 11 (Suppl 8): S67-9, 1993 Mar-Apr.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7686834&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7686834&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.29">Takigawa M, Pan HO, Enomoto M, et al.: A clonal human chondrosarcoma cell line produces an anti-angiogenic antitumor factor. Anticancer Res 10 (2A): 311-5, 1990 Mar-Apr.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1693264&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1693264&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.30">Ohba Y, Goto Y, Kimura Y, et al.: Purification of an angiogenesis inhibitor from culture medium conditioned by a human chondrosarcoma-derived chondrocytic cell line, HCS-2/8. Biochim Biophys Acta 1245 (1): 1-8, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7544625&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7544625&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.31">Sadove AM, Kuettner KE: Inhibition of mammary carcinoma invasiveness with cartilage-derived inhibitor. Surg Forum 28: 499-501, 1977.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=214885&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=214885&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.32">Langer R, Brem H, Falterman K, et al.: Isolations of a cartilage factor that inhibits tumor neovascularization. Science 193 (4247): 70-2, 1976.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=935859&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=935859&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.33">Langer R, Conn H, Vacanti J, et al.: Control of tumor growth in animals by infusion of an angiogenesis inhibitor. Proc Natl Acad Sci U S A 77 (7): 4331-5, 1980.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6159628&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6159628&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.34">Takigawa M, Shirai E, Enomoto M, et al.: Cartilage-derived anti-tumor factor (CATF) inhibits the proliferation of endothelial cells in culture. Cell Biol Int Rep 9 (7): 619-25, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4028190&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4028190&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.35">Takigawa M, Shirai E, Enomoto M, et al.: A factor in conditioned medium of rabbit costal chondrocytes inhibits the proliferation of cultured endothelial cells and angiogenesis induced by B16 melanoma: its relation with cartilage-derived anti-tumor factor (CATF). Biochem Int 14 (2): 357-63, 1987.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2437926&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2437926&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.36">Hiraki Y, Inoue H, Iyama K, et al.: Identification of chondromodulin I as a novel endothelial cell growth inhibitor. Purification and its localization in the avascular zone of epiphyseal cartilage. J Biol Chem 272 (51): 32419-26, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9405451&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9405451&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.37">Pauli BU, Memoli VA, Kuettner KE: Regulation of tumor invasion by cartilage-derived anti-invasion factor in vitro. J Natl Cancer Inst 67 (1): 65-73, 1981.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7019530&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7019530&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.38">Lee A, Langer R: Shark cartilage contains inhibitors of tumor angiogenesis. Science 221 (4616): 1185-7, 1983.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6193581&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6193581&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.39">Davis PF, He Y, Furneaux RH, et al.: Inhibition of angiogenesis by oral ingestion of powdered shark cartilage in a rat model. Microvasc Res 54 (2): 178-82, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9327389&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9327389&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.40">Sheu JR, Fu CC, Tsai ML, et al.: Effect of U-995, a potent shark cartilage-derived angiogenesis inhibitor, on anti-angiogenesis and anti-tumor activities. Anticancer Res 18 (6A): 4435-41, 1998 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9891506&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9891506&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.41">McGuire TR, Kazakoff PW, Hoie EB, et al.: Antiproliferative activity of shark cartilage with and without tumor necrosis factor-alpha in human umbilical vein endothelium. Pharmacotherapy 16 (2): 237-44, 1996 Mar-Apr.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8820467&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8820467&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.42">Oikawa T, Ashino-Fuse H, Shimamura M, et al.: A novel angiogenic inhibitor derived from Japanese shark cartilage (I). Extraction and estimation of inhibitory activities toward tumor and embryonic angiogenesis. Cancer Lett 51 (3): 181-6, 1990.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1693543&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1693543&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.43">Morris GM, Coderre JA, Micca PL, et al.: Boron neutron capture therapy of the rat 9L gliosarcoma: evaluation of the effects of shark cartilage. Br J Radiol 73 (868): 429-34, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10844870&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10844870&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.44">Dupont E, Falardeau P, Mousa SA, et al.: Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue. Clin Exp Metastasis 19 (2): 145-53, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11964078&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11964078&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.45">B&#xE9;liveau R, Gingras D, Kruger EA, et al.: The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects. Clin Cancer Res 8 (4): 1242-50, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11948139&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11948139&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.46">Liang JH, Wong KP: The characterization of angiogenesis inhibitor from shark cartilage. Adv Exp Med Biol 476: 209-23, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10949667&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10949667&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.47">Wojtowicz-Praga S: Clinical potential of matrix metalloprotease inhibitors. Drugs R D 1 (2): 117-29, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10566004&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10566004&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.48">Suzuki F: Cartilage-derived growth factor and antitumor factor: past, present, and future studies. Biochem Biophys Res Commun 259 (1): 1-7, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10334906&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10334906&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.49">Batist G, Champagne P, Hariton C, et al.: Dose-survival relationship in a phase II study of Neovastat in refractory renal cell carcinoma patients. [Abstract] Proceedings of the American Society of Clinical Oncology  21: A-1907, 2002.</li><li id="section_2.50">Loprinzi CL, Levitt R, Barton DL, et al.: Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial. Cancer 104 (1): 176-82, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15912493&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15912493&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.51">Folkman J: The role of angiogenesis in tumor growth. Semin Cancer Biol 3 (2): 65-71, 1992.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1378311&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1378311&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.52">Sipos EP, Tamargo RJ, Weingart JD, et al.: Inhibition of tumor angiogenesis. Ann N Y Acad Sci 732: 263-72, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7526758&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7526758&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.53">Li CY, Shan S, Huang Q, et al.: Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst 92 (2): 143-7, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10639516&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10639516&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.54">Alberts B, Bray D, Lewis J, et al.: Molecular Biology of the Cell. 3rd ed. New York, NY: Garland Publishing, 1994.</li><li id="section_2.55">Cremer MA, Rosloniec EF, Kang AH: The cartilage collagens: a review of their structure, organization, and role in the pathogenesis of experimental arthritis in animals and in human rheumatic disease. J Mol Med 76 (3-4): 275-88, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9535561&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9535561&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.56">Rosen J, Sherman WT, Prudden JF, et al.: Immunoregulatory effects of catrix. J Biol Response Mod 7 (5): 498-512, 1988.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2846789&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2846789&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.57">Houck JC, Jacob RA, Deangelo L, et al.: The inhibition of inflammation and the acceleration of tissue repair by cartilage powder. Surgery 51: 632-8, 1962.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14449250&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14449250&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.58">Simone CB, Simone NL, Simone CB 2nd: Shark cartilage for cancer. Lancet 351 (9113): 1440, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9593449&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9593449&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.59">Horsman MR, Alsner J, Overgaard J: The effect of shark cartilage extracts on the growth and metastatic spread of the SCCVII carcinoma. Acta Oncol 37 (5): 441-5, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9831372&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9831372&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.60">Gingras D, Batist G, B&#xE9;liveau R: AE-941 (Neovastat): a novel multifunctional antiangiogenic compound. Expert Rev Anticancer Ther 1 (3): 341-7, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12113101&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12113101&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _15
      field_pdq_section_title:
        - format: plain_text
          value: 'Antecedentes'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_15" class="pdq-sections"><p id="_16" tabindex="-1">El potencial <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43985&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043985&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">terap&#xE9;utico</a> del <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44190&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044190&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">cart&#xED;lago</a> se ha investigado durante m&#xE1;s de 30 a&#xF1;os. Como se indica m&#xE1;s arriba (para obtener m&#xE1;s informaci&#xF3;n, consultar la secci&#xF3;n de este sumario sobre <a href="/about-cancer/treatment/cam/hp/cartilage-pdq#link/_5">Informaci&#xF3;n general</a>), los productos de cart&#xED;lago se han sometido a prueba como tratamientos para personas con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45333&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045333&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44219&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044219&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">psoriasis</a> y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44188&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044188&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">artritis</a>. Los productos de cart&#xED;lago tambi&#xE9;n se han estudiado como potenciadores de la reparaci&#xF3;n de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=441269&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000441269&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">heridas</a> y para tratar a personas con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45371&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045371&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">osteoporosis</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45493&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045493&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">colitis ulcerosa</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44220&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044220&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">enteritis regional</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44183&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044183&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">acn&#xE9;</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44142&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044142&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">esclerodermia</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44207&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044207&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">hemorroides</a>, picaz&#xF3;n <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44185&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044185&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">anal</a> grave y la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45667&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045667&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">dermatitis</a> causada por el roble venenoso y la hiedra venenosa.<a href="#cit/section_3.1">1</a><a href="#cit/section_3.2">2</a><a href="#cit/section_3.3">3</a><a href="#cit/section_3.4">4</a><a href="#cit/section_3.5">5</a></p><p id="_17" tabindex="-1">En los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44195&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044195&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">estudios</a> iniciales del potencial terap&#xE9;utico del cart&#xED;lago, se utilizaron extractos de cart&#xED;lago bovino (vacuno). La capacidad de estos extractos para suprimir la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44042&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044042&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">inflamaci&#xF3;n</a> se describi&#xF3; por primera vez a principios de la d&#xE9;cada de 1960.<a href="#cit/section_3.1">1</a> El primer informe que indic&#xF3; que el cart&#xED;lago bovino contiene por lo menos un <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46739&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046739&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">inhibidor de la angiog&#xE9;nesis</a> se public&#xF3; a mediados de la d&#xE9;cada de 1970.<a href="#cit/section_3.6">6</a> El uso de extractos de cart&#xED;lago bovino para tratar a pacientes de c&#xE1;ncer y la capacidad de estos extractos para destruir de forma directa las <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46476&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046476&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE9;lulas</a> cancerosas y estimular el <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46356&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046356&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">sistema inmunitario</a> de los animales se describieron por primera vez entre mediados y fines de la d&#xE9;cada de 1980.<a href="#cit/section_3.7">7</a><a href="#cit/section_3.8">8</a><a href="#cit/section_3.9">9</a><a href="#cit/section_3.10">10</a></p><p id="_18" tabindex="-1">El primer informe en el que se indic&#xF3; que el cart&#xED;lago de tibur&#xF3;n contiene por lo menos un inhibidor de la angiog&#xE9;nesis se public&#xF3; a principios de la d&#xE9;cada de 1980.<a href="#cit/section_3.11">11</a> Sin embargo, el &#xFA;nico informe sobre un ensayo cl&#xED;nico de cart&#xED;lago de tibur&#xF3;n como tratamiento para personas con c&#xE1;ncer se public&#xF3; a fines de la d&#xE9;cada de 1990.<a href="#cit/section_3.12">12</a> El inter&#xE9;s m&#xE1;s reciente por el cart&#xED;lago de tibur&#xF3;n se debe, en parte, a la mayor abundancia de cart&#xED;lago en este animal y, seg&#xFA;n parece, su nivel m&#xE1;s alto de actividad <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44186&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044186&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">antiangiog&#xE9;nica</a>. Alrededor de 6&#xA0;% del peso corporal de un tibur&#xF3;n se compone de cart&#xED;lago, en comparaci&#xF3;n con menos de 1&#xA0;% del peso corporal de una vaca.<a href="#cit/section_3.13">13</a> Adem&#xE1;s, al considerar solo el peso, el cart&#xED;lago de tibur&#xF3;n contiene cerca de 1000 veces m&#xE1;s de actividad antiangiog&#xE9;nica que el cart&#xED;lago bovino.<a href="#cit/section_3.11">11</a></p><p id="_19" tabindex="-1">Como se indicara m&#xE1;s arriba (consultar las secciones de este sumario sobre <a href="/about-cancer/treatment/cam/hp/cartilage-pdq#link/_1">Aspectos generales</a> e <a href="/about-cancer/treatment/cam/hp/cartilage-pdq#link/_5">Informaci&#xF3;n general</a>) se propusieron por lo menos tres mecanismos de acci&#xF3;n diferentes para explicar el potencial anticancer&#xED;geno del cart&#xED;lago: 1) es <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43986&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043986&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">t&#xF3;xico</a> para las c&#xE9;lulas cancerosas; 2) estimula el sistema inmunitario; 3) inhibe la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46529&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046529&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">angiog&#xE9;nesis</a>.   Solo se dispone de pruebas limitadas para apoyar los dos primeros mecanismos de acci&#xF3;n; sin embargo, hay pruebas de mayor peso para el tercer mecanismo (consultar la secci&#xF3;n de este sumario sobre <a href="/about-cancer/treatment/cam/hp/cartilage-pdq#link/_23">Estudios precl&#xED;nicos de laboratorio o con animales</a>).</p><p id="_20" tabindex="-1">El proceso de angiog&#xE9;nesis exige por lo menos cuatro etapas coordinadas, cada una de las cuales puede ser un objetivo para la inhibici&#xF3;n. En primer lugar, los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46634&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046634&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">tumores</a> se deben comunicar con las <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44203&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044203&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE9;lulas endoteliales</a> que revisten el interior de los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45020&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045020&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">vasos sangu&#xED;neos</a> cercanos. Esta comunicaci&#xF3;n tiene lugar, en parte, a trav&#xE9;s de la secreci&#xF3;n de factores angiog&#xE9;nicos como el <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44222&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044222&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">factor de crecimiento endotelial vascular</a>.<a href="#cit/section_3.14">14</a><a href="#cit/section_3.15">15</a><a href="#cit/section_3.16">16</a><a href="#cit/section_3.17">17</a><a href="#cit/section_3.18">18</a> En segundo lugar, las c&#xE9;lulas endoteliales activadas se deben multiplicar para producir c&#xE9;lulas endoteliales nuevas que se utilizar&#xE1;n para producir nuevos vasos sangu&#xED;neos.<a href="#cit/section_3.15">15</a><a href="#cit/section_3.17">17</a><a href="#cit/section_3.18">18</a><a href="#cit/section_3.19">19</a><a href="#cit/section_3.20">20</a> En tercer lugar, las c&#xE9;lulas endoteliales que se multiplican deben migrar hacia el tumor.<a href="#cit/section_3.15">15</a><a href="#cit/section_3.16">16</a><a href="#cit/section_3.17">17</a><a href="#cit/section_3.18">18</a><a href="#cit/section_3.19">19</a><a href="#cit/section_3.20">20</a> Para lograr esto, deben producir <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46081&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046081&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">enzimas</a> llamadas <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44211&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044211&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">metaloproteinasas de matriz</a>, que las ayudan a labrar un camino a trav&#xE9;s de los elementos de tejido que las separan del tumor.<a href="#cit/section_3.18">18</a><a href="#cit/section_3.19">19</a><a href="#cit/section_3.20">20</a><a href="#cit/section_3.21">21</a><a href="#cit/section_3.22">22</a> En cuarto lugar, las nuevas c&#xE9;lulas endoteliales deben formar tubos huecos que se convertir&#xE1;n en vasos sangu&#xED;neos nuevos.<a href="#cit/section_3.17">17</a><a href="#cit/section_3.18">18</a> Es posible que algunos inhibidores de la angiog&#xE9;nesis logren bloquear m&#xE1;s de un paso en este proceso.</p><p id="_21" tabindex="-1">El cart&#xED;lago es relativamente resistente a la invasi&#xF3;n de c&#xE9;lulas tumorales <a href="#cit/section_3.23">23</a><a href="#cit/section_3.24">24</a><a href="#cit/section_3.25">25</a><a href="#cit/section_3.26">26</a><a href="#cit/section_3.27">27</a><a href="#cit/section_3.28">28</a><a href="#cit/section_3.29">29</a><a href="#cit/section_3.30">30</a> y las c&#xE9;lulas tumorales utilizan metaloproteinasas de matriz cuando migran durante el proceso de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46710&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046710&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">met&#xE1;stasis</a>.<a href="#cit/section_3.21">21</a><a href="#cit/section_3.25">25</a><a href="#cit/section_3.31">31</a><a href="#cit/section_3.32">32</a> Por lo tanto, si los inhibidores de la angiog&#xE9;nesis en el cart&#xED;lago son tambi&#xE9;n inhibidores de las metaloproteinasas de matriz, es posible que las mismas <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45065&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045065&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">mol&#xE9;culas</a> bloqueen tanto la angiog&#xE9;nesis como la met&#xE1;stasis. Tambi&#xE9;n se ha informado que otros tejidos de tibur&#xF3;n, adem&#xE1;s del cart&#xED;lago, producen sustancias <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=446109&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000446109&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">antitumorales</a>.<a href="#cit/section_3.33">33</a><a href="#cit/section_3.34">34</a><a href="#cit/section_3.35">35</a><a href="#cit/section_3.36">36</a></p><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_3.1">Houck JC, Jacob RA, Deangelo L, et al.: The inhibition of inflammation and the acceleration of tissue repair by cartilage powder. Surgery 51: 632-8, 1962.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14449250&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14449250&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.2">Prudden JF, Balassa LL: The biological activity of bovine cartilage preparations. Clinical demonstration of their potent anti-inflammatory capacity with supplementary notes on certain relevant fundamental supportive studies. Semin Arthritis Rheum 3 (4): 287-321, 1974 Summer.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4275322&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4275322&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.3">Prudden JF, Migel P, Hanson P, et al.: The discovery of a potent pure chemical wound-healing accelerator. Am J Surg 119 (5): 560-4, 1970.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=5441746&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=5441746&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.4">Cassileth BR: Shark and bovine cartilage therapies. In: Cassileth BR, ed.: The Alternative Medicine Handbook: The Complete Reference Guide to Alternative and Complementary Therapies. New York, NY: WW Norton &amp; Company, 1998, pp 197-200.</li><li id="section_3.5">Fontenele JB, Ara&#xFA;jo GB, de Alencar JW, et al.: The analgesic and anti-inflammatory effects of shark cartilage are due to a peptide molecule and are nitric oxide (NO) system dependent. Biol Pharm Bull 20 (11): 1151-4, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9401722&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9401722&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.6">Langer R, Brem H, Falterman K, et al.: Isolations of a cartilage factor that inhibits tumor neovascularization. Science 193 (4247): 70-2, 1976.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=935859&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=935859&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.7">Prudden JF: The treatment of human cancer with agents prepared from bovine cartilage. J Biol Response Mod 4 (6): 551-84, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4087031&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4087031&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.8">Romano CF, Lipton A, Harvey HA, et al.: A phase II study of Catrix-S in solid tumors. J Biol Response Mod 4 (6): 585-9, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3878861&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3878861&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.9">Durie BG, Soehnlen B, Prudden JF: Antitumor activity of bovine cartilage extract (Catrix-S) in the human tumor stem cell assay. J Biol Response Mod 4 (6): 590-5, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4087032&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4087032&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.10">Rosen J, Sherman WT, Prudden JF, et al.: Immunoregulatory effects of catrix. J Biol Response Mod 7 (5): 498-512, 1988.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2846789&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2846789&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.11">Lee A, Langer R: Shark cartilage contains inhibitors of tumor angiogenesis. Science 221 (4616): 1185-7, 1983.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6193581&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6193581&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.12">Miller DR, Anderson GT, Stark JJ, et al.: Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. J Clin Oncol 16 (11): 3649-55, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9817287&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9817287&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.13">Hunt TJ, Connelly JF: Shark cartilage for cancer treatment. Am J Health Syst Pharm 52 (16): 1756, 1760, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8528831&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8528831&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.14">Folkman J: The role of angiogenesis in tumor growth. Semin Cancer Biol 3 (2): 65-71, 1992.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1378311&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1378311&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.15">Sipos EP, Tamargo RJ, Weingart JD, et al.: Inhibition of tumor angiogenesis. Ann N Y Acad Sci 732: 263-72, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7526758&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7526758&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.16">Li CY, Shan S, Huang Q, et al.: Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst 92 (2): 143-7, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10639516&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10639516&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.17">Alberts B, Bray D, Lewis J, et al.: Molecular Biology of the Cell. 3rd ed. New York, NY: Garland Publishing, 1994.</li><li id="section_3.18">Moses MA: The regulation of neovascularization of matrix metalloproteinases and their inhibitors. Stem Cells 15 (3): 180-9, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9170209&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9170209&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.19">Stetler-Stevenson WG: Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 103 (9): 1237-41, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10225966&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10225966&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.20">Haas TL, Madri JA: Extracellular matrix-driven matrix metalloproteinase production in endothelial cells: implications for angiogenesis. Trends Cardiovasc Med 9 (3-4): 70-7, 1999 Apr-May.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10578520&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10578520&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.21">McCawley LJ, Matrisian LM: Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today 6 (4): 149-56, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10740253&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10740253&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.22">Mandal M, Mandal A, Das S, et al.: Clinical implications of matrix metalloproteinases. Mol Cell Biochem 252 (1-2): 305-29, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14577606&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14577606&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.23">Takigawa M, Pan HO, Enomoto M, et al.: A clonal human chondrosarcoma cell line produces an anti-angiogenic antitumor factor. Anticancer Res 10 (2A): 311-5, 1990 Mar-Apr.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1693264&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1693264&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.24">Ohba Y, Goto Y, Kimura Y, et al.: Purification of an angiogenesis inhibitor from culture medium conditioned by a human chondrosarcoma-derived chondrocytic cell line, HCS-2/8. Biochim Biophys Acta 1245 (1): 1-8, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7544625&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7544625&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.25">Sadove AM, Kuettner KE: Inhibition of mammary carcinoma invasiveness with cartilage-derived inhibitor. Surg Forum 28: 499-501, 1977.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=214885&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=214885&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.26">Takigawa M, Shirai E, Enomoto M, et al.: Cartilage-derived anti-tumor factor (CATF) inhibits the proliferation of endothelial cells in culture. Cell Biol Int Rep 9 (7): 619-25, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4028190&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4028190&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.27">Takigawa M, Shirai E, Enomoto M, et al.: A factor in conditioned medium of rabbit costal chondrocytes inhibits the proliferation of cultured endothelial cells and angiogenesis induced by B16 melanoma: its relation with cartilage-derived anti-tumor factor (CATF). Biochem Int 14 (2): 357-63, 1987.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2437926&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2437926&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.28">Pauli BU, Memoli VA, Kuettner KE: Regulation of tumor invasion by cartilage-derived anti-invasion factor in vitro. J Natl Cancer Inst 67 (1): 65-73, 1981.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7019530&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7019530&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.29">Liang JH, Wong KP: The characterization of angiogenesis inhibitor from shark cartilage. Adv Exp Med Biol 476: 209-23, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10949667&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10949667&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.30">Suzuki F: Cartilage-derived growth factor and antitumor factor: past, present, and future studies. Biochem Biophys Res Commun 259 (1): 1-7, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10334906&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10334906&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.31">Murray JB, Allison K, Sudhalter J, et al.: Purification and partial amino acid sequence of a bovine cartilage-derived collagenase inhibitor. J Biol Chem 261 (9): 4154-9, 1986.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3005321&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3005321&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.32">Wojtowicz-Praga S: Clinical potential of matrix metalloprotease inhibitors. Drugs R D 1 (2): 117-29, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10566004&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10566004&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.33">Pettit GR, Ode RH: Antineoplastic agents L: isolation and characterization of sphyrnastatins 1 and 2 from the hammerhead shark Sphyrna lewini. J Pharm Sci 66 (5): 757-8, 1977.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=874772&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=874772&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.34">Sigel MM, Fugmann RA: Studies on immunoglobulins reactive with tumor cells and antigens. Cancer Res 28 (7): 1457-9, 1968.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4174343&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4174343&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.35">Snodgrass MJ, Burke JD, Meetz GD: Inhibitory effect of shark serum on the Lewis lung carcinoma. J Natl Cancer Inst 56 (5): 981-4, 1976.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=994208&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=994208&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.36">Pugliese PT, Heinerman J: Devour Disease with Shark Liver Oil. Green Bay, Wis: Impakt Communications, 1999.</li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _23
      field_pdq_section_title:
        - format: plain_text
          value: 'Estudios preclínicos de laboratorio o con animales'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_23" class="pdq-sections"><p id="_24" tabindex="-1"> El potencial <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=446109&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000446109&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">antitumoral</a> del <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44190&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044190&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">cart&#xED;lago</a> se investig&#xF3; de forma exhaustiva en estudios de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44512&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044512&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">laboratorio</a> y con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=454774&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000454774&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">animales</a>. En algunos de estos estudios, se evaluaron los efectos t&#xF3;xicos de los productos de cart&#xED;lago en las <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46476&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046476&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE9;lulas</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45333&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045333&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">cancerosas</a> analizadas <em>in vitro</em>.<a href="#cit/section_4.1">1</a><a href="#cit/section_4.2">2</a><a href="#cit/section_4.3">3</a><a href="#cit/section_4.4">4</a><a href="#cit/section_4.5">5</a></p><section id="_142"><h3 id="_142_toc">Productos de cart&#xED;lago en polvo</h3><p id="_25" tabindex="-1">En un estudio, se trataron con Catrix (en venta como preparaci&#xF3;n en polvo de cart&#xED;lago bovino [vacuno]), c&#xE9;lulas de 22 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46634&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046634&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">tumores</a> humanos reci&#xE9;n aisladas (9 de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46687&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046687&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">ovario</a>, 3 de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=270740&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000270740&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">pulm&#xF3;n</a>, 2 de enc&#xE9;falo, 2 de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=304766&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000304766&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">mama</a> y 1 de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45562&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045562&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">sarcoma</a>, de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45135&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045135&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">melanoma</a>, de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46462&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046462&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">colon</a>, de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46254&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046254&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">p&#xE1;ncreas</a>, de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46133&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046133&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">cuello del &#xFA;tero</a> y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=367406&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000367406&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">test&#xED;culo</a>) y 3 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44016&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044016&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">l&#xED;neas celulares cultivadas</a> en seres humanos (<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=444971&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000444971&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer de mama</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44237&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044237&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer de colon</a> y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45795&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045795&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">mieloma</a>).<a href="#cit/section_4.1">1</a> <a href="#cit/section_4.3">3</a><a href="#cit/section_4.4">4</a> En el estudio, se inhibi&#xF3; el crecimiento de las 3 l&#xED;neas celulares cultivadas de cerca de 70&#xA0;% de las muestras tumorales en 50&#xA0;% o m&#xE1;s cuando se usaron concentraciones altas de Catrix (1&#x2013;5 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44213&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044213&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">mg</a>/<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44214&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044214&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">ml</a> del l&#xED;quido de cultivo). Sin embargo, no est&#xE1; claro si el efecto inhibidor de Catrix en este estudio fue espec&#xED;fico para el crecimiento de c&#xE9;lulas cancerosas porque no se someti&#xF3; a prueba el efecto de la preparaci&#xF3;n sobre el crecimiento de c&#xE9;lulas normales. Adem&#xE1;s, no se ha identificado el componente <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44020&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044020&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">citot&#xF3;xico</a> de Catrix y no se ha demostrado que se puedan lograr concentraciones inhibitorias equivalentes de este componente en la corriente sangu&#xED;nea de pacientes que se puedan tratar con formulaciones <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44678&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044678&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">inyectables</a> u <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44068&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044068&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">orales</a> de este producto. (Para obtener m&#xE1;s informaci&#xF3;n, consultar la secci&#xF3;n de este sumario sobre <a href="/about-cancer/treatment/cam/hp/cartilage-pdq#link/_36">Estudios cl&#xED;nicos con seres humanos</a>).</p><p id="_27" tabindex="-1"> Se notific&#xF3; que una preparaci&#xF3;n comercializada de cart&#xED;lago de tibur&#xF3;n en polvo (no se identific&#xF3; la marca) no tiene efecto sobre el crecimiento de c&#xE9;lulas de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45602&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045602&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">astrocitoma</a> humano <em>in vitro</em>.<a href="#cit/section_4.2">2</a> No obstante, el producto de cart&#xED;lago de tibur&#xF3;n evaluado en este estudio solo se examin&#xF3; en una sola concentraci&#xF3;n (0,75 mg/ml).<a href="#cit/section_4.2">2</a></p><p id="_28" tabindex="-1">El potencial estimulante del <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46356&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046356&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">sistema inmunitario</a> tambi&#xE9;n se investig&#xF3; en estudios de laboratorio y con animales.<a href="#cit/section_4.6">6</a> En un estudio, se observ&#xF3; que Catrix estimula la producci&#xF3;n de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44918&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044918&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">anticuerpos</a> de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45611&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045611&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE9;lulas B</a> de rat&#xF3;n (<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45765&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045765&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">linfocitos</a> B) tanto <em>in vitro</em> como <em>in vivo</em>. Pero solo se observ&#xF3; un aumento de la producci&#xF3;n de anticuerpos <em>in vivo</em> cuando Catrix se administr&#xF3; por inyecci&#xF3;n <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46339&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046339&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">intraperitoneal</a> o <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46682&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046682&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">intravenosa</a>. Esto no se observ&#xF3; cuando se usaron formulaciones orales de Catrix.<a href="#cit/section_4.6">6</a> En la mayor&#xED;a de los experimentos, la proliferaci&#xF3;n de c&#xE9;lulas B de rat&#xF3;n (es decir, c&#xE9;lulas normales, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44217&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044217&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">no malignas</a>) <em>in vitro</em> se inhibi&#xF3; cada vez m&#xE1;s a medida que se aumentaba la concentraci&#xF3;n de Catrix (rango de concentraci&#xF3;n probado, 1&#x2013;20 mg/ml). Si bien se notific&#xF3; que Catrix estimula la actividad de los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44054&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044054&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">macr&#xF3;fagos</a> de rat&#xF3;n <em>in vivo</em>,<a href="#cit/section_4.3">3</a>  los resultados que demuestran este efecto no se publicaron.</p><p id="_115" tabindex="-1">Los efectos del cart&#xED;lago de tibur&#xF3;n en el sistema inmunitario tambi&#xE9;n se notificaron en dos estudios en los que se us&#xF3; la misma fracci&#xF3;n de prote&#xED;na purificada que hab&#xED;a mostrado los mayores efectos inmunoestimulantes cuando se probaron.<a href="#cit/section_4.7">7</a><a href="#cit/section_4.8">8</a> En un estudio se exploraron los efectos de esta fracci&#xF3;n sobre la respuesta inmunitaria tumoral mediante la observaci&#xF3;n de la infiltraci&#xF3;n de esta fracci&#xF3;n en los linfocitos CD4 y CD8 en un modelo de tumor murino. Aunque se observ&#xF3; un aumento en la proporci&#xF3;n de linfocitos CD4/CD8 en linfocitos tumorales infiltrantes de tumores, esto no se observ&#xF3; en los linfocitos de sangre perif&#xE9;rica.<a href="#cit/section_4.8">8</a> En el segundo estudio se explor&#xF3; la respuesta del sistema inmunitario medida por la respuesta de anticuerpos, un ensayo citot&#xF3;xico, la transformaci&#xF3;n de linfocitos y la proporci&#xF3;n de c&#xE9;lulas T intratumorales en ratones. La fracci&#xF3;n exhibi&#xF3; la capacidad de aumentar la respuesta de hipersensibilidad diferida contra c&#xE9;lulas sangu&#xED;neas de oveja en ratones y de disminuir la actividad citot&#xF3;xica de linfocitos citol&#xED;ticos naturales. Adem&#xE1;s, esta fracci&#xF3;n mostr&#xF3; un fuerte efecto inhibidor sobre la proliferaci&#xF3;n y migraci&#xF3;n de c&#xE9;lulas endoteliales microvasculares del enc&#xE9;falo humano en la matriz de fibrina.<a href="#cit/section_4.7">7</a></p><p id="_35" tabindex="-1">Se publicaron otros estudios <em>in vivo</em> del potencial antitumoral del cart&#xED;lago de tibur&#xF3;n en publicaciones cient&#xED;ficas revisadas por expertos.<a href="#cit/section_4.9">9</a><a href="#cit/section_4.10">10</a><a href="#cit/section_4.11">11</a> En un estudio, se demostr&#xF3; que la administraci&#xF3;n oral de cart&#xED;lago de tibur&#xF3;n en polvo (no se identific&#xF3; la marca) inhibe la angiog&#xE9;nesis inducida qu&#xED;micamente en la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44212&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044212&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">membrana mesent&#xE9;rica</a> de ratas.<a href="#cit/section_4.9">9</a>  En otro estudio, se demostr&#xF3; que la administraci&#xF3;n oral de cart&#xED;lago de tibur&#xF3;n en polvo (no se identific&#xF3; la marca) reduce el crecimiento de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45701&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045701&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">gliosarcomas</a> GS-9L en ratas.<a href="#cit/section_4.10">10</a> En un tercer estudio, se notific&#xF3; que la administraci&#xF3;n oral de dos productos de cart&#xED;lago de tibur&#xF3;n en polvo, Sharkilage y MIA Shark Powder, no inhibi&#xF3; el crecimiento o la met&#xE1;stasis de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46595&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046595&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">carcinomas de c&#xE9;lulas escamosas</a> SCCVII en ratones.<a href="#cit/section_4.11">11</a></p><p id="_29" tabindex="-1">Se public&#xF3; un gran n&#xFA;mero de estudios de laboratorio y con animales sobre el potencial <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44186&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044186&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">antiangiog&#xE9;nico</a> del cart&#xED;lago.<a href="#cit/section_4.2">2</a><a href="#cit/section_4.9">9</a><a href="#cit/section_4.12">12</a><a href="#cit/section_4.13">13</a><a href="#cit/section_4.14">14</a><a href="#cit/section_4.15">15</a><a href="#cit/section_4.16">16</a><a href="#cit/section_4.17">17</a><a href="#cit/section_4.18">18</a><a href="#cit/section_4.19">19</a><a href="#cit/section_4.20">20</a><a href="#cit/section_4.21">21</a><a href="#cit/section_4.22">22</a><a href="#cit/section_4.23">23</a><a href="#cit/section_4.24">24</a><a href="#cit/section_4.25">25</a><a href="#cit/section_4.26">26</a><a href="#cit/section_4.27">27</a><a href="#cit/section_4.28">28</a><a href="#cit/section_4.29">29</a><a href="#cit/section_4.30">30</a><a href="#cit/section_4.31">31</a><a href="#cit/section_4.32">32</a> En general, en estos estudios se revel&#xF3; la presencia de por lo menos tres <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46739&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046739&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">inhibidores</a> de la angiog&#xE9;nesis en el cart&#xED;lago bovino <a href="#cit/section_4.13">13</a><a href="#cit/section_4.14">14</a><a href="#cit/section_4.16">16</a><a href="#cit/section_4.17">17</a><a href="#cit/section_4.18">18</a><a href="#cit/section_4.21">21</a><a href="#cit/section_4.23">23</a><a href="#cit/section_4.33">33</a> y por lo menos dos de estos en cart&#xED;lago de tibur&#xF3;n.<a href="#cit/section_4.2">2</a><a href="#cit/section_4.9">9</a><a href="#cit/section_4.25">25</a><a href="#cit/section_4.26">26</a></p></section><section id="_146"><h3 id="_146_toc">Extractos acuosos de cart&#xED;lago</h3><p id="_147" tabindex="-1">Tambi&#xE9;n se notific&#xF3; que un extracto l&#xED;quido (es decir, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43998&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043998&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">acuoso</a>) de cart&#xED;lago de tibur&#xF3;n llamado AE-941/Neovastat inhibe el crecimiento de varios tipos de c&#xE9;lulas cancerosas <em>in vitro</em>.<a href="#cit/section_4.5">5</a> Estos resultados no se publicaron en una revista cient&#xED;fica revisada por expertos y no guardan coherencia con otros resultados obtenidos por el mismo grupo de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44685&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044685&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">investigadores</a>.<a href="#cit/section_4.27">27</a><a href="#cit/section_4.34">34</a></p><p id="_148" tabindex="-1">Hay tres inhibidores de la angiog&#xE9;nesis en el cart&#xED;lago bovino que fueron muy bien caracterizados.<a href="#cit/section_4.13">13</a><a href="#cit/section_4.14">14</a><a href="#cit/section_4.16">16</a><a href="#cit/section_4.17">17</a><a href="#cit/section_4.18">18</a><a href="#cit/section_4.21">21</a><a href="#cit/section_4.23">23</a><a href="#cit/section_4.33">33</a> Se trata de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46092&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046092&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">prote&#xED;nas</a> relativamente peque&#xF1;as cuya <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44216&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044216&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">masa molecular</a> oscila entre 23&#xA0;000 y 28&#xA0;000.<a href="#cit/section_4.13">13</a><a href="#cit/section_4.14">14</a><a href="#cit/section_4.16">16</a><a href="#cit/section_4.23">23</a> Estas prote&#xED;nas, que fueron llamadas inhibidor derivado del cart&#xED;lago (CDI), factor antitumoral derivado del cart&#xED;lago (CATF) e inhibidor de la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44249&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044249&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">colagenasa</a> derivado del cart&#xED;lago (CDCI) por los investigadores que las purificaron,<a href="#cit/section_4.13">13</a><a href="#cit/section_4.14">14</a><a href="#cit/section_4.21">21</a> han demostrado bloquear la proliferaci&#xF3;n de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44203&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044203&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE9;lulas endoteliales</a> <em>in vitro</em> y la formaci&#xF3;n de nuevos <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45020&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045020&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">vasos sangu&#xED;neos</a> en la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44193&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044193&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">membrana corioalantoica</a> de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44202&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044202&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">embriones</a> de pollo.<a href="#cit/section_4.14">14</a><a href="#cit/section_4.16">16</a><a href="#cit/section_4.17">17</a><a href="#cit/section_4.18">18</a><a href="#cit/section_4.21">21</a><a href="#cit/section_4.23">23</a><a href="#cit/section_4.33">33</a> Se observ&#xF3; que dos de las prote&#xED;nas (CDI y CDCI) inhiben la actividad de la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44211&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044211&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">metaloproteinasa de matriz</a> <em>in vitro</em> <a href="#cit/section_4.13">13</a><a href="#cit/section_4.14">14</a><a href="#cit/section_4.16">16</a><a href="#cit/section_4.18">18</a> y que una (CDI) inhibe la migraci&#xF3;n de c&#xE9;lulas endoteliales <em>in vitro</em>.<a href="#cit/section_4.14">14</a><a href="#cit/section_4.16">16</a> Estas prote&#xED;nas no bloquean la proliferaci&#xF3;n de c&#xE9;lulas normales o c&#xE9;lulas tumorales <em>in vitro</em>.<a href="#cit/section_4.14">14</a><a href="#cit/section_4.16">16</a><a href="#cit/section_4.17">17</a><a href="#cit/section_4.21">21</a><a href="#cit/section_4.33">33</a> Cuando se determinaron las <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44184&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044184&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">secuencias de amino&#xE1;cidos</a> de CDI, CATF y CDCI, se descubri&#xF3; que eran las mismas que las de prote&#xED;nas conocidas como inhibidores tisulares de las metaloproteinasas de matriz 1 (TIMP-1), condromodulina I y TIMP-2, respectivamente.<a href="#cit/section_4.13">13</a><a href="#cit/section_4.14">14</a><a href="#cit/section_4.18">18</a><a href="#cit/section_4.23">23</a><a href="#cit/section_4.33">33</a></p><p id="_149" tabindex="-1">Se purific&#xF3; un cuarto inhibidor posible de la angiog&#xE9;nesis en el cart&#xED;lago bovino; no a partir del cart&#xED;lago, sino a partir del l&#xED;quido de cultivo de los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44191&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044191&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">condrocitos</a> bovinos cultivados en el laboratorio.<a href="#cit/section_4.15">15</a> Este inhibidor, que se denomin&#xF3; inhibidor derivado de condrocitos (ChDI), es una prote&#xED;na que tiene una masa molecular de aproximadamente 36&#xA0;000. Se ha informado que ChDI y CDI/TIMP-1 exhiben actividades antiangiog&#xE9;nicas similares,<a href="#cit/section_4.15">15</a><a href="#cit/section_4.16">16</a><a href="#cit/section_4.33">33</a> pero la relaci&#xF3;n entre estas prote&#xED;nas no es clara porque no se dispone de informaci&#xF3;n sobre la secuencia de amino&#xE1;cidos para ChDI. Por lo tanto, no se sabe si CDI/TIMP-1 es un producto de descomposici&#xF3;n de ChDI o si ChDI es, en realidad, el cuarto inhibidor de la angiog&#xE9;nesis identificado en el cart&#xED;lago bovino.</p><p id="_150" tabindex="-1">Como se indic&#xF3; m&#xE1;s arriba, el cart&#xED;lago de tibur&#xF3;n, como el cart&#xED;lago bovino, contiene m&#xE1;s de un tipo de inhibidor de la angiog&#xE9;nesis. Un inhibidor del cart&#xED;lago de tibur&#xF3;n, denominado U-995, contiene dos prote&#xED;nas peque&#xF1;as: una con una masa molecular de aproximadamente 14&#xA0;000 y la otra con una masa molecular de aproximadamente 10&#xA0;000.<a href="#cit/section_4.25">25</a> Ambas prote&#xED;nas exhibieron actividad antiangiog&#xE9;nica cuando se analizaron por separado. No se conoce la relaci&#xF3;n exacta entre estas dos prote&#xED;nas y su relaci&#xF3;n con los inhibidores m&#xE1;s grandes de la angiog&#xE9;nesis bovina porque no se dispone de informaci&#xF3;n sobre la secuencia de amino&#xE1;cidos para U-995. Se notific&#xF3; que U-995 inhibe la proliferaci&#xF3;n de c&#xE9;lulas endoteliales, la migraci&#xF3;n de c&#xE9;lulas endoteliales, la actividad de la metaloproteinasa de matriz <em>in vitro</em> y la formaci&#xF3;n de nuevos vasos sangu&#xED;neos en la membrana corioalantoica de embriones de pollo.<a href="#cit/section_4.25">25</a> No parece inhibir la proliferaci&#xF3;n de otros tipos de c&#xE9;lulas normales o de c&#xE9;lulas cancerosas <em>in vitro</em>. Se observ&#xF3; que la administraci&#xF3;n intraperitoneal, pero no la oral, de U-995 inhibe el crecimiento de tumores murinos de sarcoma-180 implantados de modo <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45914&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045914&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">subcut&#xE1;neo</a> en la espalda de ratones y la formaci&#xF3;n de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45315&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045315&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">met&#xE1;stasis pulmonares</a> de c&#xE9;lulas de melanoma murino B16-F10 inyectadas en las venas de la cola de ratones.<a href="#cit/section_4.25">25</a></p><p id="_151" tabindex="-1">Al parecer, el segundo inhibidor de la angiog&#xE9;nesis identificado en el cart&#xED;lago de tibur&#xF3;n fue estudiado por tres grupos de investigadores de forma separada.<a href="#cit/section_4.2">2</a><a href="#cit/section_4.26">26</a><a href="#cit/section_4.35">35</a> Este inhibidor, que uno de los grupos denomin&#xF3; SCF2,<a href="#cit/section_4.35">35</a> es un <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44218&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044218&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">proteoglucano</a> con una masa aproximada de 10&#xA0;000.  Los proteoglucanos son combinaciones de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44206&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044206&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">glucosaminoglucanos</a> y prote&#xED;nas.<a href="#cit/section_4.30">30</a> El glucosaminoglucano principal en SCF2 es el <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44210&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044210&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">sulfato de queratano</a>.<a href="#cit/section_4.35">35</a>  Se observ&#xF3; que SCF2 bloquea la proliferaci&#xF3;n de c&#xE9;lulas endoteliales <em>in vitro</em>,<a href="#cit/section_4.2">2</a><a href="#cit/section_4.26">26</a><a href="#cit/section_4.35">35</a> la formaci&#xF3;n de vasos sangu&#xED;neos nuevos en la membrana corioalantoica de embriones de pollo <a href="#cit/section_4.2">2</a><a href="#cit/section_4.26">26</a> y la angiog&#xE9;nesis inducida por tumores en las <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44199&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044199&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xF3;rneas</a> de conejos.<a href="#cit/section_4.2">2</a><a href="#cit/section_4.26">26</a></p><p id="_152" tabindex="-1">Si bien en otros estudios se demostr&#xF3; que el AE-941/Neovastat (el extracto acuoso de cart&#xED;lago de tibur&#xF3;n mencionado m&#xE1;s arriba) tiene actividad antiangiog&#xE9;nica,<a href="#cit/section_4.12">12</a><a href="#cit/section_4.27">27</a><a href="#cit/section_4.28">28</a><a href="#cit/section_4.34">34</a><a href="#cit/section_4.36">36</a><a href="#cit/section_4.37">37</a><a href="#cit/section_4.38">38</a><a href="#cit/section_4.39">39</a> no se defini&#xF3; la base molecular de esta actividad. En consecuencia, se desconoce si AE-941/Neovastat contiene U-995, SCF2 o alg&#xFA;n otro inhibidor de la angiog&#xE9;nesis. Se notific&#xF3; que AE-941/Neovastat inhibe la proliferaci&#xF3;n de c&#xE9;lulas endoteliales y la actividad de metaloproteinasas de matriz <em>in vitro</em>, as&#xED; como la formaci&#xF3;n de nuevos vasos sangu&#xED;neos en la membrana corioalantoica de embriones de pollo.<a href="#cit/section_4.12">12</a><a href="#cit/section_4.27">27</a><a href="#cit/section_4.31">31</a> Adem&#xE1;s, se observ&#xF3; que AE-941/Neovastat induce la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46524&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046524&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">apoptosis</a> de c&#xE9;lulas endoteliales al activar las caspasas, que son <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46081&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046081&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">enzimas</a> importantes en la promoci&#xF3;n y regulaci&#xF3;n de la apoptosis.<a href="#cit/section_4.32">32</a><a href="#cit/section_4.34">34</a><a href="#cit/section_4.38">38</a> Tambi&#xE9;n parece inhibir la acci&#xF3;n del <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44222&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044222&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">factor de crecimiento endotelial vascular</a> e interfiere as&#xED; con la comunicaci&#xF3;n entre las c&#xE9;lulas tumorales y los vasos sangu&#xED;neos cercanos.<a href="#cit/section_4.28">28</a><a href="#cit/section_4.34">34</a><a href="#cit/section_4.37">37</a><a href="#cit/section_4.38">38</a> Asimismo, es posible que AE-941/Neovastat inhiba la angiog&#xE9;nesis mediante la promoci&#xF3;n de la actividad del activador del plasmin&#xF3;geno tisular (tPA). Neovastat estimula la expresi&#xF3;n de tPA en las c&#xE9;lulas endoteliales mediante un aumento en la transcripci&#xF3;n del gen tPA.<a href="#cit/section_4.40">40</a> Esta activaci&#xF3;n de la transcripci&#xF3;n se relaciona con la activaci&#xF3;n de las v&#xED;as de se&#xF1;alizaci&#xF3;n de la cinasa c-Jun N-terminal (JNK) y del factor nuclear-&#x3BA; B (NF-&#x3BA; B) en un grado similar al factor de necrosis tumoral &#x3B1; (FNT-&#x3B1;).<a href="#cit/section_4.40">40</a> Adem&#xE1;s, se notific&#xF3; que AE-941/Neovastat inhibe el crecimiento de c&#xE9;lulas de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46216&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046216&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">adenocarcinoma</a> de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44560&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044560&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">mama</a> DA3 y la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46710&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046710&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">met&#xE1;stasis</a> de c&#xE9;lulas de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45963&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045963&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">carcinoma</a> de pulm&#xF3;n de Lewis <em>in vivo</em> en ratones.<a href="#cit/section_4.5">5</a><a href="#cit/section_4.27">27</a><a href="#cit/section_4.34">34</a><a href="#cit/section_4.41">41</a> En los experimentos de carcinoma de pulm&#xF3;n de Lewis, AE-941/Neovastat aument&#xF3; el efecto <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44058&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044058&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">antimetast&#xE1;sico</a> del f&#xE1;rmaco de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45214&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045214&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">quimioterapia</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45230&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045230&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">cisplatino</a>.<a href="#cit/section_4.5">5</a><a href="#cit/section_4.27">27</a><a href="#cit/section_4.34">34</a><a href="#cit/section_4.41">41</a> Se revisaron todos los aspectos de la investigaci&#xF3;n precl&#xED;nica.<a href="#cit/section_4.42">42</a></p><p id="_153" tabindex="-1">La sustancia antiangiog&#xE9;nica troponina I (TnI) derivada del cart&#xED;lago se aisl&#xF3; a partir de cart&#xED;lago humano y se produjo por la clonaci&#xF3;n y expresi&#xF3;n del ADNc de cart&#xED;lago humano. Se observ&#xF3; que inhibe espec&#xED;ficamente la angiog&#xE9;nesis <em>in vivo</em> e <em>in vitro</em>, as&#xED; como la met&#xE1;stasis tumoral <em>in vivo</em>.<a href="#cit/section_4.43">43</a> El sitio activo de Tnl se ha localizado en los residuos de 96 a 116 amino&#xE1;cidos. Se observ&#xF3; que el p&#xE9;ptido sint&#xE9;tico Glu94-Leu123 (pTnl) es un inhibidor potente de la formaci&#xF3;n de tubos de c&#xE9;lulas endoteliales y la multiplicaci&#xF3;n de c&#xE9;lulas endoteliales, y que inhibe las met&#xE1;stasis de c&#xE1;ncer pancre&#xE1;tico en un modelo de met&#xE1;stasis hep&#xE1;ticas <em>in vivo</em>.<a href="#cit/section_4.44">44</a></p></section><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_4.1">Durie BG, Soehnlen B, Prudden JF: Antitumor activity of bovine cartilage extract (Catrix-S) in the human tumor stem cell assay. J Biol Response Mod 4 (6): 590-5, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4087032&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4087032&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.2">McGuire TR, Kazakoff PW, Hoie EB, et al.: Antiproliferative activity of shark cartilage with and without tumor necrosis factor-alpha in human umbilical vein endothelium. Pharmacotherapy 16 (2): 237-44, 1996 Mar-Apr.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8820467&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8820467&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.3">Prudden JF: The treatment of human cancer with agents prepared from bovine cartilage. J Biol Response Mod 4 (6): 551-84, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4087031&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4087031&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.4">Romano CF, Lipton A, Harvey HA, et al.: A phase II study of Catrix-S in solid tumors. J Biol Response Mod 4 (6): 585-9, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3878861&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3878861&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.5">AE 941--Neovastat. Drugs R D 1 (2): 135-6, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10566006&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10566006&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.6">Rosen J, Sherman WT, Prudden JF, et al.: Immunoregulatory effects of catrix. J Biol Response Mod 7 (5): 498-512, 1988.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2846789&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2846789&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.7">Hassan ZM, Feyzi R, Sheikhian A, et al.: Low molecular weight fraction of shark cartilage can modulate immune responses and abolish angiogenesis. Int Immunopharmacol 5 (6): 961-70, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15829412&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15829412&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.8">Feyzi R, Hassan ZM, Mostafaie A: Modulation of CD(4)(+) and CD(8)(+) tumor infiltrating lymphocytes by a fraction isolated from shark cartilage: shark cartilage modulates anti-tumor immunity. Int Immunopharmacol 3 (7): 921-6, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12810349&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12810349&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.9">Davis PF, He Y, Furneaux RH, et al.: Inhibition of angiogenesis by oral ingestion of powdered shark cartilage in a rat model. Microvasc Res 54 (2): 178-82, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9327389&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9327389&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.10">Morris GM, Coderre JA, Micca PL, et al.: Boron neutron capture therapy of the rat 9L gliosarcoma: evaluation of the effects of shark cartilage. Br J Radiol 73 (868): 429-34, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10844870&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10844870&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.11">Horsman MR, Alsner J, Overgaard J: The effect of shark cartilage extracts on the growth and metastatic spread of the SCCVII carcinoma. Acta Oncol 37 (5): 441-5, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9831372&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9831372&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.12">Dupont E, Savard PE, Jourdain C, et al.: Antiangiogenic properties of a novel shark cartilage extract: potential role in the treatment of psoriasis. J Cutan Med Surg 2 (3): 146-52, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9479080&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9479080&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.13">Murray JB, Allison K, Sudhalter J, et al.: Purification and partial amino acid sequence of a bovine cartilage-derived collagenase inhibitor. J Biol Chem 261 (9): 4154-9, 1986.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3005321&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3005321&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.14">Moses MA, Sudhalter J, Langer R: Identification of an inhibitor of neovascularization from cartilage. Science 248 (4961): 1408-10, 1990.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1694043&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1694043&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.15">Moses MA, Sudhalter J, Langer R: Isolation and characterization of an inhibitor of neovascularization from scapular chondrocytes. J Cell Biol 119 (2): 475-82, 1992.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1383232&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1383232&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.16">Moses MA: A cartilage-derived inhibitor of neovascularization and metalloproteinases. Clin Exp Rheumatol 11 (Suppl 8): S67-9, 1993 Mar-Apr.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7686834&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7686834&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.17">Takigawa M, Pan HO, Enomoto M, et al.: A clonal human chondrosarcoma cell line produces an anti-angiogenic antitumor factor. Anticancer Res 10 (2A): 311-5, 1990 Mar-Apr.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1693264&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1693264&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.18">Ohba Y, Goto Y, Kimura Y, et al.: Purification of an angiogenesis inhibitor from culture medium conditioned by a human chondrosarcoma-derived chondrocytic cell line, HCS-2/8. Biochim Biophys Acta 1245 (1): 1-8, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7544625&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7544625&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.19">Langer R, Brem H, Falterman K, et al.: Isolations of a cartilage factor that inhibits tumor neovascularization. Science 193 (4247): 70-2, 1976.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=935859&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=935859&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.20">Langer R, Conn H, Vacanti J, et al.: Control of tumor growth in animals by infusion of an angiogenesis inhibitor. Proc Natl Acad Sci U S A 77 (7): 4331-5, 1980.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6159628&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6159628&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.21">Takigawa M, Shirai E, Enomoto M, et al.: Cartilage-derived anti-tumor factor (CATF) inhibits the proliferation of endothelial cells in culture. Cell Biol Int Rep 9 (7): 619-25, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4028190&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4028190&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.22">Takigawa M, Shirai E, Enomoto M, et al.: A factor in conditioned medium of rabbit costal chondrocytes inhibits the proliferation of cultured endothelial cells and angiogenesis induced by B16 melanoma: its relation with cartilage-derived anti-tumor factor (CATF). Biochem Int 14 (2): 357-63, 1987.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2437926&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=2437926&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.23">Hiraki Y, Inoue H, Iyama K, et al.: Identification of chondromodulin I as a novel endothelial cell growth inhibitor. Purification and its localization in the avascular zone of epiphyseal cartilage. J Biol Chem 272 (51): 32419-26, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9405451&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9405451&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.24">Lee A, Langer R: Shark cartilage contains inhibitors of tumor angiogenesis. Science 221 (4616): 1185-7, 1983.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6193581&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=6193581&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.25">Sheu JR, Fu CC, Tsai ML, et al.: Effect of U-995, a potent shark cartilage-derived angiogenesis inhibitor, on anti-angiogenesis and anti-tumor activities. Anticancer Res 18 (6A): 4435-41, 1998 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9891506&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9891506&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.26">Oikawa T, Ashino-Fuse H, Shimamura M, et al.: A novel angiogenic inhibitor derived from Japanese shark cartilage (I). Extraction and estimation of inhibitory activities toward tumor and embryonic angiogenesis. Cancer Lett 51 (3): 181-6, 1990.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1693543&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1693543&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.27">Dupont E, Falardeau P, Mousa SA, et al.: Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue. Clin Exp Metastasis 19 (2): 145-53, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11964078&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11964078&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.28">B&#xE9;liveau R, Gingras D, Kruger EA, et al.: The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects. Clin Cancer Res 8 (4): 1242-50, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11948139&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11948139&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.29">Cho J, Kim Y: Sharks: a potential source of antiangiogenic factors and tumor treatments. Mar Biotechnol (NY) 4 (6): 521-5, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14961226&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14961226&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.30">Alberts B, Bray D, Lewis J, et al.: Molecular Biology of the Cell. 3rd ed. New York, NY: Garland Publishing, 1994.</li><li id="section_4.31">Gingras D, Renaud A, Mousseau N, et al.: Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound. Anticancer Res 21 (1A): 145-55, 2001 Jan-Feb.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11299728&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11299728&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.32">Boivin D, Gendron S, Beaulieu E, et al.: The antiangiogenic agent Neovastat (AE-941) induces endothelial cell apoptosis. Mol Cancer Ther 1 (10): 795-802, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12492112&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12492112&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.33">Suzuki F: Cartilage-derived growth factor and antitumor factor: past, present, and future studies. Biochem Biophys Res Commun 259 (1): 1-7, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10334906&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10334906&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.34">Falardeau P, Champagne P, Poyet P, et al.: Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol 28 (6): 620-5, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11740820&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11740820&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.35">Liang JH, Wong KP: The characterization of angiogenesis inhibitor from shark cartilage. Adv Exp Med Biol 476: 209-23, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10949667&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10949667&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.36">Bukowski RM: AE-941, a multifunctional antiangiogenic compound: trials in renal cell carcinoma. Expert Opin Investig Drugs 12 (8): 1403-11, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12882625&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12882625&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.37">Gingras D, Batist G, B&#xE9;liveau R: AE-941 (Neovastat): a novel multifunctional antiangiogenic compound. Expert Rev Anticancer Ther 1 (3): 341-7, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12113101&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12113101&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.38">Gingras D, Boivin D, Deckers C, et al.: Neovastat--a novel antiangiogenic drug for cancer therapy. Anticancer Drugs 14 (2): 91-6, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12569294&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12569294&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.39">Ryoo JJ, Cole CE, Anderson KC: Novel therapies for multiple myeloma. Blood Rev 16 (3): 167-74, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12163002&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12163002&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.40">Gingras D, Nyalendo C, Di Tomasso G, et al.: Activation of tissue plasminogen activator gene transcription by Neovastat, a multifunctional antiangiogenic agent. Biochem Biophys Res Commun 320 (1): 205-12, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15207722&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15207722&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.41">Wojtowicz-Praga S: Clinical potential of matrix metalloprotease inhibitors. Drugs R D 1 (2): 117-29, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10566004&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10566004&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.42">Dredge K: AE-941 (AEterna). Curr Opin Investig Drugs 5 (6): 668-77, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15242256&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15242256&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.43">Moses MA, Wiederschain D, Wu I, et al.: Troponin I is present in human cartilage and inhibits angiogenesis. Proc Natl Acad Sci U S A 96 (6): 2645-50, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10077564&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10077564&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.44">Kern BE, Balcom JH, Antoniu BA, et al.: Troponin I peptide (Glu94-Leu123), a cartilage-derived angiogenesis inhibitor: in vitro and in vivo effects on human endothelial cells and on pancreatic cancer. J Gastrointest Surg 7 (8): 961-8; discussion 969, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14675705&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14675705&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _36
      field_pdq_section_title:
        - format: plain_text
          value: 'Estudios clínicos con seres humanos'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_36" class="pdq-sections"><p id="_96" tabindex="-1">Desde principios de la d&#xE9;cada de 1970, se han realizado por lo menos una docena de ensayos cl&#xED;nicos (<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44195&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044195&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);"></a>&#xA0;<a href="/clinicaltrials/NCT00005838">MDA-ID-99303</a>, <a href="/clinicaltrials/NCT00026117">NCCTG-971151</a>y <a href="/clinicaltrials/NCT00022282">AETERNA-AE-MM-00-02</a>) de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44190&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044190&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">cart&#xED;lago</a> como tratamiento para personas con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45333&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045333&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer</a> <a href="#cit/section_5.1">1</a><a href="#cit/section_5.2">2</a><a href="#cit/section_5.3">3</a><a href="#cit/section_5.4">4</a><a href="#cit/section_5.5">5</a><a href="#cit/section_5.6">6</a><a href="#cit/section_5.7">7</a><a href="#cit/section_5.8">8</a><a href="#cit/section_5.9">9</a><a href="#cit/section_5.10">10</a><a href="#cit/section_5.11">11</a><a href="#cit/section_5.12">12</a><a href="#cit/section_5.13">13</a><a href="#cit/section_5.14">14</a><a href="#cit/section_5.15">15</a> (consultar el <a href="/about-cancer/treatment/cam/hp/cartilage-pdq#link/_82">Cuadro</a> al final de esta secci&#xF3;n); sin embargo, solo se publicaron los resultados de siete estudios en revistas cient&#xED;ficas con revisi&#xF3;n externa.<a href="#cit/section_5.1">1</a><a href="#cit/section_5.2">2</a><a href="#cit/section_5.4">4</a><a href="#cit/section_5.8">8</a><a href="#cit/section_5.9">9</a><a href="#cit/section_5.16">16</a> No est&#xE1; claro si alguno de los pacientes en estos estudios eran ni&#xF1;os. </p><p id="_97" tabindex="-1">En el primer ensayo aleatorizado publicado en una revista cient&#xED;fica revisada por pares, 83 pacientes con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=444971&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000444971&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer de mama</a> y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=444983&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000444983&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer colorrectal</a> incurables se asignaron al azar para recibir cart&#xED;lago de tibur&#xF3;n o un <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46688&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046688&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">placebo</a>, adem&#xE1;s del tratamiento est&#xE1;ndar. No se observaron diferencias en la supervivencia o la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45417&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045417&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">calidad de vida</a> entre quienes recibieron cart&#xED;lago de tibur&#xF3;n y quienes recibieron el placebo.<a href="#cit/section_5.8">8</a> Se est&#xE1;n realizando estudios cl&#xED;nicos adicionales; sin embargo, las pruebas acumuladas hasta la fecha no son concluyentes con respecto a la eficacia del cart&#xED;lago como tratamiento para las personas con c&#xE1;ncer.</p><section id="_144"><h3 id="_144_toc">Productos de cart&#xED;lago en polvo</h3><p id="_38" tabindex="-1">En 2  de los 3 estudios cl&#xED;nicos publicados, se evalu&#xF3; el uso de Catrix, en la preparaci&#xF3;n en polvo de cart&#xED;lago bovino (vacuno) antes mencionada (para obtener m&#xE1;s informaci&#xF3;n, consultar la secci&#xF3;n de este sumario sobre <a href="/about-cancer/treatment/cam/hp/cartilage-pdq#link/_23">Estudios precl&#xED;nicos de laboratorio y con animales</a>) como tratamiento para distintos <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45301&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045301&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">tumores s&#xF3;lidos</a>.<a href="#cit/section_5.1">1</a><a href="#cit/section_5.2">2</a> Uno de estos estudios fue una <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44006&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044006&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">serie de casos</a> con 31 pacientes;<a href="#cit/section_5.1">1</a> el otro fue un <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45831&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045831&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">ensayo cl&#xED;nico de fase II</a> con 9 pacientes.<a href="#cit/section_5.2">2</a></p><p id="_39" tabindex="-1">En la serie de casos,<a href="#cit/section_5.1">1</a> todos los pacientes se trataron con Catrix <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45914&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045914&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">inyectado</a> por <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44678&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044678&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">v&#xED;a subcut&#xE1;nea</a> u <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44068&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044068&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">oral</a>; sin embargo, 3 pacientes con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46595&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046595&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">carcinoma de c&#xE9;lulas escamosas</a> de piel y 2 pacientes con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46515&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046515&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">carcinoma de c&#xE9;lulas basales</a> de piel) tambi&#xE9;n se trataron con preparaciones <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45927&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045927&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">t&#xF3;picas</a>. La <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44664&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044664&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">dosis</a> individual, la dosis total y la duraci&#xF3;n del tratamiento con Catrix en esta serie variaron de paciente a paciente; no obstante, la duraci&#xF3;n m&#xED;nima del tratamiento fue de 7 meses y la duraci&#xF3;n m&#xE1;xima fue de m&#xE1;s de 10 a&#xF1;os. Dieciocho pacientes se hab&#xED;an tratado con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44198&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044198&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">terapia convencional</a> (<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45570&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045570&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">cirug&#xED;a</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45214&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045214&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">quimioterapia</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44971&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044971&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">radioterapia</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46367&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046367&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">terapia hormonal</a>) dentro de 1 a&#xF1;o del inicio del tratamiento con Catrix; 9 pacientes recibieron terapia convencional al mismo tiempo que el tratamiento con Catrix y 7 pacientes recibieron terapia convencional antes y durante el tratamiento con Catrix. Se inform&#xF3; que 19 pacientes presentaron <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45652&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045652&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">respuesta completa</a>, 10 pacientes presentaron una <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45819&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045819&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">respuesta parcial</a> y 1 paciente present&#xF3; <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45884&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045884&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">enfermedad estable</a> despu&#xE9;s del tratamiento con Catrix. El paciente restante no respondi&#xF3; a la terapia con cart&#xED;lago. Ocho de los pacientes con respuesta completa no recibieron terapia convencional previa o simult&#xE1;nea. Cerca de la mitad de los pacientes con respuesta completa eventualmente present&#xF3; <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45862&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045862&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer recidivante</a>.</p><p id="_40" tabindex="-1">Este estudio cl&#xED;nico tuvo varias debilidades que podr&#xED;an haber afectado su resultado, incluso la ausencia de un <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44149&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044149&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">grupo de control</a> y la administraci&#xF3;n de terapia convencional previa o simult&#xE1;nea a la mayor&#xED;a de los pacientes.</p><p id="_42" tabindex="-1">Los resultados parciales de un tercer estudio cl&#xED;nico de Catrix se describen en un resumen redactado para una presentaci&#xF3;n en una conferencia cient&#xED;fica,<a href="#cit/section_5.3">3</a> pero los resultados completos de este estudio no se publicaron en una revista cient&#xED;fica con revisi&#xF3;n externa. En el estudio, se dividi&#xF3; a 35 pacientes de carcinoma de c&#xE9;lulas renales metast&#xE1;sico en 4 grupos; los pacientes de cada grupo se trataron con dosis id&#xE9;nticas de Catrix inyectado por v&#xED;a subcut&#xE1;nea u oral. Entre 22 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44029&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044029&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">pacientes evaluables</a>, se observaron 3 respuestas parciales y ninguna respuesta completa entre quienes se trataron con Catrix durante m&#xE1;s de 3 meses. Despu&#xE9;s del tratamiento con Catrix, se notific&#xF3; que 2 de los 22 pacientes evaluables ten&#xED;an enfermedad estable y 17 presentaban enfermedad progresiva. En este estudio, no se estableci&#xF3; un v&#xED;nculo entre la dosis de Catrix y la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44085&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044085&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">respuesta</a> tumoral.</p><p id="_43" tabindex="-1">El tercer estudio publicado sobre el cart&#xED;lago como tratamiento para personas con c&#xE1;ncer fue un <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45832&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045832&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">ensayo de fase I/II</a> en el que se prob&#xF3; la inocuidad y la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=346517&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000346517&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">eficacia</a> de Cartilade (una preparaci&#xF3;n de cart&#xED;lago de tibur&#xF3;n en polvo, comercialmente disponible) en 60 pacientes con diversos tipos de tumores s&#xF3;lidos avanzados.<a href="#cit/section_5.4">4</a> Todos los pacientes de este ensayo menos uno se hab&#xED;an tratado antes con terapia convencional. De acuerdo con el dise&#xF1;o del estudio, no se pod&#xED;a administrar ning&#xFA;n tratamiento anticanceroso adicional simult&#xE1;neamente con la terapia con Cartilade. No se observaron respuestas completas ni respuestas parciales en los 50 pacientes evaluables tratados con Cartilade durante por lo menos 6 semanas. Sin embargo, se inform&#xF3; que la enfermedad se estabiliz&#xF3; durante 12 o m&#xE1;s semanas en 10 de los 50 pacientes. Con el tiempo, los 10 pacientes presentaron enfermedad progresiva.</p><p id="_44" tabindex="-1">Los resultados parciales de otros tres estudios cl&#xED;nicos de cart&#xED;lago de tibur&#xF3;n en polvo se describen en dos res&#xFA;menes redactados para presentaci&#xF3;n en conferencias cient&#xED;ficas,<a href="#cit/section_5.5">5</a><a href="#cit/section_5.6">6</a> pero los resultados completos de estos estudios no se publicaron en revistas cient&#xED;ficas con revisi&#xF3;n externa. Los 3 estudios fueron ensayos cl&#xED;nicos de fase II con pacientes de enfermedad avanzada; el mismo grupo de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44685&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044685&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">investigadores</a> condujo dos de los estudios.<a href="#cit/section_5.5">5</a> En estos 3 participaron 20 pacientes de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=444971&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000444971&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer de mama</a>,<a href="#cit/section_5.5">5</a> 12 pacientes de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=445079&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000445079&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer de pr&#xF3;stata</a> <a href="#cit/section_5.5">5</a> y 12 pacientes con tumores encef&#xE1;licos <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45847&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045847&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">primarios</a>.<a href="#cit/section_5.6">6</a> Todos los pacientes se hab&#xED;an tratado antes con terapia convencional. No se permiti&#xF3; administrar ning&#xFA;n tratamiento anticanceroso de forma simult&#xE1;nea con la terapia con cart&#xED;lago. En dos estudios,<a href="#cit/section_5.5">5</a> No se identific&#xF3; el nombre del producto de cart&#xED;lago, pero en el tercer estudio <a href="#cit/section_5.6">6</a> se utiliz&#xF3; el producto comercial BeneFin. De los pacientes en cada estudio, 10 completaron por lo menos 8 semanas de tratamiento y, en consecuencia, se consideraron evaluables para la respuesta. En ninguno de los estudios se observaron respuestas completas o parciales. En el estudio de c&#xE1;ncer de mama, se notific&#xF3; que 2 pacientes evaluables tuvieron enfermedad estable que se mantuvo durante 8 semanas o m&#xE1;s; en el estudio de tumor encef&#xE1;lico, 2 pacientes evaluables tuvieron enfermedad estable que se mantuvo durante 20 semanas o m&#xE1;s; en el estudio de c&#xE1;ncer de pr&#xF3;stata, 3 pacientes evaluables tuvieron enfermedad estable que tambi&#xE9;n se mantuvo durante 20 semanas o m&#xE1;s.</p></section><section id="_145"><h3 id="_145_toc">Extractos acuosos de cart&#xED;lago</h3><p id="_41" tabindex="-1">En el ensayo de fase II,<a href="#cit/section_5.2">2</a> se administr&#xF3; Catrix solo por inyecci&#xF3;n subcut&#xE1;nea. Todos los pacientes en este ensayo presentaban <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45850&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045850&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">enfermedad progresiva</a> despu&#xE9;s de recibir radioterapia o quimioterapia. Se administraron dosis individuales id&#xE9;nticas de Catrix a cada paciente, pero la duraci&#xF3;n del tratamiento y la dosis total administrada variaron por la progresi&#xF3;n de la enfermedad o la muerte. La duraci&#xF3;n m&#xED;nima del tratamiento con Catrix en este estudio fue de 4 semanas. Un paciente (con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44988&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044988&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">carcinoma de c&#xE9;lulas renales</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44058&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044058&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">metast&#xE1;sico</a>) present&#xF3; una respuesta completa que dur&#xF3; m&#xE1;s de 39 semanas. Los 8 pacientes restantes no respondieron al tratamiento con Catrix. Los investigadores de este ensayo tambi&#xE9;n investigaron si Catrix ten&#xED;a un efecto sobre el funcionamiento del <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46356&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046356&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">sistema inmunitario</a> de estos pacientes. No hubo una tendencia o un cambio constante en el n&#xFA;mero, los porcentajes o las proporciones de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45993&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045993&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">gl&#xF3;bulos blancos</a> (es decir, el recuento total de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45765&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045765&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">linfocitos</a>, el recuento total de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44928&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044928&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE9;lulas T</a>, el recuento total de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45611&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045611&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE9;lulas B</a>, el porcentaje de c&#xE9;lulas T, el porcentaje de c&#xE9;lulas B, y la proporci&#xF3;n de las <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44594&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044594&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE9;lulas T auxiliares</a> a las <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45664&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045664&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE9;lulas T citot&#xF3;xicas</a>), aunque se encontr&#xF3; un aumento del n&#xFA;mero de c&#xE9;lulas T en tres pacientes.</p><p id="_46" tabindex="-1">Tambi&#xE9;n se examinaron en estudios cl&#xED;nicos la inocuidad y la eficacia de AE-941/Neovastat (el antes mencionado extracto <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43998&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043998&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">acuoso</a> de cart&#xED;lago de tibur&#xF3;n).<a href="#cit/section_5.9">9</a><a href="#cit/section_5.10">10</a><a href="#cit/section_5.11">11</a><a href="#cit/section_5.15">15</a><a href="#cit/section_5.17">17</a> Se notific&#xF3; que AE-941/Neovastat produce pocos efectos t&#xF3;xicos.<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43986&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043986&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);"></a>&#xA0;<a href="#cit/section_5.10">10</a><a href="#cit/section_5.11">11</a><a href="#cit/section_5.15">15</a> Adem&#xE1;s, en un ensayo cl&#xED;nico aleatorizado en el que se examin&#xF3; el efecto de AE-941/Neovastat en la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46529&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046529&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">angiog&#xE9;nesis</a> relacionada con la reparaci&#xF3;n de heridas quir&#xFA;rgicas, hubo pruebas de que este producto contiene por lo menos un componente <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44186&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044186&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">antiangiog&#xE9;nico</a> que es <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44225&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044225&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">biodisponible</a> por v&#xED;a oral.<a href="#cit/section_5.17">17</a></p><p id="_83" tabindex="-1">AE-941/Neovastat se administr&#xF3; a 331 pacientes con tumores s&#xF3;lidos avanzados (incluso tumores de pulm&#xF3;n, de pr&#xF3;stata, de mama y de ri&#xF1;&#xF3;n) en dos ensayos de fase I/II.<a href="#cit/section_5.10">10</a> Sin embargo, los resultados de estos ensayos no se notificaron en su totalidad. En un an&#xE1;lisis <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44120&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044120&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">retrospectivo</a> de un subgrupo de pacientes con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45323&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045323&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer de pulm&#xF3;n de c&#xE9;lulas no peque&#xF1;as</a> (CPCNP) en estadio avanzado, se indica que AE-941/Neovastat puede alargar la supervivencia de los pacientes con esta enfermedad.<a href="#cit/section_5.10">10</a> M&#xE1;s a&#xFA;n, en un an&#xE1;lisis <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44079&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044079&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">prospectivo</a> de 22 pacientes con carcinoma de c&#xE9;lulas renales <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45863&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045863&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">resistente al tratamiento</a>, la supervivencia fue m&#xE1;s larga en los pacientes tratados con 240 <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44214&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044214&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">ml</a>/d&#xED;a de AE-941/Neovastat que en los pacientes tratados con solo 60 ml/d&#xED;a.<a href="#cit/section_5.7">7</a><a href="#cit/section_5.10">10</a><a href="#cit/section_5.16">16</a></p><p id="_121" tabindex="-1">En 2003, con los resultados de un ensayo de fase I/II de AE-941 / Neovastat con 80 pacientes de CPCNO en estadio avanzado, se notific&#xF3; que hubo una ventaja significativa en la supervivencia de los pacientes que recibieron las dosis m&#xE1;s altas de AE-941 (2,6 ml /kg /d&#xED;a)/Neovastat. En un an&#xE1;lisis de supervivencia de 48 pacientes con CPCNP en estadios IIIA, IIIB o IV no resecable, se observ&#xF3; una ventaja en la mediana de supervivencia de <em>P</em> = 0,0026 en los pacientes que recibieron las dosis m&#xE1;s altas. El ensayo se realiz&#xF3; principalmente para explorar la inocuidad y la eficacia de AE-941/Neovastat por v&#xED;a oral cuando se administra en dosis de aumento gradual (30, 60, 120 y 240 ml/d&#xED;a). No se encontr&#xF3; toxicidad limitante de la dosis y no se observ&#xF3; respuesta tumoral.<a href="#cit/section_5.9">9</a></p><p id="_47" tabindex="-1">En 2001, se inici&#xF3; un ensayo de fase II (AETERNA-AE-MM-00-02) de AE-941/Neovastat con pacientes de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45793&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045793&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">mieloma m&#xFA;ltiple</a> <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45866&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045866&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">recidivante</a> o resistente al tratamiento. Este ensayo se cerr&#xF3; cerca de un a&#xF1;o despu&#xE9;s y no se notificaron los resultados.<a href="#cit/section_5.18">18</a></p><p id="_48" tabindex="-1">La Administraci&#xF3;n de Alimentos y Medicamentos de los Estados Unidos (FDA) aprob&#xF3; dos ensayos aleatorizados de fase III de AE-941/Neovastat con pacientes de c&#xE1;ncer en estadio avanzado. En un ensayo (MDA-ID-99303) que se complet&#xF3;, el tratamiento con AE-941/Neovastat oral y quimioterapia, y radioterapia se compar&#xF3; con el tratamiento con un placebo junto con la misma quimioterapia y radioterapia en pacientes de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45367&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045367&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">CPCNP en estadio III</a>. En el segundo ensayo, que se cerr&#xF3; a la inscripci&#xF3;n de pacientes en 2002, el tratamiento con AE-941/Neovastat oral se compar&#xF3; con el tratamiento con placebo en pacientes de carcinoma de c&#xE9;lulas renales metast&#xE1;sico. Los resultados de este segundo ensayo de fase III no se divulgaron en revistas cient&#xED;ficas con revisi&#xF3;n externa.<a href="#cit/section_5.19">19</a> Pese a que AE-941/Neovastat AE-941 recibi&#xF3; de la FDA la designaci&#xF3;n de medicamento sin inter&#xE9;s comercial en 2002 para su uso en el tratamiento del carcinoma de c&#xE9;lulas renales, AE-941/ Neovastat Aeterna Laboratories, anunci&#xF3; a comienzos de 2004 que esta solicitud se suspender&#xED;a para concentrarse en el tratamiento de CPCNP.<a href="#cit/section_5.19">19</a><a href="#cit/section_5.20">20</a> </p><p id="_154" tabindex="-1">En 2010, los resultados de un ensayo aleatorizado de fase III, con enmascaramiento doble y controlado con placebo dirigido a evaluar el efecto de la adici&#xF3;n de AE-941 a la quimioterapia y la radioterapia en la supervivencia general de pacientes con CPCNP en estadio III no resecable. Un total de 379 pacientes elegibles recibieron quimioterapia de inducci&#xF3;n seguida de quimioterapia simult&#xE1;nea con radioterapia dirigida al t&#xF3;rax; en los centros participantes se utiliz&#xF3; 1 de 2 reg&#xED;menes de quimioterapia: carboplatino y paclitaxel, o cisplatino y vinorelbina. No se observaron diferencias estad&#xED;sticamente significativas en la supervivencia general entre el grupo (n = 188) que recibi&#xF3; quimioterapia, y radioterapia junto con AE-941 (120 ml administrados oralmente 2 veces por d&#xED;a) y el grupo que recibi&#xF3; quimioterapia y radioterapia junto con placebo (n = 191). Tanto el AE-941 como el placebo se toleraron bien.<a href="#cit/section_5.21">21</a></p></section><table id="_82" class="table-default expandable-container"><caption>Administraci&#xF3;n de cart&#xED;lago para el tratamiento del c&#xE1;ncer Estudios cl&#xED;nicos con criterios de valoraci&#xF3;n terap&#xE9;uticos<span class="sup">a,b</span></caption><colgroup><col width="12.50%"><col width="12.50%"><col width="12.50%"><col width="12.50%"><col width="12.50%"><col width="12.50%"><col width="12.50%"><col width="12.50%"></colgroup>
            <THead>
            <tr>
            <th>Referencia(s) bibliogr&#xE1;fica(s) </th>
            <th>Tipo de estudio </th>
            <th>Tipo(s) de c&#xE1;ncer</th>
            <th>Producto de cart&#xED;lago (fuente)</th>
            <th>N&#xFA;mero de pacientes Tratados/de control</th>
            <th>Beneficio m&#xE1;s importante notificado<span class="sup">c</span></th>
            <th>Tratamiento simult&#xE1;neo<span class="sup">d</span></th>
            <th>Puntaje de grado de comprobaci&#xF3;n cient&#xED;fica<span class="sup">e</span></th>
            </tr>
            </THead>
            <TFoot class="pdq-footer">
            <tr>
            <td colspan="8">CPCNP = c&#xE1;ncer de pulm&#xF3;n de c&#xE9;lulas no peque&#xF1;as</td>
            </tr>
            <tr>
            <td colspan="8"><span class="sup">a</span>Para obtener m&#xE1;s informaci&#xF3;n y la definici&#xF3;n de los t&#xE9;rminos, consultar el <a href="http://www.cancer.gov/publications/dictionaries/cancer-terms/" title="http://www.cancer.gov/publications/dictionaries/cancer-terms/">Diccionario de c&#xE1;ncer del NCI</a>. </td>
            </tr>
            <tr>
            <td colspan="8"><span class="sup">b</span>Se realizaron otros estudios cl&#xED;nicos, pero no se notificaron los resultados.</td>
            </tr>
            <tr>
            <td colspan="8"><span class="sup">c</span>Pruebas m&#xE1;s s&#xF3;lidas notificadas de que el tratamiento en estudio es activo contra el c&#xE1;ncer o que mejora de otra manera el bienestar de los pacientes de c&#xE1;ncer. </td>
            </tr>
            <tr>
            <td colspan="8"><span class="sup">d</span>Se administr&#xF3; o permiti&#xF3; la administraci&#xF3;n de quimioterapia, radioterapia, terapia hormonal o terapia con citocinas al mismo tiempo que la terapia con cart&#xED;lago. </td>
            </tr>
            <tr>
            <td colspan="8"><span class="sup">e</span>Para obtener m&#xE1;s informaci&#xF3;n sobre el an&#xE1;lisis de los grados de comprobaci&#xF3;n cient&#xED;fica y una explicaci&#xF3;n de los puntajes de asignados, consultar los <a href="/publications/pdq/levels-evidence/cam">Grados de comprobaci&#xF3;n cient&#xED;fica de los estudios en humanos sobre terapias integrales, alternativas y complementarias para el c&#xE1;ncer</a>. </td>
            </tr>
            <tr>
            <td colspan="8"><span class="sup">f</span>Resultados de estudio notificados solo en forma de revisi&#xF3;n o resumen; la informaci&#xF3;n presentada para el an&#xE1;lisis de los Grados de comprobaci&#xF3;n cient&#xED;fica es insuficiente.</td>
            </tr>
            <tr>
            <td colspan="8"><span class="sup">g</span>La informaci&#xF3;n disponible para describir estos estudios por separado es insuficiente.</td>
            </tr>
            </TFoot>
            <tbody>
            <tr>
            <td>
            <a href="#cit/section_5.8">8</a>
            </td>
            <td>Ensayo de fase III aleatorizado, controlado con placebo y de enmascaramiento doble (2 grupos)</td>
            <td>C&#xE1;ncer de mama y colorrectal </td>
            <td>BeneFin (tibur&#xF3;n)</td>
            <td>42; 41 </td>
            <td>Sin diferencia estad&#xED;sticamente significativa</td>
            <td>No</td>
            <td>1i</td>
            </tr>
            <tr>
            <td>
            <a href="#cit/section_5.21">21</a>
            </td>
            <td>Ensayo de fase III aleatorizado y controlado</td>
            <td>CPCNP</td>
            <td>AE-941 (tibur&#xF3;n)</td>
            <td>188; 191</td>
            <td>Ninguno</td>
            <td>Cisplatino y vinorelbina; carboplatino y paclitaxel </td>
            <td>1iA</td>
            </tr>
            <tr>
            <td>
            <a href="#cit/section_5.1">1</a>
            </td>
            <td><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44575&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044575&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">Serie de casos no consecutivos</a></td>
            <td>Varios, en estadio avanzado o recidivante </td>
            <td>Catrix (bovino)</td>
            <td>31; Ninguno</td>
            <td>Respuesta completa,19 pacientes </td>
            <td>S&#xED; </td>
            <td>3iiiDiii </td>
            </tr>
            <tr>
            <td>
            <a href="#cit/section_5.2">2</a>
            </td>
            <td>Ensayo de fase II </td>
            <td>Varios metast&#xE1;sicos </td>
            <td>Catrix (bovino)</td>
            <td>9; Ninguno</td>
            <td>Respuesta completa, 1 paciente, carcinoma de c&#xE9;lulas renales metast&#xE1;sico </td>
            <td>No </td>
            <td>3iiiDiii </td>
            </tr>
            <tr>
            <td>
            <a href="#cit/section_5.3">3</a>
            </td>
            <td>Ensayo de fase II </td>
            <td>C&#xE9;lulas renales metast&#xE1;sicas </td>
            <td>Catrix (bovino)</td>
            <td>35; Ninguno</td>
            <td>Respuesta parcial; 3 de 22 pacientes evaluables</td>
            <td>Desconocido</td>
            <td>Ninguno<span class="sup">f</span></td>
            </tr>
            <tr>
            <td>
            <a href="#cit/section_5.10">10</a>
            <a href="#cit/section_5.16">16</a>
            </td>
            <td>Dos ensayos de fase I/II<span class="sup">g</span></td>
            <td>Varios en estadio avanzado</td>
            <td>AE-941/ Neovastat (tibur&#xF3;n) </td>
            <td>331; Ninguno </td>
            <td>Mejora de la supervivencia, dosis altas versus dosis bajas, pacientes de c&#xE1;ncer de pulm&#xF3;n de c&#xE9;lulas no peque&#xF1;as en estadio III/IV (an&#xE1;lisis retrospectivo no planificado) y pacientes de carcinoma de c&#xE9;lulas renales resistente al tratamiento (an&#xE1;lisis prospectivo)</td>
            <td>Desconocido</td>
            <td>Ninguno<span class="sup">f</span></td>
            </tr>
            <tr>
            <td>
            <a href="#cit/section_5.9">9</a>
            </td>
            <td>Ensayo de fase I/II</td>
            <td>C&#xE1;ncer de pulm&#xF3;n de c&#xE9;lulas no peque&#xF1;as en estadio avanzado:</td>
            <td>AT-941/Neovastat (tibur&#xF3;n)</td>
            <td>80; Ninguno</td>
            <td>No se encontraron efectos t&#xF3;xicos limitantes de la dosis Mejor tiempo de supervivencia en pacientes que recibieron las dosis m&#xE1;s altas cuando se realiz&#xF3; el an&#xE1;lisis de supervivencia, y enfermedad estable en un n&#xFA;mero mayor de pacientes que recibieron dosis m&#xE1;s altas. No se observ&#xF3; respuesta tumoral.</td>
            <td>S&#xED; o rechazaron la terapia est&#xE1;ndar</td>
            <td>Ninguno</td>
            </tr>
            <tr>
            <td>
            <a href="#cit/section_5.4">4</a>
            </td>
            <td>Ensayo de fase I/II </td>
            <td>Distintos tumores s&#xF3;lidos en estadio avanzado</td>
            <td>Cartilade (tibur&#xF3;n)</td>
            <td>60; Ninguno </td>
            <td>Enfermedad estable durante 12 semanas o m&#xE1;s en 10 de 50 pacientes evaluables</td>
            <td>No </td>
            <td>3iiiDiii</td>
            </tr>
            <tr>
            <td>
            <a href="#cit/section_5.5">5</a>
            </td>
            <td>Ensayo de fase II</td>
            <td>C&#xE1;ncer de mama metast&#xE1;sico o resistente al tratamiento </td>
            <td>Desconocido (tibur&#xF3;n) </td>
            <td>20; Ninguno </td>
            <td>Enfermedad estable durante 8 semanas o m&#xE1;s, 2 de 10 pacientes evaluables </td>
            <td>No </td>
            <td>Ninguno<span class="sup">f</span></td>
            </tr>
            <tr>
            <td>
            <a href="#cit/section_5.5">5</a>
            </td>
            <td>Ensayo de fase II </td>
            <td>Pr&#xF3;stata metast&#xE1;sico, resistente a las hormonas</td>
            <td>Desconocido (tibur&#xF3;n)</td>
            <td>12; Ninguno </td>
            <td>Enfermedad estable durante 20 semanas o m&#xE1;s, 3 de 10 pacientes evaluables </td>
            <td>No </td>
            <td>Ninguno<span class="sup">f</span></td>
            </tr>
            <tr>
            <td>
            <a href="#cit/section_5.6">6</a>
            </td>
            <td>Ensayo de fase II </td>
            <td>Distintos de enc&#xE9;falo en estadio avanzado </td>
            <td>BeneFin (tibur&#xF3;n) </td>
            <td>12; Ninguno </td>
            <td>Enfermedad estable durante 20 semanas o m&#xE1;s, 2 de 10 pacientes evaluables</td>
            <td>No </td>
            <td>Ninguno<span class="sup">f</span></td>
            </tr>
            </tbody>
            </table><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_5.1">Prudden JF: The treatment of human cancer with agents prepared from bovine cartilage. J Biol Response Mod 4 (6): 551-84, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4087031&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4087031&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.2">Romano CF, Lipton A, Harvey HA, et al.: A phase II study of Catrix-S in solid tumors. J Biol Response Mod 4 (6): 585-9, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3878861&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3878861&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.3">Puccio C, Mittelman A, Chun P, et al.: Treatment of metastatic renal cell carcinoma with Catrix. [Abstract] Proceedings of the American Society of Clinical Oncology  13: A-769, 246, 1994.</li><li id="section_5.4">Miller DR, Anderson GT, Stark JJ, et al.: Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. J Clin Oncol 16 (11): 3649-55, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9817287&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9817287&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.5">Leitner SP, Rothkopf MM, Haverstick L, et al.: Two phase II studies of oral dry shark cartilage powder (SCP) with either metastatic breast or prostate cancer refractory to standard treatment. [Abstract] Proceedings of the American Society of Clinical Oncology  17: A-240, 1998.</li><li id="section_5.6">Rosenbluth RJ, Jennis AA, Cantwell S, et al.: Oral shark cartilage in the treatment of patients with advanced primary brain tumors. [Abstract] Proceedings of the American Society of Clinical Oncology  18: A-554, 1999.</li><li id="section_5.7">Batist G, Champagne P, Hariton C, et al.: Dose-survival relationship in a phase II study of Neovastat in refractory renal cell carcinoma patients. [Abstract] Proceedings of the American Society of Clinical Oncology  21: A-1907, 2002.</li><li id="section_5.8">Loprinzi CL, Levitt R, Barton DL, et al.: Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial. Cancer 104 (1): 176-82, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15912493&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15912493&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.9">Latreille J, Batist G, Laberge F, et al.: Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer. Clin Lung Cancer 4 (4): 231-6, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14624712&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14624712&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.10">Falardeau P, Champagne P, Poyet P, et al.: Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol 28 (6): 620-5, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11740820&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11740820&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.11">AE 941--Neovastat. Drugs R D 1 (2): 135-6, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10566006&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10566006&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.12">Cassileth BR: Shark and bovine cartilage therapies. In: Cassileth BR, ed.: The Alternative Medicine Handbook: The Complete Reference Guide to Alternative and Complementary Therapies. New York, NY: WW Norton &amp; Company, 1998, pp 197-200.</li><li id="section_5.13">Holt S: Shark cartilage and nutriceutical update. Altern Complement Ther  1 (6): 414-16, 1995.</li><li id="section_5.14">Hunt TJ, Connelly JF: Shark cartilage for cancer treatment. Am J Health Syst Pharm 52 (16): 1756, 1760, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8528831&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8528831&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.15">AE 941. Drugs R D 5 (2): 83-9, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15293867&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15293867&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.16">Batist G, Patenaude F, Champagne P, et al.: Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. Ann Oncol 13 (8): 1259-63, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12181250&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12181250&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.17">Berbari P, Thibodeau A, Germain L, et al.: Antiangiogenic effects of the oral administration of liquid cartilage extract in humans. J Surg Res 87 (1): 108-13, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10527711&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10527711&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.18">Ryoo JJ, Cole CE, Anderson KC: Novel therapies for multiple myeloma. Blood Rev 16 (3): 167-74, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12163002&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12163002&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.19">Bukowski RM: AE-941, a multifunctional antiangiogenic compound: trials in renal cell carcinoma. Expert Opin Investig Drugs 12 (8): 1403-11, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12882625&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12882625&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.20">New treatment option for postmenopausal women with early breast cancer. Expert Rev Anticancer Ther 2 (6): 617, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12503198&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12503198&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.21">Lu C, Lee JJ, Komaki R, et al.: Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. J Natl Cancer Inst 102 (12): 859-65, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20505152&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20505152&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _57
      field_pdq_section_title:
        - format: plain_text
          value: 'Efectos adversos'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_57" class="pdq-sections"><p id="_58" tabindex="-1">Los <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46580&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046580&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">efectos secundarios</a> relacionados con la terapia de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44190&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044190&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">cart&#xED;lago</a> por lo general se describen como de gravedad leve a moderada. Se notific&#xF3; <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44042&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044042&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">inflamaci&#xF3;n</a> en los sitios de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44678&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044678&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">inyecci&#xF3;n</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44201&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044201&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">disgeusia</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=321374&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000321374&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">fatiga</a>, n&#xE1;useas, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44200&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044200&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">dispepsia</a>, fiebre, mareos y <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45676&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045676&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">edema</a> en el <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46573&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046573&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">escroto</a> despu&#xE9;s del tratamiento con el producto de cart&#xED;lago bovino Catrix.<a href="#cit/section_6.1">1</a><a href="#cit/section_6.2">2</a><a href="#cit/section_6.3">3</a> El uso de cart&#xED;lago de tibur&#xF3;n en polvo se vincul&#xF3; con n&#xE1;useas, v&#xF3;mitos, c&#xF3;licos <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46684&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046684&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">abdominales</a> o hinchaz&#xF3;n, constipaci&#xF3;n, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44039&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044039&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">hipotensi&#xF3;n</a>, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44208&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044208&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">hiperglucemia</a>, debilidad generalizada e <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45363&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045363&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">hipercalcemia</a>.<a href="#cit/section_6.4">4</a><a href="#cit/section_6.5">5</a><a href="#cit/section_6.6">6</a>  <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45632&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045632&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);"></a>La concentraci&#xF3;n alta de calcio en el cart&#xED;lago de tibur&#xF3;n puede contribuir a la presentaci&#xF3;n de la hipercalcemia.<a href="#cit/section_6.5">5</a><a href="#cit/section_6.7">7</a> Adem&#xE1;s, un caso de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=46371&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000046371&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">hepatitis</a> se relacion&#xF3; con el uso de cart&#xED;lago de tibur&#xF3;n en polvo.<a href="#cit/section_6.8">8</a>  Las n&#xE1;useas, los v&#xF3;mitos y la dispepsia son los efectos secundarios m&#xE1;s frecuentes despu&#xE9;s del tratamiento con AE-941/Neovastat, el extracto <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=43998&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000043998&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">acuoso</a> de cart&#xED;lago de tibur&#xF3;n.<a href="#cit/section_6.9">9</a></p><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_6.1">Prudden JF: The treatment of human cancer with agents prepared from bovine cartilage. J Biol Response Mod 4 (6): 551-84, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4087031&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=4087031&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.2">Romano CF, Lipton A, Harvey HA, et al.: A phase II study of Catrix-S in solid tumors. J Biol Response Mod 4 (6): 585-9, 1985.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3878861&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=3878861&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.3">Puccio C, Mittelman A, Chun P, et al.: Treatment of metastatic renal cell carcinoma with Catrix. [Abstract] Proceedings of the American Society of Clinical Oncology  13: A-769, 246, 1994.</li><li id="section_6.4">Miller DR, Anderson GT, Stark JJ, et al.: Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. J Clin Oncol 16 (11): 3649-55, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9817287&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9817287&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.5">Leitner SP, Rothkopf MM, Haverstick L, et al.: Two phase II studies of oral dry shark cartilage powder (SCP) with either metastatic breast or prostate cancer refractory to standard treatment. [Abstract] Proceedings of the American Society of Clinical Oncology  17: A-240, 1998.</li><li id="section_6.6">Rosenbluth RJ, Jennis AA, Cantwell S, et al.: Oral shark cartilage in the treatment of patients with advanced primary brain tumors. [Abstract] Proceedings of the American Society of Clinical Oncology  18: A-554, 1999.</li><li id="section_6.7">Jungi WF: Dangerous nutrition. Support Care Cancer 11 (4): 197-8, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12673456&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12673456&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.8">Ashar B, Vargo E: Shark cartilage-induced hepatitis. Ann Intern Med 125 (9): 780-1, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8929024&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8929024&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.9">Falardeau P, Champagne P, Poyet P, et al.: Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol 28 (6): 620-5, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11740820&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11740820&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _59
      field_pdq_section_title:
        - format: plain_text
          value: 'Resumen de las pruebas sobre el cartílago'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_59" class="pdq-sections"><p id="_60" tabindex="-1">
            Aunque se han llevado a cabo por lo menos una docena de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44195&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044195&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">estudios cl&#xED;nicos</a> del <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44190&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044190&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">cart&#xED;lago</a> como tratamiento para personas con <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45333&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045333&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer</a> desde principios de la d&#xE9;cada de 1970, se divulgaron relativamente pocos resultados en la literatura cient&#xED;fica con revisi&#xF3;n externa. Hay algunos pocos datos notificados de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45833&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045833&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">ensayos cl&#xED;nicos de fase III</a>. Hay estudios cl&#xED;nicos adicionales en curso. En la actualidad, no es posible recomendar el uso de cart&#xED;lago (bovino [vacuno] o tibur&#xF3;n) como tratamiento para personas con c&#xE1;ncer fuera del contexto de ensayos cl&#xED;nicos bien dise&#xF1;ados.</p><p id="_123" tabindex="-1">Para calificar los estudios con seres humanos sobre la base de la solidez estad&#xED;stica del dise&#xF1;o del estudio y la solidez <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44724&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044724&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">cient&#xED;fica</a> de los resultados mensurables del tratamiento, se asignan puntajes de <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=446533&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000446533&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">grados de comprobaci&#xF3;n cient&#xED;fica</a>  (es decir, <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=346519&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000346519&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">criterios de valoraci&#xF3;n</a>). Los dos puntajes resultantes se combinan para producir un puntaje general. Para obtener m&#xE1;s informaci&#xF3;n sobre el an&#xE1;lisis de los grados de comprobaci&#xF3;n cient&#xED;fica, consultar el sumario <a href="/publications/pdq/levels-evidence/cam">Grados de comprobaci&#xF3;n cient&#xED;fica de los estudios con seres humanos sobre terapias integrales, alternativas y complementarias para el c&#xE1;ncer</a>.</p></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _166
      field_pdq_section_title:
        - format: plain_text
          value: 'Modificaciones a este sumario (07/10/2017)'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_166" class="pdq-sections"><p id="_167" tabindex="-1">Los sumarios del <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44271&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000044271&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">PDQ</a> con informaci&#xF3;n sobre el <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=45333&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov" onclick="javascript:popWindow('defbyid','CDR0000045333&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=Cancer.gov'); return(false);">c&#xE1;ncer</a> se revisan con regularidad y se actualizan a medida que se obtiene nueva informaci&#xF3;n. Esta secci&#xF3;n describe los cambios m&#xE1;s recientes introducidos en este sumario a partir de la fecha arriba indicada.</p><p id="_168" tabindex="-1">Este sumario es nuevo.</p><p id="_disclaimerHP_3" tabindex="-1">Este sumario est&#xE1; redactado y mantenido por el <a href="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/medicina-complementaria-alternativa" title="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/medicina-complementaria-alternativa">Consejo editorial del PDQ&#xAE; sobre las terapias integrales, alternativas y complementarias</a>, que es editorialmente independiente del NCI. El sumario refleja una revisi&#xF3;n independiente de la bibliograf&#xED;a y no representa una declaraci&#xF3;n de pol&#xED;ticas del NCI o de los NIH. Para mayor informaci&#xF3;n sobre las pol&#xED;ticas de los sumarios y la funci&#xF3;n de los  consejos editoriales  del PDQ que mantienen los sumarios del PDQ, consultar en <a href="/espanol/cancer/tratamiento/mca/pro/cartilago-pdq#link/_AboutThis_1">Informaci&#xF3;n sobre este sumario del PDQ</a> y  la p&#xE1;gina sobre <a href="https://www.cancer.gov/espanol/publicaciones/pdq" title="https://www.cancer.gov/espanol/publicaciones/pdq">Banco de datos de informaci&#xF3;n de c&#xE1;ncer - PDQ&#xAE;</a>.
            </p></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _AboutThis_1
      field_pdq_section_title:
        - format: plain_text
          value: 'Información sobre este sumario del PDQ'
      field_pdq_section_html:
        - format: full_html
          value: |
            <div id="_section_AboutThis_1" class="pdq-sections"><section id="_AboutThis_2"><h3 id="_AboutThis_2_toc">Prop&#xF3;sito de este sumario</h3><p id="_AboutThis_3" tabindex="-1">Este sumario del PDQ con informaci&#xF3;n sobre el c&#xE1;ncer para profesionales de la salud proporciona informaci&#xF3;n integral revisada por expertos y con fundamento en datos probatorios sobre el uso de cart&#xED;lago (bovino y de tibur&#xF3;n) en el tratamiento de personas con c&#xE1;ncer. El prop&#xF3;sito es servir como fuente de informaci&#xF3;n y ayuda para los m&#xE9;dicos que atienden a pacientes de c&#xE1;ncer. No  ofrece pautas ni recomendaciones formales para tomar decisiones relacionadas con la atenci&#xF3;n sanitaria.</p></section><section id="_AboutThis_21"><h3 id="_AboutThis_21_toc">Revisores y actualizaciones</h3><p id="_AboutThis_22" tabindex="-1">El  <a href="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/medicina-complementaria-alternativa" title="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/medicina-complementaria-alternativa">Consejo editorial del PDQ&#xAE; sobre las terapias integrales, alternativas y complementarias</a>, cuya funci&#xF3;n editorial es independiente del Instituto Nacional del C&#xE1;ncer (NCI), revisa con regularidad este sumario y, en caso necesario,   lo actualiza. Este sumario refleja una revisi&#xF3;n bibliogr&#xE1;fica independiente y no constituye una declaraci&#xF3;n de la pol&#xED;tica del Instituto Nacional del C&#xE1;ncer ni de los Institutos Nacionales de la Salud (NIH).</p><p id="_AboutThis_26" tabindex="-1">Cada mes, los miembros de este Consejo  examinan art&#xED;culos  publicados recientemente para determinar si se deben:</p><div class="pdq-content-list"><ul id="_AboutThis_23"><li>tratar en una reuni&#xF3;n,</li><li>citar textualmente, o</li><li>sustituir o actualizar, si ya se citaron con anterioridad.</li></ul></div><p id="_AboutThis_24" tabindex="-1">Los cambios en los sumarios se deciden mediante consenso, una vez que  los integrantes del Consejo eval&#xFA;an la solidez de los datos probatorios en los art&#xED;culos publicados y determinan la forma en que se incorporar&#xE1;n al sumario.</p><p id="" tabindex="-1">Los revisores principales del sumario sobre Cart&#xED;lago (bovino y de tibur&#xF3;n) son:</p><div class="pdq-content-list"><ul id=""><li>John A. Beutler, PhD (National Cancer Institute)</li><li>Keith I. Block, MD (Block Center for Integrative Cancer Treatment &amp; University of Illinois College of Medicine)</li></ul></div><p id="_AboutThis_25" tabindex="-1">Cualquier comentario o pregunta sobre el contenido de este sumario se debe enviar mediante el   <a href="https://www.cancer.gov/espanol/contactenos/correo-electronico" title="https://www.cancer.gov/espanol/contactenos/correo-electronico">formulario de comunicaci&#xF3;n</a> en Cancer.gov/espanol del NCI.  No comunicarse con los miembros del Consejo para enviar preguntas o comentarios sobre los sumarios.  Los miembros del Consejo no responder&#xE1;n a preguntas del p&#xFA;blico. </p></section><section id="_AboutThis_9"><h3 id="_AboutThis_9_toc">Grados de comprobaci&#xF3;n cient&#xED;fica</h3><p id="_AboutThis_10" tabindex="-1">En algunas referencias bibliogr&#xE1;ficas de este sumario se indica el grado de comprobaci&#xF3;n cient&#xED;fica. El prop&#xF3;sito de estas designaciones es ayudar al lector a evaluar la solidez de los datos probatorios que sustentan el uso de  ciertas intervenciones  o enfoques. El Consejo editorial del PDQ&#xAE; sobre las terapias integrales, alternativas y complementarias emplea un <a href="/espanol/publicaciones/pdq/grados-comprobacion/cam">sistema de jerarquizaci&#xF3;n formal</a> para establecer  las designaciones del grado de comprobaci&#xF3;n cient&#xED;fica.</p></section><section id="_AboutThis_11"><h3 id="_AboutThis_11_toc">Permisos para el uso de este sumario</h3><p id="_AboutThis_12" tabindex="-1">PDQ (Physician Data Query) es una marca registrada. Se autoriza el libre uso del texto  de los documentos del PDQ. Sin embargo, no se podr&#xE1; identificar como un sumario de informaci&#xF3;n sobre c&#xE1;ncer del PDQ del  NCI,  salvo que se reproduzca en su totalidad y se actualice con regularidad. Por otra parte, se permitir&#xE1; que un autor  escriba una oraci&#xF3;n como &#x201C;En el sumario del PDQ  del NCI de informaci&#xF3;n sobre la prevenci&#xF3;n del c&#xE1;ncer de mama se describen, en breve, los siguientes riesgos: [incluir fragmento del sumario]&#x201D;.</p><p id="_AboutThis_13" tabindex="-1">Se sugiere citar la referencia bibliogr&#xE1;fica de este sumario del PDQ de la siguiente forma:</p><p id="_AboutThis_14" tabindex="-1">PDQ&#xAE; . PDQ Cart&#xED;lago (bovino y de tibur&#xF3;n). Bethesda, MD: National Cancer Institute. Actualizaci&#xF3;n:  &lt;MM/DD/YYYY&gt;. Disponible en: <a href="https://www.cancer.gov/espanol/cancer/tratamiento/mca/pro/cartilago-pdq" title="https://www.cancer.gov/espanol/cancer/tratamiento/mca/pro/cartilago-pdq">https://www.cancer.gov/espanol/cancer/tratamiento/mca/pro/cartilago-pdq</a>.  Fecha de acceso: &lt;MM/DD/YYYY&gt;. [PMID: 26389205]</p><p id="_AboutThis_15" tabindex="-1">Las im&#xE1;genes  en este sumario se reproducen  con el permiso del autor, el artista o la  editorial para uso exclusivo en los sumarios del PDQ. La utilizaci&#xF3;n de las im&#xE1;genes fuera del  PDQ requiere la autorizaci&#xF3;n del propietario, que el Instituto Nacional del C&#xE1;ncer no  puede otorgar. Para obtener m&#xE1;s informaci&#xF3;n sobre el uso de las ilustraciones de este sumario o de  otras im&#xE1;genes relacionadas con el c&#xE1;ncer, consultar <a href="https://visualsonline.cancer.gov/" title="https://visualsonline.cancer.gov/">Visuals Online</a>, una colecci&#xF3;n de m&#xE1;s de 2000 im&#xE1;genes cient&#xED;ficas.</p></section><section id="_AboutThis_16"><h3 id="_AboutThis_16_toc">Cl&#xE1;usula sobre el descargo de responsabilidad</h3><p id="_AboutThis_18" tabindex="-1">La informaci&#xF3;n en estos sumarios  no se debe utilizar como base para determinar reembolsos por parte de las aseguradoras. Para obtener m&#xE1;s informaci&#xF3;n  sobre la cobertura de seguros, consultar la p&#xE1;gina <a href="https://www.cancer.gov/espanol/cancer/manejo-del-cancer" title="https://www.cancer.gov/espanol/cancer/manejo-del-cancer">Manejo de la atenci&#xF3;n del c&#xE1;ncer</a> disponible en Cancer.gov/espanol.</p></section><section id="_AboutThis_19"><h3 id="_AboutThis_19_toc">Para obtener m&#xE1;s informaci&#xF3;n</h3><p id="_AboutThis_20" tabindex="-1">En Cancer.gov/espanol,  se ofrece m&#xE1;s informaci&#xF3;n sobre c&#xF3;mo comunicarse o recibir ayuda en  <a href="https://www.cancer.gov/espanol/contactenos" title="https://www.cancer.gov/espanol/contactenos">&#xBF;En qu&#xE9; podemos ayudarle?</a>.
            Tambi&#xE9;n se puede enviar un mensaje de  correo electr&#xF3;nico  mediante este  <a href="https://www.cancer.gov/espanol/contactenos/correo-electronico" title="https://www.cancer.gov/espanol/contactenos/correo-electronico">formulario</a>.</p></section></div>
